Psychopharmacology — MCQs

Q: Clozapine is used in:

Resistant schizophrenia. **Explanation:** **Clozapine** is an atypical (second-generation) antipsychotic and is considered the **gold standard** for the management of **Treatment-Resistant Schizophrenia (TRS)**. 1. **Why Option B is Correct:** Resistance in schizophrenia is defined as a lack of satisfactory clinical improvement despite the use of adequate doses of at least two different antipsychotics (including one atypical) for a duration of 6–8 weeks each. Clozapine is uniquely effective in these cases due to its complex receptor profile (low D2 affinity, high 5-HT2A, D4, and alpha-adrenergic blockade). It is the only antipsychotic proven to reduce suicidal behavior in schizophrenic patients. 2. **Why Other Options are Incorrect:** * **A. Depression:** First-line treatments are SSRIs/SNRIs. While some atypicals (like Quetiapine or Aripiprazole) are used as adjuncts in resistant depression, Clozapine is not used due to its side-effect profile. * **C. Mania:** Acute mania is treated with Lithium, Valproate, or standard antipsychotics (e.g., Olanzapine, Risperidone). Clozapine is reserved only for ultra-resistant cases, not as a standard indication. * **D. Delirium:** Low-dose Haloperidol is the drug of choice. Clozapine is contraindicated in delirium because its strong anticholinergic properties can worsen the confusional state. **High-Yield Clinical Pearls for NEET-PG:** * **Agranulocytosis:** The most dreaded side effect (occurs in ~1%). Mandatory **WBC monitoring** is required (weekly for the first 6 months). * **Seizures:** Clozapine carries a dose-dependent risk of seizures. * **Sialorrhea:** Paradoxical hypersalivation is a common, bothersome side effect. * **Myocarditis:** A rare but fatal side effect; monitor for tachycardia and chest pain. * **Metabolic Syndrome:** High risk of weight gain and diabetes (similar to Olanzapine).

Q: Which antipsychotic has anti-suicidal properties?

clozapine. **Explanation:** **Clozapine** is the correct answer because it is the only antipsychotic with a specifically FDA-approved indication for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder. This anti-suicidal effect is independent of its primary antipsychotic action and is believed to be mediated by its unique modulation of serotonergic (5-HT2A) and noradrenergic systems, which helps reduce impulsivity and aggression. **Analysis of Incorrect Options:** * **B. Chlorpromazine:** A typical (first-generation) antipsychotic primarily used for acute psychosis. While it treats positive symptoms, it has no proven specific anti-suicidal properties and may even worsen depressive symptoms in some patients. * **C. Aripiprazole:** A partial dopamine agonist. While effective for mood stabilization and augmentation in depression, it does not carry a specific indication for suicide prevention. * **D. Amisulpride:** A substituted benzamide that is effective for both positive and negative symptoms of schizophrenia, but lacks evidence for a direct anti-suicidal effect. **High-Yield Clinical Pearls for NEET-PG:** * **The "Rule of Two":** There are two main drugs in psychiatry known for reducing suicide risk: **Clozapine** (in Schizophrenia) and **Lithium** (in Bipolar Disorder). * **Clozapine Monitoring:** Due to the risk of **agranulocytosis**, regular monitoring of Absolute Neutrophil Count (ANC) is mandatory. * **Other Side Effects:** Clozapine is associated with the highest risk of seizures (dose-dependent), sialorrhea (drooling), myocarditis, and metabolic syndrome among antipsychotics. * **Indication:** It remains the gold standard for **Treatment-Resistant Schizophrenia** (defined as failure of two adequate trials of other antipsychotics).

Q: What is the drug of choice for a schizophrenic patient with poor oral absorption?

Clozapine. ### Explanation **Correct Option: C. Clozapine** The core concept here is the **pharmacokinetic profile** of antipsychotics. Clozapine is unique because it undergoes extensive first-pass metabolism, but more importantly, it is the only antipsychotic where **therapeutic drug monitoring (TDM)** is frequently used to overcome absorption issues or treatment resistance. In clinical scenarios involving "poor oral absorption" (often due to gastrointestinal issues or high first-pass effect), Clozapine remains the **Drug of Choice (DOC) for treatment-resistant schizophrenia**. While other drugs have parenteral formulations, Clozapine is the gold standard for patients who fail to respond to standard therapy, which often includes those with metabolic or absorption variations that render other oral medications ineffective. **Analysis of Incorrect Options:** * **A & B (Haloperidol & Fluphenazine):** These are typical antipsychotics. While they are available as long-acting decanoate injections (useful for poor *compliance*), they are not specifically indicated for poor *absorption* over Clozapine in a refractory context. * **D. Olanzapine:** An atypical antipsychotic similar to Clozapine but lacks the same level of efficacy in treatment-resistant cases. It is often a second-line choice but does not supersede Clozapine for complex absorption/resistance profiles. **High-Yield Clinical Pearls for NEET-PG:** * **Clozapine Indications:** Treatment-resistant schizophrenia (failed 2+ antipsychotics) and reducing suicidal behavior in schizophrenia. * **Adverse Effects:** Agranulocytosis (requires mandatory ANC monitoring), seizures (dose-dependent), myocarditis, and sialorrhea (hypersalivation). * **Lacks Extrapyramidal Symptoms (EPS):** Clozapine has the lowest risk of EPS and tardive dyskinesia among all antipsychotics. * **Metabolic Syndrome:** Both Clozapine and Olanzapine carry the highest risk of weight gain and diabetes.

Q: Use of lithium in pregnancy can result in which of the following abnormalities in the baby?

Ebstein's anomaly. **Explanation:** The correct answer is **Ebstein’s anomaly**. Lithium is a mood stabilizer used primarily for Bipolar Disorder. When taken during the first trimester of pregnancy, it acts as a teratogen, specifically affecting cardiac development. **1. Why Ebstein’s Anomaly is Correct:** Ebstein’s anomaly is a rare congenital heart defect characterized by the **downward displacement of the tricuspid valve** leaflets into the right ventricle ("atrialization" of the right ventricle). While the absolute risk remains low (approx. 1 in 1,000 to 2,000 exposures), it represents a significant increase compared to the general population. **2. Analysis of Incorrect Options:** * **Anencephaly:** This is a neural tube defect (NTD). NTDs are more commonly associated with **Valproate** or Carbamazepine use during pregnancy, not Lithium. * **Caudal dysgenesis syndrome:** This is a rare malformation (sacral agenesis) highly specific to **maternal diabetes mellitus**. * **Elfin facies:** This facial phenotype (along with hypercalcemia and supravalvular aortic stenosis) is characteristic of **Williams Syndrome**, a genetic deletion on chromosome 7. **Clinical Pearls for NEET-PG:** * **Monitoring:** If a pregnant woman must continue Lithium, fetal echocardiography is recommended at 18–22 weeks. * **Dosage:** Lithium clearance increases during pregnancy (due to increased GFR) and drops abruptly at delivery; close serum monitoring is vital to avoid toxicity. * **Breastfeeding:** Lithium is generally discouraged during breastfeeding as it is excreted in milk and can cause "Floppy Baby Syndrome" (hypotonia, cyanosis). * **Alternative:** Lamotrigine is often considered a safer mood stabilizer during pregnancy regarding structural malformations.

Q: Which of the following antipsychotic medications carries the least risk of metabolic side effects?

Ziprasidone. **Explanation:** The metabolic profile of second-generation (atypical) antipsychotics is a high-yield topic for NEET-PG. These drugs are associated with weight gain, dyslipidemia, and insulin resistance due to their affinity for H1 and 5-HT2C receptors. **Why Ziprasidone is Correct:** **Ziprasidone** (along with Aripiprazole and Lurasidone) is considered **metabolically neutral**. It has a very low affinity for histamine (H1) receptors, resulting in minimal weight gain and negligible impact on blood glucose or lipid levels. While it carries a risk of QTc prolongation, its metabolic safety profile is superior to most other atypicals. **Analysis of Incorrect Options:** * **Clozapine (D) & Olanzapine (B):** These are the **worst offenders**. They have the highest risk of significant weight gain, sedation, and new-onset Diabetes Mellitus. Clozapine is the most metabolic-heavy, followed closely by Olanzapine. * **Risperidone (A):** This drug carries a **moderate risk**. While less severe than Olanzapine, it still causes significant weight gain and is notably associated with the highest risk of hyperprolactinemia among atypicals. **NEET-PG High-Yield Pearls:** * **Mnemonic for Metabolic Risk (Highest to Lowest):** "**C**ome **O**n **Q**uietly **R**isperidone **A**nd **Z**iprasidone" (**C**lozapine > **O**lanzapine > **Q**uetiapine > **R**isperidone > **A**ripiprazole/**Z**iprasidone). * **Ziprasidone** must be taken **with food** (minimum 500 calories) for adequate absorption. * **Monitoring:** Patients on Clozapine/Olanzapine require regular monitoring of BMI, waist circumference, fasting glucose, and lipid profiles.

Q: A 19-year-old boy with chronic schizophrenia is treated with haloperidol 20 mg/day. One week after starting the medication, he develops restlessness, fidgeting, irritability, and an inability to remain still. What is the most appropriate management strategy?

Add a beta-blocker. **Explanation:** The clinical presentation of restlessness, fidgeting, and an inability to sit still in a patient recently started on a high-potency antipsychotic (Haloperidol) is classic for **Akathisia**. This is a common Extrapyramidal Side Effect (EPS) occurring typically within days to weeks of starting or increasing the dose of dopamine antagonists. **Why Option C is Correct:** The first-line pharmacological treatment for antipsychotic-induced akathisia is a **lipophilic beta-blocker**, such as **Propranolol**. These drugs cross the blood-brain barrier and are highly effective in reducing the subjective and objective symptoms of motor restlessness. **Why Other Options are Incorrect:** * **Option A:** Increasing the dose of Haloperidol would worsen the dopamine blockade in the nigrostriatal pathway, thereby exacerbating the akathisia. * **Option B:** While anticholinergics (e.g., Benztropine, Trihexyphenidyl) are the treatment of choice for acute dystonia and Parkinsonian symptoms, they are significantly **less effective** for akathisia. * **Option D:** Adding another antipsychotic increases the risk of polypharmacy and further EPS without addressing the current distress. **NEET-PG High-Yield Pearls:** 1. **Akathisia** is often misdiagnosed as worsening psychosis or agitation; increasing the dose in this scenario is a common clinical error. 2. **Acute Dystonia:** Occurs within hours/days; treat with IV/IM Anticholinergics (Promethazine/Benztropine). 3. **Drug-Induced Parkinsonism:** Occurs within weeks; treat with oral Anticholinergics. 4. **Tardive Dyskinesia:** Occurs after months/years of use; characterized by choreoathetoid movements (e.g., lip-smacking). Treatment involves switching to Clozapine or using VMAT2 inhibitors (Valbenazine).

Q: Beta-adrenergic receptor antagonists such as propranolol are used in the treatment of which of the following conditions?

All of the above. **Explanation:** Beta-adrenergic receptor antagonists (Beta-blockers), specifically **Propranolol**, are widely used in psychiatry to manage the peripheral autonomic symptoms of anxiety and specific drug-induced side effects. * **Performance Anxiety:** Propranolol is the drug of choice for "stage fright." It works by blocking the peripheral effects of adrenaline, thereby reducing tremors, palpitations, tachycardia, and sweating without causing the sedation associated with benzodiazepines. * **Lithium-Induced Tremor:** Fine resting tremors are a common side effect of Lithium therapy. Propranolol is the most effective treatment for managing these tremors, allowing patients to continue their mood-stabilizer regimen. * **Substance Use Disorders:** Beta-blockers are used as adjuncts in managing **Alcohol Withdrawal** (to control autonomic hyperactivity like tachycardia and hypertension) and are also used to treat **Akathisia** (subjective restlessness) caused by antipsychotics. **Clinical Pearls for NEET-PG:** 1. **Akathisia:** Propranolol is the **first-line treatment** for antipsychotic-induced akathisia. 2. **Specific Phobia:** It is used specifically for the "Performance Type" of Social Anxiety Disorder. 3. **Contraindications:** Always screen for **Asthma or COPD** before prescribing, as non-selective beta-blockers can cause life-threatening bronchospasm. They should also be avoided in patients with insulin-dependent diabetes (masks hypoglycemia symptoms) and bradycardia. 4. **Lipophilicity:** Propranolol is highly lipophilic, allowing it to cross the blood-brain barrier effectively.

Q: A patient with maniac depressive psychosis is on lithium, clozapine, and fluphenazine. During the course of treatment, he developed seizures, tremors, excessive thirst, and recurrent episodes of urination. Which drug is most likely responsible for these complications?

Lithium. ### Explanation The correct answer is **Lithium**. This question tests the ability to differentiate the side effect profiles of multiple psychotropic drugs administered simultaneously. **Why Lithium is the correct answer:** Lithium has a narrow therapeutic index and is notorious for multisystem side effects. The symptoms described in the patient are classic manifestations of Lithium toxicity and its physiological effects: * **Excessive thirst (Polydipsia) and Recurrent urination (Polyuria):** Lithium causes **Nephrogenic Diabetes Insipidus** by interfering with the action of ADH (Vasopressin) on the collecting ducts of the kidney. * **Tremors:** Fine tremors are a common side effect, while coarse tremors often indicate Lithium toxicity. * **Seizures:** At toxic levels (>2.0 mEq/L), Lithium is highly neurotoxic and can precipitate seizures. **Why other options are incorrect:** * **Clozapine:** While Clozapine is the antipsychotic most strongly associated with a dose-dependent risk of **seizures**, it does not cause polyuria or polydipsia. Its hallmark side effects are agranulocytosis, sialorrhea (drooling), and myocarditis. * **Fluphenazine:** A high-potency typical antipsychotic primarily associated with **Extrapyramidal Side Effects (EPS)** like dystonia, akathisia, and parkinsonism. It does not cause the renal symptoms described. **High-Yield Clinical Pearls for NEET-PG:** * **Monitoring:** Therapeutic drug monitoring (TDM) is essential for Lithium. Target serum levels: 0.6–1.2 mEq/L (Prophylaxis/Maintenance) and 0.8–1.5 mEq/L (Acute Mania). * **Renal Impact:** Lithium is the drug of choice for Bipolar Disorder but is contraindicated in renal failure. * **L-C-S Triad:** Remember **L**ithium, **C**lozapine, and **S**ertraline (in SSRI withdrawal) can all lower the seizure threshold, but only Lithium explains the constellation of renal and neurological symptoms provided.

Q: What is the best choice of antianxiety agent for a 40-year-old woman with generalized anxiety disorder and a history of benzodiazepine abuse?

buspirone. **Explanation:** The correct answer is **Buspirone**. **Why Buspirone is the best choice:** Generalized Anxiety Disorder (GAD) often requires long-term pharmacological management. In a patient with a history of **substance abuse or benzodiazepine (BZD) dependence**, BZDs are contraindicated due to their high potential for addiction, tolerance, and withdrawal. * **Mechanism:** Buspirone is a **5-HT1A partial agonist**. * **Clinical Advantage:** Unlike BZDs, it has **no potential for abuse or addiction**, does not cause sedation, and does not potentiate the effects of alcohol. This makes it the ideal "non-addictive" alternative for chronic anxiety in high-risk patients. **Why other options are incorrect:** * **Zolpidem (A):** This is a non-benzodiazepine sedative-hypnotic ("Z-drug") used primarily for insomnia, not GAD. While it has a different structure, it still carries a risk of dependence and misuse. * **Flurazepam (B) & Clonazepam (C):** Both are benzodiazepines. Flurazepam is long-acting and used for insomnia; Clonazepam is used for GAD and panic disorder. Both are strictly avoided in patients with a history of drug abuse due to the risk of relapse and physiological dependence. **NEET-PG High-Yield Pearls:** * **Lag Period:** Buspirone takes **2–4 weeks** to show therapeutic effects; it is not useful for acute anxiety attacks (unlike BZDs). * **Side Effects:** Dizziness, nausea, and headache are common. It does *not* cause muscle relaxation or anticonvulsant effects. * **Drug of Choice for GAD:** While SSRIs/SNRIs are first-line, Buspirone is a specific high-yield answer for GAD patients with **addiction history**.

A patient with acute psychosis, who is on haloperidol 20 mg/day for the last 2 days, has an episode characterized by tongue protrusion, oculogyric crisis, stiffness, and abnormal posture of limbs and trunk without loss of consciousness for the last 20 minutes before presenting to the casualty. This improved within a few minutes after administration of diphenhydramine HCl. What is the most likely diagnosis?

Psychopharmacology Indian Medical PG Practice Questions and MCQs

Question 1: Clozapine is used in:

A. Depression
B. Resistant schizophrenia (Correct Answer)
C. Mania
D. Delirium

Explanation: **Explanation:** **Clozapine** is an atypical (second-generation) antipsychotic and is considered the **gold standard** for the management of **Treatment-Resistant Schizophrenia (TRS)**. 1. **Why Option B is Correct:** Resistance in schizophrenia is defined as a lack of satisfactory clinical improvement despite the use of adequate doses of at least two different antipsychotics (including one atypical) for a duration of 6–8 weeks each. Clozapine is uniquely effective in these cases due to its complex receptor profile (low D2 affinity, high 5-HT2A, D4, and alpha-adrenergic blockade). It is the only antipsychotic proven to reduce suicidal behavior in schizophrenic patients. 2. **Why Other Options are Incorrect:** * **A. Depression:** First-line treatments are SSRIs/SNRIs. While some atypicals (like Quetiapine or Aripiprazole) are used as adjuncts in resistant depression, Clozapine is not used due to its side-effect profile. * **C. Mania:** Acute mania is treated with Lithium, Valproate, or standard antipsychotics (e.g., Olanzapine, Risperidone). Clozapine is reserved only for ultra-resistant cases, not as a standard indication. * **D. Delirium:** Low-dose Haloperidol is the drug of choice. Clozapine is contraindicated in delirium because its strong anticholinergic properties can worsen the confusional state. **High-Yield Clinical Pearls for NEET-PG:** * **Agranulocytosis:** The most dreaded side effect (occurs in ~1%). Mandatory **WBC monitoring** is required (weekly for the first 6 months). * **Seizures:** Clozapine carries a dose-dependent risk of seizures. * **Sialorrhea:** Paradoxical hypersalivation is a common, bothersome side effect. * **Myocarditis:** A rare but fatal side effect; monitor for tachycardia and chest pain. * **Metabolic Syndrome:** High risk of weight gain and diabetes (similar to Olanzapine).

Question 2: Which antipsychotic has anti-suicidal properties?

A. clozapine (Correct Answer)
B. chlorpromazine
C. aripiprazole
D. amisulpride

Explanation: **Explanation:** **Clozapine** is the correct answer because it is the only antipsychotic with a specifically FDA-approved indication for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder. This anti-suicidal effect is independent of its primary antipsychotic action and is believed to be mediated by its unique modulation of serotonergic (5-HT2A) and noradrenergic systems, which helps reduce impulsivity and aggression. **Analysis of Incorrect Options:** * **B. Chlorpromazine:** A typical (first-generation) antipsychotic primarily used for acute psychosis. While it treats positive symptoms, it has no proven specific anti-suicidal properties and may even worsen depressive symptoms in some patients. * **C. Aripiprazole:** A partial dopamine agonist. While effective for mood stabilization and augmentation in depression, it does not carry a specific indication for suicide prevention. * **D. Amisulpride:** A substituted benzamide that is effective for both positive and negative symptoms of schizophrenia, but lacks evidence for a direct anti-suicidal effect. **High-Yield Clinical Pearls for NEET-PG:** * **The "Rule of Two":** There are two main drugs in psychiatry known for reducing suicide risk: **Clozapine** (in Schizophrenia) and **Lithium** (in Bipolar Disorder). * **Clozapine Monitoring:** Due to the risk of **agranulocytosis**, regular monitoring of Absolute Neutrophil Count (ANC) is mandatory. * **Other Side Effects:** Clozapine is associated with the highest risk of seizures (dose-dependent), sialorrhea (drooling), myocarditis, and metabolic syndrome among antipsychotics. * **Indication:** It remains the gold standard for **Treatment-Resistant Schizophrenia** (defined as failure of two adequate trials of other antipsychotics).

Question 3: What is the drug of choice for a schizophrenic patient with poor oral absorption?

A. Haloperidol
B. Fluphenazine
C. Clozapine (Correct Answer)
D. Olanzapine

Explanation: ### Explanation **Correct Option: C. Clozapine** The core concept here is the **pharmacokinetic profile** of antipsychotics. Clozapine is unique because it undergoes extensive first-pass metabolism, but more importantly, it is the only antipsychotic where **therapeutic drug monitoring (TDM)** is frequently used to overcome absorption issues or treatment resistance. In clinical scenarios involving "poor oral absorption" (often due to gastrointestinal issues or high first-pass effect), Clozapine remains the **Drug of Choice (DOC) for treatment-resistant schizophrenia**. While other drugs have parenteral formulations, Clozapine is the gold standard for patients who fail to respond to standard therapy, which often includes those with metabolic or absorption variations that render other oral medications ineffective. **Analysis of Incorrect Options:** * **A & B (Haloperidol & Fluphenazine):** These are typical antipsychotics. While they are available as long-acting decanoate injections (useful for poor *compliance*), they are not specifically indicated for poor *absorption* over Clozapine in a refractory context. * **D. Olanzapine:** An atypical antipsychotic similar to Clozapine but lacks the same level of efficacy in treatment-resistant cases. It is often a second-line choice but does not supersede Clozapine for complex absorption/resistance profiles. **High-Yield Clinical Pearls for NEET-PG:** * **Clozapine Indications:** Treatment-resistant schizophrenia (failed 2+ antipsychotics) and reducing suicidal behavior in schizophrenia. * **Adverse Effects:** Agranulocytosis (requires mandatory ANC monitoring), seizures (dose-dependent), myocarditis, and sialorrhea (hypersalivation). * **Lacks Extrapyramidal Symptoms (EPS):** Clozapine has the lowest risk of EPS and tardive dyskinesia among all antipsychotics. * **Metabolic Syndrome:** Both Clozapine and Olanzapine carry the highest risk of weight gain and diabetes.

Question 4: Use of lithium in pregnancy can result in which of the following abnormalities in the baby?

A. Anencephaly
B. Ebstein's anomaly (Correct Answer)
C. Caudal dysgenesis syndrome
D. Elfin facies

Explanation: **Explanation:** The correct answer is **Ebstein’s anomaly**. Lithium is a mood stabilizer used primarily for Bipolar Disorder. When taken during the first trimester of pregnancy, it acts as a teratogen, specifically affecting cardiac development. **1. Why Ebstein’s Anomaly is Correct:** Ebstein’s anomaly is a rare congenital heart defect characterized by the **downward displacement of the tricuspid valve** leaflets into the right ventricle ("atrialization" of the right ventricle). While the absolute risk remains low (approx. 1 in 1,000 to 2,000 exposures), it represents a significant increase compared to the general population. **2. Analysis of Incorrect Options:** * **Anencephaly:** This is a neural tube defect (NTD). NTDs are more commonly associated with **Valproate** or Carbamazepine use during pregnancy, not Lithium. * **Caudal dysgenesis syndrome:** This is a rare malformation (sacral agenesis) highly specific to **maternal diabetes mellitus**. * **Elfin facies:** This facial phenotype (along with hypercalcemia and supravalvular aortic stenosis) is characteristic of **Williams Syndrome**, a genetic deletion on chromosome 7. **Clinical Pearls for NEET-PG:** * **Monitoring:** If a pregnant woman must continue Lithium, fetal echocardiography is recommended at 18–22 weeks. * **Dosage:** Lithium clearance increases during pregnancy (due to increased GFR) and drops abruptly at delivery; close serum monitoring is vital to avoid toxicity. * **Breastfeeding:** Lithium is generally discouraged during breastfeeding as it is excreted in milk and can cause "Floppy Baby Syndrome" (hypotonia, cyanosis). * **Alternative:** Lamotrigine is often considered a safer mood stabilizer during pregnancy regarding structural malformations.

Question 5: Which of the following antipsychotic medications carries the least risk of metabolic side effects?

A. Risperidone
B. Olanzapine
C. Ziprasidone (Correct Answer)
D. Clozapine

Explanation: **Explanation:** The metabolic profile of second-generation (atypical) antipsychotics is a high-yield topic for NEET-PG. These drugs are associated with weight gain, dyslipidemia, and insulin resistance due to their affinity for H1 and 5-HT2C receptors. **Why Ziprasidone is Correct:** **Ziprasidone** (along with Aripiprazole and Lurasidone) is considered **metabolically neutral**. It has a very low affinity for histamine (H1) receptors, resulting in minimal weight gain and negligible impact on blood glucose or lipid levels. While it carries a risk of QTc prolongation, its metabolic safety profile is superior to most other atypicals. **Analysis of Incorrect Options:** * **Clozapine (D) & Olanzapine (B):** These are the **worst offenders**. They have the highest risk of significant weight gain, sedation, and new-onset Diabetes Mellitus. Clozapine is the most metabolic-heavy, followed closely by Olanzapine. * **Risperidone (A):** This drug carries a **moderate risk**. While less severe than Olanzapine, it still causes significant weight gain and is notably associated with the highest risk of hyperprolactinemia among atypicals. **NEET-PG High-Yield Pearls:** * **Mnemonic for Metabolic Risk (Highest to Lowest):** "**C**ome **O**n **Q**uietly **R**isperidone **A**nd **Z**iprasidone" (**C**lozapine > **O**lanzapine > **Q**uetiapine > **R**isperidone > **A**ripiprazole/**Z**iprasidone). * **Ziprasidone** must be taken **with food** (minimum 500 calories) for adequate absorption. * **Monitoring:** Patients on Clozapine/Olanzapine require regular monitoring of BMI, waist circumference, fasting glucose, and lipid profiles.

Question 6: A 19-year-old boy with chronic schizophrenia is treated with haloperidol 20 mg/day. One week after starting the medication, he develops restlessness, fidgeting, irritability, and an inability to remain still. What is the most appropriate management strategy?

A. Increase the dose of haloperidol
B. Add an anticholinergic drug
C. Add a beta-blocker (Correct Answer)
D. Add another antipsychotic drug

Explanation: **Explanation:** The clinical presentation of restlessness, fidgeting, and an inability to sit still in a patient recently started on a high-potency antipsychotic (Haloperidol) is classic for **Akathisia**. This is a common Extrapyramidal Side Effect (EPS) occurring typically within days to weeks of starting or increasing the dose of dopamine antagonists. **Why Option C is Correct:** The first-line pharmacological treatment for antipsychotic-induced akathisia is a **lipophilic beta-blocker**, such as **Propranolol**. These drugs cross the blood-brain barrier and are highly effective in reducing the subjective and objective symptoms of motor restlessness. **Why Other Options are Incorrect:** * **Option A:** Increasing the dose of Haloperidol would worsen the dopamine blockade in the nigrostriatal pathway, thereby exacerbating the akathisia. * **Option B:** While anticholinergics (e.g., Benztropine, Trihexyphenidyl) are the treatment of choice for acute dystonia and Parkinsonian symptoms, they are significantly **less effective** for akathisia. * **Option D:** Adding another antipsychotic increases the risk of polypharmacy and further EPS without addressing the current distress. **NEET-PG High-Yield Pearls:** 1. **Akathisia** is often misdiagnosed as worsening psychosis or agitation; increasing the dose in this scenario is a common clinical error. 2. **Acute Dystonia:** Occurs within hours/days; treat with IV/IM Anticholinergics (Promethazine/Benztropine). 3. **Drug-Induced Parkinsonism:** Occurs within weeks; treat with oral Anticholinergics. 4. **Tardive Dyskinesia:** Occurs after months/years of use; characterized by choreoathetoid movements (e.g., lip-smacking). Treatment involves switching to Clozapine or using VMAT2 inhibitors (Valbenazine).

Question 7: Beta-adrenergic receptor antagonists such as propranolol are used in the treatment of which of the following conditions?

A. Performance anxiety
B. Substance use disorders
C. Lithium tremor
D. All of the above (Correct Answer)

Explanation: **Explanation:** Beta-adrenergic receptor antagonists (Beta-blockers), specifically **Propranolol**, are widely used in psychiatry to manage the peripheral autonomic symptoms of anxiety and specific drug-induced side effects. * **Performance Anxiety:** Propranolol is the drug of choice for "stage fright." It works by blocking the peripheral effects of adrenaline, thereby reducing tremors, palpitations, tachycardia, and sweating without causing the sedation associated with benzodiazepines. * **Lithium-Induced Tremor:** Fine resting tremors are a common side effect of Lithium therapy. Propranolol is the most effective treatment for managing these tremors, allowing patients to continue their mood-stabilizer regimen. * **Substance Use Disorders:** Beta-blockers are used as adjuncts in managing **Alcohol Withdrawal** (to control autonomic hyperactivity like tachycardia and hypertension) and are also used to treat **Akathisia** (subjective restlessness) caused by antipsychotics. **Clinical Pearls for NEET-PG:** 1. **Akathisia:** Propranolol is the **first-line treatment** for antipsychotic-induced akathisia. 2. **Specific Phobia:** It is used specifically for the "Performance Type" of Social Anxiety Disorder. 3. **Contraindications:** Always screen for **Asthma or COPD** before prescribing, as non-selective beta-blockers can cause life-threatening bronchospasm. They should also be avoided in patients with insulin-dependent diabetes (masks hypoglycemia symptoms) and bradycardia. 4. **Lipophilicity:** Propranolol is highly lipophilic, allowing it to cross the blood-brain barrier effectively.

Question 8: A patient with maniac depressive psychosis is on lithium, clozapine, and fluphenazine. During the course of treatment, he developed seizures, tremors, excessive thirst, and recurrent episodes of urination. Which drug is most likely responsible for these complications?

A. Lithium (Correct Answer)
B. Clozapine
C. Fluphenazine
D. None of the above

Explanation: ### Explanation The correct answer is **Lithium**. This question tests the ability to differentiate the side effect profiles of multiple psychotropic drugs administered simultaneously. **Why Lithium is the correct answer:** Lithium has a narrow therapeutic index and is notorious for multisystem side effects. The symptoms described in the patient are classic manifestations of Lithium toxicity and its physiological effects: * **Excessive thirst (Polydipsia) and Recurrent urination (Polyuria):** Lithium causes **Nephrogenic Diabetes Insipidus** by interfering with the action of ADH (Vasopressin) on the collecting ducts of the kidney. * **Tremors:** Fine tremors are a common side effect, while coarse tremors often indicate Lithium toxicity. * **Seizures:** At toxic levels (>2.0 mEq/L), Lithium is highly neurotoxic and can precipitate seizures. **Why other options are incorrect:** * **Clozapine:** While Clozapine is the antipsychotic most strongly associated with a dose-dependent risk of **seizures**, it does not cause polyuria or polydipsia. Its hallmark side effects are agranulocytosis, sialorrhea (drooling), and myocarditis. * **Fluphenazine:** A high-potency typical antipsychotic primarily associated with **Extrapyramidal Side Effects (EPS)** like dystonia, akathisia, and parkinsonism. It does not cause the renal symptoms described. **High-Yield Clinical Pearls for NEET-PG:** * **Monitoring:** Therapeutic drug monitoring (TDM) is essential for Lithium. Target serum levels: 0.6–1.2 mEq/L (Prophylaxis/Maintenance) and 0.8–1.5 mEq/L (Acute Mania). * **Renal Impact:** Lithium is the drug of choice for Bipolar Disorder but is contraindicated in renal failure. * **L-C-S Triad:** Remember **L**ithium, **C**lozapine, and **S**ertraline (in SSRI withdrawal) can all lower the seizure threshold, but only Lithium explains the constellation of renal and neurological symptoms provided.

Question 9: What is the best choice of antianxiety agent for a 40-year-old woman with generalized anxiety disorder and a history of benzodiazepine abuse?

A. zolpidem
B. flurazepam
C. clonazepam
D. buspirone (Correct Answer)

Explanation: **Explanation:** The correct answer is **Buspirone**. **Why Buspirone is the best choice:** Generalized Anxiety Disorder (GAD) often requires long-term pharmacological management. In a patient with a history of **substance abuse or benzodiazepine (BZD) dependence**, BZDs are contraindicated due to their high potential for addiction, tolerance, and withdrawal. * **Mechanism:** Buspirone is a **5-HT1A partial agonist**. * **Clinical Advantage:** Unlike BZDs, it has **no potential for abuse or addiction**, does not cause sedation, and does not potentiate the effects of alcohol. This makes it the ideal "non-addictive" alternative for chronic anxiety in high-risk patients. **Why other options are incorrect:** * **Zolpidem (A):** This is a non-benzodiazepine sedative-hypnotic ("Z-drug") used primarily for insomnia, not GAD. While it has a different structure, it still carries a risk of dependence and misuse. * **Flurazepam (B) & Clonazepam (C):** Both are benzodiazepines. Flurazepam is long-acting and used for insomnia; Clonazepam is used for GAD and panic disorder. Both are strictly avoided in patients with a history of drug abuse due to the risk of relapse and physiological dependence. **NEET-PG High-Yield Pearls:** * **Lag Period:** Buspirone takes **2–4 weeks** to show therapeutic effects; it is not useful for acute anxiety attacks (unlike BZDs). * **Side Effects:** Dizziness, nausea, and headache are common. It does *not* cause muscle relaxation or anticonvulsant effects. * **Drug of Choice for GAD:** While SSRIs/SNRIs are first-line, Buspirone is a specific high-yield answer for GAD patients with **addiction history**.

Question 10: A patient with acute psychosis, who is on haloperidol 20 mg/day for the last 2 days, has an episode characterized by tongue protrusion, oculogyric crisis, stiffness, and abnormal posture of limbs and trunk without loss of consciousness for the last 20 minutes before presenting to the casualty. This improved within a few minutes after administration of diphenhydramine HCl. What is the most likely diagnosis?

A. Acute dystonia (Correct Answer)
B. Akathisia
C. Tardive dyskinesia
D. Neuroleptic malignant syndrome

Explanation: ### Explanation **Correct Answer: A. Acute dystonia** **Why it is correct:** Acute dystonia is an Extrapyramidal Side Effect (EPS) characterized by sudden, involuntary, and sustained muscle contractions. It typically occurs within **hours to days** (usually <5 days) of initiating or increasing the dose of high-potency typical antipsychotics like **Haloperidol**. * **Clinical Presentation:** Common manifestations include **oculogyric crisis** (upward gaze deviation), **glossospasm** (tongue protrusion), torticollis (neck twisting), and opisthotonus (trunk arching). * **Mechanism:** It results from a sudden blockade of dopamine (D2) receptors in the nigrostriatal pathway, leading to a relative excess of cholinergic activity. * **Treatment:** It is a medical emergency that responds rapidly to **anticholinergics** (e.g., Benztropine, Trihexyphenidyl) or **antihistaminics** with anticholinergic properties (e.g., **Diphenhydramine**). **Why incorrect options are wrong:** * **B. Akathisia:** Presents as subjective motor restlessness (inability to sit still). It usually appears within days to weeks, not as acute sustained spasms. * **C. Tardive dyskinesia:** Occurs after **long-term** use (months to years) of antipsychotics. It involves choreoathetoid movements (e.g., lip-smacking) and is often irreversible. * **D. Neuroleptic Malignant Syndrome (NMS):** A life-threatening reaction characterized by the "tetrad" of muscle rigidity, fever, autonomic instability, and altered sensorium. The patient in the vignette was conscious and improved rapidly with diphenhydramine, which does not happen in NMS. **High-Yield Clinical Pearls for NEET-PG:** * **Risk Factors:** Young males are at the highest risk for acute dystonia. * **Timeline Rule of Thumb:** * **4 hours:** Acute Dystonia * **4 days:** Akathisia * **4 weeks:** Parkinsonism * **4 months/years:** Tardive Dyskinesia * **Drug of Choice (Acute):** IV/IM Promethazine or Benztropine.

Question 11: Long-term antipsychotic use may cause which of the following?

A. Depression
B. Mania
C. Schizophrenia
D. Tardive dyskinesia (Correct Answer)

Explanation: **Explanation:** **Correct Answer: D. Tardive dyskinesia** **Mechanism:** Tardive dyskinesia (TD) is a late-onset extrapyramidal side effect (EPS) resulting from the chronic use of dopamine receptor antagonists (antipsychotics). The underlying pathophysiology involves **dopamine receptor supersensitivity**. Long-term blockade of $D_2$ receptors in the nigrostriatal pathway leads to an up-regulation and increased sensitivity of these receptors. Consequently, even small amounts of dopamine trigger an exaggerated response, manifesting as involuntary, choreoathetoid movements, typically involving the tongue, face (e.g., lip-smacking), and extremities. **Analysis of Incorrect Options:** * **A. Depression:** While some patients may experience "post-psychotic depression" or "neuroleptic-induced deficit syndrome" (mimicking negative symptoms), antipsychotics are not a primary cause of clinical depression; in fact, some are used as adjuncts in treatment-resistant depression. * **B. Mania:** Antipsychotics are dopamine antagonists and are used to *treat* mania. They do not cause mania. * **C. Schizophrenia:** Antipsychotics are the primary treatment for schizophrenia. While "supersensitivity psychosis" is a theoretical risk upon abrupt withdrawal, the drugs do not cause the disease itself. **High-Yield Clinical Pearls for NEET-PG:** * **Risk Factors:** Elderly females and patients with affective disorders are at higher risk for TD. * **Management:** The first step is to reduce the dose or switch to an atypical antipsychotic with lower $D_2$ affinity (e.g., **Clozapine** or Quetiapine). * **Treatment:** VMAT-2 inhibitors (e.g., **Valbenazine**, Deutetrabenazine) are now FDA-approved for TD. * **Warning:** Anticholinergics (like Trihexyphenidyl) often **worsen** TD symptoms, unlike other EPS.

Question 12: A 30-year-old man recently started on haloperidol 30mg/day developed hyperpyrexia, muscle rigidity, akinesia, mutism, sweating, tachycardia, and increased blood pressure. Investigations showed an increased WBC count and increased creatinine phosphokinase. There is no history of any other drug intake or any signs of infection. What is the most likely diagnosis?

A. Drug overdose
B. Neuroleptic malignant syndrome (Correct Answer)
C. Drug-induced Parkinsonism
D. Tardive dyskinesia

Explanation: ### Explanation **Neuroleptic Malignant Syndrome (NMS)** is the correct diagnosis. It is a life-threatening idiosyncratic reaction to antipsychotic drugs (like Haloperidol). The pathophysiology involves massive dopamine blockade in the nigrostriatal pathway and hypothalamus. The patient presents with the classic **"tetrad"** of NMS: 1. **Hyperpyrexia:** High-grade fever. 2. **Muscle Rigidity:** Often described as "lead-pipe" rigidity. 3. **Autonomic Instability:** Tachycardia, hypertension, and diaphoresis (sweating). 4. **Altered Mental Status:** Mutism, stupor, or coma. Laboratory findings of **elevated Creatinine Phosphokinase (CPK)** (due to muscle necrosis) and **Leukocytosis** (increased WBC) are hallmark indicators that differentiate NMS from other psychiatric emergencies. **Why other options are incorrect:** * **Drug Overdose:** While Haloperidol overdose can cause sedation or extrapyramidal symptoms, it typically does not present with the specific combination of lead-pipe rigidity, hyperpyrexia, and markedly elevated CPK. * **Drug-induced Parkinsonism:** Presents with tremors, bradykinesia, and rigidity, but lacks the autonomic instability, high fever, and laboratory abnormalities seen here. * **Tardive Dyskinesia:** A late-onset side effect characterized by involuntary choreoathetoid movements (e.g., lip-smacking), not an acute febrile illness. **High-Yield Clinical Pearls for NEET-PG:** * **Treatment of Choice:** Immediate cessation of the antipsychotic, supportive care (hydration/cooling), and pharmacotherapy with **Dantrolene** (muscle relaxant) or **Bromocriptine** (dopamine agonist). * **Mnemonic (FEVER):** **F**ever, **E**ncephalopathy, **V**itals unstable, **E**levated enzymes (CPK), **R**igidity. * **Differential:** Unlike Serotonin Syndrome, NMS presents with "lead-pipe" rigidity rather than hyperreflexia and myoclonus.

Question 13: An elderly woman suffering from Schizophrenia is on antipsychotic medication. She developed purposeless involuntary facial and limb movements, constant chewing and puffing of cheeks. Which of the following drugs is least likely to be involved in this side effect?

A. Haloperidol
B. Clozapine (Correct Answer)
C. Fluphenazine
D. Loxapine

Explanation: ### Explanation The clinical presentation describes **Tardive Dyskinesia (TD)**, a late-onset extrapyramidal side effect (EPS) characterized by involuntary, choreoathetoid movements of the face, mouth (chewing, tongue protrusion), and extremities. It is caused by the up-regulation and supersensitivity of dopamine $D_2$ receptors following long-term blockade. **Why Clozapine is the correct answer:** Clozapine is an **Atypical (Second-Generation) Antipsychotic** with a unique pharmacological profile. It has a very low affinity for $D_2$ receptors and a high affinity for $D_4$ and $5-HT_{2A}$ receptors. Because it dissociates rapidly from $D_2$ receptors, it carries the **lowest risk** of causing EPS and Tardive Dyskinesia among all antipsychotics. In fact, Clozapine is often the drug of choice for patients who have already developed TD. **Analysis of Incorrect Options:** * **Haloperidol & Fluphenazine:** These are high-potency **Typical (First-Generation) Antipsychotics**. They have a strong, sustained binding to $D_2$ receptors in the nigrostriatal pathway, making them the most common culprits for inducing TD. * **Loxapine:** Although sometimes classified as a mid-potency typical antipsychotic, it behaves largely like a first-generation drug. It has significant $D_2$ blocking activity and is frequently associated with EPS and TD. **High-Yield Clinical Pearls for NEET-PG:** * **Risk Factors for TD:** Old age (as seen in this patient), female gender, and long-term use of typical antipsychotics. * **Abnormal Involuntary Movement Scale (AIMS):** The gold standard tool used for screening and monitoring TD. * **Treatment of TD:** The first step is to switch to **Clozapine** or Quetiapine. Recently, VMAT-2 inhibitors (e.g., **Valbenazine**, Deutetrabenazine) have become the preferred medical treatment. * **Note:** Anticholinergics (like Trihexyphenidyl) **worsen** Tardive Dyskinesia, unlike other EPS like Parkinsonism.

Question 14: A middle-aged man presents with restlessness, pacing, and hand tremor. He reports taking haloperidol for mania for the past two months. Which of the following conditions is the patient most likely suffering from?

A. Dystonia
B. Restless legs syndrome
C. Akathisia (Correct Answer)
D. Anhedonia

Explanation: ### Explanation **Correct Option: C. Akathisia** The patient is presenting with **Akathisia**, the most common Extrapyramidal Side Effect (EPS) associated with typical antipsychotics like Haloperidol. Akathisia is characterized by a subjective feeling of inner restlessness and an objective need to move. Clinically, this manifests as **pacing, shifting weight from foot to foot, or inability to sit still**. It typically occurs within days to weeks of starting or increasing the dose of a dopamine antagonist. **Analysis of Incorrect Options:** * **A. Dystonia:** This involves involuntary, sustained muscle contractions leading to abnormal postures (e.g., torticollis, oculogyric crisis). It usually occurs acutely (within hours to days) rather than after two months. * **B. Restless Legs Syndrome (RLS):** While symptoms are similar, RLS typically occurs at rest or before sleep and is relieved by movement. It is not primarily caused by antipsychotics, though they can exacerbate it. * **D. Anhedonia:** This is a psychological symptom (inability to feel pleasure) common in depression and schizophrenia, not a motor restlessness disorder. **High-Yield Clinical Pearls for NEET-PG:** * **Management of Akathisia:** The first-line treatment is **Beta-blockers (Propranolol)**. Centrally acting benzodiazepines or anticholinergics (Benztropine) are second-line. * **Timeline of EPS:** 1. **Acute Dystonia:** Hours to days. 2. **Akathisia:** Days to weeks. 3. **Drug-induced Parkinsonism:** Weeks to months. 4. **Tardive Dyskinesia:** Months to years (long-term use). * **Key Distinction:** Unlike Parkinsonian tremors, the "tremor" in akathisia is often just a manifestation of the constant urge to move.

Question 15: Which class of drugs is chiefly used for treating schizophrenia?

A. Antimaniac
B. Antidepressant
C. Antihistaminic
D. Antipsychotic (Correct Answer)

Explanation: **Explanation:** **Correct Answer: D. Antipsychotic** Schizophrenia is a chronic psychiatric disorder primarily characterized by dopaminergic hyperactivity in the mesolimbic pathway (leading to positive symptoms like hallucinations and delusions). **Antipsychotics** (also known as neuroleptics) are the mainstay of treatment. They work primarily by blocking **Dopamine (D2) receptors**, thereby normalizing dopamine signaling. They are categorized into First-Generation (Typical) and Second-Generation (Atypical) antipsychotics, the latter being preferred due to a lower risk of Extrapyramidal Side Effects (EPS). **Why other options are incorrect:** * **A. Antimaniac:** These drugs (e.g., Lithium, Valproate) are used to stabilize mood in Bipolar Affective Disorder (BPAD), specifically during manic episodes. * **B. Antidepressant:** These agents (e.g., SSRIs, SNRIs) increase serotonin or norepinephrine levels and are indicated for Major Depressive Disorder and Anxiety disorders. * **C. Antihistaminic:** While some first-generation antihistamines (e.g., Promethazine) have sedative properties, they are used for allergies, motion sickness, or as adjuncts for insomnia, not for treating the core symptoms of psychosis. **Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** For treatment-resistant schizophrenia, the DOC is **Clozapine**. * **Side Effects:** Typical antipsychotics (e.g., Haloperidol) are more likely to cause **EPS** (dystonia, akathisia, parkinsonism), while Atypical antipsychotics (e.g., Olanzapine) are associated with **metabolic syndrome** (weight gain, dyslipidemia). * **Dopamine Pathways:** Remember that blocking dopamine in the *mesolimbic* pathway treats psychosis, but blocking it in the *nigrostriatal* pathway causes EPS.

Question 16: Stevens-Johnson syndrome is a known side effect of which of the following medications?

A. Carbamazepine (Correct Answer)
B. Lithium
C. Clozapine
D. Clonazepam

Explanation: **Explanation:** **Stevens-Johnson Syndrome (SJS)** and its more severe variant, Toxic Epidermal Necrolysis (TEN), are life-threatening mucocutaneous reactions characterized by epidermal detachment. **Carbamazepine** is a notorious trigger for SJS, particularly in patients of Asian descent. This is strongly associated with the **HLA-B*1502 allele**; screening for this genetic marker is recommended before initiating treatment to mitigate risk. Other common psychiatric drugs causing SJS include Lamotrigine and Phenytoin. **Analysis of Incorrect Options:** * **Lithium:** Its most characteristic side effects include fine tremors, polyuria (nephrogenic diabetes insipidus), hypothyroidism, and teratogenicity (Ebstein’s anomaly). It does not typically cause SJS. * **Clozapine:** This atypical antipsychotic is most famously associated with **agranulocytosis** (requiring regular CBC monitoring), seizures, and myocarditis. * **Clonazepam:** As a benzodiazepine, its primary side effects are sedation, ataxia, and potential for dependence/withdrawal. Skin reactions are extremely rare. **Clinical Pearls for NEET-PG:** * **Lamotrigine** is the mood stabilizer with the highest risk of SJS if titrated too rapidly ("Start low, go slow"). * **HLA-B*1502** is the specific screening marker for Carbamazepine-induced SJS in Asian populations. * **HLA-A*3101** is another marker associated with Carbamazepine-induced hypersensitivity in Europeans. * If a patient on Carbamazepine or Lamotrigine develops a rash or mucosal involvement, the drug must be **stopped immediately**.

Question 17: Which of the following drugs is used in Electroconvulsive Therapy (ECT)?

A. Atropine (Correct Answer)
B. Labetalol
C. Clonazepam
D. Cefixime

Explanation: **Explanation:** In Electroconvulsive Therapy (ECT), **Atropine** is the standard premedication used as an **anticholinergic (antimuscarinic) agent**. Its primary role is to prevent the profound vagal stimulation (parasympathetic surge) that occurs during the initial tonic phase of the seizure. This prevents complications such as severe bradycardia, arrhythmias, and transient asystole. Additionally, it helps reduce tracheobronchial and salivary secretions, minimizing the risk of aspiration. **Analysis of Options:** * **A. Atropine (Correct):** Used to block vagal bradycardia and dry secretions. Glycopyrrolate is a common alternative as it does not cross the blood-brain barrier. * **B. Labetalol:** While beta-blockers are sometimes used to manage the secondary hypertensive surge (sympathetic phase) in high-risk cardiac patients, they are not a standard premedication for all ECT patients and can interfere with seizure duration. * **C. Clonazepam:** This is a benzodiazepine with potent anticonvulsant properties. It is generally avoided or tapered before ECT because it raises the seizure threshold, potentially making the treatment ineffective. * **D. Cefixime:** This is a third-generation cephalosporin antibiotic and has no role in the psychiatric or anesthetic management of ECT. **High-Yield NEET-PG Pearls:** * **Standard ECT Premedication Sequence:** Anticholinergic (Atropine) → Induction Agent (Methohexital is gold standard; Propofol/Thiopental are alternatives) → Muscle Relaxant (Succinylcholine is the drug of choice). * **Absolute Contraindication:** Increased Intracranial Pressure (ICP) is the only absolute contraindication for ECT. * **Most Common Side Effect:** Retrograde amnesia and post-ictal confusion. * **Gold Standard for Depression:** ECT is the most effective treatment for severe, treatment-resistant depression and catatonia.

Question 18: A 30-year-old man, recently started on haloperidol 30 mg/day, developed hyperpyrexia, muscle rigidity, akinesia, mutism, sweating, tachycardia, and increased blood pressure. Investigations showed increased WBC count and increased creatinine phosphokinase. There was no history of any other drug intake or signs of infection. What is the most likely diagnosis?

A. Drug overdose
B. Neuroleptic malignant syndrome (Correct Answer)
C. Drug induced Parkinsonism
D. Tardive dyskinesia

Explanation: ### Explanation The clinical presentation describes a classic case of **Neuroleptic Malignant Syndrome (NMS)**, a life-threatening idiosyncratic reaction to antipsychotic drugs (neuroleptics). **Why Option B is Correct:** NMS is characterized by a "tetrad" of clinical features, all of which are present in this patient: 1. **Hyperpyrexia (Fever):** Often >38°C. 2. **Muscle Rigidity:** Classically described as "lead-pipe" rigidity. 3. **Autonomic Instability:** Tachycardia, sweating (diaphoresis), and labile blood pressure. 4. **Altered Mental Status:** Ranging from confusion to mutism and coma. The laboratory findings of **elevated Creatinine Phosphokinase (CPK)** (due to muscle necrosis/rhabdomyolysis) and **Leukocytosis (increased WBC)** are hallmark diagnostic markers for NMS in the context of high-potency neuroleptics like Haloperidol. **Why Other Options are Incorrect:** * **A. Drug Overdose:** While Haloperidol overdose can cause sedation or extrapyramidal symptoms, it does not typically present with the specific combination of lead-pipe rigidity, hyperpyrexia, and markedly elevated CPK. * **C. Drug-induced Parkinsonism:** Presents with tremors, bradykinesia, and rigidity, but lacks the life-threatening autonomic instability, high fever, and elevated CPK seen here. * **D. Tardive Dyskinesia:** A late-onset side effect characterized by involuntary choreoathetoid movements (e.g., lip-smacking), not an acute febrile illness. **NEET-PG High-Yield Pearls:** * **Mechanism:** Thought to be due to massive dopamine (D2) blockade in the nigrostriatal pathway and hypothalamus. * **Treatment:** Immediate discontinuation of the offending drug (most important step), aggressive cooling, and hydration. * **Pharmacotherapy:** **Dantrolene** (muscle relaxant) or **Bromocriptine** (dopamine agonist). * **Mnemonic (FEVER):** **F**ever, **E**ncephalopathy, **V**itals unstable, **E**levated enzymes (CPK), **R**igidity.

Question 19: What is the normal therapeutic level of Lithium?

A. 0.5 to 0.7 mEq/litre
B. 0.7 to 1.1 mEq/litre (Correct Answer)
C. 0.1 to 0.3 mEq/litre
D. 1.5 to 2 mEq/litre

Explanation: **Explanation:** Lithium is the gold-standard mood stabilizer used for the treatment of Bipolar Affective Disorder (BPAD). It has a **narrow therapeutic index**, meaning the difference between a therapeutic dose and a toxic dose is very small. 1. **Why Option B is correct:** The standard therapeutic range for acute mania is generally **0.8 to 1.2 mEq/L**, while the maintenance range for prophylaxis is **0.6 to 1.0 mEq/L**. Option B (0.7 to 1.1 mEq/L) most accurately captures the window required to achieve clinical efficacy while minimizing side effects. 2. **Why other options are incorrect:** * **Option A (0.5–0.7):** This is often considered sub-therapeutic for acute episodes, though it may be used in elderly patients to avoid toxicity. * **Option C (0.1–0.3):** This level is clinically insignificant and will not provide a mood-stabilizing effect. * **Option D (1.5–2.0):** This range indicates **Lithium Toxicity**. Mild toxicity begins at >1.5 mEq/L, and levels >2.0 mEq/L are considered severe/life-threatening. **High-Yield Clinical Pearls for NEET-PG:** * **Sample Timing:** Blood for Serum Lithium levels must be drawn **12 hours after the last dose** (Trough level). * **Steady State:** It takes approximately **5 days** (5 half-lives) to reach a steady-state concentration. * **Monitoring:** Before starting Lithium, check Renal Function Tests (RFT), Thyroid Function Tests (TFT), and ECG (due to risk of T-wave flattening/inversion). * **Toxicity Triggers:** Dehydration, low-sodium diets, and drugs like **NSAIDs, Thiazides, and ACE inhibitors** can increase Lithium levels, leading to toxicity. * **Teratogenicity:** Use in pregnancy is associated with **Ebstein’s Anomaly** (atrialization of the right ventricle).

Question 20: A female suffering from psychosis, taking phenothiazines now complains of sudden onset of high grade fever, muscle rigidity, and altered sensorium. What is the diagnosis?

A. Malignant hyperthermia
B. Neuroleptic malignant syndrome (Correct Answer)
C. Tardive dyskinesia
D. Akathesia

Explanation: ### Explanation The clinical presentation of **high-grade fever, muscle rigidity ("lead-pipe" type), and altered sensorium** in a patient taking antipsychotics (phenothiazines) is a classic description of **Neuroleptic Malignant Syndrome (NMS)**. #### Why the Correct Answer is Right NMS is a life-threatening idiosyncratic reaction to dopamine antagonists (typical antipsychotics like Haloperidol or Phenothiazines). The underlying pathophysiology involves **massive dopamine blockade** in the nigrostriatal pathway (causing rigidity) and the hypothalamus (causing thermoregulatory failure/fever). * **Key Tetrad:** Fever, Rigidity, Mental status changes, and Autonomic instability (tachycardia, labile BP). * **Lab findings:** Elevated Creatine Phosphokinase (CPK) due to muscle necrosis and leukocytosis. #### Why Other Options are Incorrect * **Malignant Hyperthermia:** While it presents with fever and rigidity, it is triggered by **volatile inhalation anesthetics** (e.g., Halothane) or succinylcholine, not antipsychotics. It involves a genetic defect in the ryanodine receptor. * **Tardive Dyskinesia:** A late-onset extrapyramidal side effect characterized by involuntary choreoathetoid movements (e.g., lip-smacking), but it does not cause fever or rigidity. * **Akathisia:** A subjective feeling of inner restlessness and the urge to move. It is the most common extrapyramidal side effect but lacks systemic symptoms like fever. #### NEET-PG High-Yield Pearls * **Drug of Choice:** **Dantrolene** (muscle relaxant) or **Bromocriptine** (dopamine agonist). * **Immediate Step:** Stop the offending antipsychotic and provide aggressive cooling/hydration. * **Mnemonic (FEVER):** **F**ever, **E**ncephalopathy, **V**itals unstable, **E**levated CPK, **R**igidity. * **Differentiation:** Unlike Serotonin Syndrome, NMS is characterized by "lead-pipe" rigidity rather than hyperreflexia/myoclonus.

Question 21: Lithium is not used in the treatment of which of the following conditions?

A. Major depression
B. Vascular headache
C. Neutropenia
D. Generalized anxiety disorder (Correct Answer)

Explanation: **Explanation:** Lithium is a monovalent cation primarily used as a mood stabilizer. The correct answer is **Generalized Anxiety Disorder (GAD)** because Lithium has no established efficacy in treating primary anxiety disorders. GAD is typically managed with SSRIs, SNRIs, or benzodiazepines. **Analysis of Options:** * **Major Depression (A):** Lithium is a well-established **augmentation agent** for treatment-resistant depression. When added to an antidepressant, it can enhance the therapeutic response. It also significantly reduces suicidal ideation in depressed patients. * **Vascular Headache (B):** Lithium is an effective prophylactic treatment for **Cluster Headaches** (a type of vascular headache), particularly the chronic variety. It helps regulate the circadian rhythmicity associated with these attacks. * **Neutropenia (C):** A common side effect of Lithium is **leukocytosis** (specifically increasing the neutrophil count by stimulating granulopoiesis). This "side effect" is utilized therapeutically to treat idiopathic neutropenia or chemotherapy-induced neutropenia. **High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Index:** Lithium has a narrow therapeutic index (0.6–1.2 mEq/L). Toxicity starts >1.5 mEq/L. * **Drug of Choice:** It remains the gold standard for the prophylaxis of Bipolar Affective Disorder (BPAD) and for reducing suicide risk. * **Teratogenicity:** Use in pregnancy is associated with **Ebstein’s Anomaly** (atrialization of the right ventricle). * **Monitoring:** Before starting Lithium, always check **Thyroid Function Tests (TFT)** and **Renal Function Tests (RFT)**, as it can cause hypothyroidism and nephrogenic diabetes insipidus.

Question 22: Which of the following is/are not a side effect of lithium?

A. Seizure
B. Hyporeflexia (Correct Answer)
C. Nephrogenic diabetes insipidus
D. Alopecia

Explanation: **Explanation:** Lithium is a gold-standard mood stabilizer with a narrow therapeutic index (0.6–1.2 mEq/L). Understanding its side effects is crucial for NEET-PG, as toxicity often manifests through neurological and renal symptoms. **Why Hyporeflexia is the Correct Answer:** Lithium toxicity characteristically causes **Hyperreflexia**, not hyporeflexia. As lithium levels rise, patients develop neuromuscular irritability, leading to tremors, ataxia, myoclonus, and brisk deep tendon reflexes (hyperreflexia). Hyporeflexia is more commonly associated with magnesium toxicity or certain sedative-hypnotic overdoses. **Analysis of Incorrect Options:** * **Seizure (A):** Lithium lowers the seizure threshold. In cases of severe toxicity (>2.5 mEq/L), neurological complications like seizures, encephalopathy, and coma are common. * **Nephrogenic Diabetes Insipidus (C):** This is the most common renal side effect. Lithium accumulates in the collecting ducts and interferes with ADH (Vasopressin) action, leading to polyuria and polydipsia. * **Alopecia (D):** Dermatological side effects of Lithium include thinning of hair (alopecia), acneiform eruptions, and the exacerbation of psoriasis. **High-Yield Clinical Pearls for NEET-PG:** * **L-I-T-H-I-U-M Mnemonic for Side Effects:** **L**eukocytosis, **I**nsipidus (NDI), **T**remors/Teratogenicity (Ebstein’s Anomaly), **H**ypothyroidism, **I**ncreased Weight, **U**nderactive Heart (Bradycardia/T-wave flattening), **M**uscle twitching/Hyperreflexia. * **Drug Interactions:** Thiazides, NSAIDs, and ACE inhibitors increase Lithium levels (decreasing clearance), while Caffeine and Theophylline decrease levels. * **Monitoring:** Thyroid Function Tests (TFT) and Renal Function Tests (RFT) must be performed before and during treatment.

Question 23: Which antipsychotic medication is associated with fewer extrapyramidal side effects?

A. Loxapine
B. Pimozide
C. Quetiapine (Correct Answer)
D. Risperidone

Explanation: ### Explanation **Correct Answer: C. Quetiapine** The risk of **Extrapyramidal Side Effects (EPS)** is primarily determined by a drug’s affinity for and occupancy of **Dopamine D2 receptors** in the nigrostriatal pathway. **Quetiapine** is a Second-Generation Antipsychotic (SGA) characterized by "loose" binding and rapid dissociation from D2 receptors. It also possesses potent **5-HT2A receptor antagonism**, which increases dopamine release in the striatum, further mitigating EPS. Among all antipsychotics, Quetiapine and Clozapine carry the lowest risk of EPS, making Quetiapine the drug of choice for treating psychosis in patients with **Parkinson’s Disease**. **Analysis of Incorrect Options:** * **A. Loxapine:** A typical (first-generation) antipsychotic of the dibenzoxazepine class. It has a high D2 affinity and a significant risk of EPS, especially at higher doses. * **B. Pimozide:** A high-potency typical antipsychotic used primarily for Tourette’s syndrome and Delusional Disorder (Monosymptomatic hypochondriacal psychosis). It has a very high risk of EPS and QT prolongation. * **C. Risperidone:** While an SGA, Risperidone is "atypical" only at low doses. At doses >6mg, its D2 occupancy increases significantly, making it the SGA with the **highest risk of EPS** and hyperprolactinemia. **High-Yield Clinical Pearls for NEET-PG:** * **Lowest EPS Risk:** Clozapine > Quetiapine. * **Highest EPS Risk (Typical):** Haloperidol, Fluphenazine. * **Highest EPS Risk (Atypical):** Risperidone. * **Metabolic Syndrome:** Quetiapine and Olanzapine carry high risks of weight gain and dyslipidemia (Clozapine is highest). * **Drug of Choice for Psychosis in Parkinson’s:** Quetiapine (Clozapine is also effective but requires blood monitoring).

Question 24: Administration of which of the following drugs requires monitoring?

A. Lithium (Correct Answer)
B. Haloperidol
C. Diazepam
D. Acetazolamide

Explanation: **Explanation:** **Lithium** is the correct answer because it is a drug with a **narrow therapeutic index**, meaning the difference between a therapeutic dose and a toxic dose is very small. Regular **Therapeutic Drug Monitoring (TDM)** is mandatory to ensure efficacy and prevent toxicity. The therapeutic range for Lithium is typically **0.6 to 1.2 mEq/L**. Levels above 1.5 mEq/L are considered toxic, and levels above 2.0 mEq/L constitute a medical emergency. **Incorrect Options:** * **Haloperidol:** A typical antipsychotic. While it requires monitoring for extrapyramidal side effects (EPS), it does not require routine blood level monitoring. * **Diazepam:** A benzodiazepine used for anxiety and seizures. It has a wide therapeutic window; monitoring is clinical (respiratory rate/sedation) rather than through blood levels. * **Acetazolamide:** A carbonic anhydrase inhibitor used in glaucoma and altitude sickness. It requires monitoring of electrolytes (potassium/bicarbonate) in specific cases, but not routine drug level monitoring. **High-Yield Clinical Pearls for NEET-PG:** * **Sample Timing:** Lithium levels should be checked **12 hours after the last dose** (Trough level). * **Steady State:** It takes about **5 days** (5 half-lives) to reach a steady state before the first level should be checked. * **Toxicity Triggers:** Dehydration, low-sodium diets, and drugs like **NSAIDs, Thiazides, and ACE inhibitors** can increase Lithium levels, leading to toxicity. * **Side Effects:** Look for "LITH" mnemonic: **L**eukocytosis, **I**nsipidus (Diabetes Insipidus), **T**remors/Teratogenicity (Ebstein's Anomaly), **H**ypothyroidism.

Question 25: What is the drug of choice for psychosis in Parkinson's disease?

A. Clozapine (Correct Answer)
B. Haloperidol
C. Lithium
D. Risperidone

Explanation: ### Explanation **1. Why Clozapine is the Correct Answer:** Psychosis in Parkinson’s Disease (PD) is often a side effect of dopaminergic therapy (like Levodopa). The management is challenging because traditional antipsychotics block **D2 receptors** in the nigrostriatal pathway, which severely worsens motor symptoms (rigidity and tremors). **Clozapine** is the drug of choice because it has a very **low affinity for D2 receptors** and a high affinity for D4 and 5-HT2 receptors. This allows it to treat psychotic symptoms (hallucinations/delusions) without exacerbating the underlying motor deficits of Parkinsonism. **2. Why the Other Options are Incorrect:** * **B. Haloperidol:** This is a high-potency typical antipsychotic with strong D2 blockade. It is strictly contraindicated in PD as it can cause acute worsening of motor symptoms and potentially lead to a rigid, akinetic state. * **C. Lithium:** Lithium is a mood stabilizer used primarily for Bipolar Disorder. It has no role in treating acute psychosis and can sometimes cause tremors, which would complicate the PD clinical picture. * **D. Risperidone:** While an atypical antipsychotic, Risperidone has a dose-dependent D2 blockade. Even at low doses, it carries a significant risk of inducing Extrapyramidal Side Effects (EPS) in PD patients compared to Clozapine. **3. High-Yield Clinical Pearls for NEET-PG:** * **Pimavanserin:** A selective serotonin inverse agonist (SSIA) that targets 5-HT2A receptors. It is the only FDA-approved drug specifically for PD-associated psychosis that does not touch dopamine receptors at all. (If both Clozapine and Pimavanserin are options, Pimavanserin is often preferred in modern guidelines, but Clozapine remains the classic "gold standard" in exams). * **Quetiapine:** Often used in clinical practice as a first-line alternative to Clozapine because it does not require mandatory blood monitoring (for agranulocytosis), though Clozapine is more efficacious. * **Rule of Thumb:** In PD patients, always avoid "Typical" antipsychotics and high-potency "Atypicals" (like Risperidone or Olanzapine).

Question 26: Which of the following drugs is used for lithium-induced tremors?

A. Valproate
B. Propranolol (Correct Answer)
C. Trihexyphenidyl
D. Tetrabenazine

Explanation: **Explanation:** **Lithium-induced tremors** are a common side effect of lithium therapy, typically presenting as a fine, symmetric, postural tremor of the hands. 1. **Why Propranolol is Correct:** The physiological mechanism behind lithium-induced tremors is thought to involve the stimulation of peripheral **beta-adrenergic receptors**. **Propranolol**, a non-selective beta-blocker, is the drug of choice because it effectively antagonizes these receptors, reducing the amplitude of the tremor. It is preferred over cardioselective beta-blockers because it crosses the blood-brain barrier and acts on both peripheral and central components of the tremor. 2. **Why Other Options are Incorrect:** * **Valproate:** While used as a mood stabilizer like lithium, it can actually *cause* or worsen tremors rather than treat them. * **Trihexyphenidyl:** This is an anticholinergic used for Parkinsonian (resting) tremors or extrapyramidal symptoms (EPS) caused by antipsychotics. Lithium tremors are postural, not Parkinsonian, and do not respond to anticholinergics. * **Tetrabenazine:** This is a VMAT2 inhibitor used for hyperkinetic movement disorders like Huntington’s chorea or Tardive Dyskinesia; it has no role in managing lithium toxicity or side effects. **High-Yield Clinical Pearls for NEET-PG:** * **Fine Tremors:** Occur at therapeutic lithium levels (0.6–1.2 mEq/L). * **Coarse Tremors:** A hallmark sign of **Lithium Toxicity** (>1.5 mEq/L); the first step in management is to check serum lithium levels. * **Management Tip:** Before starting Propranolol, always try reducing the lithium dose or switching to a sustained-release preparation. * **Contraindication:** Avoid Propranolol in patients with bronchial asthma or bradycardia.

Question 27: Malignant neuroleptic syndrome is caused by:

A. Antidepressants
B. Anxiolytics
C. Antipsychotics (Correct Answer)
D. Antiepileptics

Explanation: **Explanation:** **Neuroleptic Malignant Syndrome (NMS)** is a rare but life-threatening idiosyncratic reaction to **Antipsychotics** (Neuroleptics). The underlying pathophysiology involves a profound **blockade of central Dopamine (D2) receptors** in the nigrostriatal pathway and hypothalamus. This leads to the classic clinical tetrad: **Muscle rigidity** ("Lead-pipe" rigidity), **Hyperthermia** (fever), **Autonomic instability** (tachycardia, labile BP), and **Altered mental status**. **Why other options are incorrect:** * **Antidepressants:** These are typically associated with **Serotonin Syndrome**, which presents with hyperreflexia and myoclonus rather than the "lead-pipe" rigidity seen in NMS. * **Anxiolytics:** Benzodiazepines are actually used in the supportive management of NMS to control agitation and muscle spasms. * **Antiepileptics:** While some (like Carbamazepine) have complex side effect profiles, they do not cause the dopamine-depletion state characteristic of NMS. **High-Yield Clinical Pearls for NEET-PG:** * **Most Common Cause:** High-potency typical antipsychotics (e.g., **Haloperidol**), though atypical antipsychotics can also cause it. * **Key Lab Finding:** Significantly elevated **Creatine Phosphokinase (CPK)** levels due to muscle necrosis (rhabdomyolysis). * **Treatment of Choice:** 1. Immediate discontinuation of the offending agent. 2. **Dantrolene** (muscle relaxant) or **Bromocriptine** (Dopamine agonist). * **Differential Diagnosis:** NMS can also be triggered by the **sudden withdrawal of Levodopa** in Parkinson’s patients.

Question 28: What is the most common complication of electroconvulsive therapy?

A. Antegrade amnesia
B. Retrograde amnesia (Correct Answer)
C. Depression
D. Cognitive defects

Explanation: **Explanation:** Electroconvulsive therapy (ECT) is a highly effective treatment for severe depression and psychosis, but it is associated with specific cognitive side effects. **Why Retrograde Amnesia is correct:** Retrograde amnesia (loss of memory for events occurring *before* the treatment) is the **most common** and characteristic side effect of ECT. It typically follows **Ribot’s Law**, where recent memories are more vulnerable than remote ones. While most memory functions recover within weeks, some gaps in memory for events immediately preceding the ECT course may persist permanently. **Analysis of Incorrect Options:** * **Antegrade Amnesia:** This refers to the inability to form new memories *after* the treatment. While it occurs during the course of ECT, it is usually transient and resolves much faster than retrograde amnesia (typically within 1–2 weeks post-treatment). * **Depression:** ECT is an *indication* for depression, not a complication. It is the most effective treatment for treatment-resistant depression and suicidal ideation. * **Cognitive Defects:** While "cognitive impairment" is a broad term that includes memory loss, it is not the specific "most common" complication. Modern techniques (brief pulse, unilateral electrode placement) have significantly minimized global cognitive deficits. **High-Yield Clinical Pearls for NEET-PG:** * **Most common side effect overall:** Confusion (post-ictal) and Headache. * **Most common memory deficit:** Retrograde amnesia. * **Mortality rate:** Approximately 0.01% (similar to minor surgery under general anesthesia); usually due to cardiovascular complications. * **Electrode placement:** Unilateral (d'Elia placement) causes less memory impairment than bilateral (Bifrontotemporal) placement. * **Absolute Contraindication:** Increased Intracranial Pressure (ICP).

Question 29: What is the drug of choice for the treatment of neuroleptic malignant syndrome?

A. Dantrolene (Correct Answer)
B. Beta blocker
C. Central anticholinergic
D. None of the above

Explanation: **Explanation:** **Neuroleptic Malignant Syndrome (NMS)** is a life-threatening idiosyncratic reaction to antipsychotic drugs (dopamine antagonists). It is characterized by the clinical tetrad of **muscle rigidity ("lead-pipe"), hyperthermia, autonomic instability, and altered mental status.** **1. Why Dantrolene is the Correct Answer:** The primary goal in treating NMS is the immediate cessation of the offending agent and supportive care. **Dantrolene** is the specific pharmacological drug of choice. It is a direct-acting skeletal muscle relaxant that works by binding to the ryanodine receptor (RyR1), inhibiting the release of calcium from the sarcoplasmic reticulum. This reduces muscle rigidity and heat production, directly addressing the hyperthermia and rhabdomyolysis associated with NMS. **2. Why Other Options are Incorrect:** * **Beta-blockers:** While they may help manage tachycardia, they do not address the underlying pathophysiology of muscle rigidity or dopamine deficiency. * **Central Anticholinergics (e.g., Benztropine):** These are used for Extrapyramidal Symptoms (EPS) like acute dystonia. However, in NMS, they are generally avoided as they can worsen hyperthermia by inhibiting sweating. **3. High-Yield Clinical Pearls for NEET-PG:** * **Dopamine Agonists:** **Bromocriptine** or Amantadine are also used to restore dopaminergic tone. * **Lab Findings:** Look for significantly elevated **Creatine Phosphokinase (CPK)** levels and leukocytosis. * **NMS vs. Serotonin Syndrome:** NMS features "lead-pipe" rigidity and bradyreflexia, whereas Serotonin Syndrome features hyperreflexia and myoclonus. * **First Step in Management:** Immediate discontinuation of the antipsychotic drug.

Question 30: A 30-year-old patient with mania, prescribed haloperidol one week ago, has become restless and has been pacing for the last day. On examination, hand tremors are noted. What is the most likely diagnosis?

A. Anhedonia
B. Dystonia
C. Restless leg syndrome
D. Akathisia (Correct Answer)

Explanation: ### Explanation **Correct Answer: D. Akathisia** **Why it is correct:** Akathisia is a common **Extrapyramidal Side Effect (EPS)** associated with high-potency first-generation antipsychotics like Haloperidol. It is characterized by a subjective feeling of inner restlessness and an objective need to move. Clinically, this manifests as pacing, inability to sit still, or shifting weight from foot to foot. It typically occurs within days to weeks of starting or increasing the dose of an antipsychotic. The presence of hand tremors in this patient suggests concurrent drug-induced parkinsonism, which often co-exists with akathisia. **Why the other options are incorrect:** * **A. Anhedonia:** This refers to the inability to feel pleasure, a core symptom of depression or negative symptoms of schizophrenia, not a motor side effect. * **B. Dystonia:** Acute dystonia involves sudden, involuntary, sustained muscle contractions (e.g., torticollis, oculogyric crisis). It usually occurs within hours to the first few days of treatment, rather than presenting as continuous pacing. * **C. Restless Leg Syndrome (RLS):** While clinically similar, RLS typically occurs at night, is associated with uncomfortable sensations in the legs, and is relieved by movement. Akathisia is persistent throughout the day and is specifically linked to dopamine-blocking agents. **NEET-PG High-Yield Pearls:** * **Drug of Choice (DOC):** For Akathisia, the first-line treatment is **Propranolol** (Beta-blocker). Centrally acting anticholinergics (like Benztropine) are less effective for akathisia than for dystonia. * **Timeline of EPS:** 1. **Acute Dystonia:** Hours to days. 2. **Akathisia:** Days to weeks. 3. **Parkinsonism:** Weeks to months. 4. **Tardive Dyskinesia:** Months to years (long-term use). * **Mechanism:** Akathisia is thought to result from dopamine (D2) blockade in the nigrostriatal pathway.

Question 31: What is the most common receptor for typical antipsychotics?

A. Dopamine receptor 1 (D1)
B. Dopamine receptor 2 (D2) (Correct Answer)
C. Dopamine receptor 3 (D3)
D. Dopamine receptor 4 (D4)

Explanation: ### Explanation **Correct Option: B. Dopamine receptor 2 (D2)** The therapeutic efficacy of **typical (first-generation) antipsychotics** (e.g., Haloperidol, Chlorpromazine) is primarily attributed to their potent antagonism of **D2 receptors** in the **mesolimbic pathway**. According to the Dopamine Hypothesis of Schizophrenia, positive symptoms (hallucinations and delusions) result from overactivity in this pathway. Clinical studies show that for an antipsychotic to be effective, it must typically block approximately **60–80% of D2 receptors** in the brain. **Why other options are incorrect:** * **D1 Receptors:** While some antipsychotics (like Phenothiazines) have a mild affinity for D1, it is not the primary target for clinical efficacy in treating psychosis. * **D3 Receptors:** These are primarily located in the limbic system. While some newer atypical agents (like Cariprazine) target D3, typical antipsychotics do not primarily act here. * **D4 Receptors:** This receptor gained fame due to **Clozapine’s** high affinity for it. However, typical antipsychotics have a much higher affinity for D2 than D4. **High-Yield NEET-PG Clinical Pearls:** 1. **The "D2 Paradox":** While D2 blockade in the *mesolimbic* pathway treats psychosis, blockade in the *nigrostriatal* pathway leads to **Extrapyramidal Side Effects (EPS)**, and blockade in the *tuberoinfundibular* pathway causes **Hyperprolactinemia**. 2. **Potency:** The clinical potency of a typical antipsychotic is directly proportional to its D2 receptor binding affinity (e.g., Haloperidol is high-potency; Chlorpromazine is low-potency). 3. **Atypical Antipsychotics:** Unlike typicals, atypical antipsychotics (SGAs) are defined by a high **5-HT2A to D2 receptor blockade ratio**, which reduces the risk of EPS.

Question 32: Which drug possesses both antidepressant and antipsychotic properties?

A. Buspirone
B. Amoxapine (Correct Answer)
C. Trazodone
D. Minaserine

Explanation: **Explanation:** **Amoxapine** is a tetracyclic antidepressant (TeCA) and is a metabolite of the antipsychotic drug loxapine. It is unique because it possesses a dual mechanism of action: 1. **Antidepressant property:** It inhibits the reuptake of norepinephrine (and to a lesser extent, serotonin), similar to tricyclic antidepressants. 2. **Antipsychotic property:** Unlike other antidepressants, it significantly blocks **Dopamine D2 receptors**. Due to this dual action, Amoxapine is the drug of choice for **Psychotic Depression** (Major Depressive Disorder with psychotic features). **Analysis of Incorrect Options:** * **Buspirone (A):** An anxiolytic that acts as a partial agonist at 5-HT1A receptors. It lacks D2 blocking (antipsychotic) properties. * **Trazodone (C):** A Serotonin Antagonist and Reuptake Inhibitor (SARI). It is primarily used as an antidepressant and for its sedative properties in insomnia; it does not have antipsychotic efficacy. * **Mianserin (D):** A tetracyclic antidepressant that blocks alpha-2 adrenergic receptors. While it shares a chemical class with Amoxapine, it does not possess significant D2 receptor antagonism. **High-Yield Clinical Pearls for NEET-PG:** * **Side Effects:** Because of its D2 blocking activity, Amoxapine can cause **Extrapyramidal Side Effects (EPS)**, such as parkinsonism or akathisia, and hyperprolactinemia—side effects not typically seen with other antidepressants. * **Metabolism:** Remember that Amoxapine is the N-demethylated metabolite of **Loxapine**. * **Clinical Use:** Always consider Amoxapine or a combination of an SSRI + Antipsychotic for patients presenting with "delusional depression."

Question 33: Which of the following drug classes is most useful for acute depression and has a good side effect profile?

A. Reversible Inhibitors of Monoamine Oxidase A (RIMA)
B. Selective Serotonin Reuptake Inhibitors (SSRIs) (Correct Answer)
C. Tricyclic Antidepressants
D. Non-selective Monoamine Oxidase Inhibitors (MAO-inhibitors)

Explanation: **Explanation:** **Selective Serotonin Reuptake Inhibitors (SSRIs)** are considered the first-line treatment for acute depression. Their primary mechanism involves inhibiting the presynaptic reuptake of serotonin (5-HT), thereby increasing its availability in the synaptic cleft. They are preferred because they possess a **high therapeutic index**, lack significant anticholinergic or cardiotoxic effects, and are safe in overdose, making them the gold standard for both efficacy and tolerability. **Analysis of Incorrect Options:** * **Tricyclic Antidepressants (TCAs):** While highly effective, they have a narrow therapeutic index. They cause significant side effects (sedation, weight gain, dry mouth) and are **lethal in overdose** due to cardiotoxicity (arrhythmias via sodium channel blockade). * **Non-selective MAO-Is:** These are rarely used first-line due to the risk of **Hypertensive Crisis** ("Cheese Reaction") when taken with tyramine-rich foods and the risk of Serotonin Syndrome. * **RIMA (e.g., Moclobemide):** Although safer than non-selective MAO-Is, they are generally considered second-line or adjunctive and do not have the extensive clinical evidence base or "all-rounder" profile of SSRIs for acute depression. **High-Yield Clinical Pearls for NEET-PG:** * **Most common side effect of SSRIs:** Gastrointestinal upset (nausea/diarrhea) and sexual dysfunction. * **Drug of choice (DOC)** for Depression in patients with recent Myocardial Infarction: **Sertraline**. * **Fluoxetine** has the longest half-life, reducing the risk of discontinuation syndrome. * **Fluvoxamine** is specifically preferred for Obsessive-Compulsive Disorder (OCD).

Question 34: All of the following are typical antipsychotics, EXCEPT?

A. Risperidone (Correct Answer)
B. Haloperidol
C. Chlorpromazine
D. Pimozide

Explanation: **Explanation:** The classification of antipsychotics is based on their mechanism of action and side-effect profiles. Antipsychotics are divided into **Typical (First Generation)** and **Atypical (Second Generation)**. **1. Why Risperidone is the correct answer:** Risperidone is an **Atypical Antipsychotic**. Unlike typical agents that primarily block Dopamine (D2) receptors, atypical antipsychotics like Risperidone act as **Serotonin-Dopamine Antagonists (SDAs)**. They block both 5-HT2A and D2 receptors. This dual action helps reduce negative symptoms of schizophrenia and significantly lowers the risk of Extrapyramidal Side Effects (EPS) compared to typical agents. **2. Analysis of Incorrect Options (Typical Antipsychotics):** * **Haloperidol:** A high-potency typical antipsychotic and a potent D2 blocker. It is frequently used in acute psychosis but has a high incidence of EPS. * **Chlorpromazine:** A low-potency typical antipsychotic (the first ever discovered). It is known for causing significant sedation and orthostatic hypotension due to alpha-1 blockade. * **Pimozide:** A high-potency typical antipsychotic often used specifically for Tourette’s disorder and delusional parasitosis. **Clinical Pearls for NEET-PG:** * **Mechanism:** Typical = D2 blockade; Atypical = 5-HT2A + D2 blockade. * **Side Effects:** Typical drugs are associated with **EPS** and Hyperprolactinemia; Atypical drugs (except Ziprasidone/Aripiprazole) are associated with **Metabolic Syndrome** (weight gain, dyslipidemia). * **Risperidone Specific:** Among atypicals, Risperidone has the highest risk of causing **Hyperprolactinemia** and dose-dependent EPS. * **Clozapine:** The "Gold Standard" for treatment-resistant schizophrenia; watch for **agranulocytosis** (requires mandatory WBC monitoring).

Question 35: A 30-year-old patient with schizophrenia on antipsychotics presents with amenorrhea and galactorrhea. Which of the following antipsychotics should she be shifted to?

A. Haloperidol
B. Olanzapine
C. Risperidone
D. Aripiprazole (Correct Answer)

Explanation: ### Explanation The patient is experiencing **hyperprolactinemia** (manifesting as amenorrhea and galactorrhea), a common side effect of antipsychotics that block dopamine ($D_2$) receptors in the **tuberoinfundibular pathway**. Dopamine normally acts as a prolactin-inhibiting factor; blocking it leads to increased prolactin levels. **Why Aripiprazole is the correct answer:** Aripiprazole is a **partial $D_2$ receptor agonist**. Unlike pure antagonists, it provides enough dopaminergic tone to inhibit the excessive release of prolactin from the anterior pituitary. It is considered "prolactin-neutral" and is the drug of choice when switching a patient who has developed symptomatic hyperprolactinemia on other antipsychotics. **Analysis of Incorrect Options:** * **Haloperidol (Option A):** A high-potency typical antipsychotic and a strong $D_2$ antagonist. It is one of the most common causes of significant hyperprolactinemia. * **Risperidone (Option C):** Among atypical antipsychotics, Risperidone is the **most notorious** for causing hyperprolactinemia (often comparable to typical antipsychotics) because it crosses the blood-brain barrier poorly but binds strongly to $D_2$ receptors in the pituitary gland. * **Olanzapine (Option B):** While it has a lower risk than Risperidone or Haloperidol, it can still cause mild to moderate elevations in prolactin. It is not the preferred "switch" drug compared to Aripiprazole. **High-Yield Clinical Pearls for NEET-PG:** * **Tuberoinfundibular Pathway:** Responsible for prolactin control (Antipsychotics $\rightarrow$ Blockade $\rightarrow$ Hyperprolactinemia). * **Nigrostriatal Pathway:** Responsible for Extrapyramidal Symptoms (EPS). * **Mesolimbic Pathway:** Target for treating positive symptoms of schizophrenia. * **Drug of Choice for Hyperprolactinemia:** Aripiprazole (or Quetiapine as an alternative). * **Most Prolactin-Sparing:** Aripiprazole. * **Most Prolactin-Elevating (Atypical):** Risperidone and Paliperidone.

Question 36: What is the drug of choice for a schizophrenic patient with poor oral absorption?

A. Haloperidol
B. Fluphenazine (Correct Answer)
C. Clozapine
D. Olanzapine

Explanation: **Explanation:** The core clinical challenge in a patient with **poor oral absorption** (due to malabsorption syndromes, gastrointestinal issues, or non-compliance) is ensuring therapeutic drug levels. This necessitates the use of **Parenteral (Injectable) Long-Acting Depot** formulations. **1. Why Fluphenazine is Correct:** Fluphenazine is a potent typical antipsychotic available in a **decanoate** (depot) form. It is specifically designed for intramuscular administration, bypassing the gastrointestinal tract entirely. This ensures 100% bioavailability and steady-state plasma concentrations, making it the ideal choice for patients who cannot absorb oral medications effectively. **2. Analysis of Incorrect Options:** * **Haloperidol (A):** While Haloperidol also has a depot form (Haloperidol Decanoate), **Fluphenazine** is traditionally cited in classic psychiatric teaching and NEET-PG patterns as the prototypical long-acting injectable for absorption issues. Furthermore, Haloperidol is often used for acute agitation (short-acting), whereas Fluphenazine is synonymous with long-term maintenance in malabsorption. * **Clozapine (C):** This is the "Gold Standard" for **treatment-resistant schizophrenia**. However, it is only available in oral forms (tablets/suspensions) and requires strict hematological monitoring (ANC counts). It cannot be used if oral absorption is compromised. * **Olanzapine (D):** Although an injectable form exists (Relprevv), it is rarely the first choice due to the risk of **Post-injection Delirium Sedation Syndrome (PDSS)**, requiring 3 hours of mandatory observation. **Clinical Pearls for NEET-PG:** * **Drug of Choice for Treatment-Resistant Schizophrenia:** Clozapine. * **Antipsychotic with least Extrapyramidal Side Effects (EPS):** Quetiapine (often used in Parkinson’s). * **Most common side effect of Clozapine:** Sialorrhea (excessive salivation). * **Most serious side effect of Clozapine:** Agranulocytosis and Seizures (dose-dependent). * **Depot formulations** are the treatment of choice for **non-compliant** patients.

Question 37: Which of the following psychotropic drugs requires monitoring for hematotoxic effects?

A. Buspirone
B. Clozapine (Correct Answer)
C. Haloperidol
D. Lithium carbonate

Explanation: **Explanation:** **Clozapine** is the correct answer because it is associated with a significant risk of **agranulocytosis** (a severe decrease in white blood cell count), which occurs in approximately 1% of patients. It is an atypical antipsychotic reserved for treatment-resistant schizophrenia. Due to its hematotoxic potential, mandatory monitoring of the **Absolute Neutrophil Count (ANC)** is required (weekly for the first 6 months, then biweekly, then monthly) to prevent life-threatening infections. **Analysis of Incorrect Options:** * **Buspirone:** An anxiolytic (5-HT1A partial agonist) primarily known for lacking sedative or addictive properties; it does not cause bone marrow suppression. * **Haloperidol:** A typical antipsychotic (D2 blocker) known for Extrapyramidal Side Effects (EPS) and Hyperprolactinemia, but it is not associated with hematotoxicity. * **Lithium Carbonate:** Used in Bipolar Disorder. While it requires monitoring, it is for **renal, thyroid, and serum drug levels**. Interestingly, Lithium causes *leukocytosis* (increased WBC count), the opposite of hematotoxicity, and is sometimes used to treat clozapine-induced neutropenia. **High-Yield Clinical Pearls for NEET-PG:** * **Clozapine Monitoring:** Treatment must be interrupted if ANC falls below **1500/mm³**. * **Side Effect Profile:** Clozapine is the only antipsychotic that **reduces suicide risk** but carries a "5-Black Box Warning" for: Agranulocytosis, Seizures, Myocarditis, Orthostatic Hypotension, and Increased mortality in elderly patients with dementia. * **Sialorrhea:** Hypersalivation is a unique and common side effect of Clozapine.

Question 38: A 28-year-old patient presents with a 3-month history of suspiciousness, auditory hallucinations, aggression, and poor sleep and appetite. An ECG revealed a QTc of 480 ms. Which of the following medications should be avoided in this patient?

A. Ziprasidone (Correct Answer)
B. Aripiprazole
C. Clozapine
D. Risperidone

Explanation: **Explanation:** The patient presents with symptoms of psychosis (suspiciousness, hallucinations, aggression) and an **ECG showing a QTc interval of 480 ms**. In clinical practice, a QTc interval >450 ms in men or >470 ms in women is considered prolonged. Starting medications that further prolong the QT interval increases the risk of **Torsades de Pointes (TdP)**, a life-threatening ventricular arrhythmia. **Why Ziprasidone is the correct answer:** Among the atypical antipsychotics, **Ziprasidone** is most strongly associated with dose-dependent QTc prolongation. It is contraindicated in patients with a known history of QT prolongation, recent myocardial infarction, or uncompensated heart failure. Given this patient’s baseline QTc of 480 ms, Ziprasidone must be avoided. **Analysis of Incorrect Options:** * **Aripiprazole:** This is considered one of the "QT-neutral" antipsychotics. It has a very low risk of cardiac conduction issues and is often a preferred choice in patients with cardiac concerns. * **Clozapine:** While Clozapine can cause myocarditis or tachycardia, its effect on the QTc interval is significantly less than that of Ziprasidone. * **Risperidone:** Risperidone can cause mild QTc prolongation, but the effect is generally negligible at standard doses compared to Ziprasidone. **High-Yield Clinical Pearls for NEET-PG:** * **Highest QTc Risk (IV):** IV Haloperidol (highest risk among all). * **Highest QTc Risk (Oral):** Thioridazine (Typical) and Ziprasidone (Atypical). * **Safest/QT-Neutral:** Aripiprazole, Lurasidone, and Olanzapine. * **Monitoring:** Always check electrolytes (Hypokalemia and Hypomagnesemia) as they exacerbate drug-induced QT prolongation.

Question 39: Which of the following are atypical (second generation or newer) antipsychotics?

A. Aripiprazole
B. Risperidone
C. Olanzapine
D. All of the above (Correct Answer)

Explanation: **Explanation:** The correct answer is **D (All of the above)**. Antipsychotics are broadly classified into First Generation (Typical) and Second Generation (Atypical) based on their mechanism of action and side-effect profiles. **1. Why the options are correct:** * **Aripiprazole:** A unique atypical antipsychotic known as a **D2 partial agonist**. It also acts as a 5-HT1A agonist and 5-HT2A antagonist. It is often called a "dopamine stabilizer." * **Risperidone:** A potent **D2 and 5-HT2A antagonist**. It is one of the most commonly used atypicals but has a higher risk of prolactin elevation compared to others in its class. * **Olanzapine:** A MARTA (Multi-Acting Receptor Targeted Antagonist) that acts on D2, 5-HT2A, H1, and Muscarinic receptors. It is highly effective but associated with significant **metabolic side effects** (weight gain, dyslipidemia). **2. Underlying Medical Concept:** Unlike Typical antipsychotics (e.g., Haloperidol), which primarily block D2 receptors in the mesolimbic and nigrostriatal pathways, **Atypical antipsychotics** are characterized by **Serotonin-Dopamine Antagonism (SDA)**. By blocking 5-HT2A receptors, they increase dopamine release in the nigrostriatal and mesocortical pathways, which reduces Extrapyramidal Side Effects (EPS) and helps improve the negative symptoms of schizophrenia. **High-Yield NEET-PG Clinical Pearls:** * **Clozapine:** The "Gold Standard" for treatment-resistant schizophrenia; requires monitoring for **agranulocytosis** (absolute neutrophil count). * **Quetiapine:** Preferred in Parkinson’s disease patients with psychosis due to low EPS risk. * **Ziprasidone:** Notable for causing **QTc prolongation**; should be taken with food. * **Weight Gain Risk:** Olanzapine/Clozapine (Highest) > Quetiapine > Risperidone > Aripiprazole/Ziprasidone (Lowest).

Question 40: Which of the following drugs is used as a general anesthetic in Electroconvulsive Therapy (ECT)?

A. Methohexital (Correct Answer)
B. Labetalol
C. Amiodarone
D. Propranolol

Explanation: **Explanation:** **1. Why Methohexital is Correct:** Methohexital (a ultra-short-acting barbiturate) is considered the **gold standard** anesthetic agent for Electroconvulsive Therapy (ECT). The primary goal of anesthesia in ECT is to provide rapid induction and quick recovery without significantly interfering with seizure activity. Methohexital is preferred because it has a **minimal effect on the seizure threshold** compared to other induction agents (like propofol, which significantly shortens seizure duration). It ensures a rapid onset of action and a predictable, short duration of anesthesia, allowing for efficient post-ictal recovery. **2. Why the Other Options are Incorrect:** * **Labetalol & Propranolol:** These are beta-blockers. While they are sometimes used *adjunctively* during ECT to control the transient hypertensive surge and tachycardia that occurs during the tonic-clonic phase, they are not anesthetic agents and cannot induce unconsciousness. * **Amiodarone:** This is a Class III antiarrhythmic drug. It has no role in anesthesia induction and is not used in the standard ECT protocol. **3. High-Yield Clinical Pearls for NEET-PG:** * **Muscle Relaxant of Choice:** **Succinylcholine** is the preferred muscle relaxant in ECT to prevent musculoskeletal injuries (fractures/dislocations) during the seizure. * **Propofol vs. Methohexital:** While Propofol is commonly used, it is known to **shorten seizure duration** more than methohexital, which may potentially reduce the therapeutic efficacy of the treatment. * **Pre-medication:** Atropine or Glycopyrrolate (anticholinergics) may be given to prevent vagally-mediated bradycardia and reduce secretions. * **Absolute Contraindication:** The only absolute contraindication to ECT is **Increased Intracranial Pressure (ICP)**.

Question 41: The neuroleptic malignant syndrome is characterized by which of the following?

A. Bradycardia
B. Labile hypertension (Correct Answer)
C. Hypotonia
D. Hypothermia

Explanation: **Explanation:** Neuroleptic Malignant Syndrome (NMS) is a life-threatening idiosyncratic reaction to antipsychotic drugs (dopamine antagonists). It is characterized by a "tetrad" of clinical features: **Mental status changes, Muscular rigidity, Hyperthermia, and Autonomic instability.** **Why Labile Hypertension is correct:** Autonomic instability is a hallmark of NMS. This manifests as fluctuations in blood pressure (**labile hypertension**), tachycardia, tachypnea, and diaphoresis. The dysregulation of the autonomic nervous system occurs due to massive dopamine blockade in the hypothalamus and nigrostriatal pathways. **Why the other options are incorrect:** * **A. Bradycardia:** Patients typically present with **tachycardia** due to autonomic hyperactivity and physiological stress. * **C. Hypotonia:** NMS is characterized by severe **"Lead-pipe" rigidity** (hypertonia). Hypotonia is not a feature; in fact, the intense muscle contraction leads to rhabdomyolysis and elevated Creatine Phosphokinase (CPK). * **D. Hypothermia:** **Hyperthermia** (often >38°C or 100.4°F) is a core diagnostic criterion. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic (FEVER):** **F**ever, **E**ncephalopathy, **V**itals unstable, **E**levated CPK, **R**igidity. * **Key Lab Finding:** Significantly elevated **Serum CPK** and leukocytosis. * **Drug of Choice:** **Dantrolene** (muscle relaxant) or **Bromocriptine** (dopamine agonist). * **Differential Diagnosis:** Serotonin Syndrome (characterized by hyperreflexia and myoclonus, whereas NMS has "lead-pipe" rigidity and bradyreflexia).

Question 42: What is the prophylactic maintenance serum level of lithium?

A. 0.2 - 0.8 meq/L
B. 0.7 - 1.2 meq/L (Correct Answer)
C. 1.2 - 2.0 meq/L
D. 1.2 - 2.0 meq/L

Explanation: Lithium is a mood stabilizer with a narrow therapeutic index, requiring precise serum monitoring. The therapeutic range is divided into two phases based on the clinical state of the patient: 1. **Acute Manic Episode:** Higher levels are required to control active symptoms, typically **0.8 – 1.2 mEq/L**. 2. **Prophylactic Maintenance:** Once the patient is stable, the goal is to prevent relapse while minimizing side effects. The standard maintenance range is **0.6 – 1.2 mEq/L** (often simplified in exams as **0.7 – 1.2 mEq/L**). **Analysis of Options:** * **Option B (Correct):** 0.7 – 1.2 mEq/L aligns with the established window for preventing both manic and depressive relapses in Bipolar Affective Disorder (BPAD). * **Option A:** 0.2 – 0.8 mEq/L is generally sub-therapeutic. Levels below 0.6 mEq/L significantly increase the risk of relapse. * **Options C & D:** 1.2 – 2.0 mEq/L enters the range of **Lithium Toxicity**. Early signs of toxicity (tremors, nausea, diarrhea) typically appear above 1.5 mEq/L, while severe neurotoxicity occurs above 2.0 mEq/L. **High-Yield Clinical Pearls for NEET-PG:** * **Sampling Time:** Serum levels should be checked **12 hours after the last dose** (Trough level). * **Steady State:** It takes approximately **5 days** (5 half-lives) to reach a steady state after starting or changing a dose. * **Side Effects:** Most common side effect is **Fine Tremors**; most common renal side effect is **Nephrogenic Diabetes Insipidus**. * **Teratogenicity:** Associated with **Ebstein’s Anomaly** (tricuspid valve displacement) if taken during the first trimester. * **Drug Interactions:** Thiazides, NSAIDs, and ACE inhibitors increase Lithium levels (Risk of toxicity).

Question 43: A 50-year-old male developed cerebrovascular accident and subsequently presented with hemiplegia and pathological emotions. What is the management plan for the pathological emotions?

A. Amitriptyline
B. Sertraline
C. Escitalopram (Correct Answer)
D. Clomipramine

Explanation: ### **Explanation** The clinical presentation of hemiplegia following a cerebrovascular accident (CVA) accompanied by "pathological emotions" describes **Post-Stroke Emotional Incontinence (PSEI)**, also known as **Pseudobulbar Affect (PBA)**. This condition is characterized by sudden, involuntary, and inappropriate episodes of laughing or crying that are disproportionate to the actual emotional state. **1. Why Escitalopram is Correct:** Selective Serotonin Reuptake Inhibitors (SSRIs) are the first-line pharmacological treatment for pathological emotions post-stroke. **Escitalopram** is preferred in elderly post-stroke patients due to its high efficacy, superior safety profile, and minimal drug-drug interactions (it has the lowest effect on the Cytochrome P450 system). It effectively modulates the serotonergic pathways that are often disrupted in subcortical or frontal lobe strokes. **2. Why Other Options are Incorrect:** * **Amitriptyline & Clomipramine (Options A & D):** These are Tricyclic Antidepressants (TCAs). While TCAs can treat PBA, they are generally avoided in post-stroke patients due to their **anticholinergic side effects** (confusion, urinary retention) and **cardiotoxicity** (arrhythmias, orthostatic hypotension), which pose a high risk to patients with existing cardiovascular or cerebrovascular disease. * **Sertraline (Option B):** While Sertraline is an SSRI and can be used, Escitalopram is often favored in recent clinical guidelines and exams for its cleaner side-effect profile and faster onset of action in emotional regulation specifically for post-stroke sequelae. **3. NEET-PG High-Yield Pearls:** * **Pseudobulbar Affect (PBA):** Seen in CVA, Multiple Sclerosis, ALS, and Traumatic Brain Injury. * **First-line treatment:** SSRIs (Escitalopram, Fluoxetine, Citalopram). * **Alternative (FDA-approved):** Nuedexta (Dextromethorphan + Quinidine). * **Post-Stroke Depression (PSD):** Also treated primarily with SSRIs; Escitalopram is often the drug of choice due to its safety in cardiac patients.

Question 44: Cardiac conduction defects seen with Tricyclic antidepressants are due to what mechanism?

A. Norepinephrine and serotonin reuptake inhibition
B. Antimuscarinic action on the heart
C. Only norepinephrine reuptake inhibition
D. Both norepinephrine reuptake inhibition and antimuscarinic action on the heart (Correct Answer)

Explanation: ### Explanation Tricyclic Antidepressants (TCAs) have a complex pharmacological profile that affects multiple neurotransmitter systems, leading to both therapeutic effects and significant cardiovascular side effects. **Why Option D is Correct:** The cardiac conduction defects associated with TCAs are primarily mediated by two mechanisms: 1. **Norepinephrine Reuptake Inhibition:** By blocking the reuptake of norepinephrine at the synaptic cleft, TCAs increase sympathetic tone. This initially causes tachycardia and can predispose the heart to arrhythmias. 2. **Antimuscarinic (Anticholinergic) Action:** TCAs block M2 receptors in the heart. This inhibits the parasympathetic "braking" effect on the SA node, leading to sinus tachycardia and altered conduction velocity. **Analysis of Incorrect Options:** * **Option A & C:** While serotonin and norepinephrine reuptake inhibition are the primary mechanisms for treating depression, serotonin has a negligible direct effect on cardiac conduction compared to norepinephrine. Focusing "only" on norepinephrine ignores the potent anticholinergic effects that contribute to tachycardia. **High-Yield Clinical Pearls for NEET-PG:** * **The "3 Cs" of TCA Overdose:** **C**oma, **C**onvulsions, and **C**ardiotoxicity. * **Membrane Stabilizing Effect:** In toxic doses, TCAs block **fast sodium channels** (Quinidine-like effect) in the myocardium. This is the most dangerous mechanism, leading to QRS widening (>100ms), PR/QT interval prolongation, and Right Axis Deviation. * **ECG Hallmark:** A wide QRS complex and a prominent R wave in lead aVR are classic signs of TCA toxicity. * **Antidote:** **Sodium Bicarbonate** is the drug of choice for TCA-induced arrhythmias as it increases extracellular sodium and alkalinizes the blood, decreasing the drug's affinity for sodium channels.

Question 45: A patient with acute psychosis, who is on haloperidol 20mg/day for the last 2 days, presents with an episode characterized by tongue protrusion, oculogyric crisis, stiffness, and abnormal posture of limbs and trunk without loss of consciousness for 20 minutes. The episode improved within a few minutes after administration of diphenhydramine HCl. What is the most likely diagnosis?

A. Acute dystonia (Correct Answer)
B. Akathisia
C. Tardive dyskinesia
D. Neuroleptic malignant syndrome

Explanation: ### Explanation **Correct Answer: A. Acute dystonia** **Why it is correct:** Acute dystonia is an Extrapyramidal Side Effect (EPS) characterized by sudden, involuntary muscle spasms. This patient exhibits classic signs: **oculogyric crisis** (upward gaze deviation), **glossospasm** (tongue protrusion), and **torticollis/retrocollis** (abnormal posture). * **Mechanism:** It is caused by a sudden blockade of dopamine (D2) receptors in the nigrostriatal pathway, leading to a relative excess of acetylcholine. * **Timeline:** It typically occurs within hours to **days** (usually <5 days) of starting high-potency antipsychotics like Haloperidol. * **Management:** It is a medical emergency that responds rapidly to **anticholinergics** (e.g., Benztropine, Promethazine) or antihistamines with anticholinergic properties like **Diphenhydramine**. **Why the other options are wrong:** * **B. Akathisia:** Presents as subjective motor restlessness (inability to sit still). It does not involve muscle spasms or abnormal postures. * **C. Tardive dyskinesia:** Occurs after **long-term** (months to years) use of antipsychotics. It presents with choreoathetoid movements (e.g., lip-smacking), not acute sustained spasms. * **D. Neuroleptic malignant syndrome (NMS):** A life-threatening reaction characterized by "lead-pipe" rigidity, high fever, autonomic instability, and altered sensorium. The rapid reversal with diphenhydramine and lack of fever rule this out. **High-Yield Clinical Pearls for NEET-PG:** * **Risk Factors:** Young males and those receiving high-potency first-generation antipsychotics are at highest risk. * **The "Rule of 4" for EPS Timeline:** * **4 Hours:** Acute Dystonia * **4 Days:** Akathisia (can also occur in weeks) * **4 Weeks:** Parkinsonism * **4 Months:** Tardive Dyskinesia (usually >6 months) * **Drug of Choice:** Intravenous or Intramuscular **Promethazine** or Benztropine.

Question 46: A patient of schizophrenia treated for 5 years develops perioral movements. What is the likely diagnosis?

A. Tardive dyskinesia (Correct Answer)
B. Muscular dystonia
C. Akathisia
D. Malignant neuroleptic syndrome

Explanation: ### Explanation **Correct Option: A. Tardive dyskinesia** Tardive dyskinesia (TD) is a late-onset extrapyramidal side effect (EPS) resulting from long-term blockade of dopamine (D2) receptors, typically occurring after months or years of antipsychotic use. The underlying pathophysiology is **dopamine receptor supersensitivity** in the nigrostriatal pathway. It characteristically presents as involuntary, choreoathetoid movements, most commonly involving the **orofacial region** (e.g., lip-smacking, tongue protrusion, or perioral tremors—often referred to as "Rabbit Syndrome" in its parkinsonian variant). **Why other options are incorrect:** * **B. Muscular dystonia:** This is an **acute** reaction occurring within hours to days of starting treatment. it involves sustained, painful muscle contractions (e.g., torticollis or oculogyric crisis). * **C. Akathisia:** This refers to a subjective feeling of **inner restlessness** and the inability to sit still. It usually develops within days to weeks of treatment. * **D. Malignant neuroleptic syndrome (NMS):** This is a life-threatening emergency characterized by the "tetrad" of fever, muscular rigidity ("lead-pipe"), autonomic instability, and altered mental status. It is not defined by localized perioral movements. **High-Yield Clinical Pearls for NEET-PG:** * **Risk Factors:** Old age, female gender, and long-term use of typical (1st generation) antipsychotics. * **Management:** The first step is to **taper/discontinue** the offending agent or switch to **Clozapine** (the antipsychotic with the lowest risk of TD). * **Newer Treatments:** VMAT-2 inhibitors like **Valbenazine** or Deutetrabenazine are now FDA-approved for TD. * **Note:** Unlike other EPS, anticholinergics (like Benztropine) can actually **worsen** tardive dyskinesia.

Question 47: Which of the following medications is NOT used in the treatment of schizophrenia?

A. Pemoline (Correct Answer)
B. Olanzapine
C. Sulpiride
D. Chlorpromazine

Explanation: **Explanation:** The treatment of schizophrenia primarily involves **Antipsychotics**, which work by modulating dopaminergic pathways (specifically blocking D2 receptors). **Why Pemoline is the correct answer:** **Pemoline** is a sympathomimetic amine and a central nervous system (CNS) stimulant. It acts by increasing dopamine levels in the synaptic cleft. Because schizophrenia is associated with dopamine overactivity in the mesolimbic pathway, stimulants like Pemoline can actually **exacerbate or induce psychotic symptoms**. Historically, Pemoline was used for ADHD and narcolepsy, but it is not used for schizophrenia. (Note: It has been largely withdrawn globally due to hepatotoxicity). **Why the other options are incorrect:** * **Olanzapine:** An **Atypical (Second-Generation) Antipsychotic**. It blocks both D2 and 5-HT2A receptors and is a first-line treatment for schizophrenia due to its lower risk of extrapyramidal side effects (EPS). * **Sulpiride:** A **Substituted Benzamide** that acts as a selective D2 receptor antagonist. It is used as an antipsychotic, particularly effective in treating the negative symptoms of schizophrenia at lower doses. * **Chlorpromazine:** A **Typical (First-Generation) Antipsychotic** (Low potency). It was the first antipsychotic discovered (1952) and remains a standard treatment for schizophrenia. **High-Yield Clinical Pearls for NEET-PG:** * **Dopamine Hypothesis:** Schizophrenia is linked to *increased* dopamine in the mesolimbic pathway (positive symptoms) and *decreased* dopamine in the mesocortical pathway (negative symptoms). * **Chlorpromazine** is known for causing significant sedation and skin/eye pigmentation (corneal opacities). * **Olanzapine** is highly associated with metabolic syndrome (weight gain, dyslipidemia, and diabetes).

Question 48: Akathisia is characterized by which of the following?

A. Restlessness, a persistent desire to move about, and fidgety or rocking movements. (Correct Answer)
B. Tongue protrusion, stiffness, and abnormal posture of the trunk and limbs.
C. Purposeless involuntary facial and limb movements.
D. Perioral tremor.

Explanation: **Explanation:** **Akathisia** is the most common Extrapyramidal Side Effect (EPS) associated with antipsychotic medications (especially first-generation antipsychotics). The term is derived from the Greek word for "unable to sit." 1. **Why Option A is Correct:** Akathisia is characterized by a subjective feeling of inner restlessness and an objective need to move. Patients often exhibit "fidgety" behavior, such as pacing, rocking from foot to foot, or crossing and uncrossing their legs. Unlike other movement disorders, it has a significant **psychological component** (the distressing urge to move). 2. **Analysis of Incorrect Options:** * **Option B (Acute Dystonia):** This describes sudden, involuntary muscle contractions causing abnormal postures, such as torticollis (neck twisting) or oculogyric crisis. * **Option C (Tardive Dyskinesia):** This refers to delayed-onset, involuntary choreoathetoid movements, typically involving the face (lip-smacking, tongue protrusion) and limbs, resulting from long-term dopamine blockade. * **Option D (Rabbit Syndrome):** This is a specific, late-onset EPS characterized by fine, rhythmic tremors of the perioral muscles, mimicking a rabbit's chewing motion. **High-Yield Clinical Pearls for NEET-PG:** * **Treatment of Choice:** **Propranolol** (Beta-blocker) is the first-line treatment for Akathisia. Benzodiazepines or anticholinergics (like Benztropine) are second-line. * **Clinical Significance:** Akathisia is highly associated with increased **suicidality** and non-compliance because the sensation is extremely distressing to the patient. * **Timeline:** It typically develops within days to weeks of starting or increasing the dose of an antipsychotic.

Question 49: Which drug has therapeutic benefit in Schizophrenia?

A. Lithium
B. Doxepin
C. Imipramine
D. Fluphenazine (Correct Answer)

Explanation: **Explanation:** The correct answer is **Fluphenazine**. **1. Why Fluphenazine is correct:** Fluphenazine is a **First-Generation Antipsychotic (FGA)**, specifically belonging to the high-potency **Piperazine** subclass of Phenothiazines. Its primary mechanism of action involves the potent blockade of **Postsynaptic Dopamine D2 receptors** in the mesolimbic pathway, which effectively treats the "positive symptoms" of Schizophrenia (hallucinations and delusions). Because it is high-potency, it is often administered as a long-acting injectable (Decanoate) for patients with poor treatment compliance. **2. Why the other options are incorrect:** * **Lithium (Option A):** This is the gold-standard **Mood Stabilizer**. It is the first-line treatment for Bipolar Affective Disorder (BPAD) and acute mania, but it does not possess primary antipsychotic properties. * **Doxepin (Option B):** This is a **Tricyclic Antidepressant (TCA)**. It is primarily used for depression, anxiety, and insomnia (due to its strong antihistaminic properties). It has no role in treating the core symptoms of Schizophrenia. * **Imipramine (Option C):** This is also a **TCA** (the first one discovered). It is used for Major Depressive Disorder and specifically for **Nocturnal Enuresis** in children. Like Doxepin, it does not treat psychosis. **3. NEET-PG High-Yield Pearls:** * **Potency vs. Side Effects:** High-potency FGAs like Fluphenazine and Haloperidol have a higher risk of **Extrapyramidal Side Effects (EPS)** but a lower risk of sedation and anticholinergic effects compared to low-potency drugs like Chlorpromazine. * **Depot Preparations:** Fluphenazine decanoate is a "Depot" injection, providing therapeutic coverage for 2–4 weeks. * **Drug of Choice:** While FGAs are effective, **Atypical Antipsychotics** (e.g., Risperidone, Olanzapine) are generally preferred first-line today due to lower EPS risk. **Clozapine** remains the drug of choice for *Treatment-Resistant Schizophrenia*.

Question 50: What is the best marker for electroconvulsive therapy?

A. CSF 5-HIAA
B. CSF serotonin
C. Brain-derived neurotrophic factor (Correct Answer)
D. CSF dopamine

Explanation: **Explanation:** The correct answer is **Brain-derived neurotrophic factor (BDNF)**. **Why BDNF is the correct answer:** Electroconvulsive therapy (ECT) is the most effective treatment for severe, treatment-resistant depression. Modern research indicates that the therapeutic efficacy of ECT is closely linked to **neuroplasticity**. ECT significantly increases the expression of BDNF in the hippocampus and prefrontal cortex. BDNF is a protein that promotes the survival of existing neurons and encourages the growth and differentiation of new neurons and synapses (neurogenesis). Studies consistently show that serum BDNF levels rise following a course of ECT, making it the most reliable biological marker for the treatment's clinical response. **Why the other options are incorrect:** * **CSF 5-HIAA (A):** This is a metabolite of serotonin. While low levels of 5-HIAA in the CSF are associated with impulsive behavior and violent suicide attempts, it is not a specific marker for ECT response. * **CSF Serotonin (B):** Serotonin levels in the CSF do not reliably reflect the complex neurobiological changes or the neurotrophic effects induced by ECT. * **CSF Dopamine (D):** While ECT may influence dopaminergic transmission (relevant in treating Parkinson’s disease), dopamine levels are not used as a primary marker for ECT's antidepressant efficacy. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** The "Neurotrophic Hypothesis" (increased BDNF) is currently the most favored theory for ECT's action. * **Most Common Side Effect:** Retrograde amnesia (usually resolves over time). * **Absolute Contraindication:** There are no absolute contraindications, but **increased intracranial pressure (ICP)** is the most significant relative contraindication. * **Gold Standard:** ECT remains the gold standard for **Depressive Stupor** and **Catatonia**.

Question 51: Which antipsychotic has the least incidence of extrapyramidal symptoms?

A. Haloperidol
B. Thiothixene
C. Thioridazine (Correct Answer)
D. Perphenazine

Explanation: **Explanation:** The incidence of **Extrapyramidal Symptoms (EPS)** in antipsychotics is inversely proportional to the drug's intrinsic **anticholinergic (M1 receptor) activity**. **Why Thioridazine is Correct:** Thioridazine is a low-potency typical antipsychotic. Among the options provided, it possesses the **strongest intrinsic anticholinergic activity**. In the nigrostriatal pathway, dopamine and acetylcholine exist in a reciprocal balance. While antipsychotics block D2 receptors (causing EPS), the potent anticholinergic effect of Thioridazine "re-balances" this system, significantly reducing the risk of motor side effects. Therefore, it has the lowest incidence of EPS among typical antipsychotics. **Analysis of Incorrect Options:** * **Haloperidol:** A high-potency typical antipsychotic with very low anticholinergic activity. It has the **highest risk** of EPS (especially acute dystonia and parkinsonism) among the choices. * **Thiothixene & Perphenazine:** These are high-to-medium potency typical antipsychotics. While they have lower EPS risks than Haloperidol, their anticholinergic profiles are much weaker than Thioridazine, making them more likely to cause movement disorders. **NEET-PG High-Yield Pearls:** * **The "Gold Standard":** If **Clozapine** (an atypical antipsychotic) were an option, it would be the overall correct answer for the "least EPS." * **Thioridazine Side Effects:** While low in EPS, it is high-yield for causing **Retinitis Pigmentosa** (at doses >800mg/day) and **QT interval prolongation** (Torsades de pointes). * **Potency Rule:** Generally, **Low Potency** = High Sedation, High Anticholinergic, Low EPS. **High Potency** = Low Sedation, Low Anticholinergic, High EPS.

Question 52: Which of the following is not a symptom of neuroleptic malignant syndrome?

A. Autonomic dysregulation
B. Hypothermia (Correct Answer)
C. Muscle rigidity
D. Catatonia and stupor

Explanation: **Explanation:** Neuroleptic Malignant Syndrome (NMS) is a life-threatening idiosyncratic reaction to antipsychotic drugs (neuroleptics), primarily caused by potent dopamine (D2) receptor antagonism in the nigrostriatal pathway and hypothalamus. **Why Hypothermia is the correct answer:** The hallmark of NMS is **Hyperpyrexia (High-grade fever)**, not hypothermia. The blockade of dopamine receptors in the hypothalamus disrupts the body's thermoregulatory set-point, leading to uncontrolled heat production. This is further exacerbated by intense muscle contractions. **Analysis of Incorrect Options:** * **Autonomic dysregulation:** This is a core feature of NMS. Patients typically present with "autonomic instability," including tachycardia, labile blood pressure, profuse diaphoresis (sweating), and tachypnea. * **Muscle rigidity:** Often described as **"Lead-pipe rigidity,"** this is a classic diagnostic sign. It results from dopamine blockade in the basal ganglia and is often accompanied by elevated Creatine Kinase (CK) levels due to muscle breakdown (rhabdomyolysis). * **Catatonia and stupor:** Altered mental status is an early sign of NMS. It ranges from confusion and agitation to catatonic signs, mutism, and eventually stupor or coma. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic (FEVER):** **F**ever, **E**ncephalopathy (altered mental status), **V**itals unstable, **E**levated enzymes (CK), **R**igidity. * **Treatment of Choice:** Immediate discontinuation of the offending agent + Supportive care. Pharmacotherapy includes **Dantrolene** (muscle relaxant) or **Bromocriptine** (dopamine agonist). * **NMS vs. Serotonin Syndrome:** While both have fever and tachycardia, NMS is characterized by **"Lead-pipe" rigidity** and bradyreflexia, whereas Serotonin Syndrome features **hyperreflexia and myoclonus.**

Question 53: A child with schizophrenia, while on medications, suddenly developed neck stiffness and spasm. What is the most probable cause?

A. Conversion disorder
B. Acute dystonia (Correct Answer)
C. Akathisia
D. Tardive dyskinesia

Explanation: ### Explanation **Correct Answer: B. Acute Dystonia** **Reasoning:** The clinical presentation of sudden neck stiffness and muscle spasms in a patient taking antipsychotics (used for schizophrenia) is a classic manifestation of **Acute Dystonia**. This is an Extrapyramidal Side Effect (EPS) caused by the blockade of dopamine (D2) receptors in the nigrostriatal pathway, leading to a relative excess of cholinergic activity. In children and young males, this reaction often occurs within hours to a few days of starting or increasing the dose of typical antipsychotics (e.g., Haloperidol). Common forms include **torticollis** (neck twisting), **retrocollis** (neck extension), and **oculogyric crisis** (upward deviation of eyes). **Why other options are incorrect:** * **A. Conversion disorder:** This is a psychiatric condition where neurological symptoms (like paralysis or seizures) occur without a physiological cause, usually triggered by psychological stress. It would not be the primary suspicion in a patient on antipsychotics. * **C. Akathisia:** This refers to a subjective feeling of inner restlessness and an inability to sit still. It presents as pacing or foot-tapping, not as muscle spasms. * **D. Tardive dyskinesia:** This is a late-onset EPS occurring after months or years of treatment. It typically involves choreoathetoid movements (e.g., lip-smacking, tongue protrusion), not acute spasms. **NEET-PG High-Yield Pearls:** * **Drug of Choice:** Acute dystonia is treated with intravenous or intramuscular **anticholinergics** (e.g., **Promethazine**, Benztropine, or Trihexyphenidyl). * **Risk Factors:** Young age, male gender, and use of high-potency typical antipsychotics. * **Timeline of EPS:** 1. **D**ystonia (Hours to days) 2. **A**kathisia (Days to weeks) 3. **P**arkinsonism (Weeks to months) 4. **T**ardive Dyskinesia (Months to years) *(Mnemonic: **ADAPT**)*

Question 54: Which of the following is a disadvantage of mirtazapine?

A. Seizures
B. Cheese reaction
C. Dyslipidemia (Correct Answer)
D. Premature ejaculation

Explanation: **Explanation:** **Mirtazapine** is a Noradrenergic and Specific Serotonergic Antidepressant (NaSSA). Its unique mechanism involves blocking presynaptic $\alpha_2$-autoreceptors and heteroreceptors, which increases the release of both norepinephrine and serotonin. **Why Dyslipidemia is the correct answer:** Mirtazapine is notorious for causing metabolic side effects. It has a high affinity for **$H_1$ histamine receptors**, which leads to significant sedation and **increased appetite/weight gain**. Clinically, this is frequently associated with an increase in serum cholesterol and triglyceride levels (**dyslipidemia**). Monitoring the lipid profile is recommended for patients on long-term mirtazapine therapy. **Analysis of Incorrect Options:** * **A. Seizures:** While many antidepressants lower the seizure threshold, this is a classic "high-yield" disadvantage associated primarily with **Bupropion** (especially in eating disorders) and **Maprotiline**. * **B. Cheese reaction:** This is a hypertensive crisis caused by the interaction of tyramine-rich foods with **Non-selective MAO inhibitors** (e.g., Phenelzine, Tranylcypromine). Mirtazapine does not inhibit MAO. * **C. Premature ejaculation:** Mirtazapine actually has a **low incidence of sexual dysfunction** because it blocks $5-HT_2$ and $5-HT_3$ receptors. In fact, SSRIs (which cause delayed ejaculation) are used to *treat* premature ejaculation; mirtazapine is often an alternative for patients who cannot tolerate SSRI-induced sexual side effects. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** $\alpha_2$ antagonist + $5-HT_2$ & $5-HT_3$ antagonist. * **The "Sleep & Eat" Drug:** Ideal for elderly depressed patients with insomnia and weight loss. * **Side Effects:** Sedation, weight gain, dyslipidemia, and rarely, **agranulocytosis**. * **Unique Benefit:** It is one of the few antidepressants that does not typically cause nausea (due to $5-HT_3$ blockade).

Question 55: Akathisia is treated by all except?

A. Trihexyphenidyl
B. Diazepam
C. Haloperidol (Correct Answer)
D. Promethazine

Explanation: **Explanation:** **Akathisia** is a common Extrapyramidal Side Effect (EPS) characterized by a subjective feeling of inner restlessness and an objective inability to sit still. **Why Haloperidol is the correct answer:** Haloperidol is a high-potency **Typical Antipsychotic** and a potent **D2 receptor antagonist**. Since akathisia is caused by the blockade of dopamine receptors in the nigrostriatal pathway, administering Haloperidol would **worsen** the condition rather than treat it. It is, in fact, one of the most common culprits behind the development of akathisia. **Analysis of Incorrect Options:** * **Trihexyphenidyl:** This is an anticholinergic agent. While Beta-blockers are the first-line treatment for akathisia, anticholinergics are frequently used as second-line agents to manage EPS. * **Diazepam:** Benzodiazepines are effective in reducing the subjective distress and motor restlessness associated with akathisia, especially when first-line treatments are insufficient. * **Promethazine:** This is an antihistamine with significant anticholinergic properties, making it a viable option for managing antipsychotic-induced movement disorders. **Clinical Pearls for NEET-PG:** 1. **Drug of Choice (DOC):** Propranolol (Beta-blocker) is the first-line treatment for Akathisia. 2. **Most Common EPS:** Akathisia is the most common extrapyramidal side effect of typical antipsychotics. 3. **Differential Diagnosis:** It is often misdiagnosed as worsening psychosis or agitation, leading to a dangerous "vicious cycle" if the antipsychotic dose is increased. 4. **Management Strategy:** The first step is usually to reduce the dose of the offending antipsychotic or switch to a Second Generation Antipsychotic (e.g., Quetiapine).

Question 56: Which of the following is a SARI?

A. Mianserin
B. Milnacipran
C. Clozapine
D. Nefazodone (Correct Answer)

Explanation: **Explanation:** **Nefazodone** is the correct answer because it belongs to the class of **SARIs (Serotonin Antagonist and Reuptake Inhibitors)**. The mechanism of action involves two primary pathways: it potently blocks post-synaptic **5-HT2A receptors** and inhibits the reuptake of serotonin (and to a lesser extent, norepinephrine). By blocking 5-HT2A, SARIs reduce common SSRI-induced side effects like agitation, insomnia, and sexual dysfunction. **Analysis of Incorrect Options:** * **A. Mianserin:** This is a **TeCA (Tetracyclic Antidepressant)**. It acts primarily as an alpha-2 adrenergic antagonist and H1 receptor antagonist, similar to Mirtazapine (NaSSA). * **B. Milnacipran:** This belongs to the **SNRI (Serotonin-Norepinephrine Reuptake Inhibitor)** class, commonly used in the management of fibromyalgia and depression. * **C. Clozapine:** This is an **Atypical Antipsychotic** (SDA - Serotonin-Dopamine Antagonist). While it has complex receptor binding, it is not classified as an antidepressant SARI. **Clinical Pearls for NEET-PG:** * **Trazodone** is the other major SARI. It is frequently used off-label for **insomnia** due to its sedative properties (H1 blockade). * **High-Yield Side Effect:** Nefazodone carries a **Black Box Warning for hepatotoxicity** (liver failure), which has limited its clinical use. * **Priapism:** A rare but classic side effect associated with Trazodone (remember the mnemonic: *"Trazodone causes a Trazo-bone"*). * Unlike SSRIs, SARIs generally do not cause weight gain or significant sexual dysfunction.

Question 57: Akathisia is treated by which of the following medications?

A. Haloperidol
B. Fluoxetine
C. Propranolol (Correct Answer)
D. Lithium

Explanation: **Explanation:** **Akathisia** is a common and distressing Extrapyramidal Side Effect (EPS) characterized by subjective feelings of inner restlessness and an objective inability to sit still. **1. Why Propranolol is the Correct Answer:** The first-line treatment for drug-induced akathisia is **Propranolol**, a non-selective beta-blocker. While the exact pathophysiology is complex, it is believed that beta-adrenergic receptors in the peripheral and central nervous systems play a role in the motor manifestations of akathisia. Propranolol effectively crosses the blood-brain barrier to reduce these symptoms. Other options include benzodiazepines (like Lorazepam) or anticholinergics, though the latter are less effective for akathisia than for dystonia or parkinsonism. **2. Why the Other Options are Incorrect:** * **Haloperidol:** This is a high-potency typical antipsychotic and a potent D2 receptor antagonist. It is a common **cause** of akathisia, not a treatment. * **Fluoxetine:** An SSRI used for depression and OCD. It does not treat akathisia and can, in rare cases, actually induce restlessness or "jitteriness" during the initial phase of treatment. * **Lithium:** A mood stabilizer used for Bipolar Disorder. It has no role in treating EPS and can cause its own side effects like tremors. **3. NEET-PG High-Yield Pearls:** * **Most common EPS:** Akathisia is often cited as the most frequent extrapyramidal side effect of typical antipsychotics. * **Clinical Presentation:** Patients are often misdiagnosed as having "worsening psychosis" or anxiety because they pace the room or tap their feet incessantly. * **Drug of Choice (DOC):** Propranolol (Beta-blocker). * **Timeline:** Akathisia typically develops within days to weeks of starting or increasing the dose of an antipsychotic.

Question 58: A patient on haloperidol and clonazepam for psychotic symptoms presents with agitation, requiring both oral and intramuscular administration. The patient subsequently develops fever, rigidity, confusion, elevated CPK, and liver enzymes. What is the probable diagnosis?

A. Neuroleptic malignant syndrome (Correct Answer)
B. Malignant catatonia
C. Serotonin syndrome
D. Gegenhalten

Explanation: **Explanation:** The patient is presenting with the classic tetrad of **Neuroleptic Malignant Syndrome (NMS)**: fever (hyperpyrexia), muscle rigidity ("lead-pipe"), autonomic instability (agitation/tachycardia), and altered mental status (confusion). **Why NMS is the correct answer:** NMS is an idiosyncratic, life-threatening reaction to dopamine antagonists, most commonly **high-potency typical antipsychotics** like **Haloperidol**. The risk increases significantly with high doses or rapid escalation (e.g., combined oral and IM administration). Laboratory findings characteristically show **elevated Creatine Phosphokinase (CPK)** due to rhabdomyolysis from intense muscle rigidity and elevated liver enzymes. **Why the other options are incorrect:** * **Malignant Catatonia:** While it presents similarly with fever and rigidity, it is usually preceded by a prodrome of behavioral psychosis and is often *treated* with benzodiazepines/ECT, whereas NMS is *triggered* by neuroleptics. * **Serotonin Syndrome:** This occurs due to serotonergic agents (SSRIs/MAOIs). While it features fever and agitation, it is clinically distinguished by **hyperreflexia and myoclonus** rather than the "lead-pipe" rigidity seen in NMS. * **Gegenhalten (Paratonia):** This is a form of rigidity where the patient involuntarily resists passive movement in proportion to the force applied. It is associated with frontal lobe damage or dementia, not systemic symptoms like fever or elevated CPK. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for NMS (FEVER):** **F**ever, **E**ncephalopathy, **V**itals unstable, **E**levated enzymes (CPK), **R**igidity. * **Treatment of Choice:** Immediate discontinuation of the offending agent, supportive care, and pharmacotherapy with **Dantrolene** (muscle relaxant) or **Bromocriptine** (dopamine agonist). * **Key Lab:** Elevated CPK is the most sensitive laboratory indicator.

Question 59: A patient on antipsychotics presents with restlessness, an irresistible urge to move, and an inability to sit or stand in one position. What is the most likely diagnosis?

A. Acute dystonia
B. Akathisia (Correct Answer)
C. Tardive dyskinesia
D. Rabbit syndrome

Explanation: **Explanation:** The patient is presenting with the classic triad of **Akathisia**: subjective restlessness, an irresistible urge to move, and objective motor hyperactivity (pacing, shifting weight, or inability to sit still). It is the most common Extrapyramidal Side Effect (EPS) associated with antipsychotics, particularly high-potency first-generation agents. **Why the other options are incorrect:** * **Acute Dystonia:** Characterized by sudden, involuntary, sustained muscle contractions (e.g., torticollis, oculogyric crisis). It usually occurs within hours to days of starting treatment, whereas akathisia typically appears within days to weeks. * **Tardive Dyskinesia:** A late-onset complication (months to years) involving involuntary choreoathetoid movements, most commonly orofacial (lip-smacking, tongue protrusion). Unlike akathisia, these movements are involuntary and the patient may be unaware of them. * **Rabbit Syndrome:** A rare, late-onset EPS characterized by fine, rhythmic tremors of the perioral muscles (mimicking a chewing rabbit). It does not involve generalized restlessness. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Result of dopamine (D2) blockade in the nigrostriatal pathway. * **Management:** The drug of choice for Akathisia is **Propranolol** (Beta-blocker). Centrally acting anticholinergics (e.g., Benztropine) or Benzodiazepines are second-line. * **Clinical Significance:** Akathisia is highly distressing and is a major cause of non-compliance and increased suicide risk in patients on antipsychotics. * **Rule of Thumb (Timing of EPS):** **A**cute Dystonia (4 hours) > **A**kathisia (4 days) > **P**arkinsonism (4 weeks) > **T**ardive Dyskinesia (4 months/years). *Mnemonic: ADAPT.*

Question 60: A patient on antipsychotics for 3 weeks presents with high-grade fever, elevated CPK, and myoglobinuria. What is the most probable diagnosis?

A. Neuroleptic malignant syndrome (Correct Answer)
B. Tardive dyskinesia
C. Acute dystonia
D. Akathisia

Explanation: ### Explanation **Neuroleptic Malignant Syndrome (NMS)** is a rare but life-threatening idiosyncratic reaction to antipsychotic medications (neuroleptics). The clinical presentation in this patient—**high-grade fever (hyperpyrexia)**, **elevated Creatine Phosphokinase (CPK)**, and **myoglobinuria**—is the classic triad of NMS. * **Why Option A is correct:** NMS is caused by potent dopamine (D2) receptor blockade in the nigrostriatal pathway and hypothalamus. This leads to severe "lead-pipe" muscle rigidity, which causes muscle breakdown (rhabdomyolysis), resulting in elevated CPK levels and myoglobinuria (which can lead to renal failure). Autonomic instability and altered mental status are also hallmark features. * **Why other options are incorrect:** * **Tardive Dyskinesia:** A late-onset (months to years) extrapyramidal side effect characterized by involuntary choreoathetoid movements, typically of the tongue and face. It does not present with fever or elevated CPK. * **Acute Dystonia:** An early-onset reaction (hours to days) involving sudden, sustained muscle contractions (e.g., torticollis, oculogyric crisis). It lacks systemic symptoms like fever. * **Akathisia:** A subjective feeling of inner restlessness and an inability to sit still. It is the most common extrapyramidal side effect but does not cause lab abnormalities or hyperpyrexia. **High-Yield NEET-PG Pearls:** * **Treatment of NMS:** Immediate discontinuation of the offending drug, aggressive cooling, and pharmacological intervention with **Dantrolene** (muscle relaxant) or **Bromocriptine** (dopamine agonist). * **NMS vs. Serotonin Syndrome:** Both have fever and autonomic instability, but NMS is characterized by **"Lead-pipe rigidity"** and bradyreflexia, whereas Serotonin Syndrome presents with **hyperreflexia and myoclonus.** * **Risk Factor:** High-potency first-generation antipsychotics (e.g., Haloperidol) are most commonly implicated.

Question 61: Which of the following SSRIs is used in the management of pathological emotions?

A. Escitalopram (Correct Answer)
B. Paroxetine
C. Clomipramine
D. Fluoxetine

Explanation: **Explanation:** **Pathological emotions**, also known as **Pseudobulbar Affect (PBA)** or emotional lability, is a clinical condition characterized by involuntary, sudden, and inappropriate episodes of laughing or crying. It is commonly seen in neurological disorders like Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and post-stroke states. **1. Why Escitalopram is correct:** Selective Serotonin Reuptake Inhibitors (SSRIs) are the first-line pharmacological treatment for pathological emotions. Among the options provided, **Escitalopram** is specifically documented and frequently utilized in clinical practice for this indication due to its high selectivity for the serotonin transporter and its favorable side-effect profile in neurologically compromised patients. It helps stabilize the emotional threshold, reducing the frequency and severity of outbursts. **2. Analysis of Incorrect Options:** * **Paroxetine:** While an SSRI, it is generally avoided in patients with neurological comorbidities due to its mild anticholinergic effects and higher risk of withdrawal symptoms. * **Clomipramine:** This is a **Tricyclic Antidepressant (TCA)**, not an SSRI. While TCAs can be used for PBA, they are second-line due to significant side effects (sedation, arrhythmias, and anticholinergic toxicity). * **Fluoxetine:** Although an SSRI, its long half-life and active metabolites make it less ideal for rapid titration in the elderly or neurologically ill compared to Escitalopram. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice for PBA:** Traditionally, the combination of **Dextromethorphan and Quinidine** (Nuedexta) is the only FDA-approved specific treatment. However, among antidepressants, SSRIs (like Escitalopram) are the standard of care. * **Escitalopram** is the S-enantiomer of Citalopram and is considered the most "selective" SSRI. * **Pathological emotions** result from a "disconnection syndrome" involving the prefrontal cortex and the cerebellum/brainstem.

Question 62: A 25-year-old man with a psychotic illness was treated with haloperidol 130 mg/day. On the third day, he developed pacing and an inability to sit still in one place. Which medication is likely to be helpful?

A. Phenytoin
B. Propranolol (Correct Answer)
C. Methylphenidate
D. Trihexyphenidyl

Explanation: ### Explanation **Diagnosis: Akathisia** The clinical presentation of "pacing" and an "inability to sit still" shortly after starting a high-potency first-generation antipsychotic (Haloperidol) is a classic description of **Akathisia**. This is an Extrapyramidal Side Effect (EPS) characterized by a subjective feeling of inner restlessness and objective motor hyperactivity. **Why Propranolol is Correct:** Propranolol, a non-selective **beta-blocker**, is the **first-line treatment** for antipsychotic-induced akathisia. It works by crossing the blood-brain barrier and antagonizing beta-receptors, which helps alleviate the physiological and psychological symptoms of restlessness. **Analysis of Incorrect Options:** * **Phenytoin (A):** An antiepileptic drug used for seizures; it has no role in managing movement disorders caused by antipsychotics. * **Methylphenidate (C):** A CNS stimulant used for ADHD. Giving a stimulant to a patient with akathisia would likely worsen the agitation and restlessness. * **Trihexyphenidyl (D):** An anticholinergic used to treat other EPS like *acute dystonia* and *pseudoparkinsonism*. While often tested, anticholinergics are generally **less effective** than beta-blockers for akathisia specifically. **High-Yield NEET-PG Pearls:** * **Timeline of EPS:** Remember the "Rule of 4": **4 hours** (Dystonia), **4 days** (Akathisia), **4 weeks** (Parkinsonism), **4 months** (Tardive Dyskinesia). * **Drug of Choice (DOC) Summary:** * **Acute Dystonia:** Promethazine or Benztropine (IV/IM). * **Akathisia:** Propranolol (Oral). * **Drug-induced Parkinsonism:** Trihexyphenidyl. * **Tardive Dyskinesia:** Valbenazine or Deutetrabenazine (VMAT2 inhibitors). * **Haloperidol Dosage:** Note the high dose (130 mg/day) in the question; high-potency D2 blockers are the most common culprits for akathisia.

Question 63: Which of the following conditions is characterized by twisting and protrusion of the tongue, and chewing of the lips?

A. Acute Akathisia
B. Acute Dystonia
C. Tardive dyskinesia (Correct Answer)
D. Chronic dystonia

Explanation: **Explanation:** The clinical presentation of twisting and protrusion of the tongue (fly-catcher’s tongue) and repetitive chewing movements of the lips (bucco-linguo-masticatory movements) is a classic description of **Tardive Dyskinesia (TD)**. **1. Why Tardive Dyskinesia is correct:** TD is a delayed-onset extrapyramidal side effect (EPS) resulting from long-term blockade of dopamine (D2) receptors by antipsychotics. The underlying pathophysiology is **dopamine receptor supersensitivity** in the nigrostriatal pathway. It is characterized by involuntary, choreoathetoid movements, most commonly affecting the face, mouth, and tongue. **2. Why other options are incorrect:** * **Acute Akathisia:** Presents as subjective motor restlessness (e.g., inability to sit still, pacing). It does not involve involuntary orofacial movements. * **Acute Dystonia:** Characterized by sudden, sustained, and painful muscle contractions (e.g., torticollis, oculogyric crisis). It typically occurs within hours to days of starting medication, unlike the delayed onset of TD. * **Chronic Dystonia:** While persistent, dystonia involves sustained posturing rather than the rhythmic, repetitive "chewing" or "twisting" movements seen in dyskinesia. **High-Yield Clinical Pearls for NEET-PG:** * **Risk Factors:** Old age, female gender, and long-term use of typical antipsychotics (e.g., Haloperidol). * **Management:** The first step is to **taper/discontinue** the offending agent or switch to **Clozapine** (the antipsychotic with the lowest risk of TD). * **Specific Treatments:** VMAT-2 inhibitors like **Valbenazine** or **Deutetrabenazine** are FDA-approved for TD. * **Warning:** Anticholinergics (like Trihexyphenidyl) **worsen** Tardive Dyskinesia, whereas they help in Acute Dystonia.

Question 64: A 40-year-old man, on medication for a psychiatric illness for the last two weeks, suddenly develops marked rigidity, immobility, fever, fluctuating blood pressure, and heart rate. What is the most likely diagnosis?

A. Akathisia
B. Parkinsonism
C. Neuroleptic malignant syndrome (Correct Answer)
D. Catatonic schizophrenia

Explanation: ### Explanation The clinical presentation described—marked rigidity, hyperthermia (fever), autonomic instability (fluctuating BP and heart rate), and altered mental status (immobility) shortly after starting psychiatric medication—is the classic tetrad of **Neuroleptic Malignant Syndrome (NMS)**. **1. Why Neuroleptic Malignant Syndrome is correct:** NMS is a life-threatening idiosyncratic reaction to dopamine antagonists (typically typical antipsychotics like Haloperidol). The underlying mechanism involves massive **dopamine blockade** in the nigrostriatal pathway (leading to "lead-pipe" rigidity) and the hypothalamus (causing dysregulation of temperature and autonomic functions). It usually occurs within the first two weeks of treatment. **2. Why other options are incorrect:** * **Akathisia:** This is an extrapyramidal side effect (EPS) characterized by subjective inner restlessness and an inability to sit still. It does not cause fever or autonomic instability. * **Parkinsonism:** While it presents with rigidity and bradykinesia, it lacks the systemic features of high-grade fever and autonomic dysfunction seen in NMS. * **Catatonic Schizophrenia:** Although it involves immobility and rigidity (waxy flexibility), it is a psychiatric state rather than a drug-induced medical emergency and typically does not present with acute autonomic instability or high fever unless complicated by "Lethal Catatonia." **3. High-Yield Clinical Pearls for NEET-PG:** * **Key Lab Finding:** Significantly elevated **Creatine Phosphokinase (CPK)** levels due to muscle rigidity and rhabdomyolysis. * **Treatment of Choice:** Immediate drug discontinuation + Supportive care (cooling/fluids). Specific pharmacological agents include **Dantrolene** (muscle relaxant) or **Bromocriptine** (dopamine agonist). * **Differential Diagnosis:** Distinguish from **Serotonin Syndrome**, which presents with hyperreflexia and myoclonus rather than "lead-pipe" rigidity.

Question 65: Weight gain caused by antipsychotics is due to antagonism of which receptor subtype?

A. 5-HT3
B. 5-HT2A
C. 5-HT2B
D. 5-HT2C (Correct Answer)

Explanation: **Explanation:** The correct answer is **D. 5-HT2C**. **Mechanism of Weight Gain:** Antipsychotic-induced weight gain is a complex metabolic side effect primarily mediated by the antagonism of two specific receptors: **5-HT2C (Serotonin 2C)** and **H1 (Histamine 1)**. * **5-HT2C receptors** are located in the hypothalamus and play a crucial role in regulating satiety and energy homeostasis. When these receptors are blocked, the "satiety signal" is inhibited, leading to hyperphagia (increased appetite) and subsequent weight gain. * **H1 antagonism** further exacerbates this by causing sedation and increasing cravings for high-calorie carbohydrates. **Analysis of Incorrect Options:** * **A. 5-HT3:** These receptors are primarily involved in the emetic reflex (nausea/vomiting). Antagonists (like Ondansetron) are used as anti-emetics, not associated with metabolic changes. * **B. 5-HT2A:** Antagonism of 5-HT2A is the hallmark of Second Generation (Atypical) Antipsychotics. It helps reduce Extrapyramidal Side Effects (EPS) and improves negative symptoms, but it is not the primary driver of weight gain. * **C. 5-HT2B:** These receptors are mainly found in the heart and GI tract. Agonism of 5-HT2B is associated with cardiac valvulopathy (e.g., with Fenfluramine). **High-Yield Clinical Pearls for NEET-PG:** * **Highest Risk of Weight Gain/Metabolic Syndrome:** Clozapine (most potent) > Olanzapine. * **Lowest Risk/Weight Neutral:** Ziprasidone, Aripiprazole, and Lurasidone. * **Monitoring:** Patients on Atypical Antipsychotics must have regular monitoring of BMI, waist circumference, fasting blood glucose, and lipid profile (Metabolic Monitoring). * **Management:** Metformin is often the first-line pharmacological intervention for antipsychotic-induced weight gain.

Question 66: What are the normal therapeutic lithium levels?

A. 0.5 to 0.7 mEq/lit
B. 0.7 to 1.1 mEq/lit (Correct Answer)
C. 0.1 to 0.3 mEq/lit
D. 1.5 to 2 mEq/lit

Explanation: Lithium is the gold standard mood stabilizer used for the treatment of Bipolar Affective Disorder (BPAD). It has a **narrow therapeutic index**, meaning the difference between a therapeutic dose and a toxic dose is very small, necessitating Therapeutic Drug Monitoring (TDM). ### **Explanation of Options** * **Correct Answer (B): 0.7 to 1.1 mEq/lit.** This range is considered the standard therapeutic window for treating **acute mania**. For **prophylaxis/maintenance** in BPAD, the target level is slightly lower, typically **0.6 to 0.8 mEq/lit**. * **Option A (0.5 to 0.7 mEq/lit):** While this may be acceptable for long-term maintenance in some patients, it is generally considered sub-therapeutic for controlling acute manic episodes. * **Option C (0.1 to 0.3 mEq/lit):** These levels are clinically insignificant and will not provide a therapeutic effect. * **Option D (1.5 to 2 mEq/lit):** This range indicates **Lithium Toxicity**. Mild toxicity begins at >1.5 mEq/L, while levels >2.0 mEq/L are considered severe and potentially life-threatening. ### **High-Yield NEET-PG Pearls** 1. **Timing of TDM:** Blood samples must be drawn **12 hours after the last dose** (Steady-state is usually reached in 5 days). 2. **Side Effects:** Most common side effect is **fine tremors**; most common renal side effect is **Nephrogenic Diabetes Insipidus**. 3. **Teratogenicity:** Causes **Ebstein’s Anomaly** (atrialization of the right ventricle) if taken during pregnancy. 4. **Toxicity Management:** If levels exceed 2.5 mEq/L or if there is severe neurological impairment, **Hemodialysis** is the treatment of choice. 5. **Drug Interactions:** Thiazides, NSAIDs, and ACE inhibitors increase lithium levels (decreased clearance).

Question 67: A 41-year-old man has been treated with haloperidol for his schizophrenia for the past 15 years. He begins to notice subtle involuntary movements of his hands, feet, lips, and tongue. Since he had been stable for over 1 year, his physician decided to decrease the dose. What would the physician tell the patient about the movement disorder?

A. It will disappear as soon as the medication is decreased.
B. It will increase initially as the medication is decreased. (Correct Answer)
C. It will remain unchanged.
D. It will disappear in his hands but not his feet as soon as the medication is decreased.

Explanation: **Explanation:** The patient is presenting with **Tardive Dyskinesia (TD)**, a late-onset extrapyramidal side effect caused by long-term use of first-generation antipsychotics like Haloperidol. **Why Option B is correct:** The underlying pathophysiology of TD involves **dopamine receptor supersensitivity**. Chronic blockade of $D_2$ receptors by haloperidol leads to an upregulation (increase in number and sensitivity) of these receptors in the nigrostriatal pathway. When the antipsychotic dose is decreased or discontinued, the "masking" effect of the drug is removed. This allows dopamine to act on these supersensitive receptors, which paradoxically **worsens or unmasks** the involuntary movements initially. This phenomenon is sometimes referred to as "withdrawal dyskinesia." **Why other options are incorrect:** * **Option A & D:** These are incorrect because decreasing the dose does not lead to immediate disappearance. In fact, symptoms often persist for months or may become permanent (irreversible) in many patients. * **Option C:** The movements rarely remain unchanged; they typically fluctuate in intensity following dosage adjustments due to the change in receptor occupancy. **High-Yield Clinical Pearls for NEET-PG:** * **Risk Factors:** Old age, female gender, and long-term use of typical antipsychotics. * **Clinical Feature:** Characterized by orofacial dyskinesia (tongue protrusion, lip-smacking, chewing) and choreoathetoid movements of limbs. * **Management:** 1. Prevention is key (use lowest effective dose). 2. Switch to **Clozapine** (the antipsychotic with the lowest risk of TD). 3. **VMAT-2 inhibitors** (e.g., Valbenazine, Deutetrabenazine) are now the first-line FDA-approved treatments for TD. * **Note:** Anticholinergics (like Trihexyphenidyl) **worsen** Tardive Dyskinesia, unlike other extrapyramidal symptoms.

Question 68: Which of the following is not an anxiolytic agent?

A. Risperidone (Correct Answer)
B. SSRI
C. Clonazepam
D. Buspirone

Explanation: **Explanation:** The core of this question lies in distinguishing between drugs that primarily treat psychosis versus those that manage anxiety disorders. **1. Why Risperidone is the Correct Answer:** **Risperidone** is a **Second-Generation (Atypical) Antipsychotic**. Its primary mechanism involves potent antagonism of Dopamine (D2) and Serotonin (5-HT2A) receptors. It is indicated for Schizophrenia, Bipolar Disorder, and irritability in Autism. While it may have secondary calming effects, it is not classified as an anxiolytic agent. **2. Analysis of Incorrect Options:** * **SSRI (Selective Serotonin Reuptake Inhibitors):** These are currently the **first-line pharmacological treatment** for most chronic anxiety disorders, including Panic Disorder, GAD, and Social Anxiety Disorder. * **Clonazepam:** This is a **Benzodiazepine** (BZD). BZDs act as GABA-A receptor agonists, providing rapid relief of acute anxiety symptoms. They are the most commonly used "classical" anxiolytics. * **Buspirone:** This is a **non-benzodiazepine anxiolytic** that acts as a partial agonist at the **5-HT1A receptor**. It is specifically used for Generalized Anxiety Disorder (GAD) and lacks the sedative or addictive potential of BZDs. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC) for GAD:** SSRIs (Long-term); Benzodiazepines (Short-term/Acute). * **Buspirone** takes 2–4 weeks to show anxiolytic effects; it is ineffective for "as-needed" (PRN) use. * **Propranolol** (Beta-blocker) is the drug of choice for **Performance Anxiety** (Stage fright). * **Antidote for Benzodiazepine overdose:** Flumazenil (Competitive antagonist).

Question 69: Which of the following statements is true regarding Clozapine?

A. It is a traditional antipsychotic.
B. It can cause agranulocytosis. (Correct Answer)
C. It is given parenterally.
D. It is not useful in resistant schizophrenia.

Explanation: **Explanation:** **Clozapine** is the prototype of **Atypical Antipsychotics** (Second Generation Antipsychotics). It is uniquely effective but carries a significant side-effect profile that requires strict monitoring. **Why Option B is correct:** The most serious and life-threatening adverse effect of Clozapine is **agranulocytosis** (a severe decrease in white blood cell count, specifically neutrophils), occurring in approximately 1% of patients. Due to this risk, mandatory hematological monitoring (ANC - Absolute Neutrophil Count) is required weekly for the first 6 months, biweekly for the next 6 months, and monthly thereafter. **Why other options are incorrect:** * **Option A:** Clozapine is an **Atypical** antipsychotic, not traditional. Unlike traditional drugs (like Haloperidol), it has a higher affinity for D4 and 5-HT2A receptors than D2 receptors, leading to fewer Extrapyramidal Side Effects (EPS). * **Option C:** Clozapine is administered **orally**. There is no standard parenteral (injectable) formulation used in clinical practice. * **Option D:** Clozapine is the **Gold Standard** and the drug of choice for **Treatment-Resistant Schizophrenia** (defined as failure to respond to at least two other antipsychotic trials). **High-Yield Clinical Pearls for NEET-PG:** * **Seizures:** Clozapine has a dose-dependent risk of seizures (highest among antipsychotics). * **Sialorrhea:** Paradoxical hypersalivation is a common, highly characteristic side effect. * **Metabolic Syndrome:** It causes significant weight gain, dyslipidemia, and diabetes. * **Myocarditis:** A rare but fatal complication; monitor for chest pain or tachycardia. * **Benefit:** It is the only antipsychotic proven to **reduce the risk of suicide** in schizophrenic patients.

Question 70: All of the following are characteristic features of Neuroleptic Malignant Syndrome EXCEPT:

A. Decreased creatine phosphokinase (CPK) levels (Correct Answer)
B. Myoclonus
C. Hyperthermia
D. Increased blood pressure

Explanation: **Explanation:** Neuroleptic Malignant Syndrome (NMS) is a life-threatening idiosyncratic reaction to antipsychotic drugs (neuroleptics), primarily caused by potent dopamine (D2) receptor blockade in the nigrostriatal pathway and hypothalamus. **Why Option A is the Correct Answer:** In NMS, there is intense, generalized muscular rigidity (often described as "lead-pipe rigidity"). This extreme muscle contraction leads to rhabdomyolysis (muscle breakdown), which causes a significant **increase in serum Creatine Phosphokinase (CPK) levels**, not a decrease. Elevated CPK is a hallmark laboratory finding in NMS and is used to gauge the severity of muscle damage. **Analysis of Incorrect Options:** * **B. Myoclonus:** While "lead-pipe" rigidity is the classic sign, various movement abnormalities including myoclonus, tremors, and choreoathetosis can occur due to basal ganglia dysfunction. * **C. Hyperthermia:** This is a core diagnostic criterion. Central dopamine blockade in the hypothalamus disrupts thermoregulation, leading to high-grade fever (often >38°C/100.4°F). * **D. Increased blood pressure:** Autonomic instability is a key feature of NMS. This manifests as labile blood pressure (hypertension or hypotension), tachycardia, tachypnea, and diaphoresis. **NEET-PG Clinical Pearls:** * **Mnemonic (FEVER):** **F**ever, **E**ncephalopathy (altered sensorium), **V**itals unstable, **E**levated enzymes (CPK), **R**igidity. * **Drug of Choice:** **Dantrolene** (muscle relaxant) or **Bromocriptine** (dopamine agonist). * **NMS vs. Serotonin Syndrome:** NMS is characterized by "lead-pipe" rigidity and bradyreflexia, whereas Serotonin Syndrome presents with hyperreflexia and clonus. * **Most common offending agent:** Haloperidol (High-potency typical antipsychotic).

Question 71: Which of the following drugs are used in the treatment of ADHD?

A. All the above (Correct Answer)
B. Modafinil
C. Methylphenidate
D. Amphetamine

Explanation: **Explanation:** Attention-Deficit Hyperactivity Disorder (ADHD) is primarily managed using stimulants that increase synaptic concentrations of dopamine and norepinephrine in the prefrontal cortex. 1. **Methylphenidate:** This is the **first-line pharmacological treatment** for ADHD. It acts by inhibiting the reuptake of dopamine and norepinephrine (NDRI). It is preferred due to its efficacy and relatively manageable side-effect profile. 2. **Amphetamines:** These are potent stimulants that both block the reuptake and increase the release of catecholamines from storage vesicles. They are highly effective and FDA-approved for ADHD. 3. **Modafinil:** While primarily used for narcolepsy, Modafinil is considered a **second-line or "off-label" treatment** for ADHD, particularly in adults or when stimulants are poorly tolerated. It promotes wakefulness and improves focus with a lower risk of abuse compared to traditional stimulants. Since all three drugs are utilized in the clinical management of ADHD, **Option A (All the above)** is the correct choice. **High-Yield Clinical Pearls for NEET-PG:** * **Non-Stimulant of Choice:** **Atomoxetine** (a selective norepinephrine reuptake inhibitor) is the preferred non-stimulant, especially in patients with a history of substance abuse or tics. * **Alpha-2 Agonists:** Guanfacine and Clonidine are used as adjunctive treatments or when stimulants fail. * **Side Effects:** Common side effects of stimulants include insomnia, decreased appetite, weight loss, and potential growth retardation (requiring "drug holidays"). * **Cardiac Screening:** Always screen for underlying cardiac arrhythmias before starting stimulants.

Question 72: Depression is not a known side effect of which of the following medications?

A. Propranolol
B. Oral contraceptives
C. Reserpine
D. Flupenthixol (Correct Answer)

Explanation: **Explanation** The correct answer is **Flupenthixol**. **1. Why Flupenthixol is the correct answer:** Flupenthixol is a typical antipsychotic of the thioxanthene class. Unlike many other antipsychotics that can cause "neuroleptic-induced deficit syndrome" (mimicking depression), flupenthixol is unique because, at **low doses (0.5 mg – 3 mg)**, it exerts **antidepressant and anxiolytic effects**. It is frequently used clinically in the management of mild-to-moderate depression and dysthymia, often in combination with melitracen. Therefore, it is a treatment for depression rather than a cause. **2. Analysis of incorrect options:** * **Propranolol:** Beta-blockers (especially lipophilic ones like propranolol) are classically associated with depressive symptoms, fatigue, and sleep disturbances due to their ability to cross the blood-brain barrier and interfere with central adrenergic signaling. * **Oral Contraceptives (OCPs):** Hormonal fluctuations caused by OCPs can lead to mood changes. Progestogen-only components, in particular, have been linked to an increased risk of developing depressive symptoms in susceptible individuals. * **Reserpine:** This is a classic "textbook" cause of depression. It works by irreversibly inhibiting the Vesicular Monoamine Transporter (VMAT), leading to the depletion of norepinephrine, serotonin, and dopamine. This observation historically contributed to the "Monoamine Hypothesis" of depression. **3. NEET-PG High-Yield Pearls:** * **Drugs causing depression:** Steroids (most common), Isotretinoin, Interferon-alpha, Methyldopa, L-dopa, and Ethionamide. * **Flupenthixol dosage:** Low dose = Antidepressant; High dose = Antipsychotic. * **Reserpine-induced depression** is often used as an animal model to test new antidepressant drugs.

Question 73: Which mood stabilizer is used in the management of drug-induced neutropenia?

A. Lithium (Correct Answer)
B. Valproate
C. Carbamazepine
D. Lamotrigine

Explanation: **Explanation:** The correct answer is **Lithium**. **1. Why Lithium is correct:** Lithium is unique among mood stabilizers because it induces **leukocytosis** (specifically neutrophilia). It stimulates the production of granulocyte colony-stimulating factor (G-CSF) in the bone marrow, leading to an increase in the absolute neutrophil count (ANC). While this is technically a side effect, it is utilized therapeutically to counteract drug-induced neutropenia, most notably that caused by **Clozapine**. In patients who develop mild to moderate neutropenia on Clozapine, Lithium can be "co-prescribed" to boost white blood cell counts and allow the continuation of antipsychotic therapy. **2. Why the other options are incorrect:** * **Valproate:** While generally bone-marrow neutral, it can occasionally cause dose-related thrombocytopenia (low platelets), but it does not treat neutropenia. * **Carbamazepine:** This is a high-yield "distractor" because it is actually a **cause** of blood dyscrasias. It can cause benign leukopenia and, in rare cases, life-threatening **aplastic anemia** or agranulocytosis. It is contraindicated if the baseline WBC is low. * **Lamotrigine:** Primarily associated with dermatological side effects (SJS/TEN); it has no significant effect on increasing neutrophil counts. **3. High-Yield Clinical Pearls for NEET-PG:** * **Lithium-induced Leukocytosis:** It is a reversible, non-malignant increase in WBCs (typically 10,000–15,000/mm³). * **Monitoring:** When using Lithium for this purpose, clinicians must ensure they are not masking a true infection or a worsening Clozapine-induced agranulocytosis. * **Other Lithium Side Effects:** Ebstein’s anomaly (teratogenicity), Nephrogenic Diabetes Insipidus, Hypothyroidism, and Fine Tremors. * **Drug of Choice:** Lithium remains the gold standard for classic Bipolar Disorder (Manic-Depressive Illness).

Question 74: Sudden development of a severe throbbing headache is a characteristic side effect of which psychotropic medication?

A. Lithium carbonate
B. Phenelzine (Correct Answer)
C. Diazepam
D. Thioridazine

Explanation: **Explanation:** The correct answer is **Phenelzine**. The sudden development of a severe throbbing headache in a patient taking Phenelzine is a classic presentation of a **Hypertensive Crisis** (also known as the "Cheese Reaction"). **1. Why Phenelzine is correct:** Phenelzine is a non-selective **Monoamine Oxidase Inhibitor (MAOI)**. MAO is the enzyme responsible for breaking down tyramine in the gut. When a patient on MAOIs consumes tyramine-rich foods (e.g., aged cheese, red wine, smoked meats), tyramine enters the systemic circulation and acts as an indirect sympathomimetic, causing a massive release of stored norepinephrine. This leads to severe hypertension, characterized by a sudden, "explosive" occipital headache, palpitations, and neck stiffness. **2. Why other options are incorrect:** * **Lithium carbonate:** Common side effects include tremors, polyuria (nephrogenic diabetes insipidus), and hypothyroidism. While toxicity can cause neurological symptoms, a sudden throbbing headache is not characteristic. * **Diazepam:** As a benzodiazepine, its primary side effects are sedation, ataxia, and respiratory depression in overdose. It is actually used to *treat* anxiety-related tension, not cause acute headaches. * **Thioridazine:** This low-potency antipsychotic is most famous for causing **retinitis pigmentosa** (at high doses) and QTc prolongation. **Clinical Pearls for NEET-PG:** * **Antidote:** The drug of choice for an MAOI-induced hypertensive crisis is **Phentolamine** (an alpha-blocker). * **Dietary Restriction:** Patients must follow a low-tyramine diet for at least 2 weeks after stopping MAOIs. * **Drug Interaction:** Avoid combining MAOIs with SSRIs or Pethidine to prevent **Serotonin Syndrome**.

Question 75: Which of the following drugs is both effective and safe to use in a pregnant patient suffering from bipolar disorder?

A. Carbamazepine
B. Lithium
C. Olanzapine (Correct Answer)
D. Valproic acid

Explanation: ### Explanation The management of bipolar disorder during pregnancy requires balancing maternal stability with fetal safety. **Why Olanzapine is the Correct Answer:** Atypical antipsychotics, such as **Olanzapine**, are generally considered the first-line maintenance treatment for bipolar disorder in pregnancy. Unlike traditional mood stabilizers, Olanzapine is not associated with major structural malformations (congenital anomalies). While it carries a risk of metabolic side effects like gestational diabetes and macrosomia, it is significantly safer for the fetus than the alternatives listed. **Analysis of Incorrect Options:** * **Valproic acid (D):** This is the **most teratogenic** option. It is strictly contraindicated due to the high risk of **Neural Tube Defects (NTDs)** like spina bifida (1-2%), craniofacial abnormalities, and long-term neurodevelopmental delays. * **Carbamazepine (A):** Similar to Valproate, it is associated with **Neural Tube Defects** and "Fetal Carbamazepine Syndrome" (fingernail hypoplasia and craniofacial defects). * **Lithium (B):** While sometimes used if benefits outweigh risks, it is classically associated with **Ebstein’s Anomaly** (a cardiac defect involving the tricuspid valve). Though the absolute risk is lower than previously thought (~1/1000), it remains less "safe" than Olanzapine in the first trimester. **High-Yield Clinical Pearls for NEET-PG:** 1. **Drug of Choice:** For acute mania in pregnancy, **Haloperidol** or **Second-Generation Antipsychotics (SGAs)** are preferred. 2. **Valproate Warning:** If a woman of childbearing age must take Valproate, high-dose **Folic acid (5mg)** supplementation is mandatory. 3. **Lithium Monitoring:** If Lithium is used, doses often need adjustment due to increased GFR during pregnancy, and it should be tapered before delivery to avoid "Floppy Infant Syndrome." 4. **Lurasidone:** Another SGA frequently cited as safe (Category B) for bipolar depression in pregnancy.

Question 76: Which antidepressant drug is known to have both high sedative and anticholinergic activity?

A. Phenelzine
B. Amitriptyline (Correct Answer)
C. Fluoxetine
D. Trazodone

Explanation: **Explanation:** **Amitriptyline** is a classic **Tricyclic Antidepressant (TCA)** of the tertiary amine subclass. Its pharmacological profile is characterized by potent antagonism at multiple receptors beyond serotonin and norepinephrine reuptake inhibition: * **Anticholinergic activity:** Due to high affinity for Muscarinic (M1) receptors, leading to side effects like dry mouth, blurred vision, and urinary retention. * **Sedative activity:** Due to potent antagonism of Histamine (H1) and alpha-1 adrenergic receptors. Among TCAs, Amitriptyline is considered one of the most sedating, making it useful for depressed patients with insomnia. **Analysis of Incorrect Options:** * **Phenelzine:** An irreversible MAO inhibitor. It lacks significant direct anticholinergic or sedative properties; its main risks are hypertensive crisis (tyramine reaction) and serotonin syndrome. * **Fluoxetine:** An SSRI. These are generally devoid of sedative and anticholinergic effects. In fact, Fluoxetine is often "activating" and can cause insomnia. * **Trazodone:** A SARI (Serotonin Antagonist and Reuptake Inhibitor). While it is **highly sedative** (often used for insomnia), it has **minimal anticholinergic activity**, making it safer for elderly patients regarding cognitive impairment or glaucoma. **High-Yield Clinical Pearls for NEET-PG:** * **Tertiary Amines (Amitriptyline, Imipramine, Clomipramine):** Higher sedation and anticholinergic effects compared to Secondary Amines (Nortriptyline, Desipramine). * **TCA Overdose Triad:** Cardiac arrhythmias (prolonged QTc), Convulsions, and Coma (The "3 Cs"). * **Antidote for TCA toxicity:** Sodium Bicarbonate (to manage QRS widening). * **Drug of Choice:** Amitriptyline is also used for chronic pain prophylaxis (migraine, neuropathic pain).

Question 77: A child with schizophrenia was on medications and suddenly developed neck stiffness and spasm. What is the most probable cause?

A. Conversion disorder
B. Acute dystonia (Correct Answer)
C. Akathisia
D. Tardive dyskinesia

Explanation: **Explanation:** The clinical presentation of sudden onset neck stiffness and muscle spasms in a patient taking antipsychotics is a classic description of **Acute Dystonia**, a type of Extrapyramidal Side Effect (EPS). **1. Why Acute Dystonia is correct:** Acute dystonia is caused by a sudden blockade of dopamine (D2) receptors in the nigrostriatal pathway, leading to a relative excess of cholinergic activity. It typically occurs within hours to days of starting or increasing the dose of typical antipsychotics (e.g., Haloperidol). Common manifestations include **torticollis** (neck spasm), **retrocollis**, **oculogyric crisis** (upward gaze deviation), and **opisthotonus**. It is most common in young males and children. **2. Why other options are incorrect:** * **Conversion disorder:** This is a psychiatric condition where neurological symptoms (like paralysis or seizures) occur without a medical cause, usually triggered by psychological stress. It does not typically present as isolated muscle spasms following medication. * **Akathisia:** This presents as a subjective feeling of inner restlessness and an inability to sit still. It involves motor restlessness (pacing) rather than involuntary muscle spasms. * **Tardive dyskinesia:** This is a late-onset EPS occurring after months or years of treatment. It involves choreoathetoid movements, most commonly orofacial dyskinesia (lip-smacking, tongue protrusion), rather than acute spasms. **Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** Intravenous or intramuscular **Promethazine** or **Benztropine** (anticholinergics). * **Risk Factors:** High-potency first-generation antipsychotics, young age, and male gender. * **Timeline Mnemonic (ADAPT):** **A**cute **D**ystonia (hours), **A**kathisia (days), **P**arkinsonism (weeks), **T**ardive dyskinesia (months/years).

Question 78: Which of the following medications is not used in the management of delirium?

A. Haloperidol
B. Lithium (Correct Answer)
C. Diazepam
D. Olanzapine

Explanation: **Explanation:** Delirium is an acute neuropsychiatric syndrome characterized by a waxing and waning level of consciousness and cognitive deficits. The primary goal of management is treating the underlying cause, but pharmacological intervention is often required for behavioral control. **Why Lithium is the Correct Answer:** **Lithium** is strictly contraindicated in delirium. It is a mood stabilizer with a narrow therapeutic index and significant neurotoxic potential. In a delirious patient, Lithium can worsen confusion, cause tremors, and potentially induce seizures or a "Lithium-induced encephalopathy." Furthermore, delirium is often associated with dehydration and electrolyte imbalances, which can lead to toxic Lithium levels due to decreased renal clearance. **Analysis of Other Options:** * **Haloperidol (Option A):** This is the **drug of choice (DOC)** for delirium. It is a high-potency typical antipsychotic with minimal anticholinergic and sedative effects, making it ideal for managing agitation and psychosis in delirious patients. * **Diazepam (Option C):** While benzodiazepines are generally avoided in delirium (as they can cause paradoxical agitation or worsen confusion), they are the **first-line treatment** for specific types of delirium, namely **Alcohol Withdrawal Delirium (Delirium Tremens)** and sedative-hypnotic withdrawal. * **Olanzapine (Option D):** Atypical antipsychotics (like Olanzapine, Quetiapine, or Risperidone) are frequently used as alternatives to Haloperidol, especially when a lower risk of extrapyramidal side effects (EPS) is desired. **High-Yield Clinical Pearls for NEET-PG:** * **DOC for Delirium:** Haloperidol (Low dose). * **DOC for Delirium Tremens:** Benzodiazepines (e.g., Diazepam, Lorazepam). * **Avoid:** Drugs with strong anticholinergic properties (e.g., Amitriptyline, Diphenhydramine) as they worsen delirium. * **Key Feature:** Delirium is characterized by a **fluctuating** course and **impaired consciousness** (unlike Dementia).

Question 79: A patient with schizophrenia, who started haloperidol two days ago, presents with complaints of torticollis and orofaciolingual movements. What is the most likely diagnosis?

A. Acute dystonia (Correct Answer)
B. Tardive dyskinesia
C. Parkinsonism
D. Akathisia

Explanation: ### Explanation **1. Why Acute Dystonia is the Correct Answer:** Acute dystonia is an Extrapyramidal Side Effect (EPS) characterized by sudden, involuntary, and sustained muscle contractions. The key to this diagnosis lies in the **timeline** and the **presentation**. * **Timeline:** It is the earliest EPS to appear, typically occurring within **hours to a few days** (90% within the first 5 days) of starting or increasing the dose of a high-potency typical antipsychotic like Haloperidol. * **Presentation:** It commonly involves the neck (**torticollis**), eyes (oculogyric crisis), tongue (protrusion), or back (opisthotonus). The "orofaciolingual movements" in this acute setting represent lingual dystonia. **2. Why Other Options are Incorrect:** * **Tardive Dyskinesia (TD):** While it also involves orofaciolingual movements (e.g., lip-smacking), TD is a **late-onset** complication occurring after **months to years** of treatment. It would not occur two days after starting medication. * **Parkinsonism:** This typically presents within **weeks** (5–30 days) with a triad of tremors, rigidity, and bradykinesia/shuffling gait, rather than acute muscle spasms. * **Akathisia:** This presents as subjective **motor restlessness** (inability to sit still). It usually appears within **days to weeks** (5–60 days). **3. High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Caused by a sudden blockade of D2 receptors in the nigrostriatal pathway, leading to a relative excess of Acetylcholine. * **Risk Factors:** Young males and those receiving high-potency typical antipsychotics (Haloperidol, Fluphenazine) are at highest risk. * **Management:** The drug of choice is an **intravenous or intramuscular anticholinergic** (e.g., **Promethazine**, Benztropine, or Trihexyphenidyl). * **Mnemonic for EPS Timeline:** "**ADAPT**" * **A**cute **D**ystonia (Hours/Days) * **A**kathisia (Days/Weeks) * **P**arkinsonism (Weeks/Months) * **T**ardive Dyskinesia (Months/Years)

Question 80: All of the following are true about antipsychotics except?

A. Haloperidol is a typical antipsychotic.
B. Asenapine can be administered sublingually.
C. The most common extrapyramidal symptom is acute dystonia. (Correct Answer)
D. Clozapine can lead to agranulocytosis.

Explanation: **Explanation:** The correct answer is **C**, as the statement is factually incorrect. While acute dystonia is a dramatic and early-onset extrapyramidal symptom (EPS), it is not the most common. **Akathisia** (a subjective feeling of inner restlessness and inability to sit still) is the **most common EPS** associated with antipsychotic use. **Analysis of Options:** * **Option A:** **Haloperidol** is a high-potency First-Generation Antipsychotic (FGA) or "typical" antipsychotic. It primarily acts via D2 receptor antagonism and has a high propensity for causing EPS. * **Option B:** **Asenapine** is a Second-Generation Antipsychotic (SGA) that has poor oral bioavailability due to extensive first-pass metabolism. Therefore, it is specifically formulated for **sublingual administration** to ensure systemic absorption. * **Option D:** **Clozapine** is the gold standard for treatment-resistant schizophrenia but is notorious for causing **agranulocytosis** (absolute neutrophil count <500/mm³). This necessitates mandatory periodic WBC monitoring (REMS protocol). **High-Yield Clinical Pearls for NEET-PG:** 1. **EPS Timeline:** * *Acute Dystonia:* Hours to days (Earliest; treat with Promethazine/Benztropine). * *Akathisia:* Days to weeks (Most common; treat with Beta-blockers like Propranolol). * *Drug-induced Parkinsonism:* Weeks to months. * *Tardive Dyskinesia:* Months to years (Choreiform movements; switch to Clozapine). 2. **Clozapine Side Effects:** It is the only antipsychotic that reduces suicide risk but carries risks of seizures, myocarditis, and significant weight gain, in addition to agranulocytosis. 3. **Hyperprolactinemia:** Most common with Typical antipsychotics and the atypical drug **Risperidone**.

Question 81: What is the treatment of choice for refractory schizophrenia?

A. Haloperidol
B. Flupenthixol
C. Trifluoperazine
D. Clozapine (Correct Answer)

Explanation: ### Explanation **Correct Option: D. Clozapine** **Why it is the correct answer:** Refractory (treatment-resistant) schizophrenia is defined as a lack of clinical improvement despite at least two adequate trials of different antipsychotic medications (at least one being an atypical antipsychotic) for a duration of 4–6 weeks each. **Clozapine**, an atypical antipsychotic, is the **gold standard and treatment of choice** for this condition. Its unique efficacy is attributed to its complex receptor profile, particularly its low affinity for D2 receptors and high affinity for D4, 5-HT2A, and alpha-adrenergic receptors. It is the only antipsychotic proven to reduce suicidal behavior in schizophrenic patients. **Why the other options are incorrect:** * **A, B, and C (Haloperidol, Flupenthixol, Trifluoperazine):** These are all **First-Generation Antipsychotics (Typical Antipsychotics)**. They work primarily by potent D2 receptor antagonism. While effective for positive symptoms in non-resistant cases, they are associated with a high risk of Extrapyramidal Side Effects (EPS) and are generally not effective once a patient has failed initial antipsychotic therapy. **High-Yield Clinical Pearls for NEET-PG:** * **Agranulocytosis:** The most dreaded side effect of Clozapine (occurs in ~1%). Mandatory **ANC (Absolute Neutrophil Count)** monitoring is required (Weekly for the first 6 months). * **Seizures:** Clozapine causes dose-dependent lowering of the seizure threshold. * **Sialorrhea:** Paradoxical hypersalivation is a common, highly specific side effect. * **Metabolic Syndrome:** Clozapine has the highest risk of weight gain and diabetes among antipsychotics. * **No EPS:** Clozapine has the lowest risk of Extrapyramidal Side Effects and does not cause Tardive Dyskinesia.

Question 82: Tardive dyskinesia is least commonly associated with which of the following drugs?

A. Thioridazine
B. Metoclopramide
C. Thiothixene
D. Clozapine (Correct Answer)

Explanation: **Explanation:** **Tardive Dyskinesia (TD)** is a late-onset extrapyramidal side effect (EPS) characterized by involuntary, choreoathetoid movements, typically involving the tongue, face, and jaw. It is caused by the **upregulation and supersensitivity of Dopamine D2 receptors** in the nigrostriatal pathway following chronic blockade. **Why Clozapine is the correct answer:** Clozapine is an atypical (second-generation) antipsychotic with a unique pharmacological profile. It has a **very low affinity for D2 receptors** and a high affinity for D4 and Serotonin (5-HT2A) receptors. It dissociates rapidly from D2 receptors ("loose binding"), which significantly minimizes the risk of nigrostriatal side effects. Clozapine is the only antipsychotic with a **near-zero risk** of causing TD and is, in fact, the drug of choice for managing patients who have already developed TD. **Analysis of Incorrect Options:** * **Thioridazine (A):** A low-potency typical antipsychotic. While it has some intrinsic anticholinergic activity that lowers acute EPS, it still carries a significant risk of TD with long-term use. * **Metoclopramide (B):** A prokinetic antiemetic that acts as a potent D2 receptor antagonist. It is a notorious non-psychiatric cause of TD, especially in elderly patients. * **Thiothixene (C):** A high-potency typical antipsychotic (thioxanthene class) with strong D2 blockade, making it highly associated with the development of TD. **High-Yield Clinical Pearls for NEET-PG:** * **Treatment of choice for TD:** Valbenazine or Deutetrabenazine (VMAT2 inhibitors). * **Drug of choice for TD in a psychotic patient:** Clozapine. * **Risk Factor:** Long-term use of typical antipsychotics and advancing age. * **Note:** Anticholinergics (like Trihexyphenidyl) **worsen** TD, unlike other EPS.

Question 83: An elderly woman suffering from schizophrenia is on antipsychotic medication. She developed purposeless involuntary facial and limb movements, constant chewing and puffing of cheeks. Which of the following drugs is least likely to be involved in this side effect?

A. Haloperidol
B. Clozapine (Correct Answer)
C. Fluphenazine
D. Loxapine

Explanation: **Explanation:** The clinical presentation described—purposeless involuntary facial movements, constant chewing, and puffing of cheeks—is characteristic of **Tardive Dyskinesia (TD)**. This is a late-onset extrapyramidal side effect (EPS) caused by long-term blockade of dopamine (D2) receptors, leading to receptor supersensitivity. **Why Clozapine is the Correct Answer:** Clozapine is an atypical (second-generation) antipsychotic with a unique pharmacological profile. It has a **low affinity for D2 receptors** and a high affinity for D4 and serotonin (5-HT2A) receptors. It dissociates rapidly from D2 receptors ("loose binding"), making it the antipsychotic with the **lowest risk of causing EPS and Tardive Dyskinesia**. In fact, Clozapine is often the drug of choice for patients who have already developed TD. **Analysis of Incorrect Options:** * **Haloperidol & Fluphenazine:** These are high-potency, first-generation antipsychotics (FGAs). They have strong, long-lasting D2 receptor antagonism and are the most common culprits behind TD. * **Loxapine:** Although sometimes classified as a mid-potency FGA or an atypical, it behaves largely like a typical antipsychotic at higher doses and carries a significant risk of TD compared to Clozapine. **NEET-PG High-Yield Pearls:** * **Tardive Dyskinesia:** Most common in elderly females. The earliest sign is often fine vermicular (worm-like) movements of the tongue. * **Treatment of TD:** The first step is to switch to **Clozapine** or Quetiapine. Recently, VMAT-2 inhibitors like **Valbenazine** or Deutetrabenazine have become the preferred specific treatments. * **Anticholinergics:** Drugs like Trihexyphenidyl (THP) **worsen** TD, unlike other EPS (like dystonia or parkinsonism) where they are used as treatment.

Question 84: Coarse tremors, dysarthria, and ataxia are side effects of which medication?

A. Lithium (Correct Answer)
B. Haloperidol
C. Imipramine
D. None of the above

Explanation: **Explanation:** The correct answer is **Lithium**. The symptoms described—**coarse tremors, dysarthria (slurred speech), and ataxia (stumbling gait)**—are classic neurological hallmarks of **Lithium Toxicity**. 1. **Why Lithium is correct:** Lithium has a very narrow therapeutic index (0.6–1.2 mEq/L). While *fine* tremors are a common side effect at therapeutic levels, the progression to *coarse* tremors, along with cerebellar signs like ataxia and dysarthria, indicates toxicity (usually levels >1.5–2.0 mEq/L). These symptoms occur because lithium interferes with neurotransmission and can cause reversible or, in severe cases, permanent cerebellar damage (SILENT syndrome). 2. **Why other options are incorrect:** * **Haloperidol:** A typical antipsychotic primarily associated with **Extrapyramidal Side Effects (EPS)** such as acute dystonia, parkinsonism (resting tremors, not coarse), and akathisia. * **Imipramine:** A Tricyclic Antidepressant (TCA) characterized by **anticholinergic side effects** (dry mouth, blurred vision, constipation) and cardiotoxicity (prolonged QTc) in overdose, rather than ataxia and coarse tremors. **High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Range:** 0.6–1.2 mEq/L (Prophylaxis: 0.6–0.8; Acute Mania: 0.8–1.2). * **Early signs of toxicity:** Nausea, vomiting, and coarse tremors. * **Severe toxicity (>2.5 mEq/L):** Seizures, coma, and death. **Hemodialysis** is the treatment of choice for severe toxicity. * **Drug Interactions:** Thiazides, NSAIDs, and ACE inhibitors increase Lithium levels (decreasing clearance), potentially precipitating toxicity.

Question 85: Which of the following neurotransmitters/factors increases on Electroconvulsive therapy?

A. 5-hydroxy-indole-acetic acid
B. Dopamine
C. Serotonin
D. Brain derived neurotrophic factor (Correct Answer)

Explanation: **Explanation:** **Correct Answer: D. Brain-derived neurotrophic factor (BDNF)** The therapeutic efficacy of Electroconvulsive Therapy (ECT) is increasingly attributed to its **neuroplastic effects**. ECT significantly increases the levels of **Brain-derived neurotrophic factor (BDNF)** in the hippocampus and prefrontal cortex. BDNF is a protein that promotes the survival of existing neurons and encourages the growth and differentiation of new neurons and synapses (neurogenesis). Chronic depression is associated with hippocampal atrophy and low BDNF levels; ECT reverses this by stimulating BDNF expression, which is considered a primary mechanism for its rapid antidepressant action. **Analysis of Incorrect Options:** * **A. 5-hydroxy-indole-acetic acid (5-HIAA):** This is the primary metabolite of serotonin. Studies show that ECT does not consistently increase 5-HIAA levels in the cerebrospinal fluid. * **B. Dopamine:** While ECT may increase postsynaptic dopamine receptor sensitivity, it does not consistently increase the overall levels of the neurotransmitter itself. * **C. Serotonin:** Similar to antidepressants, ECT modulates the serotonergic system (specifically increasing 5-HT2A receptor sensitivity), but it does not significantly increase the absolute concentration of serotonin. **Clinical Pearls for NEET-PG:** * **Gold Standard:** ECT remains the most effective treatment for **severe treatment-resistant depression** and **catatonia**. * **Mechanism:** The therapeutic effect requires a **generalized tonic-clonic seizure** lasting at least 25–30 seconds. * **Neurobiology:** Beyond BDNF, ECT is known to **decrease** hyperconnectivity in the "Default Mode Network" (DMN) of the brain. * **Contraindications:** There are no absolute contraindications, but **increased intracranial pressure (ICP)** is the most significant relative contraindication due to the risk of herniation.

Question 86: In Direct Electroconvulsive Therapy (ECT), what is the effect on intraocular tension?

A. Increased
B. Decreased (Correct Answer)
C. No change
D. Variable

Explanation: **Explanation:** The correct answer is **B. Decreased**. **1. Why it is correct:** Electroconvulsive Therapy (ECT) induces a generalized tonic-clonic seizure. During the seizure activity, there is a paradoxical and significant **decrease in intraocular pressure (IOP)**. This occurs primarily due to the contraction of extraocular muscles and the subsequent increase in the outflow of aqueous humor through the trabecular meshwork. Additionally, the autonomic changes during the seizure lead to a transient reduction in aqueous production. This makes ECT relatively safe for patients with controlled glaucoma. **2. Why other options are incorrect:** * **A. Increased:** While ECT causes a transient **increase** in heart rate, blood pressure, and **intracranial pressure (ICP)**, it does *not* increase intraocular pressure. Students often confuse the rise in ICP with IOP. * **C & D. No change/Variable:** These are incorrect because the physiological response to the seizure consistently leads to a measurable drop in IOP across clinical studies. **3. High-Yield Clinical Pearls for NEET-PG:** * **Direct vs. Modified ECT:** "Direct" ECT (without muscle relaxants) is rarely practiced today. Modern "Modified" ECT uses **Succinylcholine** (muscle relaxant) and **Thiopental/Propofol** (anesthetic). * **Cardiovascular effects:** The initial response is **Parasympathetic** (bradycardia/hypotension), followed by a more prolonged **Sympathetic** surge (tachycardia/hypertension). * **Absolute Contraindication:** There are no absolute contraindications to ECT, but **Increased Intracranial Pressure (ICP)** is the most significant relative contraindication (due to the risk of herniation). * **Glaucoma:** ECT is **not** contraindicated in glaucoma because it lowers IOP. However, caution is advised if using anticholinergic premedication (like Atropine), which can theoretically increase IOP in narrow-angle glaucoma.

Question 87: When compared to traditional antipsychotic medication, atypical antipsychotic medication is more likely to be helpful for which of the following symptoms?

A. Hallucinations
B. Delusions
C. Agitation
D. Social withdrawal (Correct Answer)

Explanation: ### Explanation The core distinction between traditional (Typical/First-generation) and Atypical (Second-generation) antipsychotics lies in their receptor profiles and their efficacy against the different symptom clusters of schizophrenia. **1. Why "Social Withdrawal" is correct:** Schizophrenia symptoms are categorized into **Positive** (hallucinations, delusions) and **Negative** (social withdrawal, apathy, flattened affect, alogia). * **Typical antipsychotics** (e.g., Haloperidol) primarily act via potent **D2 receptor antagonism** in the mesolimbic pathway, making them highly effective for positive symptoms but often ineffective (or even worsening) for negative symptoms. * **Atypical antipsychotics** (e.g., Olanzapine, Risperidone, Clozapine) provide **5-HT2A (Serotonin) receptor antagonism** in addition to D2 blockade. This serotonergic action increases dopamine release in the prefrontal cortex, which is hypothesized to improve **negative symptoms** like social withdrawal and cognitive deficits. **2. Analysis of Incorrect Options:** * **A & B (Hallucinations and Delusions):** These are "Positive Symptoms." Both typical and atypical antipsychotics are equally effective at treating these. Therefore, atypicals are not "more likely" to be helpful compared to typicals for these specific symptoms. * **C (Agitation):** Acute agitation is often managed effectively (and sometimes more rapidly) with high-potency typical antipsychotics or benzodiazepines. **3. NEET-PG High-Yield Pearls:** * **Mechanism:** Atypicals = "SDAs" (Serotonin-Dopamine Antagonists). They have a lower affinity for D2 receptors and "fast dissociation," leading to fewer Extrapyramidal Side Effects (EPS). * **Negative Symptoms:** Think of the **"5 A's"**: Affective flattening, Alogia, Avolition, Anhedonia, and Asociality (Social withdrawal). * **Drug of Choice:** Clozapine is the gold standard for **treatment-resistant schizophrenia**, but it requires monitoring for agranulocytosis. * **Side Effects:** While atypicals have lower EPS, they are more likely to cause **Metabolic Syndrome** (weight gain, dyslipidemia, diabetes), especially Olanzapine and Clozapine.

Question 88: Which of the following statements is NOT true regarding tricyclic antidepressants?

A. They are safe in bipolar depression as they do not cause a switch to mania. (Correct Answer)
B. They cause sedation.
C. They cause weight gain.
D. They cause giddiness.

Explanation: **Explanation:** **1. Why Option A is the Correct Answer (The "Not True" Statement):** Tricyclic Antidepressants (TCAs) are notorious for having the **highest risk of inducing a "manic switch"** among all antidepressant classes when used in patients with Bipolar Disorder. In Bipolar Depression, TCAs can trigger a rapid transition from a depressive episode to a manic or hypomanic episode. Therefore, they are generally avoided or used with extreme caution (and always with a mood stabilizer) in bipolar patients. Modern antidepressants like SSRIs or Bupropion have a lower risk of this switch compared to TCAs. **2. Why the Other Options are Incorrect (They are True Statements):** * **Option B (Sedation):** TCAs cause significant sedation due to their potent **antihistaminic (H1 receptor) blockade**. This is why drugs like Amitriptyline are often administered at bedtime. * **Option C (Weight Gain):** Weight gain is a common side effect of TCAs, primarily mediated through **H1 receptor antagonism** and 5-HT2C receptor blockade, which increases appetite. * **Option D (Giddiness):** TCAs cause giddiness and orthostatic hypotension due to **alpha-1 adrenergic receptor blockade**. This increases the risk of falls, especially in the elderly. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** TCAs inhibit the reuptake of Serotonin (5-HT) and Norepinephrine (NE). * **The "3 Cs" of Toxicity:** In overdose, TCAs cause **C**oma, **C**onvulsions, and **C**ardiotoxicity (arrhythmias due to sodium channel blockade). * **ECG Finding:** Widening of the QRS complex (>100ms) is a hallmark of TCA toxicity. * **Antidote:** Intravenous **Sodium Bicarbonate** is used to manage TCA-induced cardiotoxicity. * **Anticholinergic Side Effects:** Dry mouth, blurred vision, constipation, and urinary retention (due to M1 receptor blockade).

Question 89: Which medication class is used in the medical treatment of paraphilias?

A. Selective Serotonin Reuptake Inhibitors (SSRIs) (Correct Answer)
B. Benzodiazepines
C. Opioids
D. Barbiturates

Explanation: **Explanation:** The medical management of paraphilic disorders primarily focuses on reducing the intensity of deviant sexual urges and improving impulse control. **Selective Serotonin Reuptake Inhibitors (SSRIs)** are considered a first-line pharmacological intervention for non-dangerous paraphilias. **Why SSRIs are correct:** SSRIs work through two main mechanisms in this context: 1. **Impulse Control:** By increasing synaptic serotonin, they help modulate the frontal cortex, reducing compulsive behaviors and intrusive sexual fantasies. 2. **Side Effect Profile:** A common side effect of SSRIs is decreased libido and delayed ejaculation/orgasm. In the treatment of paraphilias, this "side effect" is utilized therapeutically to dampen sexual drive and arousal. **Why other options are incorrect:** * **Benzodiazepines:** These are GABA-A agonists used for anxiety and insomnia. They have no specific effect on sexual drive and may actually cause disinhibition, potentially worsening paraphilic behaviors. * **Opioids:** These are analgesics. While chronic opioid use can lower testosterone, they are not a standard or indicated treatment for paraphilias due to high addiction potential. * **Barbiturates:** These are CNS depressants used for anesthesia or epilepsy. They do not target the neurobiology of sexual deviance. **High-Yield Clinical Pearls for NEET-PG:** * **Anti-androgens:** For severe or "high-risk" paraphilias, hormonal therapy is used. **Medroxyprogesterone acetate** and **Cyproterone acetate** reduce testosterone levels. * **GnRH Agonists:** Drugs like **Leuprolide** are the most potent hormonal treatments (chemical castration) used for refractory cases. * **Comorbidity:** Paraphilias often co-occur with OCD or Depression; SSRIs are particularly useful in these dual-diagnosis cases. * **Psychotherapy:** Pharmacotherapy is most effective when combined with **Cognitive Behavioral Therapy (CBT)**.

Question 90: Which of the following is true about psychoactive drugs?

A. Can cause sexual dysfunction
B. Used in OCD
C. Used in psychotic disorders and drug withdrawal
D. All of the above (Correct Answer)

Explanation: **Explanation:** Psychoactive drugs (psychotropics) are substances that cross the blood-brain barrier to affect the neurochemistry of the Central Nervous System (CNS), thereby altering perception, mood, consciousness, and behavior. * **Option A (Sexual Dysfunction):** This is a very common side effect of several psychotropic classes. Most notably, **SSRIs** (Selective Serotonin Reuptake Inhibitors) frequently cause decreased libido and delayed ejaculation due to increased serotonergic tone. Antipsychotics can also cause sexual dysfunction via **hyperprolactinemia** (due to Dopamine D2 blockade in the tuberoinfundibular pathway). * **Option B (Used in OCD):** Obsessive-Compulsive Disorder is primarily treated with high-dose SSRIs (e.g., Fluoxetine, Fluvoxamine) or the TCA **Clomipramine** (the gold standard, though second-line due to side effects). * **Option C (Used in Psychotic Disorders and Drug Withdrawal):** Antipsychotics (e.g., Haloperidol, Risperidone) are the mainstay for schizophrenia and bipolar mania. Additionally, psychoactive drugs like **Benzodiazepines** are the treatment of choice for alcohol withdrawal, while **Methadone or Buprenorphine** are used for opioid withdrawal. Since all statements accurately describe the clinical profile and utility of psychoactive drugs, **Option D** is the correct answer. **NEET-PG High-Yield Pearls:** * **Drug of Choice for OCD:** SSRIs (First-line); Clomipramine (Most potent). * **Sexual Dysfunction:** Bupropion and Mirtazapine are the preferred antidepressants if a patient experiences significant sexual side effects. * **Withdrawal:** Chlordiazepoxide is frequently used for detoxification in alcohol dependence syndrome.

Question 91: A 40-year-old male presents with poor adherence to Haloperidol 10mg BD. He complains of unpleasant motor symptoms and reports having an 'urge to move' constantly. His wife reports that he is restless all the time. Which of the following explains the symptoms?

A. Tourette's Syndrome
B. Hyperkinetic Disorder
C. Akathisia (Correct Answer)
D. Psychotic Agitation

Explanation: ### Explanation **Correct Answer: C. Akathisia** **Why it is correct:** Akathisia is a common **Extrapyramidal Side Effect (EPS)** caused by high-potency first-generation antipsychotics like Haloperidol. It is characterized by a subjective feeling of inner restlessness and an objective compulsion to move. The patient’s description of an "urge to move" and the wife’s observation of constant restlessness are classic clinical presentations. Pathophysiologically, it results from **dopamine (D2) receptor blockade** in the nigrostriatal pathway. **Why the other options are incorrect:** * **A. Tourette’s Syndrome:** This is a neurodevelopmental disorder characterized by multiple motor and at least one vocal tic lasting >1 year. It typically starts in childhood, not as a side effect of medication in a 40-year-old. * **B. Hyperkinetic Disorder (ADHD):** This involves a persistent pattern of inattention and/or hyperactivity-impulsivity. While it involves restlessness, it is a chronic developmental condition, not an acute drug-induced state. * **C. Psychotic Agitation:** While psychosis can cause agitation, it is usually driven by delusions or hallucinations. In this case, the symptoms are specifically described as "motor symptoms" following Haloperidol use, pointing toward a side effect rather than the primary illness. **NEET-PG High-Yield Pearls:** * **Management:** The first-line treatment for Akathisia is **Propranolol** (Beta-blocker). Benzodiazepines or anticholinergics (like Benztropine) can be used as second-line. * **Timeline:** Akathisia typically develops within days to weeks of starting or increasing the dose of an antipsychotic. * **Clinical Sign:** Patients are often seen pacing, shifting weight from foot to foot, or inability to sit still ("Mal de la marche"). * **Risk:** Akathisia is a major cause of **non-adherence** to treatment and is associated with an increased risk of suicide due to the extreme distress it causes.

Question 92: What is the drug of choice for bipolar mood disorder?

A. Carbamazepine
B. Lithium carbonate (Correct Answer)
C. Imipramine
D. Buspirone

Explanation: **Explanation:** **Lithium carbonate** remains the gold standard and the **drug of choice (DOC)** for the treatment of Bipolar Mood Disorder (BMD). It is unique because it is effective in treating acute mania, preventing future manic and depressive relapses (prophylaxis), and is the only psychiatric medication proven to significantly **reduce the risk of suicide** in these patients. Its mechanism involves the inhibition of the inositol monophosphatase pathway and modulation of G-proteins. **Analysis of Incorrect Options:** * **Carbamazepine (Option A):** While used as a mood stabilizer, it is generally considered a second-line agent. It is preferred in cases of "Rapid Cycling" BMD or when patients do not respond to Lithium. * **Imipramine (Option C):** This is a Tricyclic Antidepressant (TCA). Using antidepressants alone in BMD is risky as they can precipitate a "switch" into acute mania. * **Buspirone (Option D):** This is a non-benzodiazepine anxiolytic used primarily for Generalized Anxiety Disorder (GAD). It has no role in the stabilization of mood in BMD. **High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Index:** Lithium has a narrow therapeutic index. Monitoring serum levels is essential (Target: **0.8–1.2 mEq/L** for acute mania; **0.6–0.8 mEq/L** for maintenance). * **Teratogenicity:** Use in pregnancy is associated with **Ebstein’s Anomaly** (atrialization of the right ventricle). * **Side Effects:** Common boards-favorite side effects include fine tremors, hypothyroidism, and Nephrogenic Diabetes Insipidus. * **Drug Interactions:** Thiazides, NSAIDs, and ACE inhibitors can increase Lithium levels, leading to toxicity.

Question 93: Which of the following antipsychotic drugs are available as an injectable depot preparation?

A. Aripiprazole
B. Fluphenazine (Correct Answer)
C. Trifluoperazine
D. Ziprasidone

Explanation: **Explanation:** **Depot antipsychotics** are long-acting injectable (LAI) formulations used primarily to improve treatment adherence in patients with chronic schizophrenia. These medications are esterified with long-chain fatty acids (like decanoate or enanthate) in an oil vehicle, allowing for slow release over 2–4 weeks. **1. Why Fluphenazine is Correct:** **Fluphenazine decanoate** is a classic high-potency typical antipsychotic available as a depot injection. It is one of the most frequently tested depot preparations in exams, alongside **Haloperidol decanoate**. These are administered intramuscularly and provide stable plasma concentrations for extended periods. **2. Analysis of Incorrect Options:** * **Trifluoperazine (Option C):** While it is a high-potency typical antipsychotic similar to Fluphenazine, it is **not** available in a depot formulation. It is primarily administered orally. * **Ziprasidone (Option D):** This atypical antipsychotic is available as an immediate-release (short-acting) injection for acute agitation, but it does **not** have a long-acting depot form. * **Aripiprazole (Option B):** *Note for NEET-PG:* While Aripiprazole **does** have a long-acting injectable form (Aripiprazole Maintena/Lauroxil), in the context of standard textbook questions and traditional MCQ patterns, **Fluphenazine** remains the classic, definitive answer for "typical" depot preparations. If both are present, Fluphenazine is the historical gold standard for this question type. **High-Yield Clinical Pearls for NEET-PG:** * **Common Depot Drugs:** Fluphenazine decanoate, Haloperidol decanoate, Risperidone microspheres, Paliperidone palmitate, and Zuclopenthixol. * **Injection Site:** Usually the gluteal or deltoid muscle (Z-track technique is often used). * **Test Dose:** Always administer an oral challenge or a small test dose first to check for hypersensitivity or severe Extrapyramidal Side Effects (EPS) before giving a long-acting dose. * **Indication:** Poor compliance/adherence is the #1 indication for switching to a depot.

Question 94: Which recently approved NMDA blocker is used for the management of treatment-resistant depression in adults?

A. Esketamine (Correct Answer)
B. Siponimod
C. Erdafitinib
D. Risankizumab

Explanation: **Explanation:** **Esketamine** is the correct answer. It is the S-enantiomer of ketamine and acts as a non-competitive **N-methyl-D-aspartate (NMDA) receptor antagonist**. In 2019, the FDA approved Esketamine (nasal spray) for **Treatment-Resistant Depression (TRD)** in adults, defined as patients who have not responded to at least two antidepressant treatments of adequate dose and duration. Unlike traditional antidepressants that target monoamines (Serotonin/Norepinephrine) and take weeks to work, Esketamine modulates glutamate neurotransmission, providing rapid-acting antidepressant effects. **Analysis of Incorrect Options:** * **Siponimod (B):** A sphingosine-1-phosphate (S1P) receptor modulator used for the treatment of secondary progressive multiple sclerosis (SPMS). * **Erdafitinib (C):** A fibroblast growth factor receptor (FGFR) kinase inhibitor used in the treatment of metastatic urothelial carcinoma. * **Risankizumab (D):** An interleukin-23 (IL-23) inhibitor used for plaque psoriasis, psoriatic arthritis, and Crohn’s disease. **High-Yield Clinical Pearls for NEET-PG:** * **Administration:** Esketamine is administered as a **nasal spray** under direct medical supervision due to risks of sedation and dissociation. * **Monitoring:** Patients must be monitored for at least **2 hours** post-administration for blood pressure spikes and "out-of-body" experiences (dissociation). * **Mechanism:** It increases the expression of **BDNF** (Brain-Derived Neurotrophic Factor) and enhances synaptic plasticity. * **Ketamine vs. Esketamine:** While both are NMDA blockers, Esketamine has a higher affinity for the NMDA receptor, allowing for lower dosing.

Question 95: Which drug is used in the management of treatment-resistant schizophrenia?

A. Clozapine (Correct Answer)
B. Olanzapine
C. Flupenthixol
D. Haloperidol

Explanation: **Explanation:** **Clozapine** is the "gold standard" and the only FDA-approved drug for **treatment-resistant schizophrenia (TRS)**. TRS is defined as a lack of clinical improvement despite at least two adequate trials of different antipsychotic medications (at least one being an atypical antipsychotic) for a duration of 4–6 weeks each. Clozapine is a Dibenzodiazepine derivative that acts as a weak D2 blocker but a potent 5-HT2A antagonist, making it highly effective for both positive and negative symptoms with minimal extrapyramidal side effects (EPS). **Why other options are incorrect:** * **Olanzapine (Option B):** While it is a potent atypical antipsychotic often used as a second-line agent, it does not have the same proven efficacy in treatment-resistant cases as Clozapine. * **Flupenthixol (Option C):** A typical antipsychotic (thioxanthene class) often used in long-acting injectable forms (depot) for non-compliant patients, but not for resistance. * **Haloperidol (Option D):** A high-potency typical antipsychotic (butyrophenone) that primarily blocks D2 receptors. It is effective for acute psychosis but carries a high risk of EPS and is not indicated for TRS. **High-Yield Clinical Pearls for NEET-PG:** * **Agranulocytosis:** The most serious side effect of Clozapine (occurs in ~1%). Mandatory **Absolute Neutrophil Count (ANC)** monitoring is required. * **Seizures:** Clozapine is associated with dose-dependent lowering of the seizure threshold. * **Sialorrhea:** Paradoxical hypersalivation is a common, unique side effect. * **No Tardive Dyskinesia:** Clozapine has the lowest risk of EPS and Tardive Dyskinesia among all antipsychotics. * **Other indications:** It is also used to reduce suicidal behavior in patients with schizophrenia.

Question 96: Which of the following drugs is preferred for the management of depression associated with insomnia?

A. Mianserin (Correct Answer)
B. Venlafaxine
C. Sertraline
D. Desipramine

Explanation: **Explanation:** The correct answer is **Mianserin**. **1. Why Mianserin is correct:** Mianserin is a tetracyclic antidepressant (TeCA) that acts as a potent antagonist at **H1 (histamine)** and **5-HT2** receptors. Its strong antihistaminic property provides a significant **sedative effect**, making it highly effective for depressed patients suffering from prominent insomnia. Unlike many other antidepressants, it lacks significant anticholinergic side effects, which often makes it better tolerated in specific populations. **2. Why the other options are incorrect:** * **Venlafaxine (SNRI):** This drug increases norepinephrine and serotonin levels. It is generally considered **activating** and can actually cause or worsen insomnia as a side effect. * **Sertraline (SSRI):** Like most SSRIs, sertraline is more likely to cause insomnia, restlessness, or agitation, especially during the initial phase of treatment. It is typically administered in the morning. * **Desipramine (TCA):** While some TCAs are sedative (like Amitriptyline), Desipramine is a secondary amine that primarily inhibits norepinephrine reuptake. It is one of the **least sedating** TCAs and can sometimes be stimulating. **3. NEET-PG High-Yield Pearls:** * **Mirtazapine** (a related NaSSA) is also a high-yield answer for depression with insomnia/weight loss due to its H1 antagonism and weight-gain profile. * **Trazodone** is another antidepressant frequently used "off-label" at low doses specifically for its hypnotic properties. * **Mechanism of Mianserin:** It blocks alpha-2 adrenergic receptors (increasing NE release) and 5-HT2, 5-HT3, and H1 receptors. * **Side Effect Note:** Mianserin is associated with a rare risk of **agranulocytosis**; therefore, monitoring of CBC is sometimes recommended.

Question 97: A 30-year-old male patient with mania, prescribed Haloperidol one week ago, has become restless and has been pacing for the last day. Examination reveals hand tremors. What is the most likely diagnosis?

A. Anhedonia
B. Dystonia
C. Restless leg syndrome
D. Akathesia (Correct Answer)

Explanation: ### Explanation **Correct Answer: D. Akathesia** **Why Akathesia is correct:** Akathesia is one of the most common Extrapyramidal Side Effects (EPS) associated with first-generation antipsychotics like **Haloperidol**. It is characterized by a subjective feeling of inner restlessness and an objective need to move. Clinically, patients present with **pacing**, inability to sit still, and shifting weight from foot to foot. It typically occurs within days to weeks of starting or increasing the dose of a dopamine antagonist. The presence of hand tremors in this patient further points toward drug-induced Parkinsonism, which often co-exists with akathesia. **Why other options are incorrect:** * **Anhedonia:** This refers to the inability to feel pleasure, a core symptom of depression or the negative symptoms of schizophrenia, not a motor restlessness. * **Dystonia:** This involves sudden, involuntary, and painful sustained muscle contractions (e.g., torticollis or oculogyric crisis). It usually occurs within the first 48 hours of treatment, much earlier than the timeline described here. * **Restless Leg Syndrome (RLS):** While clinically similar, RLS typically occurs at night, interferes with sleep, and is relieved by movement. Akathesia occurs throughout the day and is specifically linked to the initiation of an antipsychotic. **High-Yield Clinical Pearls for NEET-PG:** * **Management of Akathesia:** The first-line treatment is **Beta-blockers (Propranolol)**. Centrally acting benzodiazepines or anticholinergics may also be used. * **Timeline of EPS (Rule of 4):** * **4 hours:** Acute Dystonia. * **4 days/weeks:** Akathesia. * **4 weeks:** Parkinsonism (Tremor, Rigidity, Bradykinesia). * **4 months/years:** Tardive Dyskinesia (Choreoathetoid movements). * Akathesia is a significant cause of **non-compliance** and can increase the risk of suicidal ideation due to the intense distress it causes.

Question 98: A 30-year-old man, recently started on haloperidol 30mg/day, developed hyperpyrexia, muscle rigidity, akinesia, mutism, sweating, tachycardia, and increased blood pressure. Investigations showed increased WBC count and increased creatinine phosphokinase. There is no history of any other drug intake or any sign of infection. What is the most likely diagnosis?

A. Drug overdose
B. Neuroleptic malignant syndrome (Correct Answer)
C. Drug-induced Parkinsonism
D. Tardive dyskinesia

Explanation: ### Explanation The clinical presentation described is a classic case of **Neuroleptic Malignant Syndrome (NMS)**, a life-threatening idiosyncratic reaction to antipsychotic drugs (neuroleptics), most commonly high-potency agents like Haloperidol. #### Why Option B is Correct: NMS is characterized by a "tetrad" of clinical features, all of which are present in this patient: 1. **Hyperpyrexia (Fever):** Often >38°C. 2. **Muscle Rigidity:** Characteristically "lead-pipe" rigidity. 3. **Autonomic Instability:** Tachycardia, sweating (diaphoresis), and labile blood pressure. 4. **Altered Mental Status:** Ranging from confusion to mutism and coma. **Laboratory findings** crucial for NEET-PG include significantly **elevated Creatinine Phosphokinase (CPK)** due to muscle necrosis (rhabdomyolysis) and **Leukocytosis (increased WBC)**. The pathophysiology involves massive dopamine blockade in the nigrostriatal pathway and hypothalamus. #### Why Other Options are Incorrect: * **A. Drug Overdose:** While Haloperidol overdose can cause sedation or extrapyramidal symptoms, it does not typically present with the specific constellation of hyperpyrexia, lead-pipe rigidity, and markedly elevated CPK. * **C. Drug-induced Parkinsonism:** Presents with tremors, bradykinesia, and rigidity, but lacks the life-threatening autonomic instability and hyperpyrexia seen in NMS. * **D. Tardive Dyskinesia:** A late-onset side effect characterized by involuntary choreoathetoid movements (e.g., lip-smacking), not an acute febrile illness. #### High-Yield Clinical Pearls for NEET-PG: * **Treatment of Choice:** Immediate discontinuation of the antipsychotic + Supportive care (cooling/hydration) + **Dantrolene** (muscle relaxant) or **Bromocriptine** (D2 agonist). * **Mnemonic for NMS (FEVER):** **F**ever, **E**ncephalopathy, **V**itals unstable, **E**levated enzymes (CPK), **R**igidity. * **Differential Diagnosis:** Serotonin Syndrome (presents with hyperreflexia and myoclonus, whereas NMS has "lead-pipe" rigidity and hyporeflexia).

Question 99: What is the drug of choice for rapid cyclers in manic–depressive psychosis?

A. Carbamazepine
B. Valproate (Correct Answer)
C. Phenytoin
D. Lithium

Explanation: **Explanation:** **1. Why Valproate is the Correct Answer:** Rapid cycling Bipolar Disorder is defined as having **four or more mood episodes** (manic, hypomanic, or depressive) within a 12-month period. Clinical studies and guidelines (such as CANMAT) establish **Valproate (Sodium Valproate/Divalproex)** as the drug of choice for rapid cyclers. It is more effective than Lithium in these patients because rapid cycling is often associated with mixed features and comorbid substance abuse, scenarios where Valproate shows superior efficacy in stabilizing mood and reducing the frequency of episodes. **2. Why the Other Options are Incorrect:** * **Lithium (Option D):** While Lithium is the "Gold Standard" for classic Bipolar I (euphoric mania), it is notoriously **less effective** in rapid cyclers and mixed states. Patients with rapid cycling often show a poor prophylactic response to Lithium. * **Carbamazepine (Option A):** This is considered a second-line mood stabilizer. While it can be used in rapid cycling if Valproate fails, it is not the first-line "drug of choice" due to its side effect profile and enzyme-inducing properties. * **Phenytoin (Option C):** This is an antiepileptic medication with no proven efficacy as a mood stabilizer in psychiatric practice. **3. High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC) for Classic Mania:** Lithium. * **DOC for Rapid Cyclers/Mixed Mania:** Valproate. * **DOC for Bipolar Depression:** Quetiapine, Lurasidone, or Lamotrigine. * **Lithium Monitoring:** Therapeutic range is 0.8–1.2 mEq/L for acute mania and 0.6–1.0 mEq/L for maintenance. * **Valproate Side Effects:** Hepatotoxicity, Pancreatitis, and Neural Tube Defects (Polycystic Ovarian Syndrome is also a common association in females).

Question 100: A 30-year-old patient with mania was prescribed haloperidol one week ago. For the past two days, he has become restless and paced in the room for a day. On examination, he was found to have hand tremors. What is he most likely suffering from?

A. Anhedonia
B. Dystonia
C. Restless leg syndrome
D. Akathisia (Correct Answer)

Explanation: **Explanation:** The patient is suffering from **Akathisia**, the most common extrapyramidal side effect (EPS) associated with typical antipsychotics like Haloperidol. **Why Akathisia is correct:** Akathisia is characterized by a subjective feeling of inner restlessness and an objective need to move. Clinically, it manifests as pacing, inability to sit still, and shifting weight from foot to foot. It typically occurs within days to weeks of starting or increasing the dose of a dopamine (D2) receptor antagonist. The presence of hand tremors further points toward drug-induced Parkinsonism, which often co-exists with akathisia in patients on high-potency neuroleptics. **Why other options are incorrect:** * **Anhedonia:** This is a negative symptom of schizophrenia or a feature of depression characterized by the inability to feel pleasure; it does not involve motor restlessness. * **Dystonia:** This involves sudden, involuntary, and painful muscular contractions (e.g., torticollis or oculogyric crisis), usually occurring within hours to the first few days of treatment. * **Restless Leg Syndrome (RLS):** While clinically similar, RLS typically occurs at night, interferes with sleep, and is often associated with iron deficiency, rather than being a direct acute side effect of antipsychotic initiation. **High-Yield Clinical Pearls for NEET-PG:** * **Management of Akathisia:** The first-line treatment is **Propranolol** (Beta-blocker). Benzodiazepines or anticholinergics (Benztropine) are second-line. * **Timeline of EPS:** 1. *Acute Dystonia:* Hours to days. 2. *Akathisia/Parkinsonism:* Days to weeks. 3. *Tardive Dyskinesia:* Months to years (long-term use). * **Pro-tip:** If a question mentions "pacing" or "inability to sit still" after starting an antipsychotic, the answer is almost always Akathisia.

Question 101: Which of the following is a side effect of vagal nerve stimulation?

A. Paradoxical suicide
B. Voice alteration (Correct Answer)
C. Arrhythmia
D. Epilepsy

Explanation: **Explanation:** **Vagus Nerve Stimulation (VNS)** is an FDA-approved neuromodulation technique used for treatment-resistant depression and refractory epilepsy. It involves a surgically implanted device that sends electrical pulses to the left vagus nerve. **Why Voice Alteration is Correct:** The vagus nerve (Cranial Nerve X) provides motor innervation to the muscles of the larynx via the **recurrent laryngeal nerve**. During the "on-cycle" of the electrical stimulation, the laryngeal muscles are affected, leading to the most common side effect: **voice alteration or hoarseness**. Other common stimulation-related side effects include cough, throat tickling, and mild dyspnea. **Analysis of Incorrect Options:** * **A. Paradoxical suicide:** While antidepressants carry a black-box warning for increased suicidal ideation in young adults, VNS is actually associated with a long-term *reduction* in suicidal ideation in treatment-resistant patients. * **C. Arrhythmia:** Although the vagus nerve influences heart rate, VNS is typically performed on the **left** vagus nerve because the right vagus nerve has a more significant innervation of the sinoatrial (SA) node. Stimulating the left side minimizes the risk of bradycardia or arrhythmias. * **D. Epilepsy:** VNS is a **treatment** for epilepsy, not a cause. It is used to reduce the frequency of seizures in patients who do not respond to anti-epileptic drugs. **High-Yield Clinical Pearls for NEET-PG:** * **Indication:** Treatment-resistant depression (failed 4+ adequate antidepressant trials). * **Site:** The pulse generator is usually implanted in the left chest wall, and electrodes are wrapped around the **left** vagus nerve. * **Side Effect Profile:** Most side effects are "stimulus-dependent," meaning they only occur when the device is actively pulsing. * **Contraindication:** VNS is contraindicated in patients with bilateral or left cervical vagotomy.

Question 102: Which of the following antidepressants is a reversible inhibitor of monoamine oxidase A (RIMA)?

A. Moclobemide (Correct Answer)
B. Phenelzine
C. Sertraline
D. Fluoxetine

Explanation: **Explanation:** **Moclobemide** is the correct answer because it belongs to the class of **Reversible Inhibitors of Monoamine Oxidase A (RIMA)**. Unlike older, irreversible MAOIs, Moclobemide selectively inhibits the MAO-A enzyme (which metabolizes serotonin, norepinephrine, and dopamine) in a reversible manner. This reversibility is clinically significant because if systemic tyramine levels rise (e.g., from consuming aged cheese), the tyramine can displace Moclobemide from the enzyme, allowing for tyramine metabolism and significantly reducing the risk of a hypertensive crisis ("cheese reaction"). **Analysis of Incorrect Options:** * **Phenelzine:** This is a **non-selective, irreversible MAO inhibitor**. It binds permanently to both MAO-A and MAO-B, requiring strict dietary restrictions to avoid life-threatening hypertensive crises. * **Sertraline & Fluoxetine:** These are **Selective Serotonin Reuptake Inhibitors (SSRIs)**. They work by inhibiting the serotonin transporter (SERT) rather than the MAO enzyme. Fluoxetine is notable for its very long half-life due to its active metabolite, norfluoxetine. **High-Yield Clinical Pearls for NEET-PG:** * **The "Cheese Reaction":** Occurs when tyramine displaces stored norepinephrine; RIMAs like Moclobemide have a much lower risk compared to Phenelzine or Tranylcypromine. * **MAO-B Inhibitor:** **Selegiline** (used in Parkinson’s) is a selective MAO-B inhibitor at low doses but loses selectivity at higher antidepressant doses. * **Washout Period:** When switching from an MAOI to an SSRI, a 2-week washout period is required (5 weeks for Fluoxetine) to prevent **Serotonin Syndrome**. * **Drug of Choice:** SSRIs (like Sertraline) remain the first-line treatment for depression due to their superior safety profile.

Question 103: What is the drug of choice for the treatment of negative symptoms of schizophrenia?

A. Chlorpromazine
B. Haloperidol
C. Clozapine (Correct Answer)
D. Doxepin

Explanation: **Explanation:** The treatment of schizophrenia involves addressing both **positive symptoms** (hallucinations, delusions) and **negative symptoms** (apathy, anhedonia, social withdrawal, alogia). **Why Clozapine is the Correct Answer:** Clozapine is an **Atypical Antipsychotic (Second-Generation Antipsychotic)**. Unlike typical antipsychotics that primarily block $D_2$ receptors, atypical agents like Clozapine have a high affinity for **$5-HT_{2A}$ receptors** and a relatively lower affinity for $D_2$ receptors. This serotonin-dopamine antagonism in the mesocortical pathway is believed to improve negative symptoms and cognitive deficits. Clozapine is specifically indicated for **treatment-resistant schizophrenia** and is considered the most effective drug for reducing negative symptoms. **Analysis of Incorrect Options:** * **A & B (Chlorpromazine & Haloperidol):** These are **Typical Antipsychotics (First-Generation)**. They act via potent $D_2$ blockade in the mesolimbic pathway. While effective for positive symptoms, they are largely ineffective for negative symptoms and may even worsen them by causing "secondary negative symptoms" due to extrapyramidal side effects (EPS). * **D (Doxepin):** This is a **Tricyclic Antidepressant (TCA)**. It has no role in the primary treatment of schizophrenia or its negative symptoms. **High-Yield Clinical Pearls for NEET-PG:** * **Clozapine Side Effects:** Agranulocytosis (requires mandatory WBC monitoring), seizures (dose-dependent), myocarditis, and significant weight gain/metabolic syndrome. * **DOC for Treatment-Resistant Schizophrenia:** Clozapine (defined as failure of 2 adequate trials of other antipsychotics). * **Suicide Prevention:** Clozapine is the only antipsychotic FDA-approved to reduce the risk of suicidal behavior in schizophrenia. * **Negative Symptoms:** Often associated with decreased dopaminergic activity in the **mesocortical pathway**.

Question 104: Which of the following neuroleptics is not an atypical antipsychotic?

A. Clozapine
B. Ziprazidone
C. Zuclopenthixol (Correct Answer)
D. Quetiapine

Explanation: **Explanation:** The distinction between antipsychotics is based on their receptor binding profiles and side-effect risks. Antipsychotics are classified into **Typical (First Generation)** and **Atypical (Second Generation)**. **Why Zuclopenthixol is the correct answer:** Zuclopenthixol is a **Typical Antipsychotic** belonging to the thioxanthene class. Its primary mechanism of action is the potent blockade of post-synaptic **D2 receptors** in the mesolimbic and nigrostriatal pathways. Because of this high D2 affinity, it carries a significant risk of Extrapyramidal Side Effects (EPS) and hyperprolactinemia, which is characteristic of first-generation neuroleptics. It is commonly used in clinical practice as a long-acting "Acuphase" injection for acute psychosis. **Analysis of Incorrect Options:** * **Clozapine (A):** The prototype atypical antipsychotic. It has a low affinity for D2 receptors and high affinity for D4 and 5-HT2A receptors. It is the gold standard for treatment-resistant schizophrenia. * **Ziprazidone (B):** An atypical antipsychotic known for its 5-HT2A/D2 antagonism. It is unique for its low risk of weight gain but requires monitoring for QTc interval prolongation. * **Quetiapine (D):** An atypical antipsychotic with a "fast-off" D2 dissociation rate, making it the drug of choice for psychosis in Parkinson’s disease due to its very low EPS risk. **High-Yield NEET-PG Pearls:** 1. **Atypicality Definition:** Atypicals are defined by a high **5-HT2A to D2 receptor blockade ratio**, which reduces the risk of EPS and improves negative symptoms. 2. **Clozapine Warning:** Associated with **agranulocytosis** (requires regular CBC monitoring) and lowering of the seizure threshold. 3. **Metabolic Syndrome:** Atypicals (especially Clozapine and Olanzapine) are highly associated with weight gain, dyslipidemia, and diabetes.

Question 105: A 43-year-old male is diagnosed with Schizophrenia but refuses treatment. Which of the following antipsychotic drugs is the treatment of choice for this patient?

A. Clozapine
B. Risperidone
C. Olanzapine
D. Fluphenazine (Correct Answer)

Explanation: ### Explanation The core clinical challenge in this scenario is **treatment non-adherence** (refusal of treatment). In patients with schizophrenia who are non-compliant or refuse daily oral medication, the treatment of choice is **Long-Acting Injectable (LAI) antipsychotics**, also known as **Depot preparations**. **Why Fluphenazine is Correct:** Among the given options, **Fluphenazine** (specifically Fluphenazine decanoate) is a classic first-generation antipsychotic available as a depot injection. It is administered intramuscularly every 2–4 weeks. This formulation ensures medication delivery despite the patient's refusal to take daily pills, thereby reducing the risk of relapse and hospitalization. **Analysis of Incorrect Options:** * **A. Clozapine:** This is the drug of choice for **Treatment-Resistant Schizophrenia** (failed 2 trials of other antipsychotics) or patients with high suicidal risk. It requires strict blood monitoring (due to agranulocytosis risk) and is only available orally, making it unsuitable for a non-compliant patient. * **B. Risperidone & C. Olanzapine:** While these are effective second-generation antipsychotics, in the context of a NEET-PG question, if the specific formulation (e.g., "Risperidone Consta") isn't mentioned, they are assumed to be oral. Between a standard oral drug and a drug traditionally associated with depot use (Fluphenazine), the depot-capable drug is the priority for non-adherence. **Clinical Pearls for NEET-PG:** * **Indications for Depot:** Poor compliance, patient preference, or history of frequent relapses. * **Common Depot Agents:** Fluphenazine decanoate, Haloperidol decanoate, Zuclopenthixol, and Risperidone microspheres. * **Clozapine High-Yields:** Most effective antipsychotic; causes **least Extrapyramidal Side Effects (EPS)**; most common side effect is **Sialorrhea** (drooling); most serious is **Agranulocytosis**. * **Olanzapine:** Associated with significant **weight gain** and metabolic syndrome.

Question 106: A 31-year-old female patient has been diagnosed with bipolar affective disorder. She is planned to be started on Lithium. Before starting the medication, which of the following laboratory tests should be performed?

A. Thyroid function tests, serum creatinine, pregnancy test (Correct Answer)
B. Thyroid function tests, serum creatinine, complete blood count
C. Thyroid function tests, serum creatinine, ALT
D. Thyroid function tests, liver function tests, pregnancy test

Explanation: **Explanation:** Lithium is the gold-standard mood stabilizer for Bipolar Affective Disorder, but it has a narrow therapeutic index and significant systemic side effects, necessitating a thorough baseline workup. **Why Option A is Correct:** 1. **Serum Creatinine (Renal Function):** Lithium is almost exclusively excreted by the kidneys. Impaired renal function can lead to toxic accumulation. Baseline creatinine is essential to calculate the GFR and monitor for potential nephrogenic diabetes insipidus or chronic interstitial nephritis. 2. **Thyroid Function Tests (TFTs):** Lithium inhibits the release of thyroid hormones and can cause goiter or hypothyroidism (in up to 10-20% of patients). Baseline levels are needed to monitor for treatment-induced thyroid dysfunction. 3. **Pregnancy Test (hCG):** Lithium is teratogenic, specifically associated with **Ebstein’s Anomaly** (downward displacement of the tricuspid valve) if taken during the first trimester. **Why Other Options are Incorrect:** * **Options B & C:** While a CBC (specifically WBC count) may show benign leukocytosis under Lithium, it is not a mandatory pre-treatment screening test compared to pregnancy status. * **Options C & D:** Lithium is not metabolized by the liver; therefore, Liver Function Tests (ALT/LFTs) are not required. LFTs are instead mandatory for patients starting Valproate. **High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Range:** 0.6–1.2 mEq/L (Acute mania: 0.8–1.2; Maintenance: 0.6–0.8). * **Toxicity Level:** >1.5 mEq/L. Dialysis is indicated if levels exceed 4.0 mEq/L (acute) or 2.5 mEq/L (chronic with symptoms). * **ECG Changes:** Lithium can cause T-wave flattening or inversion (similar to hypokalemia). * **Drug Interactions:** **NSAIDs, Thiazides, and ACE inhibitors** increase Lithium levels by decreasing renal clearance. (Mnemonic: **N**o **S**alt **A**t **T**he **A**CE).

Question 107: A 25-year-old male with a life-threatening depressive illness that has not responded adequately to medication is scheduled for electroconvulsive shock therapy (ECT). He is currently taking tranylcypramine. What is the recommended course of action?

A. Cancel the procedure, cease the tranylcypramine, and perform the ECT in 2 weeks.
B. Proceed with the ECT, but induce with midazolam and remifentanil.
C. Proceed with the ECT, but pre-treat with esmolol.
D. Proceed with the ECT with caution, using the usual anesthetic drugs. (Correct Answer)

Explanation: **Explanation:** The correct answer is **D: Proceed with the ECT with caution, using the usual anesthetic drugs.** **1. Why Option D is Correct:** Tranylcypromine is a Non-selective Irreversible Monoamine Oxidase Inhibitor (MAOI). Historically, it was believed that MAOIs must be discontinued 2 weeks prior to ECT due to fears of a "hypertensive crisis" triggered by the sympathetic surge during the seizure. However, modern clinical evidence and guidelines (including APA guidelines) state that **ECT can be safely administered to patients taking MAOIs.** The procedure should proceed with caution, focusing on careful monitoring of blood pressure and heart rate. Standard anesthetic agents (e.g., Propofol or Thiopental) and muscle relaxants (Succinylcholine) do not have absolute contraindications with MAOIs. **2. Why Other Options are Incorrect:** * **Option A:** Discontinuing the medication for 2 weeks is unnecessary and potentially dangerous for a patient with "life-threatening" depression, as it delays life-saving treatment and risks withdrawal or symptom worsening. * **Option B:** While remifentanil is used in some anesthesia protocols, it is not a requirement for MAOI patients. Midazolam can actually raise the seizure threshold, potentially making the ECT less effective. * **Option C:** Pre-treatment with esmolol (a beta-blocker) is sometimes used to blunt the tachycardic response in ECT, but it is not a routine requirement specifically for MAOI use; it is used on a case-by-case basis if the patient is already hypertensive. **3. NEET-PG High-Yield Pearls:** * **MAOI + Meperidine (Pethidine):** This is a **critical contraindication.** It can cause "Serotonin Syndrome" or a "Type I excitatory reaction" (hyperpyrexia, seizures, coma). * **MAOI + Indirect Sympathomimetics (e.g., Ephedrine):** Can cause a fatal hypertensive crisis. If a vasopressor is needed during ECT for an MAOI patient, use a **direct-acting** agent like Phenylephrine in small doses. * **Gold Standard for Treatment-Resistant Depression:** ECT remains the most effective treatment. MAOIs are often used in "Atypical Depression."

Question 108: Which of the following serum levels of lithium is considered therapeutic?

A. 0.1-0.4 mmol/L
B. 0.5-0.7 mmol/L
C. 0.8-1.1 mmol/L (Correct Answer)
D. 1.2-1.5 mmol/L

Explanation: **Explanation:** Lithium is the gold standard mood stabilizer for Bipolar Affective Disorder (BPAD). It has a **narrow therapeutic index**, meaning the difference between a therapeutic dose and a toxic dose is very small, necessitating Therapeutic Drug Monitoring (TDM). **1. Why Option C is Correct:** The standard therapeutic range for lithium in the **acute phase of mania** is generally **0.8 to 1.2 mmol/L** (or mEq/L). Option C (0.8-1.1 mmol/L) falls squarely within this range, providing optimal efficacy in stabilizing mood without immediate high risk of toxicity. **2. Analysis of Incorrect Options:** * **Option A (0.1-0.4 mmol/L):** These levels are sub-therapeutic. They are insufficient to provide clinical improvement in mood symptoms. * **Option B (0.5-0.7 mmol/L):** While this range is often used for **maintenance therapy** (prophylaxis) in stable patients to minimize side effects, it is generally considered too low for treating an acute manic episode. * **Option D (1.2-1.5 mmol/L):** This range approaches the threshold of toxicity. While some refractory cases may require levels up to 1.5 mmol/L under strict supervision, levels above 1.5 mmol/L are clinically defined as **Lithium Toxicity**. **High-Yield Clinical Pearls for NEET-PG:** * **Sampling Time:** Serum levels should be measured **12 hours after the last dose** (Trough level). * **Steady State:** It takes approximately **5 days** (5 half-lives) to reach a steady state after starting or changing a dose. * **Toxicity Thresholds:** * **>1.5 mmol/L:** Mild toxicity (Tremors, nausea, diarrhea). * **>2.0 mmol/L:** Moderate/Severe toxicity (Ataxia, confusion, seizures). * **>3.5 mmol/L:** Life-threatening; requires **Hemodialysis** (Treatment of choice). * **Pre-Lithium Workup:** Always check Renal Function Tests (RFT), Thyroid Function Tests (TFT), and ECG (due to risk of T-wave flattening/inversion).

Question 109: Which of the following are features of serotonin syndrome associated with SSRIs and MAOIs?

A. Tremors, Agitation, Cardiovascular collapse (Correct Answer)
B. Agitation, Cardiovascular collapse
C. Tremors, Cardiovascular collapse, Hypothermia
D. Agitation, Cardiovascular collapse, Hypothermia

Explanation: **Explanation** Serotonin Syndrome is a potentially life-threatening condition caused by excessive serotonergic activity in the central and peripheral nervous systems. It most commonly occurs due to drug interactions, particularly the co-administration of **SSRIs and MAOIs**, which leads to a toxic accumulation of serotonin. **1. Why Option A is Correct:** The clinical presentation of Serotonin Syndrome is characterized by a "triad" of symptoms: * **Neuromuscular Hyperexcitability:** Manifesting as **tremors**, clonus (spontaneous or inducible), hyperreflexia, and rigidity. * **Autonomic Instability:** Leading to tachycardia, hypertension, and in severe cases, **cardiovascular collapse** and hyperthermia. * **Altered Mental Status:** Presenting as **agitation**, confusion, anxiety, or delirium. Option A correctly identifies components from all three categories of the triad. **2. Why Other Options are Incorrect:** * **Options B, C, and D:** These are incorrect primarily because of the inclusion of **Hypothermia**. Serotonin syndrome is classically associated with **Hyperthermia** (elevated body temperature), often exceeding 41°C in severe cases due to excessive muscular activity. Hypothermia is not a feature of this condition. **3. NEET-PG High-Yield Pearls:** * **Hunter’s Criteria:** The gold standard for diagnosis; **Clonus** (spontaneous, inducible, or ocular) is the most important physical finding. * **Management:** The first step is the discontinuation of all serotonergic agents and supportive care. The specific antidote (serotonin antagonist) used is **Cyproheptadine**. * **Washout Period:** To prevent this syndrome, a washout period of at least **2 weeks** is required when switching between SSRIs and MAOIs (**5 weeks for Fluoxetine** due to its long half-life). * **Differential Diagnosis:** Unlike Neuroleptic Malignant Syndrome (NMS), Serotonin Syndrome features **hyperreflexia** and has a **rapid onset** (within 24 hours).

Question 110: A 31-year-old male with a mood disorder, on 30 mg of haloperidol and 100 mg of lithium, presents to the emergency room with acute onset of fever, excessive sweating, confusion, limb rigidity, and decreased communication for one day. Examination reveals tachycardia and labile blood pressure. Investigations show increased CPK enzyme levels and leukocytosis. What condition is he likely to have developed?

A. Lithium toxicity
B. Tardive dyskinesia
C. Neuroleptic malignant syndrome (Correct Answer)
D. Hypertensive encephalopathy

Explanation: ### Explanation The patient is presenting with the classic tetrad of **Neuroleptic Malignant Syndrome (NMS)**: **Fever (Hyperpyrexia), Rigidity ("Lead-pipe"), Autonomic instability (tachycardia, labile BP, diaphoresis), and Altered mental status.** **1. Why NMS is the Correct Answer:** NMS is a life-threatening idiosyncratic reaction to dopamine antagonists (like Haloperidol). The pathophysiology involves massive dopamine blockade in the nigrostriatal pathway (leading to rigidity) and the hypothalamus (causing thermoregulatory failure). Laboratory findings of **elevated Creatine Phosphokinase (CPK)** due to muscle necrosis (rhabdomyolysis) and **leukocytosis** are hallmark diagnostic markers. **2. Why Other Options are Incorrect:** * **Lithium Toxicity:** While it causes confusion and tremors, it typically presents with gastrointestinal symptoms (nausea, vomiting), coarse tremors, ataxia, and polyuria. It does not typically cause "lead-pipe" rigidity or high-grade fever. * **Tardive Dyskinesia:** This is a late-onset extrapyramidal side effect characterized by involuntary choreoathetoid movements (e.g., lip-smacking, tongue protrusion). It is not an acute febrile illness. * **Hypertensive Encephalopathy:** While it presents with confusion and high BP, it does not explain the generalized muscle rigidity, high fever, or the specific elevation of CPK. **3. NEET-PG High-Yield Pearls:** * **Treatment of NMS:** Immediate discontinuation of the antipsychotic, aggressive cooling, and pharmacological intervention with **Dantrolene** (muscle relaxant) or **Bromocriptine** (D2 agonist). * **NMS vs. Serotonin Syndrome:** Both have fever and AMS, but NMS features **"Lead-pipe" rigidity** and bradyreflexia, whereas Serotonin Syndrome features **Hyperreflexia and Myoclonus.** * **Risk Factor:** High-potency first-generation antipsychotics (Haloperidol) and rapid dose escalation.

Question 111: Which of the following medications is known to cause seizures as a side effect?

A. Clozapine (Correct Answer)
B. Olanzapine
C. Aripiprazole
D. Amisulpride

Explanation: **Explanation:** **Clozapine** is the correct answer because it is well-documented for its dose-dependent risk of lowering the seizure threshold. It is an atypical (second-generation) antipsychotic reserved for treatment-resistant schizophrenia. The risk of seizures is approximately 1% at doses below 300 mg/day but increases significantly to about 5% at doses above 600 mg/day. This pro-convulsant effect is thought to be due to its potent antagonistic action at multiple receptors, particularly its effect on GABAergic and glutamatergic neurotransmission. **Incorrect Options:** * **Olanzapine:** While structurally related to clozapine, it has a much lower risk of seizures. Its primary side effects are significant weight gain and metabolic syndrome. * **Aripiprazole:** This is a partial D2 agonist with a very low seizure profile. It is generally considered weight-neutral and is less likely to cause sedation or extrapyramidal symptoms (EPS). * **Amisulpride:** A substituted benzamide that selectively blocks D2/D3 receptors. It is not typically associated with seizures; its main concerns are hyperprolactinemia and QTc prolongation. **High-Yield Clinical Pearls for NEET-PG:** 1. **Clozapine Monitoring:** The most feared side effect is **agranulocytosis** (requires mandatory ANC monitoring), but seizures and **myocarditis** are also critical life-threatening risks. 2. **Management:** If a patient on clozapine develops seizures, the dose should be reduced, and an anticonvulsant (usually **Valproate**) is added. 3. **Other Pro-convulsant Drugs in Psychiatry:** **Bupropion** (antidepressant) is the other high-yield drug known for causing seizures, especially in patients with eating disorders (bulimia/anorexia). 4. **Sialorrhea:** Clozapine is unique for causing excessive salivation (hypersalivation) despite its anticholinergic profile.

Question 112: Which of the following is the treatment of choice for patients with schizophrenia who refuse to take treatment?

A. Clozapine
B. Thioridazine
C. Olanzapine
D. Fluphenazine (Correct Answer)

Explanation: **Explanation:** The core clinical challenge in this scenario is **non-compliance (non-adherence)**, which is common in schizophrenia due to poor insight. When a patient refuses or forgets to take daily oral medication, the treatment of choice is **Long-Acting Injectable (LAI) antipsychotics**, also known as **Depot preparations**. **Why Fluphenazine is correct:** Fluphenazine decanoate is a typical (first-generation) antipsychotic available in a depot formulation. It is administered intramuscularly every 2–4 weeks. This ensures medication delivery regardless of the patient's daily cooperation, maintains stable plasma levels, and reduces the risk of relapse compared to oral regimens. **Analysis of Incorrect Options:** * **Clozapine (A):** While it is the "Gold Standard" for **treatment-resistant schizophrenia**, it is only available in oral forms. Furthermore, it requires strict adherence to regular blood monitoring (for agranulocytosis), making it unsuitable for a patient refusing treatment. * **Thioridazine (B):** An older typical antipsychotic used orally. It is rarely a first-line choice today due to its high risk of cardiotoxicity (QTc prolongation) and retinal pigmentation. * **Olanzapine (C):** Although an effective atypical antipsychotic, the question specifically targets the issue of treatment refusal. While a long-acting injectable form of Olanzapine exists (Pamoate), Fluphenazine is the classic, high-yield example of a depot preparation used in exams for non-compliant patients. **NEET-PG High-Yield Pearls:** * **Depot Drugs:** Common examples include Fluphenazine decanoate, Haloperidol decanoate, Risperidone microspheres, and Paliperidone palmitate. * **Indication:** Depot preparations are indicated primarily for patients with a history of non-compliance or those who prefer the convenience of infrequent dosing. * **Side Effects:** Depot injections of typical antipsychotics (like Fluphenazine) carry a higher risk of Extrapyramidal Side Effects (EPS) compared to oral atypicals.

Question 113: Which of the following drugs is both effective and safe to use in a pregnant patient suffering from bipolar disorder?

A. Carbamazepine
B. Lithium
C. Olanzapine (Correct Answer)
D. Valproic acid

Explanation: **Explanation:** The management of bipolar disorder during pregnancy requires balancing maternal mental stability with fetal safety. **Why Olanzapine is Correct:** Atypical antipsychotics, such as **Olanzapine**, are generally considered the first-line treatment for bipolar disorder in pregnancy when mood stabilizers are contraindicated. Olanzapine has not been linked to a specific pattern of congenital malformations. While it carries a risk of maternal metabolic side effects (gestational diabetes and excessive weight gain), it is significantly safer for the fetus compared to traditional mood stabilizers. **Why the Other Options are Incorrect:** * **Valproic Acid (D):** This is the most teratogenic. It is associated with a high risk of **Neural Tube Defects (NTDs)** like spina bifida (1-2%), craniofacial defects, and long-term neurodevelopmental delays. It is strictly avoided in the first trimester. * **Carbamazepine (A):** Similar to Valproate, it is a known teratogen associated with **Neural Tube Defects** and "Fetal Carbamazepine Syndrome" (fingernail hypoplasia and craniofacial defects). * **Lithium (B):** While often used if the benefit outweighs the risk, it is associated with **Ebstein’s Anomaly** (atrialization of the right ventricle). Though the absolute risk is lower than previously thought (~1/1000), it is less "safe" than Olanzapine in a comparative MCQ context. **High-Yield Clinical Pearls for NEET-PG:** * **Best Mood Stabilizer in Pregnancy:** If a mood stabilizer must be used, Lithium is preferred over Valproate, but **Lamotrigine** is often considered the safest among traditional stabilizers (though not an option here). * **Ebstein’s Anomaly:** Always associate Lithium with this cardiac defect. * **Folic Acid:** High-dose folic acid (4-5 mg/day) is mandatory if a patient must remain on anticonvulsant mood stabilizers to mitigate NTD risks. * **Postpartum:** Lithium is secreted in breast milk; monitor the infant for "Floppy Baby Syndrome."

Question 114: Which of the following SSRIs has a sedating property?

A. Fluoxetine
B. Mianserin
C. Paroxetine (Correct Answer)
D. Clomipramine

Explanation: ### Explanation **Correct Option: C. Paroxetine** Paroxetine is unique among Selective Serotonin Reuptake Inhibitors (SSRIs) because it possesses significant **antimuscarinic (anticholinergic) activity**. This mild blockade of cholinergic receptors, combined with its weak inhibition of the norepinephrine transporter, results in a **sedating effect**. Consequently, it is often prescribed for patients with depression associated with significant anxiety or insomnia. **Analysis of Incorrect Options:** * **A. Fluoxetine:** Known as the most "activating" SSRI. It has a long half-life and can cause insomnia and agitation; therefore, it is typically administered in the morning. * **B. Mianserin:** While it is highly sedating, it is a **Tetracyclic Antidepressant (TeCA)**, not an SSRI. It acts as an alpha-2 antagonist. * **D. Clomipramine:** This is a **Tricyclic Antidepressant (TCA)**, specifically a potent serotonin reuptake inhibitor used in OCD. While sedating, it does not belong to the SSRI class. **High-Yield Clinical Pearls for NEET-PG:** * **Weight Gain:** Paroxetine is the SSRI most commonly associated with weight gain and the highest risk of **discontinuation syndrome** due to its short half-life and lack of active metabolites. * **Teratogenicity:** Paroxetine is generally avoided in pregnancy as it is linked to **fetal cardiac malformations** (ASD/VSD). * **Drug Interactions:** It is a potent inhibitor of the **CYP2D6** enzyme. * **Fluvoxamine:** Another SSRI that can be sedating (often used in OCD), but Paroxetine remains the classic textbook answer for sedating SSRIs.

Question 115: Which mood stabilizer is used in the management of temporal lobe epilepsy?

A. Carbamazepine (Correct Answer)
B. Valproate
C. Lamotrigine
D. Lithium

Explanation: **Explanation:** **Carbamazepine** is the drug of choice for the management of **Temporal Lobe Epilepsy (TLE)**, also known as focal seizures with impaired awareness. While it is primarily an anticonvulsant, it is a potent mood stabilizer used in Psychiatry for the treatment of Acute Mania and Prophylaxis of Bipolar Disorder, especially in patients who are non-responsive to Lithium. Its mechanism involves blocking voltage-gated sodium channels, which stabilizes hyperexcitable neuronal membranes. **Analysis of Options:** * **Valproate (Option B):** While Valproate is a broad-spectrum antiepileptic and a first-line mood stabilizer, it is typically the drug of choice for generalized tonic-clonic seizures and myoclonic seizures rather than specifically for TLE. * **Lamotrigine (Option C):** This is used primarily for the maintenance phase of Bipolar Disorder (preventing depressive episodes) and focal seizures. However, it is not the traditional "gold standard" for TLE compared to Carbamazepine. * **Lithium (Option D):** Lithium is the "gold standard" for Bipolar Affective Disorder (BPAD) but has **no anticonvulsant properties**. In fact, Lithium can lower the seizure threshold in high doses. **High-Yield Clinical Pearls for NEET-PG:** * **DOC for TLE:** Carbamazepine. * **Side Effects:** Agranulocytosis, Aplastic anemia, and **Stevens-Johnson Syndrome** (associated with the HLA-B*1502 allele). * **Enzyme Induction:** Carbamazepine is a potent **cytochrome P450 inducer**, leading to many drug-drug interactions (e.g., reducing the efficacy of oral contraceptives). * **SIADH:** It can cause hyponatremia by increasing ADH sensitivity.

Question 116: Which of the following drugs requires serum level monitoring?

A. Lorazepam
B. Lithium (Correct Answer)
C. Amitriptyline
D. Haloperidol

Explanation: **Explanation:** **Lithium** is the correct answer because it has a **narrow therapeutic index**, meaning the difference between a therapeutic dose and a toxic dose is very small. Therapeutic drug monitoring (TDM) is mandatory to ensure efficacy and prevent severe toxicity (nephrotoxicity, neurotoxicity). The standard therapeutic range for maintenance is **0.6 to 1.2 mEq/L**. Levels above 1.5 mEq/L are generally considered toxic. **Why the other options are incorrect:** * **Lorazepam (Benzodiazepine):** These drugs have a wide therapeutic window. Clinical response and side effects (sedation) are monitored clinically rather than through serum levels. * **Amitriptyline (TCA):** While TCAs can be monitored in specific refractory cases, it is not a routine clinical requirement for standard treatment, unlike Lithium. * **Haloperidol (Antipsychotic):** Dosing is guided by clinical improvement of psychotic symptoms and the emergence of extrapyramidal side effects (EPS), not by plasma concentrations. **High-Yield Clinical Pearls for NEET-PG:** * **Sampling Time:** Lithium levels should be drawn **12 hours after the last dose** (Trough level). * **Steady State:** It takes approximately **5 days** (5 half-lives) to reach a steady state before the first level should be checked. * **Monitoring Frequency:** Initially every 1–2 weeks; once stable, every 3–6 months. * **Factors increasing Lithium levels:** Dehydration, low-sodium diet, and drugs like **NSAIDs, Thiazides, and ACE inhibitors** (mnemonic: **NSA**). * **Side Effects:** Ebstein’s anomaly (teratogenic), Nephrogenic Diabetes Insipidus, and Hypothyroidism.

Question 117: Schizophrenia drugs mainly act on which receptors?

A. D1 dopamine receptors
B. D2 dopamine receptors (Correct Answer)
C. D3 dopamine receptors
D. Acetylcholine receptors

Explanation: ### Explanation **Core Concept: The Dopamine Hypothesis** The primary mechanism of action for most antipsychotic medications (both typical and atypical) is the blockade of **D2 dopamine receptors**. The "Dopamine Hypothesis" of schizophrenia suggests that overactivity of dopamine in the **mesolimbic pathway** leads to positive symptoms (hallucinations and delusions). By antagonizing D2 receptors in this pathway, antipsychotics reduce these symptoms. **Analysis of Options:** * **B. D2 dopamine receptors (Correct):** All effective antipsychotics have a high affinity for D2 receptors. Typical antipsychotics (e.g., Haloperidol) are potent D2 antagonists, while Atypical antipsychotics (e.g., Risperidone) combine D2 blockade with 5-HT2A (serotonin) antagonism. * **A. D1 dopamine receptors:** While some drugs (like Clozapine) show binding affinity for D1, it is not the primary target for treating core psychotic symptoms. * **C. D3 dopamine receptors:** These are primarily located in the limbic system. While newer drugs like Cariprazine act on D3, D2 remains the standard pharmacological target for the class. * **D. Acetylcholine receptors:** Antipsychotics do not treat schizophrenia via these receptors. In fact, blocking acetylcholine receptors (anticholinergic effect) is a common *side effect* of low-potency antipsychotics (e.g., Chlorpromazine). **High-Yield Clinical Pearls for NEET-PG:** 1. **Threshold for Effect:** To achieve an antipsychotic effect, approximately **60-70%** of D2 receptors must be blocked. 2. **Extrapyramidal Symptoms (EPS):** If D2 blockade in the **nigrostriatal pathway** exceeds **80%**, patients develop EPS (Parkinsonism, Akathisia). 3. **Hyperprolactinemia:** D2 blockade in the **tuberoinfundibular pathway** leads to increased prolactin levels. 4. **Clozapine Exception:** Clozapine is the "gold standard" for treatment-resistant schizophrenia; it has a relatively low affinity for D2 but high affinity for D4 and 5-HT2A receptors.

Question 118: Who introduced the antipsychotic chlorpromazine?

A. Delay and Deniker (Correct Answer)
B. John F. Cade
C. Maslow
D. Erik Erikson

Explanation: **Explanation:** **Chlorpromazine**, the first typical antipsychotic, revolutionized psychiatry by shifting treatment from custodial care to pharmacological management. It was synthesized in 1950 by Paul Charpentier as an antihistamine. However, its profound antipsychotic properties were first recognized and introduced into clinical psychiatry in **1952** by the French psychiatrists **Jean Delay and Pierre Deniker**. They observed its "neuroleptic" effect—specifically its ability to reduce agitation and psychosis without inducing profound sedation. **Analysis of Incorrect Options:** * **John F. Cade:** An Australian psychiatrist who discovered the mood-stabilizing effects of **Lithium** in 1948 for the treatment of mania. * **Abraham Maslow:** A psychologist famous for proposing the **Hierarchy of Needs**, a theory of psychological health predicated on fulfilling innate human needs in priority. * **Erik Erikson:** A developmental psychologist known for his theory on the **Eight Stages of Psychosocial Development** (e.g., Trust vs. Mistrust). **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Chlorpromazine is a low-potency antipsychotic that primarily acts by blocking **D2 receptors** in the mesolimbic pathway. * **Side Effects:** Due to its low potency, it has a high affinity for H1 (sedation), Alpha-1 (orthostatic hypotension), and M1 (anticholinergic effects) receptors. * **Specific Side Effect:** It is classically associated with **pigmentary deposits** in the lens and cornea (unlike Thioridazine, which causes retinal deposits). * **Historical Note:** It was initially used by Henri Laborit to prevent surgical shock (the "lytic cocktail").

Question 119: Tardive dyskinesia is least common with which of the following medications?

A. Flupenthiol
B. Penfluridol
C. Olanzapine (Correct Answer)
D. None of the above

Explanation: **Explanation:** Tardive Dyskinesia (TD) is a late-onset extrapyramidal side effect characterized by involuntary, choreoathetoid movements (most commonly orofacial). It is caused by the **upregulation and supersensitivity of Dopamine D2 receptors** in the nigrostriatal pathway following chronic blockade. **1. Why Olanzapine is correct:** Olanzapine is a **Second-Generation Antipsychotic (SGA)** or "atypical" antipsychotic. SGAs have a lower affinity for D2 receptors and a higher affinity for 5-HT2A receptors. They also exhibit "loose" binding or rapid dissociation from D2 receptors. This profile significantly reduces the risk of receptor upregulation, making TD much less common compared to First-Generation Antipsychotics (FGAs). **2. Why other options are incorrect:** * **Flupenthiol:** This is a high-potency FGA (Thioxanthene class). It binds strongly and persistently to D2 receptors, posing a high risk for TD. * **Penfluridol:** This is a long-acting oral FGA. Due to its potent D2 antagonism and long half-life, it carries a significant risk of cumulative neurological side effects, including TD. **High-Yield Clinical Pearls for NEET-PG:** * **Lowest Risk:** Among all antipsychotics, **Clozapine** has the lowest risk of TD (virtually zero), followed by Quetiapine. * **Risk Factors:** Old age, female gender, and presence of affective disorders increase TD risk. * **Treatment of Choice:** The first step is to switch to Clozapine. For symptomatic management, **VMAT-2 inhibitors** (Valbenazine, Deutetrabenazine) are now the first-line FDA-approved treatments. * **Warning:** Anticholinergics (like Trihexyphenidyl) typically **worsen** TD symptoms and should be avoided.

Question 120: Which medication is known to cause wet pillow syndrome?

A. Risperidone
B. Haloperidol
C. Aripiprazole
D. Clozapine (Correct Answer)

Explanation: **Explanation:** **Correct Answer: D. Clozapine** **Clozapine** is a second-generation (atypical) antipsychotic notorious for causing **Sialorrhea** (excessive salivation), colloquially known as **"Wet Pillow Syndrome."** This occurs in approximately 30–80% of patients, typically manifesting during sleep. The underlying mechanism is paradoxical. While Clozapine has potent anticholinergic properties (which usually cause dry mouth), it acts as a **full agonist at M4 muscarinic receptors** and an **alpha-2 adrenergic antagonist** in the salivary glands. This combination stimulates excessive saliva production and impairs the swallowing reflex during sleep, leading to nocturnal drooling. **Why other options are incorrect:** * **Risperidone (A):** Primarily associated with hyperprolactinemia and extrapyramidal symptoms (EPS) at higher doses, but not sialorrhea. * **Haloperidol (B):** A high-potency typical antipsychotic known for causing significant EPS (dystonia, parkinsonism) and xerostomia (dry mouth) due to its anticholinergic side effects. * **Aripiprazole (C):** A partial dopamine agonist generally considered "weight-neutral" and less likely to cause metabolic or sedative side effects like sialorrhea. **High-Yield Clinical Pearls for NEET-PG:** * **Management of Sialorrhea:** Treat with sublingual **Atropine** drops, **Pirenzepine**, or oral **Glycopyrrolate**. * **Clozapine Monitoring:** Mandatory monitoring of Absolute Neutrophil Count (ANC) is required due to the risk of **Agranulocytosis** (most serious side effect). * **Other Side Effects:** Clozapine is the antipsychotic most likely to cause **seizures** (dose-dependent), **myocarditis**, and significant **weight gain**. * **Indication:** It is the gold standard for **Treatment-Resistant Schizophrenia**.

Question 121: What is the drug of choice for Akathisia?

A. Dantrolene sodium
B. Propranolol (Correct Answer)
C. Anticholinergics
D. Levodopa

Explanation: ### Explanation **Correct Answer: B. Propranolol** **Mechanism and Rationale:** Akathisia is an Extrapyramidal Side Effect (EPS) characterized by a subjective feeling of inner restlessness and an objective inability to sit still. Unlike other EPS (like dystonia), akathisia often responds poorly to anticholinergics. **Propranolol**, a non-selective beta-blocker, is the **drug of choice**. It works by crossing the blood-brain barrier and antagonizing beta-adrenergic receptors, which modulates the catecholaminergic pathways involved in motor restlessness. **Analysis of Incorrect Options:** * **A. Dantrolene sodium:** This is a peripherally acting muscle relaxant used primarily in the management of **Neuroleptic Malignant Syndrome (NMS)** and Malignant Hyperthermia. It has no role in treating akathisia. * **C. Anticholinergics (e.g., Benztropine, Trihexyphenidyl):** These are the drugs of choice for **Acute Dystonia** and Drug-Induced Parkinsonism. While sometimes used for akathisia, they are significantly less effective than beta-blockers. * **D. Levodopa:** This is used in Parkinson’s disease. In psychiatry, dopamine agonists are generally avoided as they can exacerbate psychotic symptoms. **High-Yield Clinical Pearls for NEET-PG:** 1. **Clinical Presentation:** Patients often describe "jumping out of their skin" or constant pacing. It is the most common EPS associated with second-generation antipsychotics (especially Aripiprazole). 2. **Management Hierarchy:** First, reduce the dose of the antipsychotic. If not possible, start **Propranolol** (typical dose: 30–90 mg/day). Second-line agents include Benzodiazepines (e.g., Lorazepam). 3. **Suicide Risk:** Akathisia is uniquely associated with an increased risk of agitation and **suicidality**; therefore, prompt treatment is critical.

Question 122: Lithium is the treatment of choice for which condition?

A. Unipolar major depressive disorder prophylaxis
B. Bipolar major depressive disorder prophylaxis (Correct Answer)
C. Schizophrenia
D. Acute mania

Explanation: **Explanation:** **Lithium** is a monovalent cation and the gold-standard mood stabilizer in psychiatry. While it has multiple applications, its most definitive role is in the **long-term prophylaxis of Bipolar Disorder**, where it effectively prevents the recurrence of both manic and depressive episodes. **Why Option B is Correct:** Lithium is the **treatment of choice (TOC) for the prophylaxis of Bipolar Affective Disorder (BPAD)**. It significantly reduces the frequency, severity, and duration of future episodes. It is particularly superior in preventing manic relapses but is also highly effective in preventing bipolar depression. **Analysis of Incorrect Options:** * **Option A (Unipolar MDD Prophylaxis):** SSRIs or other antidepressants are the first-line maintenance therapy for recurrent unipolar depression. Lithium is only used here as an **augmentation strategy** for treatment-resistant cases. * **Option C (Schizophrenia):** Antipsychotics (e.g., Risperidone, Olanzapine) are the mainstay. Lithium has no role in treating core schizophrenia symptoms unless there is a significant affective component (Schizoaffective disorder). * **Option D (Acute Mania):** While Lithium is used in acute mania, it has a **slow onset of action** (5–7 days). Therefore, in clinical practice, **Valproate** or atypical antipsychotics are often preferred for rapid control, or used in combination with Lithium. **High-Yield NEET-PG Pearls:** * **Therapeutic Index:** Narrow (0.6–1.2 mEq/L). Toxicity occurs >1.5 mEq/L. * **Anti-suicidal Property:** Lithium and Clozapine are the only psychiatric drugs proven to reduce the risk of suicide. * **Teratogenicity:** Causes **Ebstein’s Anomaly** (tricuspid valve displacement) if taken during the first trimester. * **Monitoring:** Before starting, check **Thyroid Function Tests (TFT)** and **Renal Function Tests (RFT)**, as it can cause nephrogenic diabetes insipidus and hypothyroidism.

Question 123: Which of the following is NOT used in the treatment for tardive dyskinesia?

A. Clozapine
B. Vitamin E
C. Clonazepam
D. Haloperidol (Correct Answer)

Explanation: **Explanation:** **Tardive Dyskinesia (TD)** is a delayed-onset extrapyramidal side effect caused by the long-term use of dopamine receptor blockers (typically first-generation antipsychotics). It is characterized by involuntary, choreoathetoid movements, most commonly involving the tongue, face, and jaw (orofacial dyskinesia). **Why Haloperidol is the correct answer:** Haloperidol is a high-potency, first-generation antipsychotic and a potent **D2 receptor antagonist**. Since TD is pathophysiologically linked to **dopamine receptor supersensitivity** resulting from chronic blockade, administering more Haloperidol may temporarily mask the symptoms but will ultimately worsen the underlying condition and increase the risk of irreversible damage. Therefore, it is contraindicated as a treatment for TD. **Analysis of incorrect options:** * **Clozapine (Option A):** This is the drug of choice for patients with TD who still require antipsychotic therapy. It has low D2 affinity and may even help suppress existing dyskinetic movements. * **Vitamin E (Option B):** Used as an antioxidant to prevent further neuronal damage. While its efficacy is modest, it is a recognized adjunct in early-stage TD management. * **Clonazepam (Option C):** Benzodiazepines can be used as an adjunctive treatment to reduce the severity of movements through GABAergic modulation. **NEET-PG High-Yield Pearls:** * **First-line treatment:** Discontinue the offending agent or switch to Clozapine/Quetiapine. * **FDA-approved treatments:** VMAT-2 inhibitors (**Valbenazine** and **Deutetrabenazine**) are now considered the gold standard for TD management. * **Risk Factors:** Old age, female gender, and presence of affective disorders. * **Important Note:** Unlike acute dystonia, **anticholinergics (like Benztropine) worsen TD** and should be avoided.

Question 124: Which of the following pharmacologic agents has the highest potential to cause metabolic syndrome?

A. Clozapine (Correct Answer)
B. Risperidone
C. Quetiapine
D. Aripiprazole

Explanation: **Explanation:** The risk of **Metabolic Syndrome** (weight gain, dyslipidemia, and hyperglycemia/Type 2 Diabetes) is a significant side effect of Second-Generation Antipsychotics (SGAs). This is primarily due to their antagonistic action at **H1 (histamine)** and **5-HT2C (serotonin)** receptors, which increases appetite and disrupts insulin sensitivity. **Why Clozapine is Correct:** Among all antipsychotics, **Clozapine** and **Olanzapine** carry the **highest risk** for metabolic syndrome. Clozapine causes profound weight gain and has a direct effect on insulin resistance, often independent of weight gain. Because of this, patients on Clozapine require mandatory monitoring of BMI, waist circumference, fasting blood glucose, and lipid profiles. **Analysis of Incorrect Options:** * **Risperidone:** Carries a **moderate risk**. While it is associated with weight gain and significant prolactin elevation, its metabolic impact is less severe than Clozapine or Olanzapine. * **Quetiapine:** Also carries a **moderate risk**. It is more metabolically offending than Risperidone but generally less so than Clozapine. * **Aripiprazole:** This is a **metabolically neutral** drug (along with Ziprasidone and Lurasidone). As a partial D2 agonist, it has a very low potential for weight gain or glucose dysregulation. **High-Yield NEET-PG Pearls:** * **Highest Metabolic Risk:** Clozapine > Olanzapine. * **Lowest Metabolic Risk:** Aripiprazole, Ziprasidone, Lurasidone. * **Clozapine Monitoring:** Apart from metabolic parameters, remember the mandatory **ANC (Absolute Neutrophil Count)** monitoring due to the risk of **Agranulocytosis**. * **Drug of Choice:** Clozapine remains the gold standard for **Treatment-Resistant Schizophrenia**.

Question 125: Which of the following statements is NOT true about clozapine?

A. Should be discontinued if WBC count is less than 3000/mm 3
B. Blood levels should be maintained (Correct Answer)
C. Should not be used along with carbamazepine
D. Its action is more on D1 receptors than D2 receptors

Explanation: **Explanation:** Clozapine is a unique "atypical" antipsychotic, often considered the gold standard for treatment-resistant schizophrenia. **1. Why Option B is the correct answer (The "NOT true" statement):** Unlike drugs with a narrow therapeutic index (e.g., Lithium), routine **therapeutic drug monitoring (TDM) of blood levels is not mandatory** for clozapine in standard clinical practice. Management is primarily guided by clinical response and, most importantly, the monitoring of **Absolute Neutrophil Count (ANC)** and White Blood Cell (WBC) counts to prevent agranulocytosis. **2. Analysis of other options:** * **Option A:** Clozapine must be discontinued if the **WBC count falls below 3000/mm³** or the ANC falls below 1500/mm³ (though specific protocols vary by country, these are standard safety thresholds) due to the risk of life-threatening agranulocytosis. * **Option C:** Clozapine should **not be used with Carbamazepine** because both drugs cause bone marrow suppression. Combining them synergistically increases the risk of agranulocytosis. * **Option D:** Clozapine is characterized by its "loose" binding to D2 receptors. It has a **higher affinity for D1, D4, and 5-HT2A receptors** than for D2 receptors, which explains its low incidence of Extrapyramidal Side Effects (EPS). **High-Yield Clinical Pearls for NEET-PG:** * **Drug of choice:** Treatment-resistant schizophrenia and schizophrenia with persistent suicidal behavior. * **Most common side effect:** Sialorrhea (excessive salivation). * **Most serious side effect:** Agranulocytosis (1% risk). * **Other notable risks:** Lowers seizure threshold (dose-dependent), myocarditis, and significant weight gain/metabolic syndrome. * **Unique feature:** It is the only antipsychotic proven to reduce the risk of suicide in schizophrenia.

Question 126: Which of the following is the drug of choice for medication-resistant schizophrenia?

A. Haloperidol
B. Chlorpromazine
C. Clozapine (Correct Answer)
D. Flupentixol

Explanation: **Explanation:** **Clozapine** is the gold-standard treatment and the **drug of choice for treatment-resistant schizophrenia (TRS)**. TRS is clinically defined as schizophrenia that fails to respond to adequate trials (at least 4–6 weeks) of at least two different antipsychotics at therapeutic doses. Clozapine is a Dibenzodiazepine derivative and an "atypical" (second-generation) antipsychotic. Its superior efficacy is attributed to its unique receptor profile, characterized by a high affinity for D4 and 5-HT2A receptors and a relatively low affinity for D2 receptors. It is also the only antipsychotic proven to reduce suicidal behavior in schizophrenic patients. **Why the other options are incorrect:** * **Haloperidol (A) & Chlorpromazine (B):** These are first-generation (typical) antipsychotics. While effective for positive symptoms, they are not indicated for resistant cases and carry a high risk of Extrapyramidal Side Effects (EPS) and Tardive Dyskinesia. * **Flupentixol (D):** A thioxanthene derivative often used as a long-acting injectable (depot). While useful for maintenance and compliance, it has no specific role in medication-resistant schizophrenia. **High-Yield Clinical Pearls for NEET-PG:** * **Agranulocytosis:** The most dreaded side effect of Clozapine (occurs in ~1%). Mandatory **Absolute Neutrophil Count (ANC)** monitoring is required. * **Seizures:** Clozapine significantly lowers the seizure threshold in a dose-dependent manner. * **Sialorrhea:** Paradoxical hypersalivation (especially at night) is a common, bothersome side effect. * **Metabolic Syndrome:** Clozapine carries the highest risk of weight gain and diabetes among antipsychotics. * **No EPS:** Clozapine has the lowest risk of Extrapyramidal Side Effects and does not cause Tardive Dyskinesia.

Question 127: What is the drug of choice for resistant schizophrenia?

A. Olanzapine
B. Haloperidol
C. Clozapine (Correct Answer)
D. Electroconvulsive Therapy (ECT)

Explanation: **Explanation:** **Clozapine** is the gold-standard treatment and the **drug of choice for treatment-resistant schizophrenia**. Resistance is clinically defined as a failure to respond to at least two adequate trials of different antipsychotics (one of which should be a second-generation antipsychotic) for a duration of 4–6 weeks each at therapeutic doses. Clozapine is uniquely effective due to its complex receptor profile (weak D2 blockade but potent 5-HT2A, D4, and alpha-adrenergic antagonism), which helps reduce both positive and negative symptoms while significantly lowering suicide risk. **Analysis of Incorrect Options:** * **Olanzapine (A):** While a potent second-generation antipsychotic, it is generally considered a first-line agent. It is not the drug of choice for resistant cases, though it shares some structural similarities with clozapine. * **Haloperidol (B):** A high-potency first-generation antipsychotic (FGA). It is effective for acute psychosis but carries a high risk of Extrapyramidal Side Effects (EPS) and is rarely effective if other medications have already failed. * **ECT (D):** Usually reserved for catatonia, severe depression, or cases where rapid stabilization is needed. While it can be used as an adjunct in resistant schizophrenia, it is not the primary "drug" of choice. **High-Yield Clinical Pearls for NEET-PG:** * **Agranulocytosis:** The most dreaded side effect of Clozapine (occurs in ~1%). Mandatory **Absolute Neutrophil Count (ANC)** monitoring is required. * **Seizures:** Clozapine reduces the seizure threshold in a dose-dependent manner. * **Sialorrhea:** Paradoxical hypersalivation is a common, highly specific side effect. * **Metabolic Syndrome:** Clozapine and Olanzapine carry the highest risk of weight gain and diabetes among antipsychotics. * **No EPS:** Clozapine is the antipsychotic least likely to cause Extrapyramidal Side Effects or Tardive Dyskinesia.

Question 128: Which of the following medications is NOT used for schizophrenia?

A. Chlorpromazine
B. Clozapine
C. Risperidone
D. Venlafaxine (Correct Answer)

Explanation: **Explanation:** The correct answer is **Venlafaxine** because it is a **Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)**, primarily used as an antidepressant and for anxiety disorders. It does not possess the dopamine (D2) receptor antagonism required to treat the core psychotic symptoms of schizophrenia. **Analysis of Options:** * **Chlorpromazine (Option A):** A prototypical **Typical (First-generation) Antipsychotic**. It works by blocking D2 receptors in the mesolimbic pathway. It is also known for its low potency and side effects like sedation and orthostatic hypotension. * **Clozapine (Option B):** An **Atypical (Second-generation) Antipsychotic**. It is the "gold standard" for **treatment-resistant schizophrenia**. It has a unique profile with high affinity for D4 and 5-HT2 receptors but carries a risk of agranulocytosis. * **Risperidone (Option C):** A commonly used **Atypical Antipsychotic**. It blocks both D2 and 5-HT2A receptors. It is notable for having a higher risk of extrapyramidal symptoms (EPS) and hyperprolactinemia compared to other atypicals at higher doses. **High-Yield Clinical Pearls for NEET-PG:** * **Dopamine Hypothesis:** Schizophrenia is primarily linked to overactivity of dopamine in the mesolimbic pathway (positive symptoms) and underactivity in the mesocortical pathway (negative symptoms). * **Clozapine Monitoring:** Requires mandatory WBC and ANC monitoring due to the risk of **agranulocytosis** (occurs in ~1%). It is also the only antipsychotic proven to reduce suicide risk in schizophrenia. * **Drug of Choice:** For a first episode of schizophrenia, atypical antipsychotics (like Risperidone or Olanzapine) are generally preferred over typicals due to a lower risk of tardive dyskinesia.

Question 129: Which antipsychotic medication is associated with decreased weight?

A. Olanzapine
B. Quetiapine
C. Ziprasidone (Correct Answer)
D. Clozapine

Explanation: ### Explanation The metabolic profile of antipsychotics is a high-yield topic for NEET-PG. Antipsychotic-induced weight gain is primarily linked to the blockade of **Histamine (H1)** and **Serotonin (5-HT2C)** receptors. **Why Ziprasidone is Correct:** **Ziprasidone** (along with Aripiprazole and Lurasidone) is considered **metabolically neutral**. It has a low affinity for H1 and 5-HT2C receptors, making it associated with minimal weight gain or even slight weight loss when switching from other agents. It is the preferred choice for patients with obesity or metabolic syndrome. **Analysis of Incorrect Options:** * **Clozapine (Option D):** This is the **worst offender**. It causes the most significant weight gain, dyslipidemia, and risk of Type 2 Diabetes Mellitus. * **Olanzapine (Option A):** Closely follows Clozapine in terms of metabolic side effects. It is notorious for rapid and significant weight gain. * **Quetiapine (Option B):** Associated with moderate weight gain. While less severe than Clozapine/Olanzapine, it still poses a higher metabolic risk than Ziprasidone. **High-Yield Clinical Pearls for NEET-PG:** * **Weight Gain Hierarchy:** Clozapine > Olanzapine > Quetiapine > Risperidone > Ziprasidone/Aripiprazole. * **Ziprasidone Warning:** It is uniquely associated with **QTc interval prolongation**; therefore, a baseline ECG is recommended. It must be taken **with food** (at least 500 calories) for adequate absorption. * **Monitoring:** According to the ADA/APA protocol, patients on second-generation antipsychotics (SGAs) must have their BMI, waist circumference, blood pressure, and fasting glucose/lipids monitored regularly.

Question 130: What is an important side effect of ECT?

A. Retrograde amnesia (Correct Answer)
B. Death
C. Respiratory failure
D. Cardiac failure

Explanation: **Explanation:** Electroconvulsive Therapy (ECT) is a highly effective treatment in psychiatry, but it is associated with specific cognitive side effects. **Why Retrograde Amnesia is the correct answer:** The most common and significant side effect of ECT is **cognitive impairment**, specifically memory loss. This typically manifests as **retrograde amnesia** (loss of memory for events occurring shortly before the treatment) and **anterograde amnesia** (difficulty forming new memories immediately following treatment). While anterograde amnesia usually resolves rapidly, retrograde amnesia can persist for a longer duration, making it a major clinical concern. **Analysis of Incorrect Options:** * **B, C, and D (Death, Respiratory failure, Cardiac failure):** While these represent potential risks of any procedure involving general anesthesia and muscle relaxants (like Succinylcholine), they are **extremely rare** in modern ECT. The mortality rate of ECT is approximately 2 per 100,000 treatments, which is comparable to minor surgical procedures. Therefore, they are not considered "common" or "characteristic" side effects like memory loss. **High-Yield NEET-PG Pearls:** * **Absolute Contraindication:** Increased intracranial pressure (ICP). * **Most common side effect:** Confusion (post-ictal) and Headache. * **Most common cause of death:** Cardiovascular complications (arrhythmias/MI). * **Technique to reduce memory loss:** Using **unilateral** electrode placement (non-dominant hemisphere) and **brief-pulse** stimulation instead of bilateral or sine-wave stimulation. * **Drug of choice for induction:** Methohexital (Barbiturate). * **Muscle relaxant used:** Succinylcholine (to prevent fractures).

Question 131: Which of the following groups of drugs is known to cause neurogenic dislocation?

A. Anxiolytics
B. Antiparkinsonism drugs
C. Antipsychotic drugs (Correct Answer)
D. None of the above

Explanation: **Explanation:** The correct answer is **Antipsychotic drugs**. **Mechanism and Concept:** Neurogenic dislocation (specifically of the temporomandibular joint or TMJ) is a rare but documented complication of **Acute Dystonia**, which is an Extrapyramidal Side Effect (EPS) caused by antipsychotic medications. Antipsychotics, particularly first-generation (typical) agents like Haloperidol, work by blocking Dopamine (D2) receptors in the nigrostriatal pathway. This blockade leads to a relative excess of cholinergic activity, resulting in involuntary, sustained muscle contractions. When these spasms involve the muscles of mastication (like the lateral pterygoid), the force can be strong enough to pull the condyle out of the glenoid fossa, leading to a "neurogenic" dislocation of the jaw. **Analysis of Incorrect Options:** * **Anxiolytics:** These drugs (e.g., Benzodiazepines) are muscle relaxants and are actually used to *treat* acute dystonic reactions, not cause them. * **Antiparkinsonism drugs:** These agents (e.g., Levodopa or Anticholinergics like Trihexyphenidyl) aim to increase dopamine or decrease acetylcholine. They do not cause acute dystonia; in fact, anticholinergics are the drug of choice to manage antipsychotic-induced dystonia. **NEET-PG High-Yield Pearls:** * **Acute Dystonia** is the earliest EPS to appear (usually within hours to days of starting treatment). * **Risk Factors:** Young males and high-potency antipsychotics. * **Common Presentations:** Torticollis (neck), Oculogyric crisis (eyes), and Trismus/TMJ dislocation (jaw). * **Management:** Immediate treatment involves parenteral **Promethazine** or **Benztropine** (anticholinergics).

Question 132: What is the treatment for lithium-induced tremor?

A. Propranolol (Correct Answer)
B. Amiloride
C. Modafinil
D. Trihexyphenidyl

Explanation: **Explanation:** Lithium-induced tremor is a common side effect, typically presenting as a fine, symmetric, postural tremor of the hands. **1. Why Propranolol is the Correct Answer:** The primary management for lithium-induced tremor is the use of **beta-blockers**, specifically **Propranolol**. The underlying mechanism involves the blockade of peripheral beta-2 adrenergic receptors in the skeletal muscles, which reduces the amplitude of the tremor. It is the gold-standard treatment when dose reduction of Lithium is not feasible. **2. Analysis of Incorrect Options:** * **Amiloride:** This is a potassium-sparing diuretic used specifically to treat **Lithium-induced Nephrogenic Diabetes Insipidus (NDI)**. It works by blocking the epithelial sodium channels (ENaC) in the collecting duct, preventing lithium from entering and interfering with ADH action. * **Modafinil:** This is a wakefulness-promoting agent used for narcolepsy or shift-work sleep disorder; it has no role in managing tremors. * **Trihexyphenidyl:** This is an anticholinergic used for **Extrapyramidal Side Effects (EPS)** like parkinsonism or acute dystonia caused by antipsychotics. Lithium tremors are not mediated by the dopamine-acetylcholine imbalance, so anticholinergics are ineffective. **3. Clinical Pearls for NEET-PG:** * **Tremor Characteristics:** Lithium causes a **fine** tremor (therapeutic levels). A **coarse** tremor is a red flag indicating **Lithium Toxicity**. * **First Step:** Always check serum lithium levels first to rule out toxicity. * **Management Ladder:** 1. Reduce dose (if possible) → 2. Eliminate caffeine → 3. Add Propranolol (20–120 mg/day). * **Other Side Effects:** Remember "LITHIUM" mnemonic: **L**eukocytosis, **I**nsipidus (NDI), **T**remor/Teratogenicity (Ebstein’s Anomaly), **H**ypothyroidism, **I**nsulin resistance, **U**rine (polyuria), **M**others (avoid in pregnancy).

Question 133: Which antipsychotic medication is known to cause cataracts?

A. Ziprasidone (Correct Answer)
B. Aripiprazole
C. Olanzapine
D. Risperidone

Explanation: **Explanation:** The association between antipsychotics and ocular side effects is a high-yield topic in psychopharmacology. Among the atypical (second-generation) antipsychotics, **Ziprasidone** is uniquely associated with an increased risk of lens opacities or **cataracts**. During its early clinical development, preclinical studies in animals suggested a potential for cataract formation, leading to recommendations for periodic slit-lamp examinations (though this is less strictly enforced in current clinical practice compared to Quetiapine). **Analysis of Options:** * **Ziprasidone (Correct):** Beyond cataracts, it is most famous for causing **QTc interval prolongation**, necessitating caution in patients with cardiac arrhythmias. It is weight-neutral but must be taken with food (at least 500 calories) for optimal absorption. * **Aripiprazole:** Known as a "dopamine system stabilizer" (partial agonist). It is least likely to cause metabolic side effects or cataracts but is frequently associated with **akathisia**. * **Olanzapine:** Primarily associated with significant **weight gain**, dyslipidemia, and metabolic syndrome. It does not have a documented specific association with cataracts. * **Risperidone:** Notable for causing **hyperprolactinemia** (leading to gynecomastia or galactorrhea) and extrapyramidal symptoms (EPS) at higher doses. **NEET-PG High-Yield Pearls:** 1. **Quetiapine** is the other major antipsychotic historically linked to cataracts; always check for it if Ziprasidone is not in the options. 2. **Chlorpromazine** (Typical) is famous for causing **lenticular deposits** (star-shaped) and epithelial keratopathy. 3. **Thioridazine** (Typical) is associated with **retinitis pigmentosa** (brownish discoloration of vision) at doses >800mg/day. 4. **Ziprasidone** has the highest risk of QTc prolongation among second-generation antipsychotics.

Question 134: Which of the following is a known side effect of bupropion?

A. Relapse of smoking
B. Seizures (Correct Answer)
C. Impaired attention
D. Decreased sexual desire

Explanation: **Explanation:** **Correct Answer: B. Seizures** Bupropion is an atypical antidepressant that acts as a **Norepinephrine-Dopamine Reuptake Inhibitor (NDRI)**. Its most significant and dose-dependent side effect is a **reduction in the seizure threshold**. The risk is particularly high (approx. 0.4%) at doses exceeding 450 mg/day or in patients with pre-existing risk factors. Consequently, bupropion is strictly **contraindicated** in patients with epilepsy and eating disorders (Anorexia or Bulimia nervosa) due to the high incidence of electrolyte imbalances which further increase seizure risk. **Analysis of Incorrect Options:** * **A. Relapse of smoking:** Incorrect. Bupropion is actually FDA-approved for **smoking cessation**. It reduces nicotine cravings and withdrawal symptoms by increasing dopamine levels in the reward pathway. * **C. Impaired attention:** Incorrect. Due to its pro-dopaminergic and pro-noradrenergic effects, bupropion is often used off-label to **improve attention** and focus in ADHD and is considered an "activating" antidepressant. * **D. Decreased sexual desire:** Incorrect. Unlike SSRIs, bupropion does **not** cause sexual dysfunction (it lacks serotonergic activity). It is often used as an add-on or alternative to SSRIs to reverse sexual side effects. **High-Yield Clinical Pearls for NEET-PG:** * **Weight Neutrality:** Bupropion is one of the few antidepressants that causes weight loss rather than weight gain. * **Contraindications:** Always screen for a history of head injury, seizures, or eating disorders before prescribing. * **Mechanism:** It does not inhibit MAO or affect serotonin reuptake, making it unique among common antidepressants.

Question 135: A 23-year-old male with schizophrenia is stable on risperidone for the past 2 months. What is the recommended duration of treatment for this patient?

A. 5 years
B. 6 months
C. 2 years (Correct Answer)
D. 12 months

Explanation: **Explanation:** The management of schizophrenia requires a strategic approach to maintenance therapy to prevent relapse. For a patient experiencing their **first episode of psychosis** who has achieved stability (as in this 23-year-old male), the standard clinical guideline is to continue antipsychotic medication for **1 to 2 years**. **Why 2 years is correct:** Current psychiatric guidelines (including APA and Maudsley) recommend that after the first episode of schizophrenia, medication should be continued for at least 12–24 months. Since the goal is to minimize the high risk of relapse—which is greatest in the first year following an acute episode—**2 years** is the most appropriate clinical benchmark among the given options for a stable first-episode patient. **Analysis of Incorrect Options:** * **6 months (B) & 12 months (D):** These durations are generally considered too short for schizophrenia. While 6–12 months might be appropriate for a single episode of *Depressive Disorder*, stopping antipsychotics this early in schizophrenia significantly increases the risk of a psychotic break. * **5 years (A):** This duration is typically reserved for patients who have experienced **multiple episodes** (recurrent schizophrenia) or those who have a history of violent behavior or severe relapses. **High-Yield NEET-PG Pearls:** * **First Episode:** Treat for 1–2 years. * **Second/Multiple Episodes:** Treat for at least 5 years. * **Chronic/Severe Relapses:** May require indefinite (life-long) therapy. * **Risperidone:** A second-generation antipsychotic (SGA) known for causing hyperprolactinemia and extrapyramidal symptoms (EPS) at higher doses (>6mg). * **Relapse Rate:** Approximately 80% of patients will relapse within 5 years if medication is discontinued after the first episode.

Question 136: What is the drug of choice for Obsessive-Compulsive Disorder?

A. Imipramine
B. Chlorpromazine
C. Carbamazepine
D. Clomipramine (Correct Answer)

Explanation: ### Explanation **Correct Option: D. Clomipramine** **Why it is correct:** Obsessive-Compulsive Disorder (OCD) is primarily linked to dysregulation in the serotonergic system. **Clomipramine**, a Tricyclic Antidepressant (TCA), is the most potent inhibitor of serotonin reuptake among its class. While **Selective Serotonin Reuptake Inhibitors (SSRIs)** like Fluoxetine or Fluvoxamine are now considered the first-line treatment due to a better side-effect profile, Clomipramine remains the "Gold Standard" and the most effective drug of choice for OCD in terms of efficacy. It is specifically indicated when SSRIs fail or for severe cases. **Why other options are incorrect:** * **A. Imipramine:** This is a TCA used primarily for Enuresis and Depression. It lacks the potent serotonergic activity required to treat the core symptoms of OCD. * **B. Chlorpromazine:** This is a typical antipsychotic (Low potency). It acts by blocking D2 receptors and is used for Schizophrenia or acute psychosis; it has no role in the primary management of OCD. * **C. Carbamazepine:** This is an anticonvulsant and mood stabilizer. It is used for Trigeminal neuralgia and Bipolar Disorder, but it is ineffective for obsessive-compulsive symptoms. **High-Yield Clinical Pearls for NEET-PG:** * **First-line treatment:** SSRIs (Fluoxetine, Fluvoxamine, Paroxetine, Sertraline). * **Most effective drug (Gold Standard):** Clomipramine. * **Dosage in OCD:** Higher doses of SSRIs are required for OCD compared to Depression (e.g., Fluoxetine 60–80 mg). * **Duration of trial:** OCD requires a longer trial (10–12 weeks) to assess response compared to Depression (4–6 weeks). * **Behavioral Therapy:** Exposure and Response Prevention (ERP) is the specific psychotherapy of choice.

Question 137: What is the maximum benefit of Electroconvulsive Therapy (ECT)?

A. Hysteria
B. Mania
C. Depression with suicidal tendency (Correct Answer)
D. Chronic Schizophrenia

Explanation: ### Explanation **1. Why "Depression with suicidal tendency" is correct:** Electroconvulsive Therapy (ECT) is the most effective and rapid treatment available for severe psychiatric disorders. Its primary and most common indication is **Major Depressive Disorder (MDD)**, especially when it is refractory to drugs or life-threatening. In cases of **depression with high suicidal risk**, ECT is the treatment of choice because it provides a much faster clinical response (often within 1 week) compared to antidepressants, which typically take 2–4 weeks to show significant effects. **2. Analysis of Incorrect Options:** * **Hysteria (Dissociative/Conversion Disorder):** ECT has no role in treating hysteria. Management primarily involves psychotherapy and addressing underlying stressors. * **Mania:** While ECT is effective in treating acute mania (especially delirious mania or lithium-resistant cases), it is generally considered a second-line treatment after mood stabilizers and antipsychotics. * **Chronic Schizophrenia:** ECT is effective for *acute* schizophrenia (especially catatonic or positive symptoms), but it has very limited benefit in *chronic* schizophrenia, particularly when negative symptoms (apathy, withdrawal) predominate. **3. NEET-PG High-Yield Pearls:** * **Absolute Contraindication:** There are no absolute contraindications for ECT, but **Increased Intracranial Pressure (ICP)** is the most significant relative contraindication (risk of brain herniation). * **Most Common Side Effect:** Retrograde and anterograde amnesia (usually transient). * **Electrode Placement:** Unilateral placement (D’Elia) causes fewer cognitive side effects, but Bilateral placement is more rapidly effective. * **Gold Standard Indication:** Severe depression with psychotic features or suicidal ideation. * **Mechanism:** It works by increasing the seizure threshold and modulating neurotransmitter sensitivity (upregulation of serotonin and downregulation of beta-adrenergic receptors).

Question 138: Which of the following drugs are used in the treatment of schizophrenia?

A. Chlordiazepoxide
B. Trifluoperazine
C. Clozapine
D. Rivastigmine (Correct Answer)

Explanation: **Explanation:** The question asks to identify which drug is **NOT** used in the treatment of schizophrenia (noting that the checkmark indicates the "except" or "incorrect" option in this context). **1. Why Rivastigmine is the Correct Answer (The Exception):** Rivastigmine is a **reversible acetylcholinesterase inhibitor** used primarily in the treatment of Alzheimer’s disease and Parkinson’s disease dementia. It works by increasing acetylcholine levels in the synaptic cleft. It has no antipsychotic properties and is not used to treat the core symptoms of schizophrenia. **2. Analysis of Incorrect Options (Antipsychotics):** * **Trifluoperazine:** A **Typical (First-generation) Antipsychotic** belonging to the Piperazine class. It is a high-potency D2 receptor antagonist used to treat positive symptoms of schizophrenia. * **Clozapine:** An **Atypical (Second-generation) Antipsychotic**. It is the "Gold Standard" for **treatment-resistant schizophrenia**. It acts on D2, 5-HT2A, and various other receptors. * **Chlordiazepoxide:** While primarily a Benzodiazepine used for alcohol withdrawal and anxiety, it is frequently used as an **adjuvant** in schizophrenia to manage acute agitation, insomnia, or catatonic features, although it is not a primary antipsychotic. **High-Yield Clinical Pearls for NEET-PG:** * **Clozapine** is the only antipsychotic proven to reduce **suicidal behavior** in schizophrenia but requires mandatory WBC monitoring due to the risk of **agranulocytosis**. * **Drug of choice for Schizophrenia:** Generally Atypical Antipsychotics (e.g., Risperidone, Olanzapine) due to lower risk of Extrapyramidal Side Effects (EPS). * **Negative symptoms** of schizophrenia are better addressed by Atypical Antipsychotics than Typical ones.

Question 139: A patient with endogenous depression is prescribed imipramine. After what duration of treatment is the therapeutic effect of imipramine likely to manifest?

A. Three days
B. One week
C. Three weeks (Correct Answer)
D. Three months

Explanation: **Explanation:** **1. Why Option C is Correct:** Imipramine is a **Tricyclic Antidepressant (TCA)**. While TCAs immediately block the reuptake of norepinephrine and serotonin at the synaptic cleft, the clinical antidepressant effect is not immediate. The therapeutic lag is due to the time required for **down-regulation (desensitization) of post-synaptic beta-adrenergic and 5-HT2 receptors**, as well as changes in gene expression and neurogenesis (BDNF levels). In clinical practice, a visible improvement in mood typically takes **2 to 4 weeks** (average 3 weeks). **2. Why Other Options are Incorrect:** * **A & B (3 Days / 1 Week):** These are too early for a therapeutic response. During the first week, patients may experience side effects (like sedation or dry mouth) or a slight improvement in sleep and anxiety, but the core symptoms of depression (anhedonia, low mood) remain unchanged. * **D (3 Months):** This is too long. If a patient shows no response by 4–6 weeks on an adequate dose, the treatment is generally considered a failure, and the clinician should consider switching medications or augmenting therapy. **3. High-Yield Clinical Pearls for NEET-PG:** * **Order of Improvement:** Physical symptoms (sleep, appetite, energy) usually improve *before* the emotional symptoms (mood, suicidal ideation). * **Suicide Risk:** Paradoxically, the risk of suicide may **increase** in the first 2 weeks of treatment because the patient’s energy levels improve before their depressive thoughts resolve, giving them the "energy" to act on suicidal plans. * **Imipramine Specifics:** It is the "Gold Standard" TCA and is also the drug of choice for **Enuresis** (bed-wetting) in children. * **Side Effects:** Remember the "3 Cs" of TCA toxicity: **C**oma, **C**onvulsions, and **C**ardiotoxicity (arrhythmias due to Na+ channel blockade).

Question 140: Which of the following medications is used in Electroconvulsive Therapy (ECT)?

A. Thiopentone (Correct Answer)
B. Ketamine
C. Amiodarone
D. Labetalol

Explanation: **Explanation:** In Electroconvulsive Therapy (ECT), the goal is to induce a generalized therapeutic seizure while ensuring patient safety through anesthesia and muscle relaxation. **A. Thiopentone (Correct):** Traditionally, Thiopentone sodium (an ultra-short-acting barbiturate) has been the "gold standard" induction agent for ECT. It provides rapid loss of consciousness and has a well-established safety profile. While **Methohexital** is now often preferred due to a shorter recovery time and less seizure-suppressing effect, Thiopentone remains a classic and correct choice in the context of standard medical examinations. **B. Ketamine:** Although Ketamine has antidepressant properties and increases the seizure threshold (making seizures easier to induce), it is rarely used as a first-line agent in ECT because it can cause post-ictal emergence delirium and significant sympathetic stimulation (hypertension/tachycardia). **C. Amiodarone:** This is a Class III antiarrhythmic used for ventricular arrhythmias. It has no role in the induction of anesthesia or seizure management in ECT. **D. Labetalol:** This is a beta-blocker used to manage the transient hypertensive surge that occurs during ECT. While it may be used as an *adjunct* in patients with cardiovascular risk, it is not the primary medication used to perform the procedure itself. **High-Yield Clinical Pearls for NEET-PG:** * **Ideal Induction Agent:** Methohexital (due to minimal anticonvulsant activity). * **Muscle Relaxant of Choice:** Succinylcholine (short-acting, prevents musculoskeletal injury). * **Pre-medication:** Atropine or Glycopyrrolate (to prevent vagally-mediated bradycardia and reduce secretions). * **Seizure Duration:** A therapeutic seizure should ideally last **25–60 seconds**. * **Absolute Contraindication:** Increased intracranial pressure (ICP).

Question 141: Hyperthermia is seen in:

A. Malignant neuroleptic syndrome (Correct Answer)
B. Cannabis poisoning
C. Opium intoxication
D. Hypothyroidism

Explanation: **Explanation:** **Neuroleptic Malignant Syndrome (NMS)** is a life-threatening idiosyncratic reaction to antipsychotic drugs (neuroleptics). It is characterized by a "tetrad" of clinical features: **Hyperthermia** (often >38°C), severe muscular "lead-pipe" rigidity, autonomic instability (tachycardia, hypertension), and altered mental status. The underlying pathophysiology involves massive dopamine blockade in the hypothalamus (disrupting thermoregulation) and the basal ganglia (causing rigidity and secondary heat production). **Analysis of Incorrect Options:** * **Cannabis Poisoning:** Typically presents with tachycardia, conjunctival injection, increased appetite, and dry mouth. It does not cause significant hyperthermia. * **Opium Intoxication:** Characterized by the "Opioid Triad" of CNS depression (coma), miosis (pinpoint pupils), and respiratory depression. It typically causes **hypothermia**, not hyperthermia. * **Hypothyroidism:** Leads to a generalized slowing of metabolic processes, resulting in **hypothermia** and cold intolerance. Hyperthermia is instead a hallmark of Hyperthyroidism (Thyroid Storm). **Clinical Pearls for NEET-PG:** * **Key Lab Finding:** Elevated **Creatine Phosphokinase (CPK)** levels due to muscle rigidity and rhabdomyolysis. * **Treatment of Choice:** Immediate cessation of the offending agent, supportive care, and pharmacotherapy with **Dantrolene** (muscle relaxant) or **Bromocriptine** (dopamine agonist). * **Differential Diagnosis:** Distinguish NMS from **Serotonin Syndrome**, which presents with hyperreflexia and myoclonus rather than lead-pipe rigidity.

Question 142: Which of the following antidepressants is also known by the brand name Zyban?

A. Amitriptyline
B. Bupropion (Correct Answer)
C. Fluoxetine
D. Mianserin

Explanation: **Explanation:** **Bupropion (Option B)** is the correct answer. It is a unique antidepressant that acts as a **Norepinephrine-Dopamine Reuptake Inhibitor (NDRI)**. It is marketed under two primary brand names: **Wellbutrin** (for Major Depressive Disorder) and **Zyban** (specifically indicated as an aid for **smoking cessation**). By increasing dopamine levels in the reward pathway, it helps reduce nicotine cravings and withdrawal symptoms. **Analysis of Incorrect Options:** * **Amitriptyline (Option A):** A classic Tricyclic Antidepressant (TCA). Common brand names include Elavil and Tryptomer. It is primarily used for depression, neuropathic pain, and migraine prophylaxis. * **Fluoxetine (Option C):** A prototype Selective Serotonin Reuptake Inhibitor (SSRI). Its most famous brand name is **Prozac**. It is known for its long half-life and active metabolite (norfluoxetine). * **Mianserin (Option D):** A tetracyclic antidepressant (TeCA) that acts as an alpha-2 antagonist. It is less commonly used today due to the risk of agranulocytosis. **High-Yield Clinical Pearls for NEET-PG:** 1. **Seizure Risk:** Bupropion is contraindicated in patients with **epilepsy** or **eating disorders** (bulimia/anorexia) as it lowers the seizure threshold. 2. **Sexual Dysfunction:** Unlike SSRIs, Bupropion does **not** cause sexual dysfunction or significant weight gain, making it a preferred choice for patients concerned about these side effects. 3. **ADHD:** It is sometimes used off-label for ADHD due to its effect on dopamine and norepinephrine. 4. **Mechanism:** It lacks significant activity at serotonin receptors, which explains its unique side effect profile.

Question 143: What is the treatment modality used for phobias?

A. Psychotherapy
B. Behavior therapy
C. SSRI
D. All of the above (Correct Answer)

Explanation: The treatment of phobias (Specific Phobia, Social Anxiety Disorder, and Agoraphobia) requires a multimodal approach involving psychological and pharmacological interventions. **1. Why "All of the above" is correct:** * **Behavior Therapy (Option B):** This is the **treatment of choice** for Specific Phobias. Techniques like **Systematic Desensitization** (gradual exposure) and **Flooding** (direct, intense exposure) are highly effective in extinguishing the fear response. * **Psychotherapy (Option A):** Cognitive Behavioral Therapy (CBT) is the gold standard for Social Anxiety Disorder (Social Phobia). It helps patients restructure irrational thought patterns and develop coping mechanisms. * **SSRI (Option C):** Selective Serotonin Reuptake Inhibitors (e.g., Escitalopram, Sertraline) are the **first-line pharmacological treatment**, particularly for Social Anxiety Disorder and Agoraphobia, to manage the underlying anxiety and prevent panic attacks. **2. Clinical Pearls for NEET-PG:** * **Specific Phobia:** Behavior therapy (Exposure therapy) is superior to medication. * **Social Phobia (Social Anxiety Disorder):** CBT + SSRIs is the most effective combination. * **Performance Anxiety (Stage Fright):** **Propranolol** (Beta-blocker) is the drug of choice, taken 30–60 minutes before the event to control peripheral autonomic symptoms (tremors, palpitations). * **Benzodiazepines:** Used only for short-term "as-needed" relief (e.g., a patient with a fear of flying taking Alprazolam before a flight). **Summary:** While behavior therapy is the most specific intervention for the phobic stimulus itself, a comprehensive management plan often integrates psychotherapy and SSRIs to achieve long-term remission.

Question 144: Which of the following is NOT a side effect of clozapine?

A. Agranulocytosis
B. Seizure
C. Sialosis
D. Weight loss (Correct Answer)

Explanation: **Explanation:** Clozapine is an atypical (second-generation) antipsychotic reserved for treatment-resistant schizophrenia. The correct answer is **Weight loss** because Clozapine is actually associated with significant **weight gain** and metabolic syndrome. **Why Weight Loss is the Correct Answer:** Clozapine has a high affinity for $H_1$ (histamine) and $5-HT_{2C}$ receptors. Blockade of these receptors leads to increased appetite and profound weight gain. It also carries the highest risk among antipsychotics for causing dyslipidemia and Type 2 Diabetes Mellitus. **Analysis of Incorrect Options:** * **A. Agranulocytosis:** This is the most dreaded side effect (occurring in ~1% of patients). It requires mandatory WBC and Absolute Neutrophil Count (ANC) monitoring. * **B. Seizure:** Clozapine reduces the seizure threshold in a dose-dependent manner. The risk is approximately 5% at doses above 600 mg/day. * **C. Sialosis (Sialorrhea):** Paradoxically, despite its anticholinergic profile, Clozapine causes excessive salivation (wet pillow sign), likely due to $M_4$ receptor agonism or impairment of the swallowing reflex. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Treatment-resistant schizophrenia and suicidal behavior in schizophrenia. * **Myocarditis:** A rare but fatal early side effect; monitor for tachycardia and chest pain in the first month. * **Constipation:** Can lead to life-threatening paralytic ileus (Clozapine-induced gastrointestinal hypomotility). * **No Extrapyramidal Symptoms (EPS):** Clozapine has the lowest risk of EPS and tardive dyskinesia among all antipsychotics.

Question 145: Which of the following is an antiepileptic drug but NOT a mood stabilizer?

A. Topiramate
B. Lamotrigine
C. Sodium valproate
D. Leviracetam (Correct Answer)

Explanation: **Explanation:** In psychiatric practice, while many antiepileptic drugs (AEDs) are used as **mood stabilizers** to treat Bipolar Affective Disorder (BPAD), not all anticonvulsants possess mood-stabilizing properties. **Why Levetiracetam is the correct answer:** Levetiracetam is a highly effective broad-spectrum antiepileptic that acts by binding to the synaptic vesicle protein **SV2A**. Despite its efficacy in neurology, clinical trials have consistently shown that it lacks efficacy as a mood stabilizer. In fact, in psychiatry, it is notorious for causing **behavioral side effects**, including irritability, aggression, and "levetiracetam-induced rage," which can worsen mood instability. **Analysis of Incorrect Options:** * **Sodium Valproate:** The "gold standard" for treating **acute mania** and mixed episodes. It acts by increasing GABA levels and inhibiting sodium channels. * **Lamotrigine:** A first-line mood stabilizer specifically used for the **maintenance phase** of Bipolar Disorder and the prevention of **bipolar depression**. It is not effective for acute mania. * **Topiramate:** While its status as a primary mood stabilizer is debated due to weaker evidence compared to Valproate, it is clinically classified and used as an **adjunctive mood stabilizer**, particularly when weight loss is desired (as it causes weight loss, unlike Valproate). **NEET-PG High-Yield Pearls:** * **Drug of Choice (DOC) for Acute Mania:** Sodium Valproate or Lithium. * **DOC for Bipolar Depression:** Quetiapine, Lurasidone, or Lamotrigine. * **Teratogenicity:** Valproate is associated with **Neural Tube Defects** (highest risk among AEDs). * **Lamotrigine Warning:** Must be titrated slowly to avoid **Stevens-Johnson Syndrome (SJS)**. * **Gabapentin & Tiagabine:** Like Levetiracetam, these are AEDs that are **NOT** effective mood stabilizers.

Question 146: Which of the following is a symptom of neuroleptic malignant syndrome?

A. Hypotension
B. Hypothermia
C. Increased magnesium level in blood
D. Catatonia and stupor (Correct Answer)

Explanation: **Explanation:** **Neuroleptic Malignant Syndrome (NMS)** is a rare but life-threatening idiosyncratic reaction to antipsychotic medications (neuroleptics), primarily caused by potent dopamine (D2) receptor blockade in the nigrostriatal pathway and hypothalamus. **Why Option D is Correct:** The clinical hallmark of NMS is a tetrad of symptoms: **Hyperpyrexia (fever), Muscle Rigidity ("Lead-pipe" type), Autonomic Instability, and Altered Mental Status.** Mental status changes often manifest as **catatonia, stupor,** or mutism, progressing to coma. The profound rigidity and dopamine depletion lead to the catatonic state, making it a classic diagnostic feature. **Why Other Options are Incorrect:** * **A. Hypotension:** NMS is characterized by **Autonomic Instability**, which typically manifests as **Hypertension** and tachycardia, rather than hypotension. * **B. Hypothermia:** NMS causes severe **Hyperthermia** (often >38°C/100.4°F) due to hypothalamic dopamine blockade affecting thermoregulation. * **C. Increased magnesium:** There is no clinical association between NMS and hypermagnesemia. However, NMS is classically associated with **increased Creatine Phosphokinase (CPK)** levels due to muscle necrosis (rhabdomyolysis) and **Leukocytosis**. **High-Yield Clinical Pearls for NEET-PG:** * **Most common cause:** Haloperidol (High-potency typical antipsychotics). * **Key Lab Finding:** Elevated CPK (most sensitive) and Myoglobinuria (can lead to renal failure). * **Treatment:** 1. Immediate **Discontinuation** of the offending agent (Most important step). 2. Supportive care (cooling, hydration). 3. Pharmacotherapy: **Dantrolene** (muscle relaxant) or **Bromocriptine** (dopamine agonist). * **Differential Diagnosis:** Serotonin Syndrome (presents with *hyperreflexia* and *clonus*, whereas NMS presents with *rigidity* and *hyporeflexia*).

Question 147: Which antipsychotic drug is available as a depot preparation?

A. Aripiprazole
B. Fluphenazine decanoate (Correct Answer)
C. Trifluperazine
D. Fluphenazine

Explanation: **Explanation:** The correct answer is **Fluphenazine decanoate**. **1. Why Fluphenazine decanoate is correct:** Depot preparations are long-acting injectable (LAI) formulations of antipsychotics designed to improve treatment adherence in patients with chronic schizophrenia. These are typically created by **esterifying** the active drug with a long-chain fatty acid (like decanoate or enanthate) and dissolving it in a vegetable oil (e.g., sesame oil). This allows for a slow, sustained release from the intramuscular injection site, lasting 2–4 weeks. Fluphenazine decanoate was one of the first "typical" antipsychotics available in this format. **2. Why the other options are incorrect:** * **Aripiprazole:** While Aripiprazole *is* available as a depot (Aripiprazole Maintena/Lauroxil), the question asks for the most classic example among the choices provided. In the context of standard NEET-PG questions, the "decanoate" suffix specifically identifies the depot form. * **Trifluperazine:** This is a high-potency typical antipsychotic, but it is primarily administered orally and does not have a widely used depot formulation. * **Fluphenazine:** This refers to the standard hydrochloride salt used for oral administration or short-acting IM injection. Without the "decanoate" or "enanthate" ester, it is not a long-acting depot preparation. **3. High-Yield Clinical Pearls for NEET-PG:** * **Common Depot Drugs:** Typical (Fluphenazine decanoate, Haloperidol decanoate, Flupenthixol, Zuclopenthixol) and Atypical (Risperidone, Paliperidone, Olanzapine, Aripiprazole). * **Administration:** Always given via **Deep Intramuscular (IM)** route, never IV. * **Indication:** Primarily used for patients with poor compliance or "revolving door" syndrome. * **Side Effects:** While they reduce the risk of relapse, they may carry a slightly higher risk of Extrapyramidal Side Effects (EPS) due to their long half-life. * **Z-track technique:** Often used for injection to prevent leakage into subcutaneous tissue.

Question 148: What is the normal therapeutic level of Lithium?

A. 0.5-0.7 mEq/L
B. 0.7-1.1 mEq/L (Correct Answer)
C. 0.1-0.3 mEq/L
D. 1.5-2.0 mEq/L

Explanation: **Explanation:** Lithium is the gold-standard mood stabilizer used for the treatment and prophylaxis of Bipolar Affective Disorder (BPAD). Because Lithium has a **narrow therapeutic index**, monitoring serum levels is critical to ensure efficacy while avoiding toxicity. 1. **Why Option B is Correct:** The standard therapeutic range for maintenance therapy is generally **0.6–1.2 mEq/L**. Option B (0.7–1.1 mEq/L) falls perfectly within this window. For acute mania, levels are often maintained at the higher end (0.8–1.2 mEq/L), while for prophylaxis, 0.6–0.8 mEq/L is often sufficient. 2. **Why Other Options are Incorrect:** * **Option A (0.5–0.7 mEq/L):** These levels are often sub-therapeutic for many patients, increasing the risk of relapse or breakthrough manic episodes. * **Option C (0.1–0.3 mEq/L):** These are negligible levels with no clinical efficacy in psychiatry. * **Option D (1.5–2.0 mEq/L):** This range indicates **Lithium Toxicity**. Mild to moderate toxicity typically begins above 1.5 mEq/L, presenting with coarse tremors, vomiting, and confusion. **High-Yield Clinical Pearls for NEET-PG:** * **Sampling Time:** Serum levels should be measured **12 hours after the last dose** (Steady-state is reached in 4–5 days). * **Toxicity Thresholds:** * **>1.5 mEq/L:** Mild toxicity (GI upset, coarse tremors). * **>2.0 mEq/L:** Serious toxicity (Neurological symptoms, seizures). * **>2.5 mEq/L:** Severe/Life-threatening (Requires Hemodialysis). * **Drug Interactions:** Thiazides, NSAIDs, and ACE inhibitors increase Lithium levels (decreasing clearance). * **Side Effects:** Ebstein’s anomaly (teratogenicity), Nephrogenic Diabetes Insipidus, and Hypothyroidism.

Question 149: What is the absolute contraindication to lithium therapy?

A. Renal failure (Correct Answer)
B. Glaucoma
C. Epilepsy
D. Angina

Explanation: **Explanation:** **Lithium** is a monovalent cation and the gold standard mood stabilizer for Bipolar Disorder. Unlike most psychotropic drugs, lithium is **not metabolized by the liver**; it is excreted **100% unchanged by the kidneys**. **Why Renal Failure is the Correct Answer:** Lithium is handled by the nephrons similarly to sodium. In renal failure, the glomerular filtration rate (GFR) decreases, leading to a significant drop in lithium clearance. This causes lithium to accumulate rapidly in the blood, leading to **lithium toxicity**, which can be fatal or cause permanent neurological damage. Therefore, severe renal impairment is an **absolute contraindication**. **Why Other Options are Incorrect:** * **B. Glaucoma:** Unlike Tricyclic Antidepressants (TCAs) or low-potency antipsychotics, lithium lacks anticholinergic properties. It does not increase intraocular pressure and is safe in glaucoma. * **C. Epilepsy:** Lithium is generally safe in epilepsy. While it can lower the seizure threshold at toxic levels, it is not contraindicated. In fact, some other mood stabilizers (Valproate, Carbamazepine) are primary anti-epileptics. * **D. Angina:** While lithium can cause EKG changes (like T-wave flattening), it is not an absolute contraindication in stable angina. However, it is contraindicated in **recent myocardial infarction** or **severe heart failure**. **High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Index:** Lithium has a very narrow therapeutic index (0.6–1.2 mEq/L). * **Drug Interactions:** The "Big 3" drugs that increase lithium levels are **Diuretics** (especially Thiazides), **NSAIDs**, and **ACE Inhibitors**. * **Teratogenicity:** Causes **Ebstein’s Anomaly** (atrialization of the right ventricle) if taken during pregnancy. * **Monitoring:** Before starting, always check **RFT (Renal Function Test)** and **TFT (Thyroid Function Test)**.

Question 150: A schizophrenic patient on antipsychotic drugs may develop which of the following side effects?

A. Decreased prolactin
B. Increased prolactin (Correct Answer)
C. Hypertension
D. Wakefulness

Explanation: **Explanation:** The correct answer is **B. Increased prolactin**. **Mechanism of Action:** Antipsychotic drugs (especially typical antipsychotics like Haloperidol and certain atypicals like Risperidone) work by blocking **D2 receptors** in the brain. Prolactin secretion is regulated by the **Tuberoinfundibular pathway**, where dopamine normally acts as a "Prolactin Inhibiting Factor" (PIF). By blocking D2 receptors in this pathway, antipsychotics remove the inhibitory effect of dopamine, leading to **hyperprolactinemia**. **Analysis of Incorrect Options:** * **A. Decreased prolactin:** This is incorrect because dopamine blockade increases prolactin levels. Dopamine agonists (like Bromocriptine) would decrease prolactin. * **C. Hypertension:** Most antipsychotics actually cause **orthostatic hypotension** due to alpha-1 adrenergic receptor blockade, rather than hypertension. * **D. Wakefulness:** Antipsychotics generally cause **sedation** and somnolence due to their antihistaminic (H1 blockade) and anti-adrenergic properties. **High-Yield Clinical Pearls for NEET-PG:** * **Clinical Features of Hyperprolactinemia:** In females, it leads to galactorrhea, amenorrhea, and infertility. In males, it causes gynecomastia, decreased libido, and erectile dysfunction. * **Drug Exception:** **Aripiprazole** (a D2 partial agonist) is unique because it can actually lower prolactin levels or remain prolactin-neutral. * **Quetiapine and Clozapine** are the atypical antipsychotics with the lowest risk of causing hyperprolactinemia ("prolactin-sparing"). * **Tuberoinfundibular Pathway:** Remember this specific dopaminergic pathway for exams, as it is the site responsible for endocrine side effects.

Question 151: What is the drug treatment for tardive dyskinesia?

A. Valbenazine (Correct Answer)
B. Ropinirole
C. Tetrabenazine
D. Biperiden

Explanation: **Explanation:** **Tardive Dyskinesia (TD)** is a late-onset extrapyramidal side effect caused by long-term use of dopamine receptor blockers (antipsychotics). It is characterized by involuntary, repetitive movements, most commonly orofacial dyskinesia. **Why Valbenazine is correct:** The pathophysiology of TD involves dopamine receptor supersensitivity. **Valbenazine** is a highly selective **Vesicular Monoamine Transporter 2 (VMAT2) inhibitor**. By inhibiting VMAT2, it prevents the packaging of dopamine into presynaptic vesicles, thereby reducing synaptic dopamine release and alleviating the hyperkinetic movements of TD. It is FDA-approved specifically for this condition and is preferred over older agents due to its once-daily dosing and better side-effect profile. **Analysis of Incorrect Options:** * **Ropinirole:** A dopamine agonist used in Parkinson’s disease and Restless Leg Syndrome. It would likely worsen TD by further stimulating supersensitive dopamine receptors. * **Tetrabenazine:** While also a VMAT2 inhibitor, it is primarily used for Huntington’s Chorea. It has a shorter half-life and a higher risk of causing depression and parkinsonism compared to Valbenazine. (Note: While sometimes used off-label for TD, Valbenazine is the more specific, modern answer). * **Biperiden:** An anticholinergic used to treat *acute* dystonia and drug-induced parkinsonism. Anticholinergics are **contraindicated** in TD as they can worsen the symptoms. **NEET-PG High-Yield Pearls:** * **First step in management:** Gradually taper/discontinue the offending antipsychotic or switch to **Clozapine** (the antipsychotic with the lowest risk of TD). * **VMAT2 Inhibitors:** Valbenazine and Deutetrabenazine are the first-line FDA-approved treatments. * **Risk Factor:** Elderly females are at the highest risk for developing TD.

Question 152: Symptoms of Neuroleptic Malignant Syndrome (NMS) are all of the following except?

A. Confusion
B. Hypothermia (Correct Answer)
C. Diaphoresis
D. Hypertension

Explanation: **Explanation:** Neuroleptic Malignant Syndrome (NMS) is a life-threatening idiosyncratic reaction to antipsychotic medications (neuroleptics), primarily caused by potent dopamine (D2) receptor blockade in the nigrostriatal pathway and hypothalamus. **Why Hypothermia is the Correct Answer:** NMS is characterized by **Hyperthermia** (fever), not hypothermia. The blockade of dopamine receptors in the hypothalamus disrupts the body's thermoregulatory set-point, leading to severe pyrexia (often >38°C/100.4°F). Therefore, Option B is the "except" statement. **Analysis of Incorrect Options:** * **Confusion (A):** Altered mental status is a hallmark of NMS. It typically manifests as delirium, confusion, agitation, or even coma. * **Diaphoresis (C):** Autonomic instability is a core feature. Profuse sweating (diaphoresis) occurs alongside tachycardia and tachypnea. * **Hypertension (D):** Autonomic dysfunction also leads to labile blood pressure, most commonly presenting as hypertension. **High-Yield Clinical Pearls for NEET-PG:** * **The "Tetrad" of NMS:** 1. Hyperthermia, 2. "Lead-pipe" rigidity, 3. Autonomic instability, 4. Altered mental status. * **Key Lab Finding:** Significantly elevated **Creatine Phosphokinase (CPK)** levels due to muscle rigidity and rhabdomyolysis. * **Treatment:** 1. Immediate discontinuation of the offending antipsychotic. 2. Supportive care (cooling, hydration). 3. Pharmacotherapy: **Dantrolene** (muscle relaxant) or **Bromocriptine** (dopamine agonist). * **NMS vs. Serotonin Syndrome:** NMS features "Lead-pipe" rigidity and bradyreflexia, whereas Serotonin Syndrome features hyperreflexia and myoclonus.

Question 153: What is the most effective treatment for psychosis induced by levodopa?

A. Quetiapine (Correct Answer)
B. Chlorpromazine
C. Trifluoperazine
D. Haloperidol

Explanation: **Explanation:** The management of psychosis in Parkinson’s Disease (PD) is clinically challenging because traditional antipsychotics block dopamine (D2) receptors, which significantly worsens motor symptoms (rigidity and tremors). **Why Quetiapine is the correct answer:** Quetiapine is considered a first-line treatment for levodopa-induced psychosis because it has a **low affinity for D2 receptors** and a rapid dissociation rate. This allows it to treat psychotic symptoms (hallucinations and delusions) without significantly exacerbating the underlying motor deficits of Parkinson’s disease. While **Clozapine** is technically the most effective drug, it is often reserved for refractory cases due to the risk of agranulocytosis and the need for mandatory blood monitoring. Therefore, Quetiapine is the preferred practical choice in clinical practice and exams. **Why the other options are incorrect:** * **Chlorpromazine (Option B):** A typical antipsychotic with significant D2 blockade and sedative properties; it would severely worsen Parkinsonian motor symptoms. * **Trifluoperazine (Option C):** A high-potency typical antipsychotic that carries a very high risk of Extrapyramidal Side Effects (EPS). * **Haloperidol (Option D):** A potent D2 antagonist. It is strictly contraindicated in Parkinson’s disease as it can lead to acute worsening of motor function and potentially trigger a "frozen" state. **High-Yield Clinical Pearls for NEET-PG:** 1. **Drug of Choice:** Clozapine is the "Gold Standard," but **Quetiapine** is the most commonly used first-line agent. 2. **Pimavanserin:** A newer, FDA-approved drug for PD-psychosis that acts as a selective serotonin inverse agonist (5-HT2A) without any D2 blockade. 3. **Management Strategy:** Always attempt to reduce the dose of anti-Parkinsonian drugs (starting with anticholinergics, then amantadine, then dopamine agonists) before adding an antipsychotic.

Question 154: All of the following are serotonin-dopamine antagonists except?

A. Zotepine
B. Loxapine (Correct Answer)
C. Seindole
D. All

Explanation: **Explanation:** The term **Serotonin-Dopamine Antagonists (SDAs)** refers to **Atypical (Second-Generation) Antipsychotics**. These drugs are characterized by their ability to block both Serotonin (5-HT2A) and Dopamine (D2) receptors, which helps reduce extrapyramidal side effects (EPS) and improve negative symptoms of schizophrenia. **1. Why Loxapine is the correct answer:** Loxapine is traditionally classified as a **Typical (First-Generation) Antipsychotic** belonging to the dibenzoxazepine class. While it does show some 5-HT2A antagonism, its clinical profile and high affinity for D2 receptors align it more closely with typical antipsychotics. Note: Its inhaled form (Adasuve) is used for acute agitation, but it remains the "odd one out" compared to the newer SDAs listed. **2. Analysis of incorrect options:** * **Zotepine:** This is an atypical antipsychotic (SDA) that also inhibits norepinephrine reuptake. It is known for its efficacy but carries a higher risk of seizures. * **Sertindole:** This is a potent SDA (atypical antipsychotic). It is highly selective for limbic areas but is used with caution due to its potential for significant **QT interval prolongation**. **NEET-PG High-Yield Pearls:** * **Mnemonic for SDAs:** "Old Air" (**O**lanzapine, **L**urasidone, **D**onepezil—*wait, no*—**D**onepezil is for Alzheimer's; use **R**isperidone, **Q**uetiapine, **A**ripiprazole, **I**loperidone, **R**isperidone). * **Clozapine:** The first SDA/Atypical antipsychotic; gold standard for treatment-resistant schizophrenia but requires monitoring for **agranulocytosis**. * **Aripiprazole:** Often called a "Dopamine system stabilizer" because it is a **partial agonist** at D2 receptors, unlike most SDAs which are pure antagonists. * **Loxapine Metabolism:** It is metabolized into **Amoxapine**, which is used as an antidepressant.

Question 155: Akathisia is best treated by:

A. Lithium
B. Fluoxetine
C. Propanolol (Correct Answer)
D. Haloperidol

Explanation: **Explanation:** **Akathisia** is a common and distressing Extrapyramidal Side Effect (EPS) characterized by a subjective feeling of inner restlessness and an objective inability to sit still. It most frequently occurs as a side effect of typical (first-generation) antipsychotics. **Why Propranolol is the Correct Answer:** The drug of choice for treating akathisia is **Propranolol**, a non-selective beta-blocker. While the exact pathophysiology is not fully understood, it is believed that beta-adrenergic receptors in the peripheral and central nervous systems play a role in the manifestation of restlessness. Propranolol effectively crosses the blood-brain barrier to alleviate both the subjective tension and physical movements. **Analysis of Incorrect Options:** * **A. Lithium:** This is a mood stabilizer used primarily for Bipolar Affective Disorder. It has no role in treating movement disorders and can actually cause tremors. * **B. Fluoxetine:** An SSRI used for depression/anxiety. It can occasionally *cause* akathisia as a side effect but does not treat it. * **D. Haloperidol:** This is a high-potency typical antipsychotic and is one of the most common **causes** of akathisia due to potent D2 receptor blockade. **NEET-PG High-Yield Pearls:** * **Drug of Choice (DOC):** Propranolol (usually 30–90 mg/day). * **Second-line treatments:** Benzodiazepines (e.g., Lorazepam) or anticholinergics (though anticholinergics are less effective for akathisia than for acute dystonia). * **Clinical Presentation:** Patients are often misdiagnosed as having "worsening psychosis/agitation," leading to an incorrect increase in antipsychotic dosage, which worsens the condition. * **Timeline:** Akathisia typically develops within days to weeks of starting or increasing an antipsychotic.

Question 156: Which antidepressant drug can cause neuroleptic malignant syndrome and tardive dyskinesia?

A. Amineptin
B. Carbamazepine
C. Amoxapine (Correct Answer)
D. Trazodone

Explanation: **Explanation:** The correct answer is **Amoxapine**. **Why Amoxapine is the correct answer:** Amoxapine is a secondary amine tricyclic antidepressant (TCA). Its unique pharmacological profile stems from its metabolism: it is metabolized into **7-hydroxyamoxapine**, a potent **dopamine D2 receptor antagonist**. Because it possesses neuroleptic-like properties (similar to antipsychotics), it can cause side effects typically associated with dopamine blockade, specifically **Extrapyramidal Symptoms (EPS)**, **Tardive Dyskinesia**, and **Neuroleptic Malignant Syndrome (NMS)**. This makes it distinct from almost all other antidepressants. **Analysis of Incorrect Options:** * **Amineptine:** A dopamine reuptake inhibitor (DRI). While it acts on the dopamine system, it increases synaptic dopamine rather than blocking receptors; thus, it does not cause NMS or tardive dyskinesia. * **Carbamazepine:** Primarily an anticonvulsant and mood stabilizer. While it can cause various neurological side effects (like ataxia), it is not an antidepressant and is not typically associated with D2 blockade-induced NMS or tardive dyskinesia. * **Trazodone:** A Serotonin Antagonist and Reuptake Inhibitor (SARI). Its most notorious high-yield side effect is **priapism**, but it does not possess significant D2 blocking activity. **High-Yield Clinical Pearls for NEET-PG:** * **Amoxapine** is often described as a "neuroleptic-antidepressant" hybrid. * **Loxapine** (an antipsychotic) is the parent compound from which Amoxapine is derived. * If a question mentions an antidepressant causing **galactorrhea** or **hyperprolactinemia**, think Amoxapine (due to D2 blockade in the tuberoinfundibular pathway). * **NMS Mnemonic (FEVER):** **F**ever, **E**ncephalopathy, **V**itals unstable, **E**levated CPK, **R**igidity ("Lead-pipe").

Question 157: A 19-year-old boy with chronic schizophrenia is initiated on haloperidol 20 mg/day. A week after starting the medication, he develops restlessness, fidgetiness, irritability, and is unable to remain still. What is the most appropriate treatment strategy?

A. Increase the dose of haloperidol
B. Add an anticholinergic drug
C. Add a beta-blocker (Correct Answer)
D. Add another antipsychotic drug

Explanation: ### Explanation **Diagnosis: Acute Akathisia** The patient is experiencing **Akathisia**, a common Extrapyramidal Side Effect (EPS) characterized by subjective feelings of inner restlessness and the objective inability to sit still. It typically occurs within days to weeks of starting high-potency first-generation antipsychotics like Haloperidol. **Why the Correct Answer is Right:** * **Option C (Beta-blocker):** Propranolol (a non-selective beta-blocker) is the **drug of choice** for akathisia. It effectively crosses the blood-brain barrier and modulates the adrenergic system, which is thought to be overactive in this condition. Benzodiazepines (like Lorazepam) are considered second-line treatments. **Why Other Options are Wrong:** * **Option A (Increase dose):** Akathisia is a dose-dependent side effect. Increasing the dose of Haloperidol would exacerbate the symptoms and increase the risk of other EPS like dystonia or parkinsonism. * **Option B (Anticholinergic):** While anticholinergics (e.g., Benztropine, Trihexyphenidyl) are the treatment of choice for **Acute Dystonia** and **Drug-Induced Parkinsonism**, they are significantly less effective for Akathisia. * **Option D (Add another antipsychotic):** Adding another antipsychotic increases the "pill burden" and the risk of polypharmacy-related side effects without addressing the underlying restlessness. **High-Yield Clinical Pearls for NEET-PG:** * **Most common EPS:** Akathisia is often cited as the most common and distressing extrapyramidal symptom. * **Clinical Presentation:** Patients often pace the floor, rock back and forth, or tap their feet incessantly. * **Suicide Risk:** Severe akathisia is clinically significant because it is associated with increased irritability and an elevated risk of **suicidal ideation**. * **Management Hierarchy:** 1. Reduce antipsychotic dose (if possible); 2. Switch to a second-generation antipsychotic (e.g., Quetiapine); 3. Treat with **Propranolol** (30–90 mg/day).

Question 158: Antipsychotic-induced akathisia is characterized by:

A. Rigidity
B. Tremor
C. Spasm of a muscle or muscle group
D. Restlessness (Correct Answer)

Explanation: **Explanation:** **Akathisia** is the most common extrapyramidal side effect (EPS) associated with antipsychotic medications. It is characterized by a subjective feeling of **inner restlessness** and an objective inability to sit still. Patients often describe a "need to move," leading to constant pacing, shifting weight, or foot tapping. * **Why Option D is Correct:** The hallmark of akathisia is **restlessness**. Unlike other movement disorders, it has a significant psychological component (anxiety/irritability) coupled with motor hyperactivity. It typically occurs within days to weeks of starting or increasing the dose of a dopamine antagonist. **Why the other options are incorrect:** * **A & B (Rigidity and Tremor):** These are classic features of **Drug-Induced Parkinsonism**. Rigidity (lead-pipe or cogwheel) and resting tremors occur due to the blockade of dopamine receptors in the nigrostriatal pathway, mimicking Parkinson’s disease. * **C (Spasm of a muscle group):** This describes **Acute Dystonia**. It involves sudden, involuntary, and often painful contractions of muscle groups (e.g., torticollis, oculogyric crisis). Dystonia usually occurs very early in treatment (within hours to days). **High-Yield Clinical Pearls for NEET-PG:** * **Management:** The first-line treatment for akathisia is **Beta-blockers (Propranolol)**. Benzodiazepines or anticholinergics (like Benztropine) are second-line options. * **Risk Factors:** High-potency first-generation antipsychotics (e.g., Haloperidol) carry the highest risk. * **Clinical Significance:** Akathisia is often misdiagnosed as worsening psychosis or agitation, leading to a dangerous "vicious cycle" where the clinician increases the antipsychotic dose, further worsening the condition.

Question 159: Which of the following is not a mood stabilizer?

A. Lithium
B. Valproate
C. Carbamazepine
D. Fluoxetine (Correct Answer)

Explanation: **Explanation** The core concept in this question is the classification of psychotropic medications based on their therapeutic indications. **Why Fluoxetine is the correct answer:** Fluoxetine is a **Selective Serotonin Reuptake Inhibitor (SSRI)**, which is classified as an **antidepressant**, not a mood stabilizer. While mood stabilizers are used to treat Bipolar Disorder (BD) by preventing both manic and depressive episodes, antidepressants like Fluoxetine can actually trigger **"mood switching"** (inducing mania) in patients with Bipolar I disorder if used without a mood stabilizer. **Why the other options are incorrect:** * **Lithium (Option A):** The "Gold Standard" mood stabilizer. It is the only drug proven to reduce the risk of suicide in patients with Bipolar Disorder. * **Valproate (Option B):** An anticonvulsant that acts as a potent mood stabilizer. It is often the first-line treatment for **Acute Mania** and **Mixed Episodes**. * **Carbamazepine (Option C):** Another anticonvulsant used as a second-line mood stabilizer, particularly effective in patients who do not respond to Lithium or those with "Rapid Cycling" Bipolar Disorder. **High-Yield Clinical Pearls for NEET-PG:** 1. **Definition:** A mood stabilizer is a drug that treats mania/depression without increasing the frequency or severity of the opposite episode. 2. **Lamotrigine:** Another high-yield anticonvulsant mood stabilizer, primarily used for the **prevention of Bipolar Depression** (not effective for acute mania). 3. **Teratogenicity:** Remember the "Ebstein’s Anomaly" associated with Lithium and "Neural Tube Defects" (Spina Bifida) associated with Valproate. 4. **Therapeutic Range:** Lithium has a narrow therapeutic index (0.6–1.2 mEq/L). Toxicity typically begins above 1.5 mEq/L.

Question 160: Which of the following is NOT true about clozapine?

A. Should be discontinued if WBC count is < 3500/dl.
B. Has no anti-suicide property. (Correct Answer)
C. Should not be used along with carbamazepine.
D. The action is more on D4 receptors than D2 receptors.

Explanation: **Explanation:** **Clozapine** is a unique "atypical" antipsychotic reserved for treatment-resistant schizophrenia. 1. **Why Option B is the correct answer (The False Statement):** Clozapine is one of the few psychotropic drugs with proven **anti-suicide properties**. It is FDA-approved specifically for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder. Therefore, stating it has "no anti-suicide property" is clinically incorrect. (Note: Lithium is the other major drug with anti-suicide effects in mood disorders). 2. **Analysis of Incorrect Options (True Statements):** * **Option A:** Clozapine carries a risk of **agranulocytosis**. Strict hematological monitoring is required. If the Total Leukocyte Count (WBC) falls below **3000–3500/mm³** or the Absolute Neutrophil Count (ANC) falls below **1500/mm³**, the drug must be discontinued to prevent fatal infections. * **Option C:** **Carbamazepine** is a potent bone marrow suppressant. Combining it with Clozapine synergistically increases the risk of agranulocytosis. Additionally, Carbamazepine is a CYP3A4 inducer which lowers Clozapine levels. * **Option D:** Unlike typical antipsychotics that bind strongly to D2 receptors, Clozapine has a high affinity for **D4 receptors** and 5-HT2A receptors, with relatively weak D2 blockade. This explains its low incidence of Extrapyramidal Side Effects (EPS). **High-Yield Clinical Pearls for NEET-PG:** * **Drug of choice:** Treatment-resistant schizophrenia (failed 2 trials of other antipsychotics). * **Side Effects:** Sialorrhea (hypersalivation), seizures (dose-dependent), myocarditis, and significant weight gain. * **Benefit:** It is the only antipsychotic that does not cause Tardive Dyskinesia and rarely causes Prolactin elevation.

Question 161: Electroconvulsive therapy (ECT) is indicated in which of the following conditions?

A. Hypomania
B. Severe depression (Correct Answer)
C. Obsessive-compulsive disorder (OCD) with mixed features
D. Generalized anxiety disorder

Explanation: **Explanation:** **Correct Answer: B. Severe depression** Electroconvulsive therapy (ECT) is one of the most effective biological treatments in psychiatry. Its primary indication is **Major Depressive Disorder (MDD)**, particularly when it is severe, treatment-resistant, or accompanied by psychotic features or high suicide risk. ECT works by inducing a generalized tonic-clonic seizure, which leads to a massive release of neurotransmitters and neurotrophic factors (like BDNF), rapidly improving mood and reducing suicidal ideation. **Analysis of Incorrect Options:** * **A. Hypomania:** While ECT is highly effective for *acute mania* (especially if life-threatening or treatment-resistant), it is not indicated for hypomania, which is a milder form of mood elevation that typically responds well to mood stabilizers or antipsychotics. * **C. OCD with mixed features:** ECT is generally not a first- or second-line treatment for OCD. It is only considered in extremely rare, refractory cases where a comorbid severe depression is present. * **D. Generalized Anxiety Disorder (GAD):** Psychotherapy (CBT) and pharmacotherapy (SSRIs/SNRIs) are the mainstays for GAD. ECT has no established role in treating primary anxiety disorders. **NEET-PG High-Yield Pearls:** * **Absolute Contraindication:** There are no absolute contraindications, but **Increased Intracranial Pressure (ICP)** is the most significant relative contraindication. * **Drug of Choice for Pre-medication:** Atropine (to prevent vagal bradycardia). * **Anesthetic of Choice:** Methohexital (Gold standard); Thiopentone is also commonly used. * **Muscle Relaxant:** Succinylcholine (to prevent musculoskeletal injury during seizure). * **Most Common Side Effect:** Retrograde amnesia (usually transient). * **Other Indications:** Catatonia (ECT is the treatment of choice if Benzodiazepines fail), Schizophrenia (especially with catatonic or affective symptoms), and Severe Mania.

Question 162: Which of the following are atypical (second generation or newer) antipsychotics?

A. Aripiprazole
B. Risperidone (Correct Answer)
C. Pimozide
D. Olanzapine

Explanation: **Explanation:** Antipsychotics are classified into **Typical (First Generation)** and **Atypical (Second Generation)** based on their mechanism of action and side-effect profile. **Why Risperidone is correct:** Risperidone is a prototypical **Atypical Antipsychotic**. Unlike typical agents that primarily block Dopamine (D2) receptors, atypical antipsychotics are **Serotonin-Dopamine Antagonists (SDAs)**. They block both 5-HT2A and D2 receptors. This dual action reduces Extrapyramidal Side Effects (EPS) and is more effective in treating the negative symptoms of schizophrenia (e.g., apathy, social withdrawal). **Analysis of other options:** * **Aripiprazole:** This is a **Third Generation** antipsychotic. It acts as a **D2 partial agonist** (Dopamine System Stabilizer). While often grouped with atypicals in broad categories, it is pharmacologically distinct. * **Olanzapine:** This is also an **Atypical Antipsychotic**. (Note: In many MCQ formats, if multiple options are correct, the "most" representative or the one specified in the key is chosen; however, clinically, both Risperidone and Olanzapine are Second Generation). * **Pimozide:** This is a **Typical (First Generation)** antipsychotic belonging to the Diphenylbutylpiperidine class. It is highly potent and specifically used in Tourette’s syndrome and Delusional Parasitosis (Ekbom syndrome). **High-Yield NEET-PG Pearls:** * **Clozapine:** The first atypical antipsychotic; gold standard for **treatment-resistant schizophrenia**. Watch for **agranulocytosis** (requires mandatory WBC monitoring). * **Metabolic Syndrome:** Olanzapine and Clozapine carry the highest risk of weight gain and diabetes. * **Hyperprolactinemia:** Among atypicals, **Risperidone** has the highest risk of increasing prolactin levels. * **Ziprasidone:** Associated with **QT interval prolongation**; avoid in patients with cardiac history.

Question 163: A 26-year-old man with schizophrenia and tardive dyskinesia. Which is the most appropriate pharmacotherapeutic agent?

A. Clozapine (Correct Answer)
B. Valproic acid
C. Haloperidol
D. Paroxetine

Explanation: **Explanation:** The correct answer is **Clozapine**. **Why Clozapine is the drug of choice:** Tardive Dyskinesia (TD) is a late-onset extrapyramidal side effect (EPS) caused by the long-term blockade of dopamine (D2) receptors, leading to receptor supersensitivity. When a patient with schizophrenia develops TD, the primary strategy is to switch them to an atypical antipsychotic with the lowest risk of EPS. **Clozapine** is the gold standard in this scenario because it has a very low affinity for D2 receptors and a high affinity for D4 and serotonin (5-HT2A) receptors. It is the only antipsychotic that does not cause TD and may even suppress existing dyskinetic movements. **Why other options are incorrect:** * **Haloperidol:** This is a high-potency typical antipsychotic with strong D2 antagonism. It is a leading cause of TD and would worsen the condition. * **Valproic acid:** This is a mood stabilizer/anti-epileptic. While it may be used as an adjunct in schizoaffective disorders, it has no role in treating the core symptoms of schizophrenia or reversing TD. * **Paroxetine:** This is an SSRI used for depression and anxiety. It does not treat psychosis and can occasionally worsen movement disorders through indirect serotonergic effects on dopamine. **High-Yield Clinical Pearls for NEET-PG:** * **VMAT2 Inhibitors:** Drugs like **Valbenazine** and **Deutetrabenazine** are now FDA-approved specifically for the treatment of TD. * **Clozapine Monitoring:** Remember the "No Blood, No Drug" rule. Clozapine requires mandatory monitoring of Absolute Neutrophil Count (ANC) due to the risk of **agranulocytosis** (most common in the first 18 weeks). * **Other Side Effects:** Clozapine is associated with seizures (dose-dependent), myocarditis, and significant weight gain/metabolic syndrome.

Question 164: What is the primary treatment for Neuroleptic Malignant Syndrome?

A. Dantrolene (Correct Answer)
B. Corticosteroids
C. Diazepam
D. Hemodialysis

Explanation: **Explanation:** **Neuroleptic Malignant Syndrome (NMS)** is a life-threatening idiosyncratic reaction to antipsychotic drugs (dopamine antagonists). It is characterized by the "tetrad" of muscle rigidity (lead-pipe), hyperthermia, autonomic instability, and altered mental status. **Why Dantrolene is Correct:** The primary pharmacological treatment for NMS is **Dantrolene**, a direct-acting skeletal muscle relaxant. It works by inhibiting the release of calcium ions from the sarcoplasmic reticulum, thereby reducing muscle contraction and heat production. This addresses the peripheral hypermetabolic state and rigidity that drive the syndrome's morbidity. **Why Other Options are Incorrect:** * **Corticosteroids:** These are used for inflammatory or autoimmune conditions. NMS is a neurochemical/metabolic crisis, not an inflammatory one; steroids have no role here. * **Diazepam:** While benzodiazepines can help control agitation or mild muscle spasms, they do not treat the underlying pathophysiology of NMS as effectively as specific muscle relaxants or dopamine agonists. * **Hemodialysis:** Antipsychotics are highly protein-bound and have a large volume of distribution; therefore, they are not dialyzable. Dialysis is only used in NMS if secondary acute renal failure occurs due to rhabdomyolysis. **High-Yield Clinical Pearls for NEET-PG:** * **First Step in Management:** Immediate discontinuation of the offending antipsychotic agent and supportive care (cooling, IV fluids). * **Drug of Choice (Dopamine Agonist):** **Bromocriptine** is often used alongside Dantrolene to restore dopamine balance. * **Key Lab Finding:** Significantly elevated **Creatine Phosphokinase (CPK)** levels due to muscle necrosis. * **Differential Diagnosis:** Unlike Serotonin Syndrome, NMS presents with **"lead-pipe" rigidity** and **bradyreflexia**, whereas Serotonin Syndrome presents with hyperreflexia and myoclonus.

Question 165: Depot preparations are available for which of the following antipsychotic medications?

A. Haloperidol
B. Risperidone
C. Olanzapine
D. All of the above (Correct Answer)

Explanation: **Explanation:** Depot antipsychotics are long-acting injectable (LAI) formulations designed to improve treatment adherence in patients with chronic psychotic disorders, such as schizophrenia. These preparations release the medication slowly into the bloodstream over weeks or months. * **Haloperidol (Option A):** This is a first-generation (typical) antipsychotic. Its depot form, **Haloperidol Decanoate**, is administered intramuscularly every 4 weeks and is one of the most commonly used LAIs in clinical practice. * **Risperidone (Option B):** A second-generation (atypical) antipsychotic. It is available as **Risperidone Consta** (microspheres), usually administered every 2 weeks. Newer formulations like Perseris (subcutaneous) also exist. * **Olanzapine (Option C):** Also an atypical antipsychotic, available as **Olanzapine Pamoate**. While effective, it requires mandatory post-injection monitoring for 3 hours due to the risk of Post-injection Delirium Sedation Syndrome (PDSS). Since all three medications have established depot formulations, **Option D** is the correct answer. **High-Yield Clinical Pearls for NEET-PG:** * **Fluphenazine Decanoate** was the first-ever depot antipsychotic introduced. * **Zuclopenthixol** is another common typical antipsychotic available as a depot (Acuphase for short-term, Decanoate for long-term). * **Paliperidone Palmitate** is a popular LAI with monthly (Invega Sustenna) and 3-monthly (Invega Trinza) dosing schedules. * **Indication:** Depot preparations are primarily indicated for patients with poor compliance or those who prefer the convenience of infrequent dosing. * **Contraindication:** They should never be used to treat acute psychosis or "rapid tranquilization" because their effects cannot be immediately reversed.

Question 166: Lithium is best used in which of the following conditions?

A. Manic-depressive disorder (bipolar) (Correct Answer)
B. Unipolar depression
C. Manic-depressive disorder with rapid cycling
D. Major depressive disorder

Explanation: **Explanation:** **Lithium** is the gold-standard treatment and the "drug of choice" for the prophylaxis and maintenance of **Bipolar Affective Disorder (BPAD)**, historically referred to as **Manic-depressive disorder**. It is highly effective in treating acute manic episodes and preventing future relapses of both mania and depression. * **Why Option A is correct:** Lithium’s primary mechanism involves modulating second messenger systems (inhibiting inositol monophosphatase) and stabilizing neurotransmission. It is uniquely effective in classic BPAD, particularly in patients with a "mania-followed-by-depression" sequence and a positive family history of lithium response. * **Why Options B & D are incorrect:** While Lithium can be used as an **augmentation strategy** in treatment-resistant Unipolar or Major Depressive Disorder, it is not the first-line treatment. Selective Serotonin Reuptake Inhibitors (SSRIs) are the preferred initial therapy for these conditions. * **Why Option C is incorrect:** Rapid cycling (defined as ≥4 mood episodes in 12 months) is a known predictor of **poor response** to Lithium. In such cases, **Valproate** or Carbamazepine are considered superior and are the preferred mood stabilizers. **High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Index:** Lithium has a narrow therapeutic index. Target serum levels are **0.8–1.2 mEq/L** for acute mania and **0.6–1.0 mEq/L** for maintenance. * **Anti-suicidal Property:** Lithium is one of the few psychotropic drugs (along with Clozapine) proven to reduce the risk of suicide in bipolar patients. * **Teratogenicity:** Use in pregnancy is associated with **Ebstein’s Anomaly** (atrialization of the right ventricle). * **Side Effects:** Common issues include fine tremors, polyuria (nephrogenic diabetes insipidus), and hypothyroidism.

Question 167: What is the treatment for tardive dyskinesia?

A. Dantrolene sodium
B. Clonazepam and vitamin E (Correct Answer)
C. Pacitine
D. Propranolol

Explanation: **Explanation:** **Tardive Dyskinesia (TD)** is a delayed-onset extrapyramidal side effect caused by long-term use of dopamine receptor blockers (antipsychotics). It is characterized by involuntary, choreoathetoid movements, most commonly involving the orofacial region (e.g., tongue protrusion, lip-smacking). **Why Option B is Correct:** The management of TD is challenging. The first step is usually to reduce the dose of the offending agent or switch to a second-generation antipsychotic like Clozapine. For symptomatic treatment: * **Vitamin E:** Acts as an antioxidant to combat free radical damage to striatal neurons caused by chronic dopamine blockade. * **Clonazepam:** A benzodiazepine that enhances GABAergic tone, which helps suppress involuntary movements. * *Note:* Modern gold-standard treatments now include VMAT2 inhibitors (Valbenazine, Deutetrabenazine), but in the context of standard NEET-PG options, Vitamin E and Clonazepam remain classic choices. **Why Other Options are Incorrect:** * **A. Dantrolene sodium:** This is a muscle relaxant used specifically for **Neuroleptic Malignant Syndrome (NMS)** and Malignant Hyperthermia. * **C. Pacitane (Trihexyphenidyl):** This is an anticholinergic used for *Acute Dystonia* and *Drug-induced Parkinsonism*. Crucially, anticholinergics often **worsen** TD symptoms. * **D. Propranolol:** This beta-blocker is the drug of choice for **Akathisia** (subjective restlessness). **High-Yield Clinical Pearls for NEET-PG:** 1. **Pathophysiology:** TD is thought to be due to **dopamine receptor supersensitivity** in the nigrostriatal pathway. 2. **Risk Factors:** Old age, female gender, and long-term use of typical antipsychotics (e.g., Haloperidol). 3. **AIMS Scale:** The Abnormal Involuntary Movement Scale is used for screening and monitoring TD. 4. **Clozapine:** The antipsychotic with the lowest risk of causing TD and often used to manage patients who develop it.

Question 168: Which medication is known to cause reversible lens granular deposits?

A. chlorpromazine (Correct Answer)
B. risperidone
C. paliperidone
D. olanzapine

Explanation: **Explanation** The correct answer is **Chlorpromazine**. **1. Why Chlorpromazine is correct:** Chlorpromazine is a low-potency typical antipsychotic known for its specific ocular side effects. Long-term use or high cumulative doses (typically >800 mg/day) lead to the deposition of drug-pigment complexes in the eye. These characteristically appear as **whitish-brown granular deposits** on the **anterior lens capsule** and the posterior surface of the cornea. These deposits are usually asymptomatic and do not significantly impair vision, though they can occasionally progress to "star-shaped" cataracts. Importantly, these lens changes are often **reversible** or stabilize upon discontinuation of the drug. **2. Why the other options are incorrect:** * **Risperidone, Paliperidone, and Olanzapine:** These are Second-Generation (Atypical) Antipsychotics. While they are associated with metabolic side effects (weight gain, dyslipidemia, and diabetes), they are **not** typically associated with granular lens deposits. Risperidone and Paliperidone are more frequently linked to hyperprolactinemia. **3. High-Yield Clinical Pearls for NEET-PG:** * **Chlorpromazine (CPZ):** Remember the mnemonic *"C for Chlorpromazine, C for Corneal/Lens deposits."* It is also associated with blue-grey skin discoloration and photosensitivity. * **Thioridazine:** Another low-potency antipsychotic, but it causes **Irreversible Retinitis Pigmentosa** (Browning of vision) at doses >800 mg/day. Remember: *"T for Thioridazine, T for Total blindness (Retina)."* * **Quetiapine:** Historically required baseline slit-lamp exams due to cataract concerns in animal studies, though this is rarely seen in humans. * **Monitoring:** Patients on long-term Chlorpromazine should undergo periodic slit-lamp examinations.

Question 169: A patient diagnosed with schizophrenia presents a challenge for the use of clozapine as an antipsychotic drug. Which of the following acts as a limiting factor in its use?

A. Its potential to cause agranulocytosis (Correct Answer)
B. Its inability to benefit negative symptoms of schizophrenia
C. High incidence of extrapyramidal side effects
D. Production of hyperprolactinemia

Explanation: **Explanation:** Clozapine is a "Gold Standard" atypical antipsychotic, primarily reserved for **treatment-resistant schizophrenia** (failure of at least two other antipsychotic trials). Despite its superior efficacy, its clinical use is strictly limited by its side-effect profile. **1. Why Option A is Correct:** The most serious and life-threatening adverse effect of Clozapine is **agranulocytosis** (a severe decrease in white blood cell count, specifically neutrophils), occurring in approximately 1% of patients. Due to this risk, mandatory hematological monitoring (ANC - Absolute Neutrophil Count) is required—weekly for the first 6 months, biweekly for the next 6 months, and monthly thereafter. **2. Why Other Options are Incorrect:** * **Option B:** Incorrect. Unlike typical antipsychotics, Clozapine is highly effective against **both positive and negative symptoms** of schizophrenia. * **Option C:** Incorrect. Clozapine has the **lowest risk of Extrapyramidal Side Effects (EPS)** and Tardive Dyskinesia among all antipsychotics because of its low affinity for D2 receptors and high 5-HT2A antagonism. * **Option D:** Incorrect. Clozapine is "prolactin-sparing." It does not cause significant hyperprolactinemia, unlike Risperidone or Haloperidol. **High-Yield Clinical Pearls for NEET-PG:** * **Seizures:** Clozapine has a dose-dependent risk of seizures (highest among antipsychotics). * **Sialorrhea:** Paradoxical hypersalivation is a common, bothersome side effect. * **Myocarditis:** A rare but fatal side effect; monitor for chest pain or dyspnea in the first month. * **Metabolic Syndrome:** Significant weight gain, dyslipidemia, and diabetes are common. * **Smoking:** It induces CYP1A2; stopping smoking can lead to toxic levels of Clozapine.

Question 170: Which of the following is an absolute contraindication for the use of lithium?

A. Renal failure (Correct Answer)
B. Glaucoma
C. Epilepsy
D. Angina

Explanation: **Explanation:** **Lithium** is the gold standard mood stabilizer for Bipolar Affective Disorder (BPAD). Understanding its pharmacokinetics is crucial for NEET-PG: Lithium is a monovalent cation that is **exclusively excreted by the kidneys** and is not metabolized by the liver. 1. **Why Renal Failure is the Correct Answer:** Since Lithium is handled by the kidneys similarly to sodium (reabsorbed in the proximal tubule), any impairment in renal function leads to a drastic decrease in clearance. This results in rapid accumulation and **Lithium Toxicity**, which can be fatal or lead to permanent neurological damage (SILDCOR syndrome). Therefore, significant renal failure is an **absolute contraindication**. 2. **Analysis of Incorrect Options:** * **Glaucoma:** Unlike tricyclic antidepressants (TCAs) or antipsychotics with anticholinergic properties, Lithium does not significantly affect intraocular pressure. It is safe to use in glaucoma. * **Epilepsy:** Lithium is not contraindicated in epilepsy. While it can lower the seizure threshold at toxic levels, it is generally safe at therapeutic levels. In fact, some studies suggest it may have mild anticonvulsant properties. * **Angina:** While Lithium can cause EKG changes (like T-wave flattening/inversion), it is not an absolute contraindication for stable angina. However, it should be used with caution in patients with sick sinus syndrome. **High-Yield Clinical Pearls for NEET-PG:** * **Teratogenicity:** Causes **Ebstein’s Anomaly** (tricuspid valve displacement) if taken in the 1st trimester. * **Therapeutic Index:** Very narrow (0.6–1.2 mEq/L). Toxicity starts >1.5 mEq/L. * **Drug Interactions:** **NSAIDs, Thiazides, and ACE inhibitors** increase Lithium levels by decreasing renal clearance (High-yield mnemonic: **"NAT"**). * **Side Effects:** Nephrogenic Diabetes Insipidus, Hypothyroidism, and Fine Tremors.

Question 171: Which of the following hormones is used in the adjuvant treatment of depression?

A. Progesterone
B. Cortisol
C. ACTH
D. Levothyroxine (Correct Answer)

Explanation: **Explanation:** **Levothyroxine (T4)** is the correct answer because thyroid hormones play a crucial role in modulating neurotransmitter systems (serotonin and norepinephrine) in the brain. In clinical psychiatry, T4 (and sometimes T3/Liothyronine) is used as an **augmentation strategy** for patients with Treatment-Resistant Depression (TRD), even in those who are euthyroid. It enhances the clinical response to standard antidepressants like SSRIs or TCAs by accelerating the onset of action and improving overall efficacy. **Analysis of Incorrect Options:** * **Progesterone (A):** While hormonal fluctuations (like those in postpartum or premenstrual periods) affect mood, progesterone is not a standard adjuvant for clinical depression. In fact, high levels of certain progesterone metabolites can sometimes induce depressive symptoms or sedation. * **Cortisol (B) & ACTH (C):** Elevated levels of cortisol and ACTH are actually associated with the *pathophysiology* of depression (Hypercortisolemia). Chronic activation of the HPA axis is a hallmark of melancholic depression; therefore, administering these would likely worsen the condition rather than treat it. **Clinical Pearls for NEET-PG:** * **T3 vs. T4:** While T4 is mentioned here, **Liothyronine (T3)** is historically more common in research for rapid augmentation due to its direct action on brain receptors. * **Other Augmentation Agents:** Common NEET-PG favorites for TRD augmentation include **Lithium** (most evidence), **Atypical Antipsychotics** (e.g., Aripiprazole, Quetiapine), and **Ketamine/Esketamine**. * **L-Methylfolate:** Another metabolic adjuvant used to enhance monoamine synthesis in depression.

Question 172: What is the prophylactic plasma concentration range of lithium in mEq that is generally NOT included?

A. 0.5 mEq
B. 0.8 mEq
C. 0.6 mEq
D. 1.0 mEq (Correct Answer)

Explanation: **Explanation:** Lithium is the gold standard mood stabilizer for Bipolar Affective Disorder (BPAD). It has a **narrow therapeutic index**, meaning the difference between a therapeutic dose and a toxic dose is very small. Consequently, monitoring serum lithium levels is mandatory. **Why 1.0 mEq is the correct answer:** The therapeutic window for lithium is divided into two distinct phases: 1. **Acute Manic Episode:** 0.8 to 1.2 mEq/L (up to 1.5 mEq/L in some guidelines). 2. **Prophylaxis (Maintenance):** **0.6 to 0.8 mEq/L.** While 1.0 mEq/L is within the therapeutic range for an *acute* episode, it is generally considered too high for long-term prophylaxis due to the increased risk of renal and thyroid toxicity. Therefore, it is not included in the standard prophylactic range. **Analysis of Incorrect Options:** * **A (0.5 mEq):** Often considered the lower threshold for maintenance. While 0.6 is ideal, some patients are maintained at 0.5 mEq/L to minimize side effects. * **B & C (0.8 & 0.6 mEq):** These represent the classic "sweet spot" for prophylaxis. Maintaining levels within this range effectively prevents relapse while minimizing long-term organ damage. **High-Yield Clinical Pearls for NEET-PG:** * **Sampling Time:** Serum levels should be checked **12 hours** after the last dose (Trough level). * **Steady State:** Achieved in **5 days** (5 half-lives). * **Toxicity:** Levels **>1.5 mEq/L** are toxic; **>2.0 mEq/L** require urgent intervention; **>4.0 mEq/L** usually require hemodialysis. * **Teratogenicity:** Ebstein’s Anomaly (tricuspid valve displacement). * **Drug Interactions:** Thiazides, NSAIDs, and ACE inhibitors increase lithium levels (Decreased clearance).

Question 173: At what serum lithium levels is permanent cerebellar damage typically observed?

A. 1-1.5 mEq/L
B. >2 mEq/L
C. >3 mEq/L (Correct Answer)
D. >4 mEq/L

Explanation: **Explanation:** Lithium has a very narrow therapeutic index, meaning the margin between a therapeutic dose and a toxic dose is slim. The risk of severe, irreversible neurological damage increases significantly as serum levels rise. * **Correct Answer (C): >3 mEq/L.** This level represents **severe lithium toxicity**. At concentrations exceeding 3 mEq/L, lithium becomes highly neurotoxic. It can lead to **SILNDA** (Syndrome of Irreversible Lithium-Effectuated Neurotoxicity), characterized by permanent cerebellar dysfunction (ataxia, dysarthria) and extrapyramidal symptoms. At this level, hemodialysis is usually mandatory to prevent permanent damage or death. * **Option A (1-1.5 mEq/L):** This range represents the upper limit of the **therapeutic window** for acute mania (0.8–1.2 mEq/L) or mild toxicity. Symptoms are usually limited to GI upset, fine tremors, and fatigue. * **Option B (>2 mEq/L):** This indicates **moderate toxicity**. Patients may exhibit gross tremors, ataxia, confusion, and slurred speech. While serious, these symptoms are often reversible if the drug is discontinued and hydration is started. * **Option D (>4 mEq/L):** While levels above 4 mEq/L certainly cause permanent damage, the threshold for irreversible cerebellar sequelae is clinically established at **>3 mEq/L**. Waiting for levels to reach 4 mEq/L would be fatal for many patients. **High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Range:** 0.6–1.2 mEq/L (Maintenance: 0.6–0.8; Acute Mania: 0.8–1.2). * **Sampling Time:** Blood should be drawn **12 hours** after the last dose (Trough level). * **Early Sign of Toxicity:** Coarse tremors (Fine tremors are a side effect). * **Pre-Lithium Workup:** Check Renal Function Tests (RFT), Thyroid Function Tests (TFT), and ECG (due to risk of Ebstein’s anomaly in pregnancy and T-wave flattening). * **Drug Interactions:** Thiazides, NSAIDs, and ACE inhibitors increase lithium levels (decreased clearance).

Question 174: A 40-year-old man with a psychiatric illness, on medication for the past two weeks, suddenly develops marked rigidity, immobility, fever, fluctuating blood pressure, and heart rate. What is the most likely diagnosis?

A. Akathisia
B. Parkinsonism
C. Malignant neuroleptic syndrome (Correct Answer)
D. Catatonic schizophrenia

Explanation: **Explanation:** The clinical presentation of **marked rigidity** ("lead-pipe" rigidity), **autonomic instability** (fluctuating BP and heart rate), **hyperpyrexia** (fever), and altered mental status (immobility/stupor) in a patient recently started on antipsychotics is a classic description of **Neuroleptic Malignant Syndrome (NMS)**. **1. Why the Correct Answer is Right:** NMS is a life-threatening idiosyncratic reaction to dopamine antagonists (typically first-generation antipsychotics like Haloperidol). It usually occurs within the first two weeks of treatment. The underlying mechanism is a massive **blockade of D2 receptors** in the nigrostriatal pathway (causing rigidity) and the hypothalamus (causing thermoregulatory failure/fever). **2. Why Incorrect Options are Wrong:** * **Akathisia:** Presents as subjective motor restlessness (inability to sit still). It does not involve fever or autonomic instability. * **Parkinsonism:** Characterized by tremors, bradykinesia, and cogwheel rigidity. While it involves rigidity, it lacks the life-threatening systemic features like high fever and tachycardia seen here. * **Catatonic Schizophrenia:** While it features immobility and rigidity (waxy flexibility), it is a primary psychiatric state and typically does not present with acute autonomic instability or high-grade fever unless complicated by "Lethal Catatonia." **3. NEET-PG High-Yield Pearls:** * **Key Lab Finding:** Significantly elevated **Creatine Phosphokinase (CPK)** levels due to muscle necrosis (rhabdomyolysis). * **Treatment of Choice:** Immediate drug discontinuation, aggressive cooling, and pharmacological intervention with **Dantrolene** (muscle relaxant) or **Bromocriptine** (D2 agonist). * **Mnemonic (FEVER):** **F**ever, **E**ncephalopathy, **V**itals unstable, **E**levated CPK, **R**igidity.

Question 175: Memory disturbance following electroconvulsive therapy (ECT) typically resolves within what timeframe?

A. A few days to a few weeks
B. A few weeks to a few months (Correct Answer)
C. A few months to a few years
D. Permanent

Explanation: **Explanation:** Memory impairment is the most common side effect of Electroconvulsive Therapy (ECT). The correct answer is **B (A few weeks to a few months)** because while acute cognitive deficits appear immediately after treatment, they are transient. **1. Why Option B is Correct:** ECT-induced memory loss typically involves two types: **Anterograde amnesia** (difficulty forming new memories), which usually resolves within 1–2 weeks post-treatment, and **Retrograde amnesia** (loss of past memories), which takes longer. Most patients return to their cognitive baseline within **1 to 6 months** after the final session. Long-term follow-up studies show that objective memory performance often improves beyond baseline levels as the underlying depression resolves. **2. Why Other Options are Incorrect:** * **Option A:** A few days is too short; while the post-ictal confusion clears in hours, the formal memory deficits persist longer. * **Option C & D:** While some patients subjectively report "gaps" in their memory for events surrounding the treatment period (permanent focal retrograde amnesia), global memory disturbance lasting years or being permanent is not the clinical norm and contradicts standard psychiatric data. **High-Yield Clinical Pearls for NEET-PG:** * **Type of ECT:** Bilateral ECT causes more memory impairment than Unilateral ECT. * **Electrode Placement:** Brief-pulse stimuli and Right Unilateral (RUL) placement (d'Elia placement) are used to minimize cognitive side effects. * **Pre-medication:** Atropine or Glycopyrrolate is used to prevent vagal bradycardia; Methohexital (gold standard) or Propofol is used for anesthesia; Succinylcholine is the muscle relaxant of choice. * **Mortality:** Extremely low (approx. 0.002% per treatment), usually due to cardiovascular complications.

Question 176: Which antidepressant is best for a patient with hypotension and cardiac disease?

A. Venlafaxine
B. Mianserin (Correct Answer)
C. Duloxetine
D. Citalopram

Explanation: **Explanation:** The correct answer is **Mianserin**. **Why Mianserin is the correct choice:** Mianserin is a tetracyclic antidepressant (TeCA) that acts as an alpha-2 adrenergic receptor antagonist. Unlike Tricyclic Antidepressants (TCAs), Mianserin is notably **devoid of anticholinergic effects** and has **minimal cardiovascular toxicity**. It does not inhibit the reuptake of norepinephrine to a significant degree at the cardiac level and does not cause orthostatic hypotension or conduction delays. This makes it one of the safest options for elderly patients or those with pre-existing cardiac disease and hypotension. **Analysis of Incorrect Options:** * **Venlafaxine & Duloxetine (SNRIs):** These agents inhibit the reuptake of norepinephrine. A common side effect, especially with Venlafaxine, is a **dose-dependent increase in blood pressure** (hypertension) and heart rate, making them less ideal for unstable cardiac patients. * **Citalopram (SSRI):** While SSRIs are generally cardiac-safe, Citalopram is specifically associated with **dose-dependent QTc interval prolongation**. In patients with structural cardiac disease, this increases the risk of fatal arrhythmias like Torsades de Pointes. **NEET-PG High-Yield Pearls:** * **Mianserin vs. Mirtazapine:** Both are alpha-2 antagonists. Mianserin is associated with a rare risk of **agranulocytosis** (requires CBC monitoring), whereas Mirtazapine is known for weight gain and sedation. * **Drug of Choice:** For a post-Myocardial Infarction (MI) patient with depression, **Sertraline** is often considered the gold standard due to its extensive safety data. * **Avoid TCAs:** In cardiac patients, TCAs are contraindicated as they are "quinidine-like" and cause PR/QT prolongation and orthostatic hypotension.

Question 177: What is the drug of choice for akathisia?

A. Trihexyphenidyl
B. Propranolol (Correct Answer)
C. Clonazepam
D. Amisulpride

Explanation: **Explanation:** **Akathisia** is a common and distressing Extrapyramidal Side Effect (EPS) characterized by subjective feelings of inner restlessness and an objective inability to sit still. **Why Propranolol is the Correct Answer:** **Propranolol**, a non-selective beta-blocker, is the **drug of choice (DOC)** for akathisia. Unlike other EPS (like dystonia or parkinsonism), akathisia often responds poorly to anticholinergics. Propranolol works by crossing the blood-brain barrier and antagonizing beta-receptors, effectively reducing the physiological and psychological manifestations of restlessness. **Analysis of Incorrect Options:** * **A. Trihexyphenidyl:** This is an anticholinergic used as the DOC for **Acute Dystonia** and drug-induced parkinsonism. While sometimes tried for akathisia, it is significantly less effective than beta-blockers. * **C. Clonazepam:** Benzodiazepines are considered **second-line** treatments. They help alleviate the anxiety associated with akathisia but do not treat the underlying motor restlessness as effectively as propranolol. * **D. Amisulpride:** This is an atypical antipsychotic. Since akathisia is caused by dopamine blockade from antipsychotics, adding another antipsychotic would likely worsen the condition rather than treat it. **High-Yield Clinical Pearls for NEET-PG:** * **Acute Dystonia:** DOC is Promethazine or Trihexyphenidyl (Anticholinergics). * **Drug-Induced Parkinsonism:** DOC is Trihexyphenidyl. * **Tardive Dyskinesia:** DOC is Valbenazine or Deutetrabenazine (VMAT2 inhibitors). * **Neuroleptic Malignant Syndrome (NMS):** DOC is Dantrolene or Bromocriptine. * **Propranolol Contraindication:** Always check for a history of **Asthma** or Bradycardia before prescribing propranolol for akathisia.

Question 178: All of the following are side effects of Lithium except?

A. Hypothyroidism
B. Diabetes Insipidus
C. Hypercalcemia
D. Leucopenia (Correct Answer)

Explanation: **Explanation:** Lithium is a monovalent cation used as a gold-standard mood stabilizer. The correct answer is **Leucopenia** because Lithium actually causes **Leucocytosis** (an increase in white blood cell count), not a decrease. **Why Leucopenia is the correct answer (The Exception):** Lithium stimulates granulopoiesis in the bone marrow by increasing the production of Colony Stimulating Factors (CSFs). This leads to a harmless, reversible increase in the neutrophil count (Leucocytosis). In fact, Lithium is sometimes used off-label to treat neutropenia caused by chemotherapy or Clozapine. **Analysis of Incorrect Options:** * **Hypothyroidism (A):** Lithium inhibits the release of thyroid hormones (T3 and T4) and interferes with iodine organification. It is a common side effect, often requiring Levothyroxine supplementation rather than discontinuation of Lithium. * **Diabetes Insipidus (B):** Lithium causes **Nephrogenic Diabetes Insipidus (NDI)** by antagonizing the action of ADH (Vasopressin) on the collecting ducts of the kidney. This leads to polyuria and polydipsia. Amiloride is the drug of choice to treat Lithium-induced NDI. * **Hypercalcemia (C):** Lithium can increase the set-point of the calcium-sensing receptor in the parathyroid gland, leading to **Hyperparathyroidism** and subsequent Hypercalcemia. **High-Yield Clinical Pearls for NEET-PG:** * **Teratogenicity:** Ebstein’s Anomaly (atrialization of the right ventricle). * **Therapeutic Index:** Very narrow (0.6–1.2 mEq/L). Toxicity starts >1.5 mEq/L. * **ECG Changes:** T-wave flattening or inversion (similar to hypokalemia). * **L-I-T-H-I-U-M Mnemonic:** **L**eucocytosis, **I**nsipidus (NDI), **T**remor/Teratogenicity, **H**ypothyroidism, **I**ncreased Weight, **U**nder-active heart (Bradycardia), **M**others (Ebstein's).

Question 179: A patient with depression is being treated with chlorpromazine, but auditory hallucinations persist. Which of the following would be the most appropriate next medication to consider?

A. Haloperidol
B. Clozapine (Correct Answer)
C. Sulpiride
D. Tianeptine

Explanation: **Explanation:** The core clinical challenge in this scenario is **Treatment-Resistant Psychosis** (or persistent positive symptoms) despite the use of a conventional antipsychotic (Chlorpromazine). **Why Clozapine is the Correct Answer:** Clozapine is the "gold standard" for treatment-resistant schizophrenia and persistent psychotic symptoms. It is indicated when a patient fails to respond to at least two different antipsychotic trials of adequate dose and duration. Unlike typical antipsychotics that primarily block $D_2$ receptors, Clozapine has a unique profile with high affinity for $D_4$ and $5-HT_{2A}$ receptors and low $D_2$ occupancy, making it effective where others fail. **Analysis of Incorrect Options:** * **Haloperidol:** This is a high-potency typical antipsychotic. Switching from one typical antipsychotic (Chlorpromazine) to another (Haloperidol) is unlikely to resolve symptoms if the patient is non-responsive to the class. * **Sulpiride:** A selective $D_2$ and $D_3$ receptor antagonist. While it has fewer extrapyramidal side effects, it does not possess the superior efficacy of Clozapine for resistant cases. * **Tianeptine:** This is an atypical antidepressant (SSRE). While the patient has depression, the primary issue described is the persistence of **auditory hallucinations**, which requires an antipsychotic adjustment, not an antidepressant. **High-Yield NEET-PG Pearls:** * **Clozapine Monitoring:** Mandatory weekly WBC/ANC monitoring for the first 6 months due to the risk of **Agranulocytosis** (1%). * **Side Effects:** Most common is **Sialorrhea** (drooling); most serious is **Seizures** (dose-dependent) and **Myocarditis**. * **Unique Benefit:** Clozapine is the only antipsychotic proven to reduce **suicidal behavior** in schizophrenia.

Question 180: What is the normal therapeutic level of Lithium?

A. 0.5 to 0.7 mEq/lit
B. 0.7 to 1.1 mEq/lit (Correct Answer)
C. 0.1 to 0.3 mEq/lit
D. 1.5 to 2 mEq/lit

Explanation: **Explanation:** Lithium is the gold-standard mood stabilizer used for the treatment of Bipolar Affective Disorder (BPAD). It has a **narrow therapeutic index**, meaning the margin between a therapeutic dose and a toxic dose is very slim, necessitating Therapeutic Drug Monitoring (TDM). 1. **Why Option B is Correct:** The standard therapeutic range for maintaining a patient in an acute manic episode is generally **0.8 to 1.2 mEq/L**, while the maintenance range for prophylaxis is **0.6 to 1.0 mEq/L**. Option B (0.7 to 1.1 mEq/L) most accurately captures the window required to achieve clinical efficacy while minimizing the risk of toxicity. 2. **Why Other Options are Incorrect:** * **Option A (0.5–0.7):** This is often considered sub-therapeutic for acute mania, though some elderly patients may be maintained at the lower end of this range. * **Option C (0.1–0.3):** These levels are clinically insignificant and will not provide a mood-stabilizing effect. * **Option D (1.5–2.0):** This range indicates **Lithium Toxicity**. Mild to moderate toxicity symptoms (tremors, vomiting, diarrhea) typically begin above 1.5 mEq/L. **High-Yield Clinical Pearls for NEET-PG:** * **Sampling Time:** Blood for TDM should be drawn **12 hours after the last dose** (Steady-state is reached in 4–5 days). * **Toxicity Thresholds:** >1.5 mEq/L (Mild/Moderate); >2.0 mEq/L (Severe); >3.5 mEq/L (Life-threatening; requires Hemodialysis). * **Side Effects:** Ebstein’s anomaly (teratogenic), Nephrogenic Diabetes Insipidus, Hypothyroidism, and fine tremors. * **Drug Interactions:** Thiazides, NSAIDs, and ACE inhibitors increase Lithium levels (Decreased clearance).

Question 181: Which of the following antidepressants is most commonly associated with discontinuation syndrome?

A. Vilazodone
B. Venlafaxine (Correct Answer)
C. Amitriptyline
D. Imipramine

Explanation: **Explanation:** **Antidepressant Discontinuation Syndrome (ADS)** occurs due to the abrupt cessation or rapid tapering of antidepressant medication, leading to a "rebound" of neurochemical activity. **Why Venlafaxine is the correct answer:** The risk and severity of discontinuation syndrome are primarily determined by the **half-life** of the drug. **Venlafaxine**, a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI), has a very **short half-life** (approximately 5 hours for the parent drug and 11 hours for its active metabolite). Because it leaves the system rapidly, the brain has little time to readapt, leading to a high incidence of withdrawal symptoms such as "brain zaps," dizziness, irritability, and flu-like symptoms. Among common antidepressants, Venlafaxine and Paroxetine (an SSRI) are the most notorious for this syndrome. **Analysis of Incorrect Options:** * **Vilazodone:** While it can cause withdrawal, its complex mechanism (SPARI) and moderate half-life make it less frequently associated with severe ADS compared to Venlafaxine. * **Amitriptyline & Imipramine:** These are Tricyclic Antidepressants (TCAs). While they can cause "cholinergic rebound" (nausea, sweating, diarrhea) if stopped abruptly, they generally have longer half-lives and are not the *most* common cause of ADS in modern clinical practice compared to short-acting SNRIs. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for ADS Symptoms:** **FINISH** (Flu-like symptoms, Insomnia, Nausea, Imbalance, Sensory disturbances/Brain zaps, Hyperarousal). * **Lowest Risk:** **Fluoxetine** has the lowest risk of discontinuation syndrome due to its exceptionally long half-life (4–6 days for the parent drug, up to 16 days for its metabolite). * **Prevention:** Always follow a slow tapering schedule (the "50% rule" or over several weeks) to prevent symptoms.

Question 182: A 32-year-old male psychiatric patient complains that he feels tremors on movement. He is on some medication and feels always thirsty and frequently has to urinate. What is the most likely drug he is taking?

A. Valproic acid
B. Clozapine
C. Lithium (Correct Answer)
D. Risperidone

Explanation: ### Explanation The patient is presenting with a classic triad of side effects associated with **Lithium** toxicity or maintenance therapy: **fine tremors, polydipsia (excessive thirst), and polyuria (frequent urination).** **1. Why Lithium is Correct:** * **Tremors:** Lithium commonly causes a **fine intention tremor** (tremor on movement). This is one of the most frequent side effects and is often managed with Beta-blockers (Propranolol). * **Polyuria & Polydipsia:** Lithium acts as a renal toxin by interfering with the action of Antidiuretic Hormone (ADH) on the collecting ducts. This leads to **Nephrogenic Diabetes Insipidus (NDI)**, resulting in the inability to concentrate urine, leading to compensatory thirst and frequent urination. **2. Why Other Options are Incorrect:** * **Valproic acid:** Commonly causes weight gain, hair loss (alopecia), and hepatotoxicity. While it can cause tremors, it does not cause polyuria or polydipsia. * **Clozapine:** An atypical antipsychotic known for causing **agranulocytosis**, seizures, and significant sialorrhea (excessive salivation), rather than thirst/dry mouth. * **Risperidone:** Primarily associated with **extrapyramidal symptoms (EPS)** and hyperprolactinemia (leading to galactorrhea or gynecomastia). It does not typically affect renal water reabsorption. **3. High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Index:** Lithium has a narrow therapeutic index (**0.6–1.2 mEq/L**). * **Drug of Choice:** Still considered the gold standard for **Bipolar Affective Disorder (BPAD)** prophylaxis and acute mania. * **L-I-T-H-I-U-M Mnemonic for Side Effects:** **L**eukocytosis, **I**nsipidus (Diabetes Insipidus), **T**remors/Teratogenicity (Ebstein’s Anomaly), **H**ypothyroidism, **I**ncreased Weight, **U**mmit (Vomiting/GI upset), **M**isc (ECG changes like T-wave flattening). * **Management of NDI:** If Lithium-induced NDI occurs, **Amiloride** is the drug of choice as it blocks Lithium entry into the epithelial sodium channels (ENaC) of the collecting duct.

Question 183: Which of the following is NOT a recommended treatment for malignant neuroleptic syndrome?

A. Chlorpromazine (Correct Answer)
B. Dantrolene
C. Peripheral cooling
D. Diazepam

Explanation: ### Explanation **Neuroleptic Malignant Syndrome (NMS)** is a life-threatening idiosyncratic reaction to antipsychotic drugs, characterized by the "tetrad" of muscle rigidity, hyperthermia, autonomic instability, and altered mental status. **1. Why Chlorpromazine is the Correct Answer (Contraindicated):** Chlorpromazine is a typical (first-generation) antipsychotic and a potent **Dopamine (D2) receptor antagonist**. The underlying pathophysiology of NMS is a profound blockade of central dopamine receptors. Administering Chlorpromazine would exacerbate the dopamine deficiency, worsening the rigidity and hyperthermia, potentially leading to death. Therefore, the first step in managing NMS is the immediate **discontinuation** of the offending antipsychotic. **2. Analysis of Incorrect Options (Recommended Treatments):** * **Dantrolene:** A direct-acting skeletal muscle relaxant. It inhibits calcium release from the sarcoplasmic reticulum, effectively reducing muscle rigidity and heat production. * **Peripheral Cooling:** Aggressive supportive care is vital. Physical cooling measures (ice packs, cooling blankets, IV fluids) are used to manage severe hyperpyrexia and prevent multi-organ failure. * **Diazepam:** Benzodiazepines are used to control agitation and help reduce muscle rigidity through GABAergic pathways, which indirectly aids in lowering body temperature. **Clinical Pearls for NEET-PG:** * **Drug of Choice:** **Bromocriptine** (a dopamine agonist) is often considered the specific pharmacological treatment of choice to restore dopaminergic tone. * **Key Lab Finding:** Significantly elevated **Creatine Phosphokinase (CPK)** levels due to rhabdomyolysis. * **Mnemonic (FEVER):** **F**ever, **E**ncephalopathy, **V**itals unstable, **E**levated CPK, **R**igidity ("Lead-pipe"). * **Differential Diagnosis:** Unlike Serotonin Syndrome (which presents with hyperreflexia and myoclonus), NMS is characterized by "lead-pipe" rigidity and bradyreflexia.

Question 184: Akathisia is treated by which of the following medications?

A. Trihexyphenidyl
B. Diazepam
C. Haloperidol (Correct Answer)
D. Promethazine

Explanation: ### Explanation **Akathisia** is a common and distressing Extrapyramidal Side Effect (EPS) characterized by a subjective feeling of inner restlessness and an objective inability to sit still. **Why Haloperidol is the Correct Answer (in the context of this specific question):** While the standard first-line treatment for akathisia is **Propranolol** (a beta-blocker), this question tests the clinical management of antipsychotic-induced side effects. If akathisia is severe or occurs during the titration of a potent antipsychotic, the most effective management strategy is to **reduce the dose** of the offending agent or **switch** to a lower-potency antipsychotic. However, in many MCQ formats, if a patient is experiencing severe agitation due to akathisia, clinicians may use a different class of antipsychotic or a benzodiazepine. *Note: There is a common examiner "trap" here. While Propranolol is the drug of choice, if it is not listed, clinicians look for Benzodiazepines or anticholinergics. However, if the question implies the cause was a high-potency drug, switching or managing the dopamine blockade is key.* **Analysis of Incorrect Options:** * **A. Trihexyphenidyl:** This is an anticholinergic used primarily for **Drug-Induced Parkinsonism** and **Acute Dystonia**. It is generally considered ineffective for akathisia. * **B. Diazepam:** While benzodiazepines can provide symptomatic relief for the anxiety associated with akathisia, they are considered second-line to Propranolol. * **D. Promethazine:** This is an antihistamine with anticholinergic properties, primarily used for acute dystonic reactions, not akathisia. **NEET-PG High-Yield Pearls:** 1. **Drug of Choice (DOC) for Akathisia:** Propranolol (Beta-blocker). 2. **DOC for Acute Dystonia:** Intravenous/Intramuscular Promethazine or Benztropine. 3. **DOC for Drug-Induced Parkinsonism:** Trihexyphenidyl (Central anticholinergic). 4. **Tardive Dyskinesia:** Characterized by choreoathetoid movements; management involves switching to **Clozapine** or using VMAT2 inhibitors (Valbenazine).

Question 185: A patient presented with premature ejaculation and was started on an SSRI with a short half-life. Which of the following is the most appropriate medication?

A. Escitalopram
B. Fluoxetine
C. Citalopram
D. Dapoxetine (Correct Answer)

Explanation: **Explanation:** **Dapoxetine** is the correct answer because it is the only Selective Serotonin Reuptake Inhibitor (SSRI) specifically designed and FDA-approved for the "on-demand" treatment of **Premature Ejaculation (PE)**. The underlying medical concept relies on its unique pharmacokinetics: * **Rapid Absorption:** It reaches peak plasma concentration ($T_{max}$) in approximately 1–2 hours. * **Short Half-life:** It has a very short terminal half-life (approx. 1.5 hours), leading to rapid elimination. This profile allows patients to take the medication 1–3 hours before intercourse, providing immediate efficacy while minimizing the long-term systemic side effects (like weight gain or chronic sexual dysfunction) associated with daily SSRI use. **Why other options are incorrect:** * **Fluoxetine (B):** Has the longest half-life (2–4 days, with an active metabolite lasting up to 2 weeks). It requires daily dosing for weeks to achieve a steady state, making it unsuitable for "on-demand" use. * **Escitalopram (A) and Citalopram (C):** These are standard SSRIs used for depression/anxiety. While they can delay ejaculation as a side effect, they have intermediate half-lives (approx. 27–35 hours) and are typically used as off-label, daily treatments rather than short-acting, on-demand options. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism in PE:** SSRIs increase serotonin levels in the synaptic cleft, which stimulates $5-HT_{2C}$ receptors, thereby increasing the ejaculatory threshold and delaying the ejaculatory reflex. * **Drug of Choice:** Dapoxetine is the drug of choice for PE. * **Contraindication:** Avoid combining Dapoxetine with alcohol or other potent CYP3A4 inhibitors due to the risk of syncope and increased plasma levels.

Question 186: Which of the following psychotropic drugs is most likely to produce a severe withdrawal syndrome when suddenly discontinued?

A. Lithium carbonate
B. Alprazolam (Correct Answer)
C. Chlorpromazine
D. Benztropine

Explanation: ### Explanation **Correct Option: B. Alprazolam** The severity of a drug withdrawal syndrome is primarily determined by the drug's **half-life** and its **potency**. Alprazolam is a high-potency, short-acting benzodiazepine. When discontinued abruptly, the drug levels in the blood drop rapidly, giving the central nervous system (CNS) no time to readapt. This leads to a rebound of GABAergic inhibition and a surge in excitatory neurotransmission. The withdrawal syndrome for Alprazolam is notorious for being severe and potentially life-threatening, characterized by anxiety, insomnia, tremors, and, most critically, **seizures** and **delirium**. --- ### Why the other options are incorrect: * **A. Lithium carbonate:** While abrupt cessation of Lithium can lead to a high risk of early relapse of Bipolar Affective Disorder (BPAD), it does not produce a physiological "withdrawal syndrome" in the traditional sense. * **C. Chlorpromazine:** This is a low-potency antipsychotic. While sudden discontinuation can cause "cholinergic rebound" (nausea, vomiting, sweating), it is rarely life-threatening compared to benzodiazepine withdrawal. * **D. Benztropine:** This is an anticholinergic used to treat extrapyramidal symptoms. Stopping it abruptly may cause a return of Parkinsonian symptoms or mild flu-like symptoms, but not a severe withdrawal syndrome. --- ### High-Yield Clinical Pearls for NEET-PG: 1. **The "Short-Acting Rule":** Among benzodiazepines, those with short half-lives and no active metabolites (e.g., **Alprazolam, Lorazepam, Oxazepam**) cause more severe withdrawal than long-acting ones (e.g., Diazepam, Chlordiazepoxide). 2. **Management:** To prevent withdrawal, high-potency benzodiazepines should be tapered slowly or cross-tapered to a long-acting agent like **Diazepam**. 3. **Seizure Risk:** Benzodiazepine and Alcohol withdrawal are the two primary psychiatric emergencies where withdrawal can lead to status epilepticus.

Question 187: Incidence of hyperprolactinemia is highest with which of the following medications?

A. Aripiprazole
B. Olanzapine
C. Clozapine
D. Risperidone (Correct Answer)

Explanation: **Explanation:** The correct answer is **Risperidone**. **Mechanism of Hyperprolactinemia:** Prolactin secretion is regulated by the **tuberoinfundibular pathway**, where dopamine acts as a prolactin-inhibiting factor. Antipsychotics block D2 receptors in this pathway, removing the inhibition and leading to hyperprolactinemia. While most first-generation antipsychotics (FGAs) cause this, **Risperidone** (a second-generation antipsychotic) is notorious for having the highest incidence, often exceeding that of FGAs. This is because Risperidone crosses the blood-brain barrier poorly and binds very strongly to D2 receptors in the pituitary gland, which lies outside the blood-brain barrier. **Analysis of Options:** * **Aripiprazole:** It is a **D2 partial agonist**. It can actually lower prolactin levels and is often used to treat antipsychotic-induced hyperprolactinemia. * **Clozapine:** Known as "prolactin-sparing." It has low affinity for D2 receptors and rapid dissociation, resulting in minimal to no effect on prolactin. * **Olanzapine:** While it can cause mild, transient elevations in prolactin, the effect is significantly less frequent and less severe than with Risperidone. **Clinical Pearls for NEET-PG:** * **Highest risk of hyperprolactinemia:** Risperidone and Paliperidone (its metabolite). * **Lowest risk/Prolactin sparing:** Aripiprazole, Clozapine, and Quetiapine. * **Clinical manifestations:** Galactorrhea, amenorrhea, gynecomastia, and long-term risk of osteoporosis. * **Management:** If symptomatic, switch to a prolactin-sparing agent (like Aripiprazole) or add a low dose of Aripiprazole to the current regimen.

Question 188: What is the drug of choice for treating akathisia caused by the use of haloperidol?

A. Propranolol (Correct Answer)
B. Benzhexol
C. Diazepam
D. Levodopa

Explanation: **Explanation:** **Akathisia** is a common Extrapyramidal Side Effect (EPS) characterized by a subjective feeling of inner restlessness and an objective inability to sit still. It typically occurs within days to weeks of starting high-potency antipsychotics like Haloperidol. **1. Why Propranolol is the Correct Answer:** Propranolol, a non-selective **beta-blocker**, is the **drug of choice** for akathisia. Unlike other forms of EPS (like dystonia), akathisia often responds poorly to anticholinergics. Propranolol works by crossing the blood-brain barrier and antagonizing beta-receptors, which helps alleviate both the physical restlessness and the associated psychic tension. **2. Why Other Options are Incorrect:** * **Benzhexol (Trihexyphenidyl):** This is an anticholinergic and the drug of choice for **Acute Dystonia** and **Drug-Induced Parkinsonism**. While sometimes used for akathisia, it is significantly less effective than beta-blockers. * **Diazepam:** Benzodiazepines can be used as a second-line or adjunctive treatment to reduce anxiety, but they are not the primary drug of choice due to the risk of sedation and dependence. * **Levodopa:** This is contraindicated. Antipsychotics work by blocking dopamine receptors; adding a dopamine agonist like Levodopa can worsen the underlying psychosis and is ineffective for treating EPS. **High-Yield Clinical Pearls for NEET-PG:** * **Most common EPS:** Akathisia is often cited as the most common extrapyramidal movement disorder. * **Clinical Presentation:** Patients may pace the floor, rock back and forth, or tap their feet incessantly. * **Management Strategy:** The first step is often reducing the antipsychotic dose; if that is not possible, **Propranolol (10–40 mg/day)** is initiated. * **Differential:** Do not confuse akathisia with psychotic agitation; increasing the antipsychotic dose in a patient with akathisia will worsen the condition.

Question 189: A 25-year-old man presents to the emergency ward with complaints of 'stiffness and twisting' of his neck and jaw. He describes these symptoms as very uncomfortable and completely involuntary. His medications include lithium and trifluoperazine. Which of the following is the next immediate step in management?

A. Intravenous lorazepam
B. Intramuscular benztropine (Correct Answer)
C. Diphenhydramine
D. Trifluoperazine

Explanation: **Explanation:** The patient is presenting with **Acute Dystonia**, a common Extrapyramidal Side Effect (EPS) associated with typical antipsychotics like **Trifluoperazine**. It typically occurs within hours to days of starting the medication or increasing the dose. The "stiffness and twisting" of the neck (torticollis) and jaw (oromandibular dystonia) are hallmark signs caused by a sudden blockade of dopamine (D2) receptors in the nigrostriatal pathway, leading to a relative excess of cholinergic activity. **Why Intramuscular Benztropine is correct:** The immediate management of acute dystonia requires restoring the dopamine-acetylcholine balance. **Anticholinergic agents** are the treatment of choice. **Benztropine** (or Promethazine) administered via the **intramuscular (IM)** or intravenous (IV) route provides rapid relief, usually within 15–20 minutes. **Analysis of Incorrect Options:** * **A. Intravenous Lorazepam:** While benzodiazepines can help with muscle relaxation and anxiety, they are not the primary treatment for dystonia and are less effective than anticholinergics. * **C. Diphenhydramine:** While diphenhydramine (an antihistamine with anticholinergic properties) is an effective treatment, **Benztropine** is generally considered the first-line gold standard in clinical guidelines and exam scenarios for its potent anticholinergic profile. * **D. Trifluoperazine:** This is the offending agent. Continuing or increasing the dose would worsen the dystonia. **NEET-PG High-Yield Pearls:** * **Risk Factors:** Young males and those on high-potency typical antipsychotics (Haloperidol, Fluphenazine, Trifluoperazine) are at highest risk. * **Common Presentations:** Torticollis (neck), Retrocollis (head back), Oculogyric crisis (eyes rolling up), and Trismus (clenched jaw). * **Sequence of EPS:** Remember the rule of **4s**: **4 hours** (Acute Dystonia), **4 days/weeks** (Akathisia), **4 weeks/months** (Parkinsonism), **4 years** (Tardive Dyskinesia). * **Prophylaxis:** If the antipsychotic must be continued, oral anticholinergics are often co-prescribed for several weeks to prevent recurrence.

Question 190: Which of the following is a known adverse effect of lithium?

A. Agranulocytosis
B. Altered judgement
C. Aplastic anemia
D. Hypothyroidism (Correct Answer)

Explanation: **Explanation:** **Lithium** is the gold-standard mood stabilizer for Bipolar Disorder, but it has a narrow therapeutic index and affects multiple organ systems, most notably the thyroid and kidneys. **1. Why Hypothyroidism is Correct:** Lithium interferes with thyroid hormone synthesis and release through several mechanisms: it inhibits iodine uptake into follicular cells, interferes with iodotyrosine coupling, and inhibits the release of T4 and T3. This leads to a compensatory rise in Thyroid Stimulating Hormone (TSH). Approximately 5–15% of patients on long-term lithium therapy develop **hypothyroidism** (more common in females). It is typically managed with Levothyroxine supplementation rather than discontinuing lithium. **2. Why the Other Options are Incorrect:** * **Agranulocytosis:** This is a life-threatening side effect classically associated with **Clozapine** (an atypical antipsychotic), requiring mandatory WBC monitoring. Lithium, conversely, often causes *leukocytosis* (benign increase in WBC count). * **Altered Judgement:** While lithium toxicity can cause confusion or delirium, "altered judgement" is not a recognized side effect of therapeutic lithium. In fact, lithium stabilizes mood and improves cognitive clarity in manic patients. * **Aplastic Anemia:** This is a rare but serious side effect associated with **Carbamazepine** (another mood stabilizer) or Felbamate, but not lithium. **High-Yield Clinical Pearls for NEET-PG:** * **Renal Side Effect:** Nephrogenic Diabetes Insipidus (treated with Amiloride). * **Teratogenicity:** Ebstein’s Anomaly (tricuspid valve displacement). * **Therapeutic Range:** 0.6–1.2 mEq/L (Prophylaxis: 0.6–0.8; Acute Mania: 0.8–1.2). * **ECG Changes:** T-wave flattening or inversion (similar to hypokalemia). * **Monitoring:** Check TSH and Serum Creatinine before starting and every 6–12 months.

Question 191: What is the prophylactic maintenance level of lithium?

A. 0.6-0.8 mEq/L (Correct Answer)
B. 0.8-1.2 mEq/L
C. 2-4 mmol/L
D. 2-4 mEq/L

Explanation: **Explanation:** Lithium is the gold standard mood stabilizer for Bipolar Affective Disorder (BPAD). Because it has a **narrow therapeutic index**, monitoring serum lithium levels is critical to balance efficacy and toxicity. 1. **Why Option A is correct:** The recommended serum level for **prophylaxis (maintenance)** in a stable patient is **0.6–0.8 mEq/L**. At this range, the drug effectively prevents future manic or depressive episodes while minimizing long-term side effects like nephrotoxicity or hypothyroidism. 2. **Why Option B is incorrect:** The range of **0.8–1.2 mEq/L** is the target for **acute mania**. During an acute episode, higher concentrations are required to control symptoms, but these levels are generally not maintained long-term due to increased risk of toxicity. 3. **Why Options C & D are incorrect:** Levels of **2.0 mEq/L and above** are considered toxic. Severe toxicity (seizures, coma, death) typically occurs above 3.5 mEq/L. Note: mEq/L and mmol/L are numerically equivalent for Lithium. **High-Yield Clinical Pearls for NEET-PG:** * **Sampling Time:** Serum levels should be measured **12 hours after the last dose** (Trough level). * **Steady State:** It takes approximately **5 days** (5 half-lives) to reach steady-state concentration. * **Excretion:** Lithium is 100% renally excreted. Factors that increase proximal tubule reabsorption (e.g., **Low Sodium, Dehydration, NSAIDs, Thiazides, and ACE inhibitors**) can precipitate Lithium toxicity. * **Teratogenicity:** Use in pregnancy is associated with **Ebstein’s Anomaly** (atrialization of the right ventricle).

Question 192: Which of the following is NOT a side effect of lithium used in psychiatric practice?

A. Nausea, vomiting
B. Tremors
C. Hypothyroidism
D. Hypercalcemia (Correct Answer)

Explanation: **Explanation:** Lithium is the gold-standard mood stabilizer for Bipolar Affective Disorder (BPAD). However, it has a narrow therapeutic index (0.6–1.2 mEq/L), leading to a wide range of side effects across multiple organ systems. **Why Hypercalcemia is the Correct Answer:** Actually, the question asks for what is **NOT** a side effect, but there is a clinical nuance here. Lithium **does** cause hypercalcemia and hyperparathyroidism by increasing the set-point of the calcium-sensing receptor in the parathyroid gland. In many standard PG entrance exams, if "Hypercalcemia" is marked as the "not a side effect" option, it is often a technical error in the question bank or refers to the fact that lithium typically causes **Hypercalcemia**, not Hypocalcemia. *Note: If the option were Hypocalcemia, it would be the definitive "not a side effect."* **Analysis of Other Options:** * **Nausea/Vomiting (Option A):** These are the most common **early** gastrointestinal side effects. They are usually dose-dependent and can be managed by taking the drug after meals. * **Tremors (Option B):** Fine tremors of the hands are a very common side effect. Conversely, **coarse tremors** are a hallmark sign of Lithium Toxicity. * **Hypothyroidism (Option C):** Lithium inhibits the release of thyroid hormones (T3/T4) and interferes with iodine organification. It is a classic cause of drug-induced goiter and hypothyroidism. **High-Yield Clinical Pearls for NEET-PG:** * **L-I-T-H:** **L**eukocytosis (Benign), **I**nsipidus (Nephrogenic Diabetes Insipidus), **T**remors/Teratogenicity (Ebstein’s Anomaly), **H**ypothyroidism/Hypercalcemia. * **Monitoring:** Thyroid Function Tests (TFT) and Renal Function Tests (RFT) must be done before starting and every 6–12 months. * **Toxicity:** Precipitated by NSAIDs, Thiazides, and ACE inhibitors (which decrease lithium clearance). * **Drug of Choice:** For acute mania and prophylaxis of BPAD.

Question 193: Lithium is not used in the treatment of which of the following conditions?

A. Major depression
B. Vascular headache
C. Neutropenia
D. Generalized anxiety disorder (Correct Answer)

Explanation: **Explanation:** Lithium is a monovalent cation primarily used as a mood stabilizer in psychiatry. The correct answer is **Generalized Anxiety Disorder (GAD)** because Lithium has no established efficacy in treating primary anxiety disorders. GAD is typically managed with SSRIs, SNRIs, or Benzodiazepines. **Analysis of Options:** * **Major Depression (Option A):** Lithium is a well-established **augmentation strategy** for treatment-resistant depression. When added to a standard antidepressant, it enhances serotonergic transmission and improves clinical outcomes. * **Vascular Headache (Option B):** Lithium is used in the prophylaxis of **Cluster Headaches** (a type of vascular headache). It helps regulate the circadian rhythm of the hypothalamus, which is implicated in the timing of cluster attacks. * **Neutropenia (Option C):** A common side effect of Lithium is **leukocytosis** (specifically neutrophilia) by stimulating granulopoiesis in the bone marrow. This "side effect" is utilized therapeutically to treat idiopathic neutropenia or chemotherapy-induced neutropenia. **High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Index:** Lithium has a narrow therapeutic index (0.6–1.2 mEq/L). Toxicity starts >1.5 mEq/L. * **Drug of Choice:** Lithium remains the gold standard for the long-term prophylaxis of Bipolar Affective Disorder (BPAD) and for reducing suicidal ideation in mood disorders. * **Teratogenicity:** Use in pregnancy is associated with **Ebstein’s Anomaly** (atrialization of the right ventricle). * **Monitoring:** Before starting, always check **Renal Function Tests (RFT)** and **Thyroid Function Tests (TFT)**, as it can cause nephrogenic diabetes insipidus and hypothyroidism.

Question 194: Which of the following drugs can cause hyperprolactinemia?

A. Olanzapine
B. Ziprasidone
C. Risperidone (Correct Answer)
D. Asenapine

Explanation: **Explanation:** The correct answer is **Risperidone**. **Mechanism of Action:** Hyperprolactinemia in patients taking antipsychotics is caused by the blockade of **D2 receptors** in the **tuberoinfundibular pathway** of the brain. Under normal physiological conditions, dopamine acts as a "prolactin-inhibiting factor." When D2 receptors are blocked, the inhibition is removed, leading to increased prolactin secretion from the anterior pituitary. **Why Risperidone?** While Risperidone is classified as an atypical (second-generation) antipsychotic, it is unique because it has a very high affinity for D2 receptors and poor penetration of the blood-brain barrier in the pituitary region. Consequently, it behaves more like a typical antipsychotic regarding prolactin elevation. It is the **most common atypical antipsychotic** associated with significant hyperprolactinemia, often causing galactorrhea, amenorrhea, and gynecomastia. **Analysis of Incorrect Options:** * **Olanzapine:** While it can cause mild, transient elevations in prolactin, it is generally considered "prolactin-sparing" compared to Risperidone. * **Ziprasidone & Asenapine:** These are second-generation antipsychotics with low potential for prolactin elevation. They dissociate quickly from D2 receptors, minimizing the impact on the tuberoinfundibular pathway. **High-Yield Clinical Pearls for NEET-PG:** * **Highest Risk:** Typical antipsychotics (e.g., Haloperidol) and Risperidone/Paliperidone. * **Lowest Risk (Prolactin-sparing):** Aripiprazole (a D2 partial agonist), Quetiapine, and Clozapine. * **Management:** If hyperprolactinemia occurs, the drug of choice to add (if switching is not possible) is **Aripiprazole**, as its partial agonism helps lower prolactin levels. * **Clinical Features:** Look for "Amenorrhea-Galactorrhea syndrome" in females and "Gynecomastia/Sexual dysfunction" in males.

Question 195: What is true regarding akathisia?

A. Treatment is by anticholinergics. (Correct Answer)
B. The patient wanders away from home.
C. It presents with hallucinations.
D. Behavioral therapy is required.

Explanation: **Explanation:** **Akathisia** is the most common extrapyramidal side effect (EPS) associated with antipsychotic medications (especially first-generation antipsychotics). It is characterized by a subjective feeling of inner restlessness and an objective need to be in constant motion. **Why Option A is Correct:** The primary management for akathisia involves reducing the dose of the offending antipsychotic or switching to a drug with lower EPS potential. Pharmacologically, **centrally acting anticholinergics** (e.g., Procyclidine, Benztropine) and **Beta-blockers** (Proanolol is considered the drug of choice) are the mainstays of treatment. Anticholinergics help restore the dopamine-acetylcholine balance in the nigrostriatal pathway. **Why Other Options are Incorrect:** * **Option B:** Wandering away from home is characteristic of a **Dissociative Fugue** or certain dementias, not akathisia. In akathisia, the patient moves restlessly (pacing, tapping feet) but remains aware of their surroundings. * **Option C:** Akathisia is a motor/sensory side effect; it does not involve **hallucinations**, which are psychotic symptoms. * **Option D:** Akathisia is a drug-induced physiological reaction. **Behavioral therapy** is ineffective; medical intervention or dosage adjustment is mandatory. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** Proanolol (Beta-blocker) is often cited as the most effective treatment for akathisia. * **Clinical Presentation:** Patients often describe "jumping out of their skin" or an inability to sit still. * **Differential Diagnosis:** Must be distinguished from psychotic agitation; increasing the antipsychotic dose will worsen akathisia but improve agitation. * **Timeline:** Usually occurs within days to weeks of starting or increasing antipsychotic medication.

Question 196: Which of the following conditions makes antipsychotics relatively safer to use?

A. Infertility
B. Hypertension (Correct Answer)
C. Epilepsy
D. All of the above

Explanation: **Explanation:** The correct answer is **Hypertension**. This question tests your understanding of the side-effect profile of antipsychotics and their contraindications. **1. Why Hypertension is the correct answer:** Most antipsychotics (especially low-potency typicals like Chlorpromazine and certain atypicals like Clozapine) cause **orthostatic hypotension** due to **alpha-1 adrenergic blockade**. In patients with hypertension, this side effect may actually lead to a reduction in blood pressure. While blood pressure must still be monitored to avoid profound hypotension, the presence of hypertension does not pose an inherent risk of exacerbation by the drug, unlike the other conditions listed. **2. Why the other options are incorrect:** * **Infertility:** Antipsychotics (especially Risperidone and typicals) are potent **D2 receptor antagonists** in the tuberoinfundibular pathway. This leads to **hyperprolactinemia**, which suppresses the HPO axis, causing amenorrhea and galactorrhea in women and decreased spermatogenesis in men. Thus, they can worsen or cause infertility. * **Epilepsy:** Antipsychotics **lower the seizure threshold**. This is a significant concern in patients with pre-existing epilepsy. Clozapine and Chlorpromazine carry the highest risk of inducing seizures. **High-Yield Clinical Pearls for NEET-PG:** * **Clozapine:** Highest risk of seizures (dose-dependent) and agranulocytosis. * **Thioridazine:** Known for QTc prolongation and retinitis pigmentosa. * **Hyperprolactinemia:** Least common with Aripiprazole (D2 partial agonist) and Quetiapine. * **Metabolic Syndrome:** Most common with Clozapine and Olanzapine; least common with Ziprasidone and Aripiprazole.

Question 197: All are indications of lithium except?

A. Neutropenia
B. Major Depression
C. Vasculogenic Headache
D. Generalized anxiety disorder (Correct Answer)

Explanation: **Explanation:** The correct answer is **Generalized Anxiety Disorder (GAD)**. Lithium is primarily classified as a mood stabilizer and does not have a primary role or FDA approval for the treatment of GAD. The first-line treatments for GAD are SSRIs, SNRIs, and benzodiazepines (for short-term use). **Analysis of Options:** * **Neutropenia:** Lithium induces **leukocytosis** (specifically neutrophilia) by stimulating the production of granulocyte colony-stimulating factor (G-CSF). Clinically, it is used off-label to treat Felty’s syndrome and chemotherapy-induced neutropenia. * **Major Depression:** While not a first-line monotherapy, Lithium is a well-established **augmentation strategy** for treatment-resistant Major Depressive Disorder (MDD). It is also highly effective in reducing suicidal ideation in these patients. * **Vasculogenic Headache:** Lithium is a first-line agent for the prophylaxis of **Cluster Headaches** (a type of trigeminal autonomic cephalalgia/vasculogenic headache), particularly the chronic form. **High-Yield Clinical Pearls for NEET-PG:** 1. **Therapeutic Window:** Narrow (0.6–1.2 mEq/L). Toxicity usually starts >1.5 mEq/L. 2. **Drug of Choice:** Acute Mania and prophylaxis of Bipolar Affective Disorder (BPAD). 3. **Teratogenicity:** Ebstein’s Anomaly (atrialization of the right ventricle). 4. **Side Effects (LITHIUM Mnemonic):** **L**eukocytosis, **I**nsipidus (Nephrogenic Diabetes Insipidus), **T**remors/Teratogenicity, **H**ypothyroidism, **I**ncreased **U**rine, **M**others (Ebstein's). 5. **Excretion:** 100% renal; it competes with Sodium. Thiazides, NSAIDs, and ACE inhibitors can increase Lithium levels, leading to toxicity.

Question 198: Which serum lithium level is suggestive of toxicity?

A. 2 mEq/L (Correct Answer)
B. 4 mEq/L
C. 6 mEq/L
D. 8 mEq/L

Explanation: Lithium is a mood stabilizer with a **narrow therapeutic index**, meaning the margin between a therapeutic dose and a toxic dose is very small. Regular monitoring of serum lithium levels is mandatory for patient safety. ### **Explanation of the Correct Answer** The therapeutic range for lithium is generally **0.6 to 1.2 mEq/L**. Toxicity typically manifests when serum levels exceed **1.5 mEq/L**. * **Mild to Moderate Toxicity (1.5–2.0 mEq/L):** Presents with vomiting, abdominal pain, ataxia, dizziness, and coarse tremors. * **Severe Toxicity (>2.0 mEq/L):** Can lead to seizures, coma, cardiac arrhythmias, and permanent neurological damage. Among the given options, **2 mEq/L** is the earliest threshold indicating significant toxicity requiring immediate clinical intervention. ### **Explanation of Incorrect Options** * **4, 6, and 8 mEq/L:** While these levels are indeed toxic, they represent extreme, life-threatening emergencies. In clinical practice and exams, toxicity is defined by the *lowest* level that crosses the therapeutic threshold. Levels above 3.5–4.0 mEq/L are often fatal and usually necessitate emergency hemodialysis. ### **High-Yield NEET-PG Pearls** * **Monitoring:** Serum levels should be checked **12 hours after the last dose** (Trough level). * **Steady State:** It takes about **5 days** to reach a steady state after starting or changing a dose. * **Side Effects:** Fine tremors (therapeutic), Coarse tremors (toxic), Nephrogenic Diabetes Insipidus, and Ebstein’s Anomaly (teratogenic). * **Drug Interactions:** **NSAIDs, Thiazides, and ACE inhibitors** increase lithium levels by decreasing renal clearance (Mnemonic: **"NAT"**). * **Management of Toxicity:** Hydration is first-line; **Hemodialysis** is the treatment of choice for severe toxicity (>2.5–4.0 mEq/L or if the patient is symptomatic).

Question 199: Which of the following is an extrapyramidal side effect of antipsychotics?

A. Dystonia (Correct Answer)
B. Akathisia
C. Seizures
D. Diarrhoea

Explanation: **Explanation:** **Extrapyramidal Side Effects (EPS)** are drug-induced movement disorders caused by the blockade of dopamine (D2) receptors in the **nigrostriatal pathway** [1]. This is most commonly associated with First-Generation Antipsychotics (e.g., Haloperidol). **1. Why Dystonia is Correct:** **Acute Dystonia** is a classic EPS characterized by sudden, involuntary muscle spasms. Common presentations include torticollis (neck twisting), grimacing, and **oculogyric crisis** (upward deviation of eyes). It typically occurs within hours to days of starting treatment or increasing the dose. **2. Analysis of Incorrect Options:** * **Akathisia (Option B):** While Akathisia (subjective restlessness) is indeed an EPS [1], in the context of single-choice questions where "Dystonia" is the primary textbook example of an acute motor spasm, it serves as a distractor if Dystonia is the intended focus. *Note: In many clinical exams, both are EPS; however, Dystonia is the most "definitive" motor spasm.* * **Seizures (Option C):** This is a neurological side effect (lowering of seizure threshold), particularly with **Clozapine** [2], but it is not classified as an extrapyramidal motor symptom. * **Diarrhoea (Option D):** Antipsychotics typically have **anticholinergic** properties, which cause constipation, not diarrhoea. **High-Yield Clinical Pearls for NEET-PG:** * **Timeline of EPS:** 1. **Acute Dystonia:** Hours to days (Treatment: Promethazine or Benztropine) [1]. 2. **Akathisia:** Days to weeks (Treatment: Beta-blockers like Propranolol) [1]. 3. **Drug-induced Parkinsonism:** Weeks to months (Treatment: Trihexyphenidyl) [1]. 4. **Tardive Dyskinesia:** Months to years (Choreoathetoid movements; Treatment: Valbenazine) [1]. * **Pathophysiology:** EPS occurs when D2 blockade in the striatum leads to a relative **excess of Acetylcholine**. This is why anticholinergics are used for management [1].

Question 200: What is the drug of choice for panic disorders?

A. Nitrazepam
B. Imipramine (Correct Answer)
C. Diazepam
D. Clonidine

Explanation: **Explanation:** **1. Why Imipramine is the correct answer:** Imipramine is a **Tricyclic Antidepressant (TCA)** and was historically the first drug proven effective for the treatment of panic disorder. It works by inhibiting the reuptake of norepinephrine and serotonin. While **Selective Serotonin Reuptake Inhibitors (SSRIs)** are currently considered the first-line treatment in modern clinical practice due to a better side-effect profile, **Imipramine remains the classic "Drug of Choice" (DOC) in many standard textbooks and traditional NEET-PG patterns** because of its established efficacy in preventing panic attacks. **2. Why the other options are incorrect:** * **Nitrazepam:** This is a long-acting benzodiazepine primarily used for insomnia. It is not indicated for the long-term management of panic disorder. * **Diazepam:** While a benzodiazepine (like Alprazolam) can provide rapid relief for acute anxiety, it is generally avoided as a long-term DOC due to the risks of sedation, cognitive impairment, and dependence. It does not treat the underlying pathophysiology as effectively as antidepressants. * **Clonidine:** An alpha-2 agonist used primarily for hypertension and opioid withdrawal. While it can reduce some autonomic symptoms of anxiety, it is not a primary treatment for panic disorder. **3. High-Yield Clinical Pearls for NEET-PG:** * **Current First-line:** SSRIs (e.g., Sertraline, Paroxetine) are the modern first-line agents. * **Acute Attack:** For immediate relief of a panic attack, short-acting benzodiazepines like **Alprazolam** are used. * **Treatment Duration:** Pharmacotherapy for panic disorder should typically continue for 8–12 months to prevent relapse. * **Cognitive Behavioral Therapy (CBT):** This is the most effective non-pharmacological treatment and is often combined with medication.

Question 201: Which mood stabilizer has anti-suicidal properties?

A. Lithium (Correct Answer)
B. Carbamazepine
C. Lamotrigine
D. Valproate

Explanation: **Explanation:** **Lithium** is the gold-standard mood stabilizer and is uniquely recognized for its potent **anti-suicidal properties**. Unlike other mood stabilizers, its ability to reduce the risk of completed suicide and suicide attempts in patients with Bipolar Disorder and Major Depressive Disorder is independent of its mood-stabilizing effect. The exact mechanism is not fully understood but is thought to involve the reduction of impulsivity and aggression by modulating serotonergic neurotransmission. **Analysis of Incorrect Options:** * **Carbamazepine (B):** While effective for acute mania and prophylaxis, it has no proven specific anti-suicidal efficacy. * **Lamotrigine (C):** Excellent for preventing bipolar depression, but it does not possess the specific anti-suicidal profile associated with Lithium. * **Valproate (D):** A first-line agent for mania (especially rapid cycling), but studies have not consistently demonstrated a reduction in suicide rates comparable to Lithium. **High-Yield Clinical Pearls for NEET-PG:** * **The "Anti-Suicide" Duo:** Only two psychiatric medications are classically recognized for reducing suicide risk: **Lithium** (in Bipolar/Mood disorders) and **Clozapine** (in Schizophrenia). * **Therapeutic Index:** Lithium has a narrow therapeutic index. Target serum levels are **0.8–1.2 mEq/L** for acute mania and **0.6–1.0 mEq/L** for maintenance. * **Monitoring:** Before starting Lithium, always check **Thyroid Function Tests (TFT)** and **Renal Function Tests (RFT)**, as it can cause hypothyroidism and nephrogenic diabetes insipidus. * **Teratogenicity:** Lithium use in pregnancy is associated with **Ebstein’s Anomaly** (tricuspid valve displacement).

Question 202: Which of the following is not associated with neuroleptic malignant syndrome?

A. Haloperidol
B. Metoclopramide
C. Domperidone
D. Amantadine (Correct Answer)

Explanation: **Explanation:** Neuroleptic Malignant Syndrome (NMS) is a life-threatening idiosyncratic reaction to **dopamine antagonists**. The pathophysiology involves a massive blockade of central dopamine receptors (D2), leading to the classic tetrad of hyperthermia, muscular "lead-pipe" rigidity, autonomic instability, and altered mental status. **Why Amantadine is the correct answer:** Amantadine is a **dopaminergic agonist** (it increases dopamine release and inhibits reuptake). It is used to treat Parkinson’s disease and extrapyramidal symptoms. Because NMS is caused by a *deficiency* of dopamine activity, Amantadine is actually used as a **treatment** for NMS, not a cause. Importantly, the **sudden withdrawal** of Amantadine (or Levodopa) can precipitate NMS. **Analysis of Incorrect Options:** * **Haloperidol:** A high-potency typical antipsychotic and the most common culprit associated with NMS due to its strong D2 receptor antagonism. * **Metoclopramide:** Although used as an antiemetic, it is a central D2 receptor antagonist and is a well-known non-antipsychotic cause of NMS. * **Domperidone:** Like metoclopramide, it is a dopamine antagonist. While it primarily acts peripherally, it can cross the blood-brain barrier in certain conditions or high doses, potentially contributing to NMS. **NEET-PG High-Yield Pearls:** * **Key Lab Finding:** Significantly elevated **Creatine Phosphokinase (CPK)** levels and leukocytosis. * **Drug of Choice:** **Dantrolene** (muscle relaxant) is the specific treatment, often combined with **Bromocriptine** (dopamine agonist). * **Mnemonic (FEVER):** **F**ever, **E**ncephalopathy, **V**itals unstable, **E**levated enzymes (CPK), **R**igidity. * **Differential:** Unlike Serotonin Syndrome, NMS presents with "lead-pipe" rigidity and bradyreflexia, rather than hyperreflexia and myoclonus.

Question 203: What is a treatment for unipolar depression?

A. Fluoxetine
B. Sertraline
C. Citalopram
D. All of the above (Correct Answer)

Explanation: **Explanation:** The correct answer is **D. All of the above**. Unipolar depression (Major Depressive Disorder) is primarily managed using **Selective Serotonin Reuptake Inhibitors (SSRIs)** as the first-line pharmacological intervention. SSRIs work by inhibiting the presynaptic reuptake of serotonin (5-HT), thereby increasing its availability in the synaptic cleft. * **Fluoxetine (Option A):** A prototype SSRI with the longest half-life (due to its active metabolite, norfluoxetine). It is often the preferred choice in children and adolescents. * **Sertraline (Option B):** An SSRI known for its safety profile in patients with cardiovascular disease (post-MI). It has a lower risk of drug-drug interactions compared to fluoxetine. * **Citalopram (Option C):** A highly selective SSRI. While effective, it requires monitoring for dose-dependent QTc prolongation. Since all three medications belong to the SSRI class and are FDA-approved first-line treatments for unipolar depression, "All of the above" is the correct choice. **High-Yield Clinical Pearls for NEET-PG:** * **First-line for MDD:** SSRIs (due to better tolerability and lower toxicity in overdose compared to TCAs). * **Lag period:** Antidepressants typically take **2–4 weeks** to show clinical improvement. * **Side Effects:** Most common include GI upset, sexual dysfunction (most common long-term side effect), and sleep disturbances. * **Serotonin Syndrome:** A potential life-threatening complication when SSRIs are combined with MAOIs; characterized by the triad of autonomic instability, neuromuscular hyperactivity, and altered mental status. * **Discontinuation Syndrome:** Least common with Fluoxetine (due to long half-life) and most common with Paroxetine.

Question 204: Which of the following is NOT an anxiolytic drug?

A. Melatonin (Correct Answer)
B. Haloperidol
C. Alprazolam
D. Sertraline

Explanation: **Explanation:** The correct answer is **Melatonin**. Melatonin is a hormone produced by the pineal gland that regulates the sleep-wake cycle (circadian rhythm). While it is used clinically for insomnia and jet lag, it does not possess intrinsic anxiolytic (anxiety-reducing) properties. **Analysis of Options:** * **Alprazolam:** A Benzodiazepine (BZD) that acts as a positive allosteric modulator of the $GABA_A$ receptor. It is a classic, fast-acting anxiolytic used for panic disorders and generalized anxiety. * **Sertraline:** An SSRI (Selective Serotonin Reuptake Inhibitor). Although primarily classified as an antidepressant, SSRIs are the **first-line long-term treatment** for most anxiety disorders (GAD, Social Anxiety, Panic Disorder). * **Haloperidol:** A typical antipsychotic (D2 blocker). While its primary indication is psychosis, it is frequently used "off-label" in acute clinical settings as a chemical restraint to manage severe agitation and acute anxiety associated with delirium or psychosis. **High-Yield Clinical Pearls for NEET-PG:** * **First-line for Acute Anxiety:** Benzodiazepines (e.g., Alprazolam, Diazepam) due to immediate onset. * **First-line for Chronic Anxiety:** SSRIs (e.g., Sertraline, Escitalopram) due to better safety profiles and lack of dependence. * **Buspirone:** A 5-HT1A partial agonist; it is a pure anxiolytic that lacks sedative, hypnotic, or muscle relaxant properties. * **Propranolol:** Used for "Performance Anxiety" to control peripheral autonomic symptoms (tremors, tachycardia).

Question 205: Which of the SSRIs is used in the management of panic disorder?

A. Paroxetine (Correct Answer)
B. Sertraline
C. Trazodone
D. Escitalopram

Explanation: **Explanation:** **Selective Serotonin Reuptake Inhibitors (SSRIs)** are considered the first-line pharmacological treatment for **Panic Disorder** due to their efficacy and favorable side-effect profile compared to older antidepressants. **Why Paroxetine is the correct answer:** While several SSRIs are effective for panic disorder, **Paroxetine** was the first SSRI to receive FDA approval specifically for this indication. It is highly effective in reducing the frequency and intensity of panic attacks and associated anticipatory anxiety. In the context of NEET-PG questions, when a single "best" SSRI is sought for panic disorder, Paroxetine is frequently the classic textbook answer. **Analysis of Incorrect Options:** * **Sertraline & Escitalopram:** These are also SSRIs and are clinically used to treat panic disorder. However, in multiple-choice formats where only one option must be selected, Paroxetine is often prioritized due to its historical status as the prototype for this indication. * **Trazodone:** This is a Serotonin Antagonist and Reuptake Inhibitor (SARI). It is primarily used for depression with insomnia due to its sedative properties; it is not a first-line treatment for panic disorder. **High-Yield Clinical Pearls for NEET-PG:** * **Start Low, Go Slow:** In panic disorder, patients are often hypersensitive to the initial stimulatory effects of SSRIs (which can mimic a panic attack). Treatment should start at half the usual antidepressant dose. * **DOC:** SSRIs are the **Drug of Choice** for long-term management of Panic Disorder. * **Acute Management:** Benzodiazepines (like Alprazolam or Clonazepam) are used for immediate relief of acute attacks but are avoided for long-term use due to dependence risk. * **Side Effect Profile:** Paroxetine is the most **anticholinergic** SSRI and has the shortest half-life, leading to a higher risk of **Discontinuation Syndrome**.

Question 206: "Wet Pillow Syndrome" is caused by

A. Imipramine
B. Bromocriptine
C. Clozapine (Correct Answer)
D. Amitriptyline

Explanation: **Explanation:** **Clozapine** is the correct answer. **"Wet Pillow Syndrome"** refers to **sialorrhea** (excessive salivation), which is a paradoxical and common side effect of Clozapine, occurring in up to 30–50% of patients. It is most prominent at night, leading to drooling that soaks the patient's pillow. * **Mechanism:** While Clozapine is an anticholinergic drug (which usually causes dry mouth), it causes sialorrhea likely through its **M4 receptor agonism** in the salivary glands and its **alpha-2 adrenergic antagonism**, which inhibits the swallowing reflex during sleep. * **Management:** It is often treated with peripheral anticholinergics like **Glycopyrrolate** or sublingual **Atropine** drops. **Why the other options are incorrect:** * **Imipramine & Amitriptyline (TCAs):** These are potent **muscarinic antagonists**. Their primary side effect is **Xerostomia** (dry mouth), the exact opposite of sialorrhea. * **Bromocriptine:** This is a dopamine agonist used in Parkinson’s and Prolactinomas. It does not typically cause excessive salivation; common side effects include nausea, orthostatic hypotension, and hallucinations. **High-Yield Clinical Pearls for NEET-PG:** * **Clozapine** is the "Gold Standard" for **Treatment-Resistant Schizophrenia**. * **Most Serious Side Effect:** Agranulocytosis (requires mandatory ANC monitoring). * **Most Common Side Effect:** Sedation. * **Most Common Cause of Death:** Myocarditis/Cardiomyopathy. * **Other Key Side Effects:** Lowers seizure threshold (dose-dependent), weight gain, and metabolic syndrome.

Question 207: Which of the following statements is true about neuroleptic malignant syndrome?

A. General antipsychotics are more associated with its development. (Correct Answer)
B. Symptoms include rigidity, fever, and altered consciousness.
C. Dantrolene is an effective treatment for improving symptoms.
D. Bromocriptine can be used in the management of neuroleptic malignant syndrome.

Explanation: **Explanation:** **Neuroleptic Malignant Syndrome (NMS)** is a rare but life-threatening idiosyncratic reaction to dopamine antagonists. **1. Why Option A is Correct:** While all antipsychotics can cause NMS, **First-Generation Antipsychotics (Typical/General Antipsychotics)** like Haloperidol and Fluphenazine are more frequently associated with its development due to their high potency and strong D2 receptor antagonism. High doses, rapid titration, and parenteral administration further increase this risk. **2. Analysis of Other Options:** * **Options B, C, and D:** While these statements are clinically **true** (NMS does present with the tetrad of rigidity, fever, autonomic instability, and altered sensorium; and Dantrolene/Bromocriptine are used for treatment), in the context of this specific MCQ format, Option A is highlighted as the primary pharmacological association being tested. *Note: In many standard exams, B, C, and D are also considered correct facts; however, the question likely seeks the most fundamental epidemiological association.* **3. Clinical Pearls for NEET-PG:** * **The Tetrad (FEVER):** **F**ever, **E**ncephalopathy (Altered mental status), **V**itals unstable (Autonomic instability), **E**levated enzymes (CPK), and **R**igidity ("Lead-pipe" variety). * **Pathophysiology:** Central D2 receptor blockade in the hypothalamus (fever) and basal ganglia (rigidity). * **Key Lab Finding:** Significantly elevated **Serum Creatine Phosphokinase (CPK)** and leukocytosis. * **Management:** 1. Immediate discontinuation of the offending agent (Most important step). 2. Supportive care (Hydration/Cooling). 3. **Dantrolene** (Muscle relaxant) or **Bromocriptine/Amantadine** (Dopamine agonists). * **Differential Diagnosis:** Serotonin Syndrome (presents with hyperreflexia and myoclonus, unlike the lead-pipe rigidity of NMS).

Question 208: Metabolic syndrome is most commonly associated as a side effect with which of the following groups of medications?

A. Anti-anxiety drugs
B. Anti-depressant drugs
C. Anti-psychotic drugs (Correct Answer)
D. Anti-cholinergic drugs

Explanation: **Explanation:** **Metabolic Syndrome**—characterized by weight gain, dyslipidemia, hyperglycemia (insulin resistance), and hypertension—is a hallmark side effect of **Second-Generation Antipsychotics (SGAs)**, also known as Atypical Antipsychotics. **Why Anti-psychotic drugs are the correct answer:** The mechanism involves the blockade of **Histamine (H1)** and **Serotonin (5-HT2C)** receptors, particularly in the hypothalamus. This leads to increased appetite, hyperphagia, and rapid weight gain. Additionally, these drugs directly interfere with insulin signaling and lipid metabolism. Among antipsychotics, **Clozapine** and **Olanzapine** carry the highest risk, while Ziprasidone and Aripiprazole are considered "metabolically neutral." **Why other options are incorrect:** * **Anti-anxiety drugs (e.g., Benzodiazepines):** These primarily cause sedation, cognitive impairment, and potential dependence, but do not typically cause metabolic derangements. * **Anti-depressant drugs:** While some (like Mirtazapine or TCAs) cause weight gain, they are not as universally or severely linked to the full spectrum of metabolic syndrome as antipsychotics are. SSRIs are generally weight-neutral. * **Anti-cholinergic drugs:** These cause "dry" side effects (dry mouth, blurred vision, constipation, urinary retention) and tachycardia, but do not impact glucose or lipid metabolism. **NEET-PG High-Yield Pearls:** * **Highest Risk:** Clozapine > Olanzapine. * **Lowest Risk:** Ziprasidone, Aripiprazole, Lurasidone. * **Monitoring:** Patients on SGAs require regular monitoring of BMI, waist circumference, fasting blood sugar, and lipid profile (as per ADA/APA guidelines). * **Drug of Choice:** If a patient develops metabolic syndrome, switching to a "weight-neutral" antipsychotic or adding **Metformin** is often considered.

Question 209: What is the most common cardiac adverse effect of lithium?

A. Arrhythmia
B. Cardiomyopathy
C. Bradycardia (Correct Answer)
D. Hypotension

Explanation: **Explanation:** Lithium is the gold-standard mood stabilizer for Bipolar Disorder, but it has a narrow therapeutic index and significant multisystem side effects. **Why Bradycardia is the correct answer:** The most common cardiac manifestation of lithium therapy is **T-wave inversion or flattening** (similar to hypokalemia), which is usually benign. However, among the clinical cardiac adverse effects, **Sinus Bradycardia** and **Sinus Node Dysfunction (Sick Sinus Syndrome)** are the most frequently reported. Lithium interferes with the electrical conduction system of the heart by inhibiting the influx of sodium ions through the pacemaker channels, leading to a decrease in the firing rate of the sinoatrial (SA) node. **Analysis of Incorrect Options:** * **A. Arrhythmia:** While lithium can cause arrhythmias (like ventricular tachycardia) in cases of severe toxicity, they are less common than simple bradycardia at therapeutic or mildly toxic levels. * **B. Cardiomyopathy:** This is not a recognized side effect of lithium. Cardiomyopathy is more commonly associated with chronic alcohol use or certain antipsychotics (like Clozapine-induced myocarditis). * **D. Hypotension:** Lithium does not typically affect peripheral vascular resistance or blood pressure directly. **High-Yield NEET-PG Pearls:** * **ECG Changes:** T-wave flattening/inversion is the most common *electrocardiographic* finding (benign). * **Teratogenicity:** Lithium use in pregnancy is associated with **Ebstein’s Anomaly** (atrialization of the right ventricle). * **Monitoring:** Before starting lithium, baseline **ECG, Renal Function Tests (RFT), and Thyroid Function Tests (TFT)** are mandatory. * **Therapeutic Range:** 0.6–1.2 mEq/L (Prophylaxis: 0.6–0.8; Acute Mania: 0.8–1.2). Toxicity usually starts >1.5 mEq/L.

Question 210: Dryness of mouth is caused by antipsychotics due to their:

A. Anticholinergic action (Correct Answer)
B. Antiadrenergic action
C. Antidopaminergic action
D. Antihistaminic action

Explanation: **Explanation:** The correct answer is **A. Anticholinergic action**. **Mechanism of Action:** Antipsychotics (especially first-generation agents like Chlorpromazine and low-potency neuroleptics) often possess significant affinity for **Muscarinic (M1) receptors**. By blocking these receptors, they inhibit the parasympathetic nervous system's stimulation of the salivary glands. Since acetylcholine is the primary neurotransmitter responsible for inducing salivation, its antagonism leads to **Xerostomia** (dryness of mouth). **Analysis of Incorrect Options:** * **B. Antiadrenergic action:** Blockade of alpha-1 adrenergic receptors primarily leads to orthostatic hypotension, reflex tachycardia, and nasal congestion, rather than dry mouth. * **C. Antidopaminergic action:** This is the primary therapeutic mechanism of antipsychotics (D2 blockade). It is responsible for the antipsychotic effect and extrapyramidal side effects (EPS) like parkinsonism and dystonia, but not autonomic side effects like dry mouth. * **D. Antihistaminic action:** Blockade of H1 receptors is primarily associated with sedation and weight gain. **NEET-PG High-Yield Clinical Pearls:** * **Low-potency vs. High-potency:** Low-potency antipsychotics (e.g., Chlorpromazine, Thioridazine) have **higher** anticholinergic activity compared to high-potency drugs (e.g., Haloperidol). * **The "Anti-SLUDGE" Effect:** Anticholinergic side effects can be remembered by the mnemonic: Dry mouth, blurred vision (cycloplegia), constipation, and urinary retention. * **Clozapine Paradox:** While most antipsychotics cause dry mouth, **Clozapine** is unique because it often causes **Sialorrhea** (excessive salivation), likely due to its agonist action at M4 receptors or impairment of the swallowing reflex. * **Management:** Patients are often advised to use sugarless gum or frequent sips of water to manage xerostomia.

Question 211: Which of the following extrapyramidal effects is seen on chronic use of antipsychotics?

A. Dystonia
B. Akathisia
C. Tardive dyskinesia (Correct Answer)
D. Parkinsonism

Explanation: **Explanation:** Extrapyramidal Side Effects (EPS) of antipsychotics are classified based on their time of onset. The correct answer is **Tardive Dyskinesia (TD)** because it is the only option listed that occurs as a **late-onset (chronic)** complication. **1. Why Tardive Dyskinesia is correct:** TD typically develops after months or years of antipsychotic treatment (usually >6 months). It is characterized by involuntary, choreoathetoid movements, most commonly involving the tongue (darting), mouth (smacking), and face. The underlying pathophysiology is believed to be **upregulation and supersensitivity of Dopamine (D2) receptors** in the nigrostriatal pathway following chronic blockade. **2. Why other options are incorrect:** * **Dystonia:** This is an **acute** reaction occurring within hours to days of starting treatment. It involves sustained muscle contractions (e.g., torticollis, oculogyric crisis). * **Akathisia:** This is the most common EPS and usually appears within days to weeks. It is characterized by subjective feelings of inner restlessness and an inability to sit still. * **Parkinsonism:** This subacute reaction (tremor, rigidity, bradykinesia) typically appears within weeks of initiating or increasing the dose of a neuroleptic. **High-Yield Clinical Pearls for NEET-PG:** * **Treatment of TD:** The first step is to reduce the dose or switch to a second-generation antipsychotic (specifically **Clozapine**). Valbenazine or Deutetrabenazine (VMAT2 inhibitors) are FDA-approved treatments. * **Contraindication:** Anticholinergics (like Benztropine) often **worsen** Tardive Dyskinesia, whereas they are the treatment of choice for Acute Dystonia. * **Risk Factor:** Elderly females are at the highest risk for developing TD.

Question 212: What is the usual adult maintenance dose of Clozapine?

A. 150 mg
B. 250 mg
C. 300 mg (Correct Answer)
D. 500 mg

Explanation: **Explanation:** Clozapine is an atypical (second-generation) antipsychotic reserved for treatment-resistant schizophrenia. The correct answer is **300 mg**, as this represents the standard target maintenance dose for most adult patients to achieve therapeutic efficacy. **1. Why 300 mg is Correct:** The initiation of Clozapine requires slow titration to minimize side effects like orthostatic hypotension and seizures. While the starting dose is 12.5 mg once or twice daily, it is gradually increased by 25–50 mg/day. The **usual adult maintenance dose** typically ranges between **300 mg and 450 mg per day** (administered in divided doses). 300 mg is the established clinical benchmark for the lower end of the effective maintenance range. **2. Analysis of Incorrect Options:** * **150 mg (Option A):** This is generally considered a sub-therapeutic dose for maintenance in most adults, though it may be used during the titration phase or in elderly/sensitive patients. * **250 mg (Option B):** While closer to the target, it is still slightly below the standard 300–450 mg maintenance range defined in most pharmacological guidelines (e.g., Maudsley, FDA). * **500 mg (Option D):** While some patients require up to 600–900 mg (maximum limit), 500 mg is above the "usual" starting maintenance point and carries a higher risk of dose-dependent seizures. **High-Yield Clinical Pearls for NEET-PG:** * **Indication:** Treatment-resistant schizophrenia (failure of ≥2 antipsychotics, one being an atypical). * **Black Box Warning:** **Agranulocytosis** (requires mandatory WBC and ANC monitoring). * **Side Effects:** Sialorrhea (excessive salivation), sedation, weight gain, and lowering of the seizure threshold. * **Myocarditis:** A rare but fatal side effect; monitor for chest pain or tachycardia in the first month. * **Therapeutic Range:** Plasma levels >350 ng/mL are generally required for a response.

Question 213: Which one of the following antipsychotic drugs is considered the best in the treatment of resistant schizophrenia?

A. Olanzapine
B. Clozapine (Correct Answer)
C. Risperidone
D. Chlorpromazine

Explanation: **Explanation:** **Clozapine** is the gold-standard treatment for **treatment-resistant schizophrenia (TRS)**. TRS is clinically defined as schizophrenia that fails to respond to at least two adequate trials of different antipsychotic medications (one of which must be a second-generation antipsychotic) for a duration of 4–6 weeks each. Clozapine’s unique efficacy is attributed to its complex receptor profile, including low D2 receptor affinity and high affinity for D4, 5-HT2A, and alpha-adrenergic receptors. It is the only antipsychotic proven to reduce suicidal behavior in schizophrenic patients. **Why other options are incorrect:** * **Olanzapine (A) & Risperidone (C):** These are second-generation (atypical) antipsychotics. While they are first-line treatments for schizophrenia due to a lower risk of extrapyramidal symptoms (EPS) compared to typical agents, they do not possess the specific efficacy required to manage resistant cases. * **Chlorpromazine (D):** This is a first-generation (typical), low-potency antipsychotic. It is primarily used for acute psychosis but is associated with significant sedation and autonomic side effects. It is not effective for treatment-resistant symptoms. **High-Yield Clinical Pearls for NEET-PG:** * **Agranulocytosis:** The most dreaded side effect of Clozapine (occurs in ~1%). Mandatory **Absolute Neutrophil Count (ANC)** monitoring is required. * **Seizures:** Clozapine significantly lowers the seizure threshold in a dose-dependent manner. * **Sialorrhea:** Paradoxical hypersalivation is a common, bothersome side effect. * **Metabolic Syndrome:** Clozapine and Olanzapine carry the highest risk of weight gain and diabetes among antipsychotics. * **No EPS:** Clozapine has the lowest risk of causing Extrapyramidal Symptoms and Tardive Dyskinesia.

Question 214: All of the following are side effects of Clozapine except?

A. Agranulocytosis
B. Myocarditis
C. Seizures
D. Weight loss (Correct Answer)

Explanation: **Explanation:** Clozapine is a unique "atypical" antipsychotic reserved for treatment-resistant schizophrenia. The correct answer is **Weight loss** because Clozapine is actually associated with significant **weight gain** and metabolic syndrome. 1. **Why Weight Loss is the Correct Answer:** Clozapine has a high affinity for $H_1$ (histamine) and $5-HT_{2C}$ receptors. Blockade of these receptors leads to increased appetite and profound weight gain. It also carries the highest risk among antipsychotics for causing dyslipidemia and Type 2 Diabetes Mellitus. 2. **Analysis of Incorrect Options:** * **Agranulocytosis:** This is the most dreaded side effect (occurring in ~1%). It requires mandatory WBC and ANC (Absolute Neutrophil Count) monitoring. * **Myocarditis:** A rare but potentially fatal idiosyncratic reaction, usually occurring within the first 4–8 weeks of treatment. * **Seizures:** Clozapine reduces the seizure threshold in a dose-dependent manner. The risk is significantly higher at doses above 600 mg/day. **High-Yield Clinical Pearls for NEET-PG:** * **Sialorrhea (Drooling):** Paradoxically, though it has anticholinergic properties, Clozapine commonly causes excessive salivation (often nocturnal). * **Constipation:** It can cause life-threatening paralytic ileus due to potent anticholinergic effects. * **No EPS/Hyperprolactinemia:** Clozapine is unique because it rarely causes Extrapyramidal Side Effects or increases prolactin levels. * **DOC (Drug of Choice):** For treatment-resistant schizophrenia and schizophrenia with persistent suicidal behavior.

Question 215: What is the most common congenital anomaly associated with lithium use during pregnancy?

A. Cardiac malformations (Correct Answer)
B. Neural tube defects
C. Renal anomaly
D. Fetal hydantoin syndrome

Explanation: **Explanation:** **1. Why Cardiac Malformations are Correct:** Lithium is a known teratogen, particularly when administered during the first trimester of pregnancy. While the absolute risk is lower than previously thought, the most common category of anomalies associated with lithium use is **cardiac malformations**. Specifically, lithium is classically associated with **Ebstein’s Anomaly**, a rare defect characterized by the downward displacement of the tricuspid valve into the right ventricle ("atrialization" of the ventricle). While Ebstein’s is the most *specific* association, general cardiac septal defects are numerically more common in lithium-exposed infants. **2. Why the Other Options are Incorrect:** * **B. Neural Tube Defects:** These (e.g., spina bifida) are primarily associated with **Valproate** and **Carbamazepine** due to their interference with folate metabolism. * **C. Renal Anomaly:** While lithium causes renal side effects in adults (like Nephrogenic Diabetes Insipidus), it is not the primary congenital concern. However, "Floppy Baby Syndrome" and neonatal hypothyroidism can occur if lithium is used near term. * **D. Fetal Hydantoin Syndrome:** This is a specific constellation of defects (cranial-facial abnormalities, hypoplastic nails/digits) caused by maternal use of **Phenytoin**. **High-Yield Clinical Pearls for NEET-PG:** * **Risk Ratio:** The risk of Ebstein’s anomaly in the general population is 1 in 20,000; with lithium exposure, it increases to approximately 1 in 1,000. * **Management:** If a patient on lithium plans to conceive, the drug should ideally be tapered. If pregnancy is discovered, a **fetal echocardiogram** and Level II ultrasound are mandatory at 18–20 weeks. * **Breastfeeding:** Lithium is generally **avoided** during breastfeeding as it is excreted in high concentrations in breast milk, risking lithium toxicity in the neonate.

Question 216: Neuroleptic malignant syndrome is characterized by all EXCEPT?

A. Hyperthermia
B. Increased blood pressure and heart rate
C. Hypothermia (Correct Answer)
D. Immobility rigidity

Explanation: **Explanation:** Neuroleptic Malignant Syndrome (NMS) is a rare but life-threatening idiosyncratic reaction to antipsychotic medications (neuroleptics), primarily caused by potent **dopamine (D2) receptor blockade** in the nigrostriatal pathway and hypothalamus. **Why Hypothermia is the Correct Answer:** Hypothermia is the opposite of what occurs in NMS. The hallmark of NMS is **Hyperthermia** (Option A). Central dopamine blockade in the hypothalamus disrupts the body's thermoregulatory set-point, leading to severe fever (often >38°C or 100.4°F). Therefore, hypothermia is not a feature of this syndrome. **Analysis of Other Options:** * **Increased BP and Heart Rate (Option B):** Autonomic instability is a core feature of NMS. This manifests as tachycardia, labile blood pressure (hypertension or hypotension), diaphoresis (profuse sweating), and tachypnea. * **Immobility Rigidity (Option D):** Severe "lead-pipe" muscle rigidity is a diagnostic criterion. This intense muscle contraction leads to decreased mobility and can cause **Rhabdomyolysis**, resulting in elevated Creatine Phosphokinase (CPK) levels. **NEET-PG High-Yield Pearls:** * **Mnemonic (FEVER):** **F**ever, **E**ncephalopathy (altered sensorium), **V**itals unstable, **E**levated CPK/Enzymes, **R**igidity. * **Treatment of Choice:** Immediate discontinuation of the offending drug, aggressive cooling, and pharmacological intervention with **Dantrolene** (muscle relaxant) or **Bromocriptine** (dopamine agonist). * **Key Lab Finding:** Significantly elevated **Serum Creatine Phosphokinase (CPK)** and leukocytosis. * **Differential Diagnosis:** Serotonin Syndrome (presents with hyperreflexia and myoclonus, whereas NMS presents with "lead-pipe" rigidity and bradyreflexia).

Question 217: What is the drug of choice for prophylaxis of mania?

A. Lithium (Correct Answer)
B. Haloperidol
C. Clozapine
D. Carbamazepine

Explanation: **Explanation:** **Lithium** is the gold-standard **Drug of Choice (DOC) for the prophylaxis of Bipolar Affective Disorder (BPAD)**, including both manic and depressive episodes. It is a mood stabilizer that effectively reduces the frequency and severity of relapses. For prophylaxis, therapeutic serum lithium levels are maintained between **0.6 – 0.8 mEq/L** (lower than the 0.8 – 1.2 mEq/L required for acute mania). **Analysis of Incorrect Options:** * **B. Haloperidol:** This is a typical antipsychotic used for the **acute management** of manic symptoms (agitation, psychosis) due to its rapid onset. However, it is not used for long-term prophylaxis as it does not stabilize mood and carries a high risk of Extrapyramidal Side Effects (EPS). * **C. Clozapine:** An atypical antipsychotic reserved for **treatment-resistant schizophrenia** or refractory mania. It is not a first-line prophylactic agent due to the risk of agranulocytosis. * **D. Carbamazepine:** An anticonvulsant used as a **second-line** mood stabilizer. It is preferred in "Rapid Cyclers" or patients who do not respond to Lithium, but it is not the primary DOC. **High-Yield Clinical Pearls for NEET-PG:** * **Teratogenicity:** Lithium is associated with **Ebstein’s Anomaly** (atrialization of the right ventricle) if taken during pregnancy. * **Monitoring:** Before starting Lithium, check **Thyroid Function Tests (TFTs)** and **Renal Function Tests (RFTs)**, as it can cause hypothyroidism and nephrogenic diabetes insipidus. * **Narrow Therapeutic Index:** Lithium toxicity occurs >1.5 mEq/L; hemodialysis is the treatment of choice for severe toxicity (>3.5 mEq/L). * **Drug Interactions:** Thiazides, NSAIDs, and ACE inhibitors can increase lithium levels, leading to toxicity.

Question 218: Lithium is used in a pregnant woman. Which of the following congenital anomalies may occur in the fetus?

A. Tetralogy of Fallot
B. Bicuspid atresia
C. Ebstein's anomaly (Correct Answer)
D. Pulmonary stenosis

Explanation: **Explanation:** **Ebstein’s Anomaly** is the classic, high-yield association with **Lithium** use during the first trimester of pregnancy. It is a rare congenital cardiac defect characterized by the downward displacement of the septal and posterior leaflets of the **tricuspid valve** into the right ventricle. This results in "atrialization" of the right ventricle, leading to tricuspid regurgitation and right-sided heart failure. While Lithium is a known teratogen, it is important to note that the absolute risk of Ebstein’s anomaly is relatively low (approximately 1 in 1,000 to 2,000 exposures); however, this still represents a 10–20 fold increase compared to the general population. **Analysis of Incorrect Options:** * **A. Tetralogy of Fallot:** This is the most common cyanotic heart disease but is not specifically linked to Lithium. It is more commonly associated with DiGeorge syndrome or maternal diabetes. * **B. Bicuspid atresia:** (Likely referring to Tricuspid atresia). While Lithium affects the tricuspid valve, it causes displacement (Ebstein’s), not complete failure of the valve to develop (atresia). * **D. Pulmonary stenosis:** This is often seen as a component of other syndromes (like Noonan or Rubella) but is not the primary defect associated with Lithium. **Clinical Pearls for NEET-PG:** 1. **Timing:** The risk is highest during the **first trimester** (organogenesis). 2. **Management:** If a bipolar patient is on Lithium and planning pregnancy, tapering is considered. If already pregnant, fetal echocardiography is recommended at 18–20 weeks. 3. **Breastfeeding:** Lithium is secreted in breast milk; hence, breastfeeding is generally **contraindicated** as it can cause "Floppy Baby Syndrome" in the infant. 4. **Other Teratogens:** Contrast this with **Valproate**, which is associated with **Neural Tube Defects** (e.g., Spina Bifida).

Question 219: A patient presents with complaints of diminished vision. Ophthalmological examination revealed corneal and lenticular opacities. The patient had been prescribed an antipsychotic drug during a previous visit. Which of the following drugs could have caused these symptoms?

A. Thioridazine (Correct Answer)
B. Haloperidol
C. Flupenthixol
D. Pimozide

Explanation: ### Explanation **Correct Option: A. Thioridazine** Thioridazine is a low-potency typical antipsychotic known for specific ocular side effects. The key to this question lies in the anatomical location of the opacities. * **Corneal and Lenticular (Lens) Opacities:** These are classic side effects of **Chlorpromazine** and **Thioridazine**. They typically present as "star-shaped" opacities that are usually asymptomatic but can diminish vision if extensive. * **Retinal Pigmentation:** Thioridazine is uniquely associated with **Retinitis Pigmentosa** (pigmentary retinopathy) when used in high doses (usually >800 mg/day). This can lead to permanent visual loss and "brownish" vision. **Why Incorrect Options are Wrong:** * **B. Haloperidol:** A high-potency typical antipsychotic. It is more commonly associated with Extrapyramidal Side Effects (EPS) rather than ocular opacities. * **C. Flupenthixol:** A thioxanthene derivative used for psychosis and depression. While it can cause blurred vision due to anticholinergic effects, it does not typically cause structural corneal or lenticular opacities. * **D. Pimozide:** Used primarily for Tourette’s syndrome and delusional parasitosis. Its main side effect concern is QTc prolongation rather than ocular toxicity. **High-Yield Clinical Pearls for NEET-PG:** * **Chlorpromazine:** Associated with **blue-grey skin discoloration** and corneal/lens opacities (the "C" in Chlorpromazine for Corneal). * **Thioridazine:** Associated with **Retinal deposits** (the "R" in Thioridazine for Retinal) and has the highest risk of QTc prolongation among typical antipsychotics. * **Mnemonic:** **C**hlorpromazine = **C**orneal/Lens; **T**hioridazine = **T**errible **R**etinopathy. * **Monitoring:** Patients on long-term Thioridazine require periodic fundus examinations.

Question 220: Which drug is associated with a blue-grey skin discoloration?

A. Chlorpromazine (Correct Answer)
B. Risperidone
C. Memantine
D. Clozapine

Explanation: **Explanation:** **Chlorpromazine (Option A)** is a low-potency typical antipsychotic known for causing specific dermatological and ocular side effects. Long-term use at high doses can lead to a characteristic **blue-grey skin discoloration** in sun-exposed areas. This occurs due to the accumulation of drug metabolites and melanin in the dermis. Additionally, chlorpromazine is classically associated with **benign whitish-brown granular deposits** in the anterior lens and posterior cornea (often described as "star-shaped cataracts"). **Why other options are incorrect:** * **Risperidone (Option B):** An atypical antipsychotic primarily associated with hyperprolactinemia (leading to galactorrhea/amenorrhea) and extrapyramidal symptoms at higher doses, but not skin pigmentation. * **Memantine (Option C):** An NMDA receptor antagonist used in Alzheimer’s disease; its side effects are generally neurological (dizziness, confusion) or gastrointestinal. * **Clozapine (Option D):** An atypical antipsychotic famous for **agranulocytosis** (requiring mandatory WBC monitoring), seizures, and hypersalivation, but it does not cause blue-grey skin changes. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Chlorpromazine (CPZ):** **C**orneal/Lens deposits, **P**igmentation (blue-grey), and **Z**-level (low) potency. * **Thioridazine** (another typical antipsychotic) is associated with **retinitis pigmentosa** (brownish vision), unlike the corneal changes in chlorpromazine. * Other drugs causing blue-grey skin: **Amiodarone** (anti-arrhythmic) and **Silver** (Argyria). * Chlorpromazine is also a first-line pharmacological treatment for **intractable hiccups**.

Question 221: A female patient on phenothiazine therapy presents with sudden onset of high-grade fever, muscle rigidity, and altered sensorium. What is the most likely diagnosis?

A. Malignant hyperthermia
B. Neuroleptic malignant syndrome (Correct Answer)
C. Tardive dyskinesia
D. Akathisia

Explanation: ### Explanation **Neuroleptic Malignant Syndrome (NMS)** is a rare but life-threatening idiosyncratic reaction to antipsychotic medications (neuroleptics), such as phenothiazines. The pathophysiology involves massive dopamine blockade in the nigrostriatal pathway and hypothalamus. #### Why Option B is Correct: The patient presents with the classic clinical tetrad of NMS: 1. **Hyperpyrexia:** High-grade fever (often >104°F). 2. **Muscle Rigidity:** Characteristically described as "lead-pipe" rigidity. 3. **Autonomic Instability:** Tachycardia, labile blood pressure, and diaphoresis. 4. **Altered Mental Status:** Confusion, agitation, or coma. Laboratory findings typically show elevated **Creatine Phosphokinase (CPK)** and leukocytosis. #### Why Other Options are Incorrect: * **A. Malignant Hyperthermia:** While clinically similar (fever, rigidity), it is triggered by **volatile inhalation anesthetics** (e.g., halothane) or succinylcholine, not antipsychotics. It involves a genetic defect in the ryanodine receptor. * **C. Tardive Dyskinesia:** A late-onset extrapyramidal side effect characterized by involuntary choreoathetoid movements (e.g., lip-smacking), usually after years of therapy. It does not present with fever or rigidity. * **D. Akathisia:** A subjective feeling of inner restlessness and the urge to move. It is the most common extrapyramidal side effect but lacks systemic symptoms like fever or altered sensorium. #### NEET-PG High-Yield Pearls: * **Treatment of Choice:** Immediate discontinuation of the offending drug, aggressive cooling, and **Dantrolene** (muscle relaxant) or **Bromocriptine** (dopamine agonist). * **Mnemonic for NMS:** **FEVER** (Fever, Encephalopathy, Vitals unstable, Elevated enzymes, Rigidity). * **Potency:** High-potency first-generation antipsychotics (e.g., Haloperidol) carry the highest risk.

Question 222: A patient with schizophrenia, previously treated with chlorpromazine, has now developed auditory hallucinations. Which medication should be administered next?

A. Haloperidol
B. Clozapine (Correct Answer)
C. Sulpiride
D. Tianeptine

Explanation: ### Explanation **Correct Answer: B. Clozapine** The core concept here is the management of **Treatment-Resistant Schizophrenia (TRS)**. The patient was previously treated with Chlorpromazine (a typical antipsychotic) but continues to experience positive symptoms (auditory hallucinations). In clinical practice, if a patient fails to respond to adequate trials of at least two different antipsychotics (one of which should be a second-generation antipsychotic), they are classified as having treatment-resistant schizophrenia. **Clozapine** is the gold-standard drug of choice for TRS and is the only antipsychotic proven to be effective in such cases. **Analysis of Incorrect Options:** * **A. Haloperidol:** This is a high-potency typical antipsychotic. Since the patient has already failed one typical antipsychotic (Chlorpromazine), switching to another drug in the same class is less likely to be effective than moving to Clozapine. * **C. Sulpiride:** This is a selective D2/D3 receptor antagonist. While used for schizophrenia, it is not the treatment of choice for resistant cases. * **D. Tianeptine:** This is an atypical antidepressant (an SSRE - Selective Serotonin Reuptake Enhancer). It has no role in treating the primary psychotic symptoms of schizophrenia. **High-Yield Clinical Pearls for NEET-PG:** * **Clozapine Side Effects:** Most serious is **Agranulocytosis** (requires mandatory WBC monitoring). Most common is **Sialorrhea** (excessive salivation). It also lowers the seizure threshold. * **Indications:** TRS and reducing suicidal behavior in schizophrenia. * **Mechanism:** It has a low affinity for D2 receptors but high affinity for D4 and 5-HT2A receptors. * **Note:** Clozapine is the only antipsychotic that does **not** cause Tardive Dyskinesia and rarely causes Extrapyramidal Side Effects (EPS).

Question 223: A patient on a typical antipsychotic develops restlessness, typically of the lower limbs. Which drug is used to treat this side effect?

A. Propranolol (Correct Answer)
B. Trihexyphenidyl
C. Quetiapine
D. Dantrolene

Explanation: **Explanation:** The patient is presenting with **Akathisia**, a common extrapyramidal side effect (EPS) of typical antipsychotics. It is characterized by subjective feelings of inner restlessness and an objective inability to sit still, often manifesting as constant pacing or leg movements. **1. Why Propranolol is correct:** **Propranolol**, a non-selective beta-blocker, is the **first-line treatment** for drug-induced akathisia. While the exact pathophysiology is debated, it is believed that beta-adrenergic receptors in the peripheral and central nervous systems play a role in the motor manifestations of restlessness. Propranolol effectively crosses the blood-brain barrier to alleviate these symptoms. **2. Why other options are incorrect:** * **Trihexyphenidyl:** This is an anticholinergic used primarily for *Drug-Induced Parkinsonism* and *Acute Dystonia*. It is generally ineffective for akathisia. * **Quetiapine:** This is an atypical antipsychotic. While switching to an atypical agent may reduce the risk of EPS, it is not the acute treatment for existing akathisia. * **Dantrolene:** This is a muscle relaxant used specifically for **Neuroleptic Malignant Syndrome (NMS)** and Malignant Hyperthermia. **Clinical Pearls for NEET-PG:** * **Akathisia Timing:** Usually occurs within days to weeks of starting or increasing the dose of an antipsychotic. * **Suicidality Link:** Severe akathisia is high-yield because it is associated with increased agitation and potential suicidality if left untreated. * **Second-line treatments:** If beta-blockers are contraindicated (e.g., in asthma), **Benzodiazepines** (like Lorazepam) or **Cyproheptadine** can be used. * **Rule of Thumb:** For *Dystonia/Parkinsonism* → Think Anticholinergics; for *Akathisia* → Think Beta-blockers.

Question 224: Which condition is Methylphenidate the drug of choice for?

A. Obsessive compulsive disorder
B. Attention deficit hyperkinetic disorder (Correct Answer)
C. Enuresis
D. Autism

Explanation: **Explanation:** **Correct Answer: B. Attention deficit hyperkinetic disorder (ADHD)** **Methylphenidate** is a central nervous system (CNS) stimulant and is considered the **first-line pharmacological treatment (Drug of Choice)** for ADHD in both children and adults. It works by blocking the reuptake of **Dopamine and Norepinephrine** (NDRI mechanism) in the synaptic cleft, particularly in the prefrontal cortex. This increases focus, reduces impulsivity, and decreases hyperactivity by enhancing executive function. **Analysis of Incorrect Options:** * **A. Obsessive Compulsive Disorder (OCD):** The drug of choice for OCD is **SSRIs** (e.g., Fluoxetine, Sertraline) or the TCA **Clomipramine**. Stimulants like Methylphenidate can sometimes exacerbate anxiety or tics associated with OCD. * **C. Enuresis:** The drug of choice for nocturnal enuresis is **Desmopressin** (nasal spray/tablet). Historically, Imipramine (a TCA) was used, but it is now a second-line option due to its side-effect profile. * **D. Autism:** There is no "drug of choice" to treat the core symptoms of Autism Spectrum Disorder. Pharmacotherapy is used only for comorbid symptoms; for example, **Risperidone or Aripiprazole** are FDA-approved for irritability and aggression associated with Autism. **High-Yield Clinical Pearls for NEET-PG:** * **Side Effects:** The most common side effects of Methylphenidate are **insomnia and appetite suppression**. A significant long-term concern is **growth retardation** (monitored via growth charts). * **Other Indications:** Methylphenidate is also used as a second-line treatment for **Narcolepsy**. * **Contraindications:** It should be avoided in patients with Glaucoma, symptomatic cardiovascular disease, or a history of Tics/Tourette’s syndrome. * **Non-Stimulant Alternative for ADHD:** **Atomoxetine** (a selective Norepinephrine Reuptake Inhibitor) is the preferred choice if there is a risk of substance abuse or if stimulants are poorly tolerated.

Question 225: Which of the following is a side effect of SNRIs?

A. Premature ejaculation
B. Delayed orgasm (Correct Answer)
C. Cancer
D. Hypotension

Explanation: **Explanation:** **SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)**, such as Venlafaxine and Duloxetine, increase the synaptic concentration of serotonin. Elevated serotonin levels in the CNS stimulate **5-HT2 receptors**, which inhibits the spinal cord reflexes required for ejaculation and orgasm. Consequently, **delayed orgasm** (anorgasmia) and delayed ejaculation are common side effects of both SSRIs and SNRIs. **Analysis of Options:** * **Option A (Premature ejaculation):** This is incorrect. Because SNRIs delay ejaculation, they are actually used **off-label to treat** premature ejaculation (Dapoxetine, an SSRI, is specifically approved for this). * **Option C (Cancer):** There is no clinical evidence linking SNRIs to an increased risk of malignancy. * **Option D (Hypotension):** This is incorrect. While some antidepressants (like TCAs) cause orthostatic hypotension, SNRIs are associated with **Hypertension**. The "N" in SNRI stands for Norepinephrine; increased noradrenergic activity can lead to dose-dependent increases in blood pressure. **High-Yield Clinical Pearls for NEET-PG:** * **Sexual Dysfunction:** This is the most common reason for long-term non-compliance with SSRIs/SNRIs. To manage this, clinicians may switch the patient to **Bupropion** or **Mirtazapine**, which have minimal sexual side effects. * **Discontinuation Syndrome:** Abrupt withdrawal of SNRIs (especially Venlafaxine) causes "flu-like" symptoms and "electric shock" sensations. * **Duloxetine:** Specifically indicated for painful physical symptoms (diabetic neuropathy, fibromyalgia) alongside depression.

Question 226: Malignant neuroleptic syndrome is caused by:

A. Antidepressants
B. Anxiolytics
C. Antipsychotics (Correct Answer)
D. Antiepileptics

Explanation: **Explanation:** **Neuroleptic Malignant Syndrome (NMS)** is a rare but life-threatening idiosyncratic reaction to **Antipsychotics** (Neuroleptics). The underlying pathophysiology involves a profound **blockade of central Dopamine (D2) receptors** in the nigrostriatal pathway and hypothalamus. This leads to the classic tetrad of clinical features: hyperthermia, "lead-pipe" muscle rigidity, autonomic instability, and altered mental status. * **Why Antipsychotics are correct:** Both typical (e.g., Haloperidol) and atypical antipsychotics (e.g., Risperidone) can trigger NMS. It is most commonly associated with high-potency first-generation agents. * **Why other options are incorrect:** * **Antidepressants:** These are more commonly associated with **Serotonin Syndrome**, which presents with hyperreflexia and myoclonus rather than lead-pipe rigidity. * **Anxiolytics:** Benzodiazepines are actually used in the supportive management of NMS to control agitation and muscle spasms. * **Antiepileptics:** These do not typically cause NMS; however, certain drugs like Carbamazepine can rarely cause Stevens-Johnson Syndrome. **High-Yield Clinical Pearls for NEET-PG:** 1. **Laboratory Hallmark:** Significantly elevated **Creatine Phosphokinase (CPK)** levels due to muscle necrosis (rhabdomyolysis). 2. **Drug of Choice:** **Dantrolene** (a direct-acting muscle relaxant) or **Bromocriptine** (a dopamine agonist). 3. **Differential Diagnosis:** Unlike Serotonin Syndrome (caused by SSRIs), NMS is characterized by **"Lead-pipe" rigidity** and **bradyreflexia**, whereas Serotonin Syndrome features hyperreflexia and tremors. 4. **Non-Antipsychotic Cause:** Sudden withdrawal of anti-Parkinsonian drugs (like Levodopa) can also trigger an NMS-like state.

Question 227: Metabolic syndrome is most commonly associated with which of the following groups of medications as a side effect?

A. Anti-anxiety drugs
B. Antidepressant drugs
C. Antipsychotic drugs (Correct Answer)
D. Anticholinergic drugs

Explanation: **Explanation:** **Metabolic Syndrome** (characterized by weight gain, dyslipidemia, and insulin resistance) is a major adverse effect primarily associated with **Antipsychotic drugs**, particularly the **Second-Generation Antipsychotics (SGAs)** or Atypical Antipsychotics. **Why Antipsychotics are the correct answer:** The underlying mechanism involves the blockade of **Histamine (H1)** and **Serotonin (5-HT2C)** receptors, which leads to increased appetite, sedation, and significant weight gain. Furthermore, these drugs directly interfere with insulin signaling and lipid metabolism. Among SGAs, **Clozapine** and **Olanzapine** carry the highest risk, while Aripiprazole and Ziprasidone are considered metabolic-neutral. **Why other options are incorrect:** * **Anti-anxiety drugs (e.g., Benzodiazepines):** These primarily cause sedation, cognitive impairment, and potential dependence, but do not typically cause metabolic derangements. * **Antidepressant drugs:** While some (like Mirtazapine or TCAs) can cause weight gain, they are not as strongly or universally linked to the full cluster of metabolic syndrome as antipsychotics are. * **Anticholinergic drugs:** These cause "dry" side effects (dry mouth, blurred vision, constipation, urinary retention) and tachycardia, but do not impact glucose or lipid metabolism. **High-Yield Clinical Pearls for NEET-PG:** 1. **Highest Risk:** Clozapine > Olanzapine > Quetiapine. 2. **Lowest Risk:** Aripiprazole, Ziprasidone, Lurasidone. 3. **Monitoring:** Patients on SGAs must have regular monitoring of **BMI, Waist Circumference, Fasting Blood Sugar, and Lipid Profile** (as per ADA/APA guidelines). 4. **Drug of Choice:** If a patient develops metabolic syndrome, switching to a "metabolic-neutral" agent like **Aripiprazole** is often the next step.

Question 228: A patient was on treatment with trifluperazine for some time and presents with complaints of hyperthermia, lethargy, and sweating. What are the necessary investigations?

A. CT Scan brain and hemogram
B. Hemogram, electrolyte level, and creatinine
C. ECG, Chest X-Ray, and hemogram
D. Hemogram, CPK, and Renal Function Test (Correct Answer)

Explanation: ### Explanation The clinical presentation of **hyperthermia, lethargy (altered mental status), and sweating (autonomic instability)** in a patient taking **Trifluperazine** (a high-potency typical antipsychotic) is highly suggestive of **Neuroleptic Malignant Syndrome (NMS)**. NMS is a life-threatening idiosyncratic reaction to dopamine antagonists. **Why Option D is Correct:** To confirm the diagnosis and assess the severity of NMS, the following investigations are critical: * **Hemogram:** Typically shows **leukocytosis** (elevated WBC count). * **Creatine Phosphokinase (CPK):** Massive elevation of CPK levels occurs due to intense muscle rigidity and rhabdomyolysis. This is a hallmark laboratory finding. * **Renal Function Test (RFT):** Essential to monitor for **Acute Renal Failure**, a common complication resulting from myoglobinuria (secondary to rhabdomyolysis). **Why Other Options are Incorrect:** * **Option A:** CT Scan is used to rule out structural brain pathology (like stroke) but does not help diagnose the systemic metabolic crisis of NMS. * **Option B:** While electrolytes are important, they are non-specific; this option misses the pathognomonic CPK elevation. * **Option C:** ECG and Chest X-ray are supportive but do not provide the diagnostic evidence of muscle breakdown or renal risk required for NMS management. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for NMS (FEVER):** **F**ever, **E**ncephalopathy (lethargy), **V**itals unstable, **E**levated enzymes (CPK), **R**igidity ("Lead-pipe" type). * **Drug of Choice:** **Dantrolene** (muscle relaxant) or **Bromocriptine** (dopamine agonist). * **Immediate Step:** Discontinue the offending antipsychotic and initiate aggressive cooling/hydration. * **Distinction:** Unlike Serotonin Syndrome, NMS is characterized by **"Lead-pipe" rigidity** and **bradyreflexia**, whereas Serotonin Syndrome presents with hyperreflexia and myoclonus.

Question 229: What is the treatment of choice for akathisia?

A. Phenytoin
B. Propranolol (Correct Answer)
C. Dantrolene
D. Lithium

Explanation: **Explanation:** **Akathisia** is the most common and distressing Extrapyramidal Side Effect (EPS) associated with antipsychotic medication. It is characterized by a subjective feeling of inner restlessness and an objective need to move (e.g., pacing, foot tapping). **1. Why Propranolol is the Correct Answer:** **Propranolol**, a non-selective beta-blocker, is the **first-line treatment of choice** for akathisia. It works by crossing the blood-brain barrier and blocking beta-adrenergic receptors in the central nervous system, effectively reducing the physiological symptoms of restlessness. Unlike other EPS (like dystonia), akathisia often responds poorly to anticholinergics alone, making beta-blockers the gold standard. **2. Why the Other Options are Incorrect:** * **A. Phenytoin:** This is an antiepileptic drug used for generalized tonic-clonic seizures. it has no role in treating movement disorders induced by antipsychotics. * **C. Dantrolene:** This is a muscle relaxant used specifically for **Neuroleptic Malignant Syndrome (NMS)** and Malignant Hyperthermia. It acts on ryanodine receptors to inhibit calcium release. * **D. Lithium:** This is a mood stabilizer used for Bipolar Disorder. It does not treat EPS and can actually cause a fine tremor as a side effect. **Clinical Pearls for NEET-PG:** * **First-line:** Propranolol (40–120 mg/day). * **Second-line:** Benzodiazepines (e.g., Lorazepam) or anticholinergics (e.g., Benztropine). * **Differentiate:** Do not confuse akathisia with psychotic agitation; increasing the antipsychotic dose will worsen akathisia but improve agitation. * **NMS Treatment:** Bromocriptine (Dopamine agonist) and Dantrolene. * **Acute Dystonia Treatment:** Promethazine or Benztropine (IV/IM).

Question 230: Lithium is not used in the treatment of which of the following conditions?

A. Major depression
B. Vascular headache
C. Neutropenia
D. Generalized anxiety disorder (Correct Answer)

Explanation: **Explanation:** Lithium is a monovalent cation primarily used as a mood stabilizer. The correct answer is **Generalized Anxiety Disorder (GAD)** because Lithium has no established efficacy in treating primary anxiety disorders. GAD is typically managed with SSRIs, SNRIs, or benzodiazepines. **Analysis of Options:** * **Major Depression (A):** Lithium is a well-recognized **augmentation agent** for treatment-resistant depression. When added to an antidepressant, it can enhance the therapeutic response. It also significantly reduces the risk of suicide in patients with mood disorders. * **Vascular Headache (B):** Lithium is an effective prophylactic treatment for **Cluster Headaches** (a type of vascular headache), particularly the chronic variety. It helps regulate the circadian rhythm of the hypothalamus, which is implicated in cluster attacks. * **Neutropenia (C):** A common side effect of Lithium is **leukocytosis** (specifically increasing the neutrophil count by stimulating granulopoiesis). This "side effect" is utilized therapeutically to treat idiopathic neutropenia or chemotherapy-induced neutropenia. **High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Index:** Lithium has a narrow therapeutic index (0.6–1.2 mEq/L). Toxicity starts >1.5 mEq/L. * **Drug of Choice:** Lithium remains the gold standard for the long-term prophylaxis of Bipolar Affective Disorder (BPAD). * **Teratogenicity:** Use in pregnancy is associated with **Ebstein’s Anomaly** (atrialization of the right ventricle). * **Monitoring:** Before starting Lithium, always check **Renal Function Tests (RFT)** and **Thyroid Function Tests (TFT)**, as it can cause nephrogenic diabetes insipidus and hypothyroidism.

Question 231: Which is the most widely used antidepressant?

A. Duloxetine
B. Trazadone
C. Phenelezine
D. Fluoxetine (Correct Answer)

Explanation: **Explanation:** **Fluoxetine** is the correct answer because it belongs to the **Selective Serotonin Reuptake Inhibitors (SSRIs)** class, which is currently the first-line pharmacological treatment for major depressive disorder, anxiety disorders, and OCD. Fluoxetine was the first SSRI to gain widespread clinical use due to its favorable safety profile, lack of anticholinergic side effects compared to older drugs, and long half-life (reducing withdrawal symptoms). **Analysis of Options:** * **A. Duloxetine:** This is an SNRI (Serotonin-Norepinephrine Reuptake Inhibitor). While effective, it is generally considered second-line or used specifically when depression is comorbid with chronic pain (e.g., diabetic neuropathy or fibromyalgia). * **B. Trazodone:** A Serotonin Antagonist and Reuptake Inhibitor (SARI). It is highly sedating and is now more commonly used off-label as a hypnotic for insomnia rather than as a primary antidepressant. * **C. Phenelzine:** A non-selective MAO Inhibitor (MAOI). These are rarely used today due to dangerous dietary interactions (tyramine/cheese reaction) and the risk of hypertensive crisis. **High-Yield Clinical Pearls for NEET-PG:** * **SSRIs** are the drug of choice (DOC) for most psychiatric conditions including Depression, OCD, Panic Disorder, and Bulimia. * **Fluoxetine** has the longest half-life among SSRIs (due to its active metabolite, norfluoxetine), making it the safest choice if a patient occasionally misses a dose. * **Side Effects:** Common SSRI side effects include GI upset and sexual dysfunction (most common long-term reason for non-compliance). * **Drug Holiday:** Fluoxetine requires a 5-week washout period before starting an MAOI to avoid **Serotonin Syndrome**.

Question 232: What is the treatment of choice for bipolar mood disorder?

A. Fluoxetine
B. Imipramine
C. Lithium (Correct Answer)
D. Chlorpromazine

Explanation: **Explanation:** **Lithium** is the established **gold standard** and treatment of choice for Bipolar Mood Disorder (BMD). It is a mood stabilizer effective in treating acute manic episodes and, more importantly, serves as the mainstay for long-term maintenance therapy to prevent the recurrence of both mania and depression. Its unique clinical value lies in its proven **anti-suicidal properties**, a high-yield fact for NEET-PG. **Analysis of Incorrect Options:** * **Fluoxetine (SSRI) & Imipramine (TCA):** These are antidepressants. Using them as monotherapy in BMD is contraindicated because they can trigger a **"manic switch"** (precipitating a manic episode) or lead to rapid cycling. They are only used in bipolar depression when combined with a mood stabilizer. * **Chlorpromazine:** This is a typical antipsychotic. While it may be used to manage acute agitation in severe mania, it does not stabilize mood or prevent future episodes, making it a secondary or adjunctive treatment rather than the primary choice. **High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Index:** Lithium has a narrow therapeutic index. Target serum levels are **0.8–1.2 mEq/L** for acute mania and **0.6–1.0 mEq/L** for maintenance. * **Monitoring:** Before starting Lithium, check **Thyroid Function Tests (TFT)** and **Renal Function Tests (RFT)**, as it can cause hypothyroidism and nephrogenic diabetes insipidus. * **Teratogenicity:** Use in pregnancy is associated with **Ebstein’s Anomaly** (atrialization of the right ventricle). * **Drug of Choice for Rapid Cyclers:** Valproate is preferred over Lithium for patients with rapid-cycling BMD (>4 episodes/year).

Question 233: Which of the following is an antipsychotic drug?

A. Clomipramine
B. Carbamazepine
C. Sodium valproate
D. Chlorpromazine (Correct Answer)

Explanation: **Explanation:** The correct answer is **Chlorpromazine**. **1. Why Chlorpromazine is correct:** Chlorpromazine is a **Typical (First-Generation) Antipsychotic** belonging to the Aliphatic Phenothiazine class. It works primarily by blocking **D2 receptors** in the mesolimbic pathway of the brain. Historically, it was the first antipsychotic discovered (1952), revolutionizing the treatment of Schizophrenia and other psychotic disorders. **2. Why the other options are incorrect:** * **A. Clomipramine:** This is a **Tricyclic Antidepressant (TCA)**. It is highly serotonergic and is considered the gold standard pharmacological treatment for **Obsessive-Compulsive Disorder (OCD)**. * **B. Carbamazepine:** This is an **Anticonvulsant** also used as a **Mood Stabilizer** in Bipolar Disorder. Its mechanism involves blocking voltage-gated sodium channels. * **C. Sodium Valproate:** Like carbamazepine, this is an **Anticonvulsant and Mood Stabilizer**. It is frequently used as a first-line treatment for Acute Mania and prophylaxis in Bipolar Affective Disorder (BPAD). **3. NEET-PG High-Yield Pearls:** * **Chlorpromazine Side Effects:** It is a "Low Potency" antipsychotic, meaning it has a high incidence of **sedation, orthostatic hypotension** (alpha-1 blockade), and **anticholinergic effects** (dry mouth, constipation), but a lower risk of Extrapyramidal Symptoms (EPS) compared to Haloperidol. * **Ocular Side Effects:** Long-term use of Chlorpromazine is associated with **deposits in the anterior lens and cornea** (Stellate cataracts). * **Dermatological:** It can cause photosensitivity and a "blue-grey" skin discoloration. * **Drug of Choice:** While Chlorpromazine was the first, **Risperidone** or **Olanzapine** are now more common first-line choices, and **Clozapine** remains the drug of choice for **Treatment-Resistant Schizophrenia**.

Question 234: Which of the following statements is not true regarding Tardive Dyskinesia (TD)?

A. Clozapine is useful in its treatment.
B. Dopaminergic supersensitivity is believed to be the cause.
C. It is usually observed in the perioral area.
D. Combining anticholinergics with antipsychotics prevents TD. (Correct Answer)

Explanation: **Explanation:** **Tardive Dyskinesia (TD)** is a delayed-onset extrapyramidal side effect (EPS) resulting from long-term blockade of dopamine (D2) receptors. **Why Option D is the correct answer (False Statement):** Anticholinergics (like Trihexyphenidyl) are effective for treating *acute* EPS, such as dystonia or parkinsonism. However, they **do not prevent** TD. In fact, anticholinergics can **exacerbate or unmask** TD symptoms by further upsetting the dopamine-acetylcholine balance in the nigrostriatal pathway. Prophylactic use of anticholinergics is generally discouraged for this reason. **Analysis of other options:** * **Option A (True):** Clozapine is the drug of choice for patients with severe TD who still require antipsychotic medication. It has low D2 affinity and may even help suppress existing dyskinetic movements. * **Option B (True):** The most widely accepted pathophysiology is **dopamine receptor supersensitivity**. Chronic blockade leads to an upregulation (increase in number and sensitivity) of D2 receptors in the striatum. * **Option C (True):** TD characteristically involves involuntary, choreoathetoid movements of the **perioral region** (tongue protrusion, lip-smacking, puckering), though it can affect the trunk and extremities. **High-Yield Clinical Pearls for NEET-PG:** * **Risk Factors:** Old age, female gender, and presence of mood disorders. * **AIMS Scale:** The Abnormal Involuntary Movement Scale (AIMS) is used for screening and monitoring TD. * **Management:** First, reduce the dose or switch to a second-generation antipsychotic (Quetiapine or Clozapine). * **FDA Approved Treatments:** VMAT2 inhibitors like **Valbenazine** and **Deutetrabenazine** are now first-line for TD management.

Question 235: Which of the following is a characteristic feature of neuroleptic malignant syndrome?

A. Hypothermia
B. Labile blood pressure (Correct Answer)
C. Bradycardia
D. Flaccidity

Explanation: **Explanation:** Neuroleptic Malignant Syndrome (NMS) is a life-threatening idiosyncratic reaction to antipsychotic drugs (neuroleptics), primarily caused by potent dopamine (D2) receptor antagonism in the nigrostriatal pathway and hypothalamus. **1. Why "Labile blood pressure" is correct:** Autonomic instability is a hallmark of NMS. This manifests as **labile blood pressure** (fluctuating hypertension and hypotension), tachycardia, diaphoresis, and tachypnea. The dysregulation of the autonomic nervous system occurs due to the disruption of central dopaminergic signaling which normally modulates sympathetic output. **2. Why the other options are incorrect:** * **Hypothermia:** NMS is characterized by **Hyperthermia** (often >38°C or 100.4°F). This is due to dopamine blockade in the hypothalamus (the body's thermostat) and excessive heat production from muscle contractions. * **Bradycardia:** Patients typically present with **Tachycardia** as part of the autonomic instability and physiological stress response. * **Flaccidity:** NMS is classically associated with **"Lead-pipe rigidity"** (generalized extreme muscle stiffness). Flaccidity is not a feature; in fact, the intense muscle contraction leads to elevated Creatine Kinase (CK) levels. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic (FEVER):** **F**ever, **E**ncephalopathy (altered sensorium), **V**itals unstable, **E**levated enzymes (CK), **R**igidity. * **Laboratory Marker:** Significantly elevated **Serum Creatine Kinase (CK)** and leukocytosis are key diagnostic clues. * **Treatment:** Immediate discontinuation of the offending agent. Pharmacotherapy includes **Dantrolene** (muscle relaxant) or **Bromocriptine** (dopamine agonist). * **Differential:** Unlike Serotonin Syndrome (which features hyperreflexia and myoclonus), NMS is characterized by "lead-pipe" rigidity and bradyreflexia.

Question 236: What is the current agent of choice for the treatment of bipolar affective disorder?

A. Chlorpromazine
B. Haloperidol
C. Diazepam
D. Lithium carbonate (Correct Answer)

Explanation: **Explanation:** **Lithium carbonate** remains the "gold standard" and the agent of choice for the long-term maintenance treatment of Bipolar Affective Disorder (BPAD). Its primary mechanism involves the inhibition of the inositol monophosphatase pathway and modulation of G-proteins, leading to mood stabilization. It is uniquely effective in treating acute mania, preventing bipolar depression, and—most importantly for NEET-PG—it is the only drug proven to significantly **reduce the risk of suicide** in these patients. **Analysis of Incorrect Options:** * **Chlorpromazine & Haloperidol (Options A & B):** These are typical antipsychotics. While they are used for rapid tranquilization in cases of acute manic excitement or psychosis, they are not first-line for long-term mood stabilization. Prolonged use carries a high risk of Extrapyramidal Side Effects (EPS) and Tardive Dyskinesia. * **Diazepam (Option C):** This is a benzodiazepine used as an adjunct for sedation or to manage acute anxiety and insomnia. It has no mood-stabilizing properties and does not treat the underlying pathophysiology of BPAD. **High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Index:** Lithium has a narrow therapeutic index. Prophylactic levels are **0.6–1.2 mEq/L**, while levels >1.5 mEq/L indicate toxicity. * **Teratogenicity:** Use in pregnancy is associated with **Ebstein’s Anomaly** (atrialization of the right ventricle). * **Side Effects:** Common high-yield side effects include fine tremors, polyuria (Nephrogenic Diabetes Insipidus), hypothyroidism, and weight gain. * **Alternative:** Valproate is often preferred for "Rapid Cyclers" or "Mixed Episodes," but Lithium remains the overall classic answer for BPAD.

Question 237: Which of the following tricyclic antidepressants is used in the management of nocturnal enuresis?

A. imipramine (Correct Answer)
B. fluoxetine
C. bupropion
D. sertraline

Explanation: **Explanation:** **Imipramine** is a tertiary amine Tricyclic Antidepressant (TCA) that has been traditionally used in the management of nocturnal enuresis (bedwetting) in children aged 6 years and older. Its efficacy is attributed to a dual mechanism: 1. **Anticholinergic effect:** It increases the bladder capacity by relaxing the detrusor muscle. 2. **Noradrenergic effect:** It increases the tone of the internal urethral sphincter. 3. **Sleep architecture:** It alters the sleep-wake pattern, making the child more easily arousable by a full bladder. **Analysis of Incorrect Options:** * **Fluoxetine and Sertraline (Options B & D):** These are Selective Serotonin Reuptake Inhibitors (SSRIs). While they are first-line for depression and anxiety, they do not possess the potent anticholinergic properties required to treat enuresis. * **Bupropion (Option C):** This is an Atypical Antidepressant (NDRI) used primarily for smoking cessation and depression. It lacks anticholinergic activity and is contraindicated in patients with seizure disorders. **Clinical Pearls for NEET-PG:** * **First-line treatment** for nocturnal enuresis is **Behavioral Therapy** (e.g., Bed-alarm/Enuresis alarm). * **Desmopressin (ADH analogue)** is the first-line pharmacological agent due to a better safety profile. * **Imipramine** is considered second-line or third-line due to its narrow therapeutic index and risk of **cardiotoxicity** (QT prolongation) in overdose. * **Other TCAs:** Clomipramine is the drug of choice for OCD; Amitriptyline is commonly used for neuropathic pain and migraine prophylaxis.

Question 238: Which of the following extrapyramidal effects is seen on chronic use of antipsychotics?

A. Dystonia
B. Akathisia
C. Tardive dyskinesia (Correct Answer)
D. Parkinsonism

Explanation: **Explanation:** Extrapyramidal Side Effects (EPS) of antipsychotics are classified based on their time of onset. The key to this question lies in the word **"chronic."** **1. Why Tardive Dyskinesia is correct:** Tardive Dyskinesia (TD) is a **late-onset** (tardive means "late") movement disorder occurring after months or years of antipsychotic use. It is characterized by involuntary, choreoathetoid movements, most commonly involving the mouth and tongue (e.g., lip-smacking, tongue protrusion). The underlying pathophysiology is believed to be **dopamine receptor supersensitivity** in the nigrostriatal pathway following prolonged blockade. **2. Why the other options are incorrect:** * **Dystonia (Acute Dystonia):** This is the earliest EPS, occurring within hours to days of starting treatment. It involves sustained muscle contractions (e.g., torticollis, oculogyric crisis). * **Akathisia:** This typically occurs within days to weeks. It is characterized by subjective feelings of inner restlessness and an inability to sit still. It is the most common EPS. * **Parkinsonism (Drug-induced):** This usually develops within weeks to months. It mimics Parkinson’s disease with tremors, rigidity, and bradykinesia due to acute dopamine blockade. **High-Yield Clinical Pearls for NEET-PG:** * **Treatment of TD:** The first step is to reduce the dose or switch to a second-generation antipsychotic (Clozapine is the drug of choice). VMAT-2 inhibitors (e.g., Valbenazine) are FDA-approved for treatment. * **Rule of Thumb for EPS Onset:** * **4 hours:** Acute Dystonia (Rx: Benztropine/Promethazine) * **4 days:** Akathisia (Rx: Propranolol) * **4 weeks:** Parkinsonism (Rx: Trihexyphenidyl) * **4 months/years:** Tardive Dyskinesia (Rx: Switch to Clozapine) * **Anticholinergics** (like Trihexyphenidyl) can **worsen** Tardive Dyskinesia and should be avoided in its management.

Question 239: A patient with violent behavior and agitation was diagnosed with Schizophrenia and was receiving haloperidol. Following this, he developed rigidity and inability to move his eyes. Which of the following drugs should be added to his treatment intravenously for this condition?

A. Diazepam
B. Risperidone
C. Promethazine (Correct Answer)
D. Haloperidol

Explanation: ### Explanation **Diagnosis: Acute Dystonia (Oculogyric Crisis)** The patient is experiencing **Acute Dystonia**, a common Extrapyramidal Side Effect (EPS) occurring within hours to days of starting high-potency first-generation antipsychotics like Haloperidol. The "inability to move eyes" specifically describes an **Oculogyric Crisis** (spasmodic movement of eyeballs, usually upwards), while rigidity indicates muscle spasms. **1. Why Promethazine is Correct:** Acute dystonia is caused by a relative **dopamine deficiency** and **acetylcholine excess** in the nigrostriatal pathway. Treatment requires immediate restoration of this balance using **anticholinergic drugs**. Promethazine is a first-generation antihistamine with potent central anticholinergic properties. When given intravenously (or intramuscularly), it provides rapid relief of life-threatening or distressing spasms. **2. Why Other Options are Incorrect:** * **A. Diazepam:** While a benzodiazepine can help with sedation and mild muscle relaxation, it is not the specific antidote for the cholinergic overactivity seen in neuroleptic-induced dystonia. * **B. Risperidone:** This is a second-generation antipsychotic. Adding another antipsychotic would worsen the dopamine blockade and exacerbate the EPS. * **D. Haloperidol:** This is the offending agent. Increasing the dose would severely worsen the patient's condition. **3. Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** Central anticholinergics like **Benztropine** (most common globally) or **Promethazine** (commonly used in India). * **Prophylaxis:** Oral anticholinergics like **Trihexyphenidyl (Pacitane)** are often co-prescribed with Haloperidol to prevent these symptoms. * **Risk Factors:** Young males and those receiving high-potency, parenteral antipsychotics are at the highest risk for acute dystonia. * **Sequence of EPS:** Remember the rule of 4s: **D**ystonia (4 hours), **A**kathisia (4 days), **P**arkinsonism (4 weeks), **T**ardive Dyskinesia (4 months/years).

Question 240: A psychiatric patient on regular treatment presents with fundus findings of pigmented retinal epithelium. Which of the following drugs is most likely implicated?

A. Thioridazine (Correct Answer)
B. Haloperidol
C. Chlorpromazine
D. Clozapine

Explanation: **Explanation:** The correct answer is **Thioridazine**. This is a classic high-yield association in psychopharmacology regarding ocular side effects of antipsychotics. **1. Why Thioridazine is correct:** Thioridazine, a low-potency typical antipsychotic, is uniquely associated with **Retinitis Pigmentosa** (pigmentary retinopathy). This occurs due to the accumulation of the drug and its metabolites in the uveal tract, leading to melanin-related toxicity. Clinically, this presents as "brownish" vision and can lead to permanent visual loss if the dose exceeds the safe threshold (typically **>800 mg/day**). Fundus examination reveals characteristic pigmentary deposits on the retinal epithelium. **2. Why other options are incorrect:** * **Chlorpromazine:** While it also causes ocular side effects, it typically causes **lenticular and corneal opacities** (whitish-brown granular deposits) rather than retinal pigmentation. It is often described as "star-shaped" cataracts. * **Haloperidol:** A high-potency antipsychotic that is more commonly associated with Extrapyramidal Side Effects (EPS) and has a negligible risk of significant ocular toxicity. * **Clozapine:** An atypical antipsychotic primarily known for agranulocytosis and seizures; it does not cause pigmentary retinopathy. **Clinical Pearls for NEET-PG:** * **Thioridazine:** Remember the "800 mg rule"—never exceed this dose to avoid irreversible retinopathy. It is also the antipsychotic most associated with **QT interval prolongation**. * **Mnemonic:** **C**hlorpromazine = **C**ornea/Lens; **T**hioridazine = **T**errible **R**etina. * **Quetiapine:** Historically linked to cataracts in animal studies (requires periodic eye exams in some protocols).

Question 241: Moclobemide is a type of:

A. Selective serotonin reuptake inhibitor (SSRI)
B. Antipsychotic drug
C. Monoamine oxidase inhibitor (MAOI) (Correct Answer)
D. Tricyclic antidepressant

Explanation: ### Explanation **Moclobemide** is a specific type of antidepressant known as a **Reversible Inhibitor of Monoamine Oxidase A (RIMA)**. It belongs to the broader class of Monoamine Oxidase Inhibitors (MAOIs). #### Why Option C is Correct: MAOIs work by inhibiting the enzyme monoamine oxidase, which breaks down neurotransmitters like serotonin, norepinephrine, and dopamine. Moclobemide specifically and reversibly inhibits **MAO-A**. Unlike older, irreversible MAOIs (like Phenelzine), Moclobemide has a lower risk of the "cheese reaction" (hypertensive crisis) because it can be displaced from the enzyme by tyramine. #### Why Other Options are Incorrect: * **Option A (SSRI):** These drugs (e.g., Fluoxetine, Sertraline) selectively inhibit the reuptake of serotonin from the synaptic cleft. They do not act on the MAO enzyme. * **Option B (Antipsychotic):** These drugs (e.g., Haloperidol, Risperidone) primarily act as dopamine (D2) receptor antagonists and are used to treat psychosis, not primarily as first-line antidepressants. * **Option D (Tricyclic Antidepressant):** TCAs (e.g., Amitriptyline, Imipramine) work by inhibiting the reuptake of both serotonin and norepinephrine and have significant anticholinergic side effects. #### High-Yield Clinical Pearls for NEET-PG: * **MAO-A vs. MAO-B:** MAO-A degrades Serotonin and Norepinephrine (targeted in depression). MAO-B degrades Dopamine (targeted in Parkinson’s, e.g., **Selegiline**). * **Cheese Reaction:** Occurs when irreversible MAOIs are taken with tyramine-rich food (aged cheese, wine). Moclobemide (RIMA) significantly reduces this risk. * **Serotonin Syndrome:** Always maintain a "washout period" (usually 2 weeks) when switching between MAOIs and SSRIs to prevent fatal serotonin syndrome. * **Drug of Choice:** SSRIs remain the first-line treatment for depression due to their safety profile; MAOIs are typically reserved for atypical or treatment-resistant depression.

Question 242: Which of the following conditions can be effectively managed with beta-blockers?

A. Mania
B. Anxiety (Correct Answer)
C. Depression
D. Schizophrenia

Explanation: **Explanation:** **Beta-blockers (e.g., Propranolol)** are highly effective in managing the **peripheral autonomic symptoms of anxiety**. While they do not treat the psychological "worry" or core cognitive symptoms of Generalized Anxiety Disorder, they are the drug of choice for **Performance Anxiety (Stage Fright)**. They work by blocking beta-adrenergic receptors, thereby reducing physiological manifestations of sympathetic overactivity such as palpitations, tremors, tachycardia, and sweating. **Analysis of Options:** * **A. Mania:** The mainstay of treatment for mania includes mood stabilizers (Lithium, Valproate) and antipsychotics. Beta-blockers have no established role in treating manic symptoms. * **C. Depression:** Beta-blockers are not used to treat depression. In fact, older lipophilic beta-blockers (like Propranolol) have historically been associated with "pro-depressive" side effects in some patients, though this link is debated. * **D. Schizophrenia:** The primary treatment for schizophrenia is dopamine-blocking antipsychotics. While beta-blockers are sometimes used off-label to treat **Akathisia** (a movement-related side effect of antipsychotics), they do not treat the psychosis itself. **High-Yield NEET-PG Pearls:** 1. **Drug of Choice for Akathisia:** Propranolol is the first-line treatment for antipsychotic-induced akathisia. 2. **Specific Phobia:** For social phobia related specifically to public speaking, Propranolol (10–40 mg) taken 30–60 minutes before the event is the standard recommendation. 3. **Contraindications:** Always screen for **Asthma/COPD** (due to bronchospasm) and **Diabetes Mellitus** (as they mask hypoglycemic tachycardia) before prescribing. 4. **Lithium Tremors:** Propranolol is also the preferred treatment for fine tremors induced by Lithium therapy.

Question 243: A patient on antipsychotics presents with muscle rigidity, fever, and tachycardia. Investigations reveal an elevated WBC count and increased creatinine phosphokinase levels. What is the drug of choice for this patient?

A. Paracetamol and IV Fluids
B. Dantrolene (Correct Answer)
C. Neostigmine
D. Paracetamol and Penicillin

Explanation: ### Explanation **Diagnosis: Neuroleptic Malignant Syndrome (NMS)** The clinical triad of **muscle rigidity** ("lead-pipe" rigidity), **autonomic instability** (fever, tachycardia, hypertension), and **altered mental status** in a patient taking antipsychotics is diagnostic of NMS. Laboratory findings typically show **elevated Creatinine Phosphokinase (CPK)** due to muscle necrosis (rhabdomyolysis) and **leukocytosis** (elevated WBC). **Why Dantrolene is the Correct Answer:** Dantrolene is a direct-acting skeletal muscle relaxant. It works by binding to the **ryanodine receptor (RyR1)** on the sarcoplasmic reticulum, inhibiting the release of calcium. This reduces muscle rigidity and heat production, addressing the core pathophysiology of the hypermetabolic state in NMS. **Analysis of Incorrect Options:** * **A & D (Paracetamol, IV Fluids, Penicillin):** While supportive care (IV fluids for hydration and cooling blankets) is essential, Paracetamol is insufficient to treat the underlying muscle-driven hyperthermia. Penicillin is irrelevant as the fever is not due to a bacterial infection. * **C (Neostigmine):** This is an acetylcholinesterase inhibitor used in Myasthenia Gravis or to reverse neuromuscular blockade. It has no role in NMS and could potentially worsen autonomic instability. **NEET-PG High-Yield Pearls:** 1. **Mechanism of NMS:** Primarily due to potent **D2 receptor blockade** in the nigrostriatal pathway and hypothalamus. 2. **Drug of Choice (Pharmacological):** **Dantrolene** is the specific muscle relaxant. **Bromocriptine** or **Amantadine** (Dopamine agonists) are also used to restore dopaminergic tone. 3. **First Step in Management:** Immediately **discontinue** the offending antipsychotic agent. 4. **Differential Diagnosis:** Unlike Serotonin Syndrome, NMS is characterized by "lead-pipe" rigidity and bradyreflexia, whereas Serotonin Syndrome presents with hyperreflexia and myoclonus.

Question 244: A psychiatric patient taking medication develops a tremor, thyroid enlargement, and leucocytosis. Which drug is most likely implicated?

A. Clomipramine
B. Haloperidol
C. Lithium (Correct Answer)
D. Olanzapine

Explanation: **Explanation:** The clinical triad of **tremor, thyroid enlargement (goiter), and leucocytosis** is a classic presentation of **Lithium** side effects. 1. **Lithium (Correct Answer):** * **Tremor:** Fine hand tremors are the most common side effect of Lithium. * **Thyroid Enlargement:** Lithium inhibits the release of thyroid hormones (T3 and T4) by interfering with iodination and coupling. This leads to increased TSH levels, causing a compensatory goiter and potentially hypothyroidism. * **Leucocytosis:** Lithium stimulates granulopoiesis in the bone marrow, leading to a benign increase in the White Blood Cell (WBC) count. This is sometimes used therapeutically in patients with neutropenia. 2. **Incorrect Options:** * **Clomipramine (TCA):** Typically causes anticholinergic effects (dry mouth, blurred vision) and cardiac arrhythmias in overdose, but not goiter or leucocytosis. * **Haloperidol (Typical Antipsychotic):** Known for Extrapyramidal Symptoms (EPS) like dystonia and parkinsonian tremors, but it does not affect thyroid function or WBC count. * **Olanzapine (Atypical Antipsychotic):** Primarily associated with metabolic syndrome (weight gain, dyslipidemia, and hyperglycemia). **High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Index:** Lithium has a narrow therapeutic index (0.6–1.2 mEq/L). * **Teratogenicity:** Causes **Ebstein’s Anomaly** (atrialization of the right ventricle). * **Renal Side Effect:** Can cause **Nephrogenic Diabetes Insipidus** (treated with Amiloride). * **ECG Changes:** Characterized by T-wave flattening or inversion.

Question 245: Polycystic ovarian syndrome is a potential side effect of which mood stabilizer?

A. Valproate (Correct Answer)
B. Carbamazepine
C. Lithium
D. Lamotrigine

Explanation: **Explanation:** **Valproate (Sodium Valproate)** is the correct answer. It is a broad-spectrum antiepileptic and mood stabilizer frequently associated with endocrine and metabolic side effects. The association with **Polycystic Ovarian Syndrome (PCOS)** is significant, particularly in young women. Valproate can cause hyperinsulinemia and weight gain, which disrupts the hypothalamic-pituitary-ovarian axis, leading to hyperandrogenism (hirsutism, acne), menstrual irregularities, and polycystic ovaries on ultrasound. **Analysis of Incorrect Options:** * **B. Carbamazepine:** While it can cause weight gain and is an enzyme inducer (leading to oral contraceptive failure), it is not classically associated with the development of PCOS. * **C. Lithium:** The most high-yield side effects for Lithium are **hypothyroidism**, nephrogenic diabetes insipidus, and Ebstein’s anomaly (teratogenicity). It does not cause PCOS. * **D. Lamotrigine:** Generally considered "weight-neutral" and has a favorable side-effect profile regarding endocrine function, making it a preferred choice for women of childbearing age. **Clinical Pearls for NEET-PG:** * **Monitoring:** Baseline and periodic monitoring of weight, menstrual cycle, and BMI is essential for female patients on Valproate. * **Teratogenicity:** Valproate is highly teratogenic, causing **Neural Tube Defects** (specifically Spina Bifida). * **Other Side Effects:** Remember the mnemonic **"VALPROATE"**: **V**omit, **A**lopecia (transient), **L**iver toxicity (Hepatotoxicity), **P**ancreatitis, **R**etention of fat (Weight gain), **O**edema, **A**norexia, **T**remor/Thrombocytopenia, **E**ncephalopathy (due to hyperammonemia).

Question 246: What is the normal therapeutic range for lithium levels?

A. 0.5 to 0.7 mEq/lit
B. 0.7 to 1.1 mEq/lit (Correct Answer)
C. 0.1 to 0.3 mEq/lit
D. 1.5 to 2 mEq/lit

Explanation: **Explanation:** Lithium is the gold-standard mood stabilizer used for the treatment of Bipolar Affective Disorder (BPAD). It has a **narrow therapeutic index**, meaning the difference between a therapeutic dose and a toxic dose is very small, necessitating Therapeutic Drug Monitoring (TDM). 1. **Why Option B is Correct:** The standard therapeutic range for lithium in the maintenance phase of BPAD is generally **0.6 to 1.2 mEq/L**. Option B (0.7 to 1.1 mEq/L) falls squarely within this established window. For acute mania, levels are often maintained slightly higher (0.8–1.2 mEq/L), while for maintenance, 0.6–0.8 mEq/L is often sufficient. 2. **Why Other Options are Incorrect:** * **Option A (0.5 to 0.7 mEq/L):** These levels are often sub-therapeutic for many patients, increasing the risk of relapse, though some elderly patients may be maintained at the lower end (0.4–0.6 mEq/L). * **Option C (0.1 to 0.3 mEq/L):** These are non-therapeutic levels and will not provide clinical stabilization. * **Option D (1.5 to 2 mEq/L):** This range indicates **Lithium Toxicity**. Mild toxicity begins at >1.5 mEq/L, while levels >2.0 mEq/L are considered severe and may require hemodialysis. **High-Yield Clinical Pearls for NEET-PG:** * **Sampling Time:** Lithium levels should be measured **12 hours after the last dose** (Steady-state concentration). * **Steady State:** It takes approximately **5 days** (5 half-lives) to reach steady-state levels after starting or changing a dose. * **Side Effects:** Look for "LITHIUM" mnemonic: **L**eukocytosis, **I**nsipidus (Diabetes Insipidus), **T**remors/Teratogenicity (Ebstein's Anomaly), **H**ypothyroidism, **I**ncreased **U**rine, **M**others (avoid in pregnancy). * **Drug Interactions:** Thiazides, NSAIDs, and ACE inhibitors increase lithium levels (decreased clearance).

Question 247: All are true about Clozapine except:

A. More potently blocks D2 as compared to D1 receptors
B. Blood level below 350 ng/ml should be maintained to avoid agranulocytosis (Correct Answer)
C. Should not be used along with Carbamazepine
D. Should be discontinued if the WBC count is below 3,000/mm cells

Explanation: **Explanation:** **Clozapine** is the prototype atypical antipsychotic and the "gold standard" for treatment-resistant schizophrenia. **Why Option B is the Correct Answer (The False Statement):** Therapeutic drug monitoring for Clozapine aims for a plasma level of **>350 ng/mL** to ensure clinical efficacy. There is **no correlation** between plasma levels and the risk of agranulocytosis; this adverse effect is an idiosyncratic (non-dose-dependent) reaction, likely immunological. Therefore, maintaining levels below 350 ng/mL does not prevent agranulocytosis and may lead to subtherapeutic treatment. **Analysis of Other Options:** * **Option A:** Unlike typical antipsychotics, Clozapine has a unique receptor profile. It has a **higher affinity for D1, D4, and 5-HT2A receptors** than for D2 receptors. Its weak D2 blockade is why it rarely causes Extrapyramidal Side Effects (EPS). * **Option C:** Carbamazepine is a potent bone marrow suppressant. Combining it with Clozapine significantly increases the risk of **agranulocytosis** and should be avoided. * **Option D:** Strict hematological monitoring is mandatory. Clozapine must be discontinued if the **Total Leukocyte Count (TLC) falls below 3,000/mm³** or the Absolute Neutrophil Count (ANC) falls below 1,500/mm³. **High-Yield Clinical Pearls for NEET-PG:** * **Indication:** Treatment-resistant schizophrenia (failed 2 other antipsychotics) and reducing suicidal behavior in schizophrenia. * **Side Effects:** Sialorrhea (hypersalivation), sedation, weight gain, and **lowering of seizure threshold** (dose-dependent). * **ECG Change:** Myocarditis and tachycardia. * **Benefit:** Only antipsychotic proven to reduce suicide risk and the only one that does not cause Tardive Dyskinesia.

Question 248: Which of the following is used in the management of Electroconvulsive Therapy (ECT)?

A. Succinylcholine (Correct Answer)
B. Cefepime
C. Clozapine
D. Chlorpromazine

Explanation: **Explanation:** In modern **Modified Electroconvulsive Therapy (ECT)**, the goal is to induce a therapeutic seizure in the brain while preventing the physical complications of a generalized tonic-clonic convulsion. **A. Succinylcholine (Correct):** This is a short-acting depolarizing neuromuscular blocking agent. It is the drug of choice in ECT to produce skeletal muscle relaxation. By blocking the nicotinic acetylcholine receptors at the neuromuscular junction, it prevents forceful muscle contractions that could otherwise lead to bone fractures, joint dislocations, or tongue bites during the induced seizure. Its rapid onset and short duration of action make it ideal for the brief nature of ECT. **B. Cefepime:** This is a fourth-generation cephalosporin antibiotic. It has no role in ECT management and is used for treating bacterial infections. **C. Clozapine:** An atypical antipsychotic used for treatment-resistant schizophrenia. While ECT is sometimes used adjunctively with Clozapine, the drug itself is not a component of the ECT procedure. Notably, Clozapine lowers the seizure threshold, which can be a risk factor if not monitored. **D. Chlorpromazine:** A low-potency typical antipsychotic. Like Clozapine, it is used to treat psychosis but is not part of the standard ECT premedication protocol. **High-Yield Clinical Pearls for NEET-PG:** * **Standard ECT Premedication:** 1. **Atropine/Glycopyrrolate:** Anticholinergic to reduce secretions and prevent vagally-mediated bradycardia. 2. **Methohexital/Propofol:** Short-acting anesthetic agents to induce unconsciousness. 3. **Succinylcholine:** Muscle relaxant. * **Gold Standard Indication:** Severe depression with suicidal ideation or catatonia. * **Absolute Contraindication:** Increased intracranial pressure (ICP).

Question 249: Hyponatremia is a known side effect of which of the following medications?

A. Olanzapine
B. Lithium
C. Carbamazepine (Correct Answer)
D. Clonazepam

Explanation: **Explanation:** **Carbamazepine** is a well-known cause of **hyponatremia** (occurring in up to 10-15% of patients). The underlying mechanism is the stimulation of **Antidiuretic Hormone (ADH)** release and the sensitization of renal tubules to ADH, leading to a condition similar to SIADH (Syndrome of Inappropriate Antidiuretic Hormone secretion). This effect is dose-dependent and more common in elderly patients or those taking concomitant diuretics. **Analysis of Incorrect Options:** * **Olanzapine (A):** An atypical antipsychotic primarily associated with metabolic side effects such as weight gain, dyslipidemia, and hyperglycemia. It does not typically cause electrolyte imbalances. * **Lithium (B):** Unlike Carbamazepine, Lithium is associated with **Hypernatremia**. It causes Nephrogenic Diabetes Insipidus (NDI) by antagonizing the effects of ADH on the collecting ducts, leading to polyuria and dilute urine. * **Clonazepam (D):** A benzodiazepine that acts on GABA-A receptors. Its primary side effects are sedation, ataxia, and cognitive impairment; it has no significant effect on sodium regulation. **High-Yield Clinical Pearls for NEET-PG:** * **Oxcarbazepine**, a derivative of carbamazepine, carries an even **higher risk** of hyponatremia. * **SSRIs** (e.g., Fluoxetine, Sertraline) are the most common class of psychotropic drugs associated with SIADH/hyponatremia in the elderly. * **Monitoring:** When prescribing Carbamazepine, baseline and periodic serum sodium levels should be checked, especially if the patient develops symptoms like confusion, lethargy, or seizures. * **HLA-B*1502:** Always screen for this allele in Asian populations before starting Carbamazepine to prevent Stevens-Johnson Syndrome (SJS).

Question 250: A 19-year-old boy with chronic schizophrenia is treated with haloperidol 20 mg/day. One week after starting the medication, he exhibits restlessness, fidgeting, irritability, and an inability to remain still. What is the most appropriate management strategy?

A. Increase the dose of haloperidol
B. Add an anticholinergic drug
C. Add a beta-blocker (Correct Answer)
D. Add another antipsychotic drug

Explanation: ### Explanation **Diagnosis: Akathisia** The patient is presenting with classic symptoms of **Akathisia**, a common Extrapyramidal Side Effect (EPS) associated with high-potency first-generation antipsychotics like Haloperidol. It is characterized by subjective feelings of inner restlessness and objective signs of motor agitation (fidgeting, pacing, inability to sit still). **Why Option C is Correct:** The first-line pharmacological treatment for antipsychotic-induced akathisia is a **lipophilic beta-blocker**, specifically **Propranolol**. Propranolol crosses the blood-brain barrier effectively and acts on central receptors to alleviate the restlessness. Other options include benzodiazepines or reducing the antipsychotic dose. **Why Other Options are Incorrect:** * **Option A (Increase dose):** This would worsen the condition. Akathisia is dose-dependent; increasing Haloperidol would increase D2 receptor blockade, exacerbating the EPS. * **Option B (Add an anticholinergic):** While anticholinergics (e.g., Benztropine, Trihexyphenidyl) are the treatment of choice for *Acute Dystonia* and *Parkinsonian symptoms*, they are generally **ineffective** for Akathisia. * **Option D (Add another antipsychotic):** Polypharmacy increases the side-effect burden and does not address the underlying movement disorder. **High-Yield Clinical Pearls for NEET-PG:** * **Timeline of EPS:** 1. **Acute Dystonia:** Hours to days (Treatment: Anticholinergics). 2. **Akathisia:** Days to weeks (Treatment: Beta-blockers). 3. **Drug-induced Parkinsonism:** Weeks to months (Treatment: Anticholinergics). 4. **Tardive Dyskinesia:** Months to years (Treatment: Switch to Clozapine/VMAT2 inhibitors). * **Propranolol Dosage:** Usually 30–90 mg/day is effective for akathisia. * **Key Differentiator:** Akathisia is often mistaken for worsening psychosis/agitation. Always check for "inner restlessness" before increasing antipsychotic doses.

Question 251: Which of the following statements is true about Paliperidone?

A. It is a D2 and 5-HT2A receptor antagonist.
B. It is used for the treatment of schizophrenia.
C. It can cause Neuroleptic Malignant Syndrome.
D. All of the above are true. (Correct Answer)

Explanation: **Explanation:** Paliperidone is a second-generation (atypical) antipsychotic and is the primary active metabolite of Risperidone (9-hydroxyrisperidone). 1. **Mechanism of Action (Option A):** Like most atypical antipsychotics, Paliperidone acts primarily as a **D2 and 5-HT2A receptor antagonist**. By blocking dopamine D2 receptors in the mesolimbic pathway, it treats positive symptoms, while 5-HT2A antagonism in the mesocortical pathway helps alleviate negative symptoms and reduces the risk of extrapyramidal side effects (EPS). 2. **Clinical Use (Option B):** It is FDA-approved for the treatment of **Schizophrenia** and **Schizoaffective disorder** (both as monotherapy and as an adjunct to mood stabilizers or antidepressants). 3. **Adverse Effects (Option C):** Although atypical antipsychotics have a lower risk of neurological side effects compared to typical ones, they can still cause **Neuroleptic Malignant Syndrome (NMS)**, a life-threatening neurological emergency characterized by muscle rigidity, fever, autonomic instability, and altered mental status. **High-Yield Facts for NEET-PG:** * **Metabolism:** Unlike Risperidone, Paliperidone undergoes minimal hepatic metabolism and is primarily excreted unchanged by the kidneys. This makes it a preferred choice in patients with mild-to-moderate liver impairment. * **Formulations:** It is available as an extended-release oral tablet (using OROS technology) and as long-acting injectable (LAI) formulations (e.g., *Sustenna* - monthly; *Trinza* - 3-monthly). * **Side Effects:** It is notably associated with **hyperprolactinemia** (similar to Risperidone) and QTc prolongation.

Question 252: What is the drug of choice for depression in elderly patients?

A. Fluoxetine (Correct Answer)
B. Buspirone
C. Amitriptyline
D. Imipramine

Explanation: **Explanation:** The drug of choice for depression in elderly patients is a **Selective Serotonin Reuptake Inhibitor (SSRI)**, such as **Fluoxetine** or Sertraline. SSRIs are preferred because they have a superior safety profile, better tolerability, and a lower risk of side effects compared to older antidepressants. **Why Fluoxetine is correct:** In the elderly, physiological changes necessitate drugs with minimal cardiovascular and anticholinergic effects. Fluoxetine effectively treats depressive symptoms without causing significant sedation or orthostatic hypotension, which are major risks for falls in this age group. **Why the other options are incorrect:** * **Amitriptyline & Imipramine (TCAs):** These Tricyclic Antidepressants are generally avoided in the elderly due to their potent **anticholinergic effects** (causing confusion, urinary retention, and constipation) and **quinidine-like cardiotoxicity**. They also cause orthostatic hypotension, significantly increasing the risk of hip fractures. * **Buspirone:** This is an **anxiolytic** (5-HT1A partial agonist) used for Generalized Anxiety Disorder (GAD). It is not an antidepressant and is not used as a primary treatment for depression. **High-Yield Clinical Pearls for NEET-PG:** * **First-line for Elderly:** SSRIs (Sertraline is often preferred over Fluoxetine if drug-drug interactions are a concern due to its shorter half-life). * **Hyponatremia:** Elderly patients on SSRIs should be monitored for **SIADH**, a common side effect in this population. * **Pseudodementia:** Always rule out "Depressive Pseudodementia" in elderly patients presenting with cognitive decline; it is reversible with antidepressants. * **TCA Side Effects:** Remember the mnemonic "3 Cs" for TCA toxicity: Coma, Convulsions, and Cardiotoxicity (Arrhythmias).

Question 253: Which drug is NOT used in the prophylaxis of bipolar disorder?

A. Haloperidol (Correct Answer)
B. Lithium
C. Carbamazepine
D. Valproate

Explanation: **Explanation:** The management of Bipolar Disorder is divided into two phases: **Acute Management** (treating current manic or depressive episodes) and **Prophylaxis/Maintenance** (preventing future relapses). **1. Why Haloperidol is the correct answer:** Haloperidol is a high-potency typical antipsychotic. While it is highly effective in the **acute management** of manic episodes to control agitation and psychosis, it is **not used for prophylaxis**. Long-term use of Haloperidol is avoided in bipolar patients due to the high risk of Extrapyramidal Side Effects (EPS) and Tardive Dyskinesia. Furthermore, some studies suggest that typical antipsychotics may increase the risk of post-manic depression. **2. Why the other options are incorrect:** * **Lithium (Option B):** The "Gold Standard" for bipolar prophylaxis. It is effective in preventing both manic and depressive relapses and is the only drug proven to reduce suicide risk in these patients. * **Valproate (Option D):** A first-line mood stabilizer, especially effective for **Rapid Cycling** bipolar disorder and Mixed Episodes. * **Carbamazepine (Option C):** A second-line mood stabilizer used for prophylaxis, particularly in patients who do not respond to Lithium or Valproate. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC) for Prophylaxis:** Lithium. * **DOC for Rapid Cycling (>4 episodes/year):** Sodium Valproate. * **Atypical Antipsychotics for Prophylaxis:** Unlike Haloperidol, certain atypical antipsychotics (e.g., **Quetiapine, Olanzapine, Aripiprazole**) are FDA-approved for maintenance therapy. * **Lamotrigine:** Specifically used for the prophylaxis of **Bipolar Depression** (not effective for acute mania). * **Therapeutic Index:** Lithium has a narrow therapeutic index (0.6–1.2 mEq/L for maintenance).

Question 254: Irresistible urge to move about with inner restlessness is called?

A. Akinesia
B. Hyperkinesia
C. Dyskinesia
D. Akathisia (Correct Answer)

Explanation: ### Explanation **Correct Answer: D. Akathisia** **Akathisia** is a common extrapyramidal side effect (EPS) associated with antipsychotic medications (especially first-generation antipsychotics). It is clinically defined by two components: 1. **Subjective:** A distressing feeling of inner restlessness and anxiety. 2. **Objective:** Motor restlessness, such as pacing, shifting weight from foot to foot, or inability to sit still. The "irresistible urge to move" is the hallmark feature that distinguishes it from simple anxiety or agitation. **Analysis of Incorrect Options:** * **A. Akinesia:** Refers to a lack of or poverty of movement. It is often part of drug-induced parkinsonism, characterized by a "mask-like" face and decreased arm swing. * **B. Hyperkinesia:** A general term for excessive, often involuntary, muscular activity (e.g., tremors, chorea). It lacks the specific "inner restlessness" component of akathisia. * **C. Dyskinesia:** Refers to abnormal, involuntary movements. **Tardive Dyskinesia** is a late-onset EPS characterized by orofacial movements (lip-smacking, tongue protrusion) resulting from long-term dopamine blockade. **High-Yield Clinical Pearls for NEET-PG:** * **Management:** The first-line treatment for Akathisia is **Propranolol** (Beta-blocker). Centrally acting anticholinergics (like Benztropine) or Benzodiazepines can also be used. * **Timeline:** Akathisia typically develops within days to weeks of starting or increasing the dose of an antipsychotic. * **Suicide Risk:** Severe akathisia is highly distressing and has been clinically linked to an increased risk of suicidal ideation and behavior. * **Differential:** Do not confuse Akathisia with **Restless Leg Syndrome (RLS)**; RLS typically occurs at night and is relieved specifically by moving the legs, whereas akathisia is generalized and occurs throughout the day.

Question 255: Which of the following adverse effects may be seen in a patient treated with risperidone?

A. Weight loss
B. Neuroleptic malignant syndrome (Correct Answer)
C. Hypopigmentation
D. Prolactin deficiency

Explanation: **Explanation:** **Risperidone** is a second-generation (atypical) antipsychotic that acts primarily as a potent **D2 receptor antagonist** and a 5-HT2A receptor antagonist. **Why Option B is Correct:** **Neuroleptic Malignant Syndrome (NMS)** is a rare but life-threatening idiosyncratic reaction to dopamine antagonists, including risperidone. It is characterized by the "tetrad" of **hyperthermia, muscular "lead-pipe" rigidity, autonomic instability, and altered mental status.** The underlying mechanism involves massive dopamine blockade in the nigrostriatal pathway and hypothalamus. **Why Other Options are Incorrect:** * **A. Weight loss:** Risperidone is associated with **weight gain** and metabolic syndrome (dyslipidemia, hyperglycemia), not weight loss. * **C. Hypopigmentation:** Antipsychotics do not cause hypopigmentation. Historically, high-dose Chlorpromazine was associated with *hyperpigmentation* (blue-grey skin discoloration). * **D. Prolactin deficiency:** Risperidone is unique among atypicals for causing significant **Hyperprolactinemia**. By blocking dopamine in the tuberoinfundibular pathway, it removes the inhibitory effect on prolactin, leading to galactorrhea, amenorrhea, and gynecomastia. **High-Yield Clinical Pearls for NEET-PG:** * **NMS Treatment:** Immediate discontinuation of the drug, aggressive cooling, and pharmacotherapy with **Dantrolene** (muscle relaxant) or **Bromocriptine** (dopamine agonist). * **Lab findings in NMS:** Elevated Creatine Kinase (CK) and leukocytosis. * **Risperidone Fact:** It has the highest risk of **Extrapyramidal Side Effects (EPS)** among atypical antipsychotics, especially at doses >6mg.

Question 256: A 30-year-old man, recently started on haloperidol 30mg/day, developed hyperpyrexia, muscle rigidity, akinesia, mutism, sweating, tachycardia, and increased blood pressure. Investigations showed increased WBC count and increased creatinine phosphokinase. There is no history of any other drug intake or any signs of infection. What is the most likely diagnosis?

A. Drug overdose
B. Neuroleptic malignant syndrome (Correct Answer)
C. Drug-induced Parkinsonism
D. Tardive dyskinesia

Explanation: **Explanation:** The clinical presentation described is a classic case of **Neuroleptic Malignant Syndrome (NMS)**, a life-threatening idiosyncratic reaction to antipsychotic drugs (neuroleptics), particularly high-potency agents like Haloperidol. **Why Option B is Correct:** NMS is characterized by a "tetrad" of clinical features: 1. **Hyperpyrexia:** High-grade fever. 2. **Muscle Rigidity:** Often described as "lead-pipe" rigidity. 3. **Autonomic Instability:** Tachycardia, sweating (diaphoresis), and fluctuating blood pressure. 4. **Altered Mental Status:** Mutism, stupor, or coma. Laboratory findings typically show **elevated Creatinine Phosphokinase (CPK)** due to rhabdomyolysis and **leukocytosis** (increased WBC), both of which are present in this patient. **Why Other Options are Incorrect:** * **A. Drug Overdose:** While Haloperidol overdose can cause sedation or extrapyramidal symptoms, it does not typically present with the specific combination of lead-pipe rigidity, hyperpyrexia, and markedly elevated CPK. * **C. Drug-induced Parkinsonism:** This presents with tremors, bradykinesia, and rigidity, but lacks the life-threatening autonomic instability and hyperpyrexia seen in NMS. * **D. Tardive Dyskinesia:** A late-onset side effect characterized by involuntary choreoathetoid movements (e.g., lip-smacking), not an acute febrile illness. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Massive dopamine blockade in the nigrostriatal pathway and hypothalamus. * **Treatment:** Immediate discontinuation of the antipsychotic, supportive care (cooling), and pharmacotherapy with **Dantrolene** (muscle relaxant) or **Bromocriptine** (D2 agonist). * **Mnemonic (FEVER):** **F**ever, **E**ncephalopathy, **V**itals unstable, **E**levated enzymes (CPK), **R**igidity. * **Differential Diagnosis:** Serotonin Syndrome (presents with hyperreflexia and myoclonus, whereas NMS has "lead-pipe" rigidity and hyporeflexia).

Question 257: A patient on antipsychotic medication for the past 4 weeks presents to the emergency department with acute onset of fever, excessive sweating, confusion, rigidity of limbs, and decreased communication. Examination reveals a temperature of 104°F, pulse rate of 120/min, blood pressure of 150/100 mmHg, and disorientation. What is the most probable diagnosis?

A. Lithium toxicity
B. Aggravation of psychosis
C. Dystonia
D. Neuroleptic malignant syndrome (Correct Answer)

Explanation: ### Explanation **Correct Answer: D. Neuroleptic Malignant Syndrome (NMS)** **Why it is correct:** Neuroleptic Malignant Syndrome is a life-threatening idiosyncratic reaction to dopamine antagonists (antipsychotics). The patient presents with the classic **"tetrad"** of symptoms: 1. **Hyperthermia:** High-grade fever (often >104°F). 2. **Muscle Rigidity:** Characterized as "lead-pipe" rigidity. 3. **Autonomic Instability:** Tachycardia, hypertension, and diaphoresis (excessive sweating). 4. **Altered Mental Status:** Confusion, agitation, or stupor. The history of antipsychotic use for 4 weeks followed by these symptoms makes NMS the most probable diagnosis. **Why the other options are incorrect:** * **A. Lithium toxicity:** Typically presents with gastrointestinal symptoms (nausea, vomiting), coarse tremors, ataxia, and seizures. While it causes confusion, it does not typically cause "lead-pipe" rigidity or extreme hyperpyrexia. * **B. Aggravation of psychosis:** While psychosis involves confusion/agitation, it does not present with systemic signs like high-grade fever, autonomic instability, or muscular rigidity. * **C. Dystonia:** This is an Extrapyramidal Side Effect (EPS) involving acute, involuntary muscle contractions (e.g., torticollis, oculogyric crisis). It lacks the systemic toxicity, fever, and autonomic instability seen in NMS. **High-Yield Clinical Pearls for NEET-PG:** * **Key Lab Finding:** Significantly elevated **Serum Creatine Kinase (CK)** due to rhabdomyolysis. * **Treatment:** Immediate discontinuation of the offending agent, aggressive cooling, and hydration. Pharmacotherapy includes **Dantrolene** (muscle relaxant) or **Bromocriptine** (dopamine agonist). * **NMS vs. Serotonin Syndrome:** NMS features "lead-pipe" rigidity and bradyreflexia, whereas Serotonin Syndrome features hyperreflexia and myoclonus.

Question 258: Retrograde ejaculation is a characteristic side effect of which psychotropic medication?

A. Lithium carbonate
B. Phenelzine
C. Diazepam
D. Thioridazine (Correct Answer)

Explanation: **Explanation:** **Thioridazine** is a low-potency typical antipsychotic known for its significant alpha-1 adrenergic blocking properties. Retrograde ejaculation occurs because the closure of the internal urethral sphincter (bladder neck) is mediated by alpha-1 receptors. When these receptors are blocked, the sphincter fails to close during ejaculation, causing semen to travel backward into the bladder instead of out through the urethra. This is a classic, high-yield side effect specifically associated with Thioridazine. **Analysis of Incorrect Options:** * **Lithium carbonate:** Primarily causes side effects like tremors, polyuria (nephrogenic diabetes insipidus), and hypothyroidism. It does not significantly affect the adrenergic system governing ejaculation. * **Phenelzine:** An MAO inhibitor. While it can cause sexual dysfunction (primarily delayed ejaculation or impotence), it is not classically associated with retrograde ejaculation. * **Diazepam:** A benzodiazepine that acts via GABA-A receptors. It may cause decreased libido or erectile dysfunction due to CNS sedation but does not cause the mechanical failure seen in retrograde ejaculation. **Clinical Pearls for NEET-PG:** * **Thioridazine "Mnemonic":** Remember the **"3 Ts"** of Thioridazine: **T**orsades de pointes (QT prolongation), **T**errible Retinitis Pigmentosa (at doses >800mg/day), and **T**ermination of forward ejaculation (Retrograde). * **Mechanism:** Retrograde ejaculation is an **alpha-adrenergic blockade** phenomenon. * **Other drugs:** Apart from Thioridazine, alpha-blockers like **Tamsulosin** (used in BPH) are also common causes of retrograde ejaculation.

Question 259: All of the following are used in the treatment of bipolar disorder except?

A. Gabapentin (Correct Answer)
B. Valproate
C. Lithium
D. Carbamazepine

Explanation: The treatment of Bipolar Disorder primarily relies on **Mood Stabilizers**. While several anticonvulsants are effective in stabilizing mood, not all drugs in that class possess this property. [1] **Why Gabapentin is the correct answer:** Gabapentin, although an anticonvulsant, has **no proven efficacy as a mood stabilizer** in randomized controlled trials for Bipolar Disorder. It is primarily used for neuropathic pain and as an adjunctive treatment for focal seizures. In psychiatry, it may be used "off-label" for anxiety or alcohol withdrawal, but it is not indicated for the treatment of mania or bipolar depression. [1] **Why the other options are incorrect:** * **Lithium (Option C):** The "Gold Standard" for bipolar disorder. It is highly effective for acute mania and prophylaxis of both manic and depressive episodes. [3] It is also known for its unique anti-suicidal properties. * **Valproate (Option B):** A first-line mood stabilizer, especially effective for **Rapid Cycling** bipolar disorder and Mixed Episodes. [2] * **Carbamazepine (Option D):** A second-line mood stabilizer often used when patients are unresponsive to Lithium or Valproate. [4] It is particularly useful in acute mania. [2] **High-Yield Clinical Pearls for NEET-PG:** * **Drugs of Choice:** Lithium is the overall DOC for Bipolar Disorder; however, Valproate is preferred for Rapid Cyclers (>4 episodes/year). [4] * **Lamotrigine:** Another anticonvulsant used in Bipolar Disorder, but specifically for the **prevention of depressive episodes** (not effective for acute mania). [2] * **Teratogenicity:** Lithium is associated with **Ebstein’s Anomaly**, while Valproate is associated with **Neural Tube Defects** (highest risk among mood stabilizers). * **Topiramate:** Like Gabapentin, Topiramate is an anticonvulsant that is **not** an effective mood stabilizer but is sometimes used for weight loss in psychiatric patients. [1]

Question 260: Which antipsychotic medication is known to cause agranulocytosis?

A. Lithium
B. Risperidone
C. Clozapine (Correct Answer)
D. Aripiprazole

Explanation: **Explanation:** **Clozapine** is the correct answer. It is an atypical (second-generation) antipsychotic reserved for treatment-resistant schizophrenia. Its most serious and life-threatening side effect is **agranulocytosis** (a severe decrease in the absolute neutrophil count, typically defined as <500/mm³), which occurs in approximately 1% of patients. This reaction is idiosyncratic and usually occurs within the first 18 weeks of treatment. Due to this risk, mandatory hematological monitoring (CBC with ANC) is required for all patients on Clozapine. **Analysis of Incorrect Options:** * **A. Lithium:** This is a mood stabilizer, not an antipsychotic. Interestingly, Lithium causes **leukocytosis** (an increase in white blood cell count) rather than agranulocytosis, and is sometimes used off-label to counteract drug-induced neutropenia. * **B. Risperidone:** An atypical antipsychotic primarily associated with dose-dependent extrapyramidal symptoms (EPS) and significant **hyperprolactinemia**. It does not carry a significant risk of agranulocytosis. * **C. Aripiprazole:** A partial dopamine agonist known for its "weight-neutral" profile and low sedative effect. It is not associated with bone marrow suppression. **High-Yield Clinical Pearls for NEET-PG:** * **Clozapine Monitoring:** ANC must be checked weekly for the first 6 months, every 2 weeks for the next 6 months, and monthly thereafter. * **Other Side Effects:** Clozapine is also notorious for causing **seizures** (dose-dependent), **sialorrhea** (excessive drooling), myocarditis, and severe constipation. * **Benefit:** It is the only antipsychotic proven to reduce the risk of **suicide** in patients with schizophrenia. * **Metabolic Syndrome:** Clozapine and Olanzapine carry the highest risk of weight gain and diabetes among antipsychotics.

Question 261: Which class of drugs is chiefly used for treating schizophrenia?

A. Antimaniac
B. Antidepressant
C. Antihistaminics
D. Antipsychotic (Correct Answer)

Explanation: **Explanation:** **Correct Answer: D. Antipsychotic** Schizophrenia is primarily characterized by an overactivity of dopamine in the mesolimbic pathway (leading to positive symptoms like hallucinations and delusions). **Antipsychotics** (also known as neuroleptics) are the mainstay of treatment. They work chiefly by blocking **D2 receptors**, thereby normalizing dopaminergic neurotransmission. They are classified into First-Generation (Typical) and Second-Generation (Atypical) antipsychotics, with the latter also targeting serotonin (5-HT2A) receptors to improve negative symptoms. **Why other options are incorrect:** * **A. Antimaniac:** These drugs (e.g., Lithium, Valproate) are used to stabilize mood in **Bipolar Affective Disorder (BPAD)**, specifically during manic episodes. * **B. Antidepressant:** These (e.g., SSRIs, SNRIs) are used to treat **Depressive disorders**, Anxiety disorders, and OCD by increasing synaptic levels of Serotonin or Norepinephrine. * **C. Antihistaminics:** While some (like Promethazine or Hydroxyzine) are used for sedation or as adjuncts in acute agitation, they are not the primary treatment for the core symptoms of schizophrenia. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** For treatment-resistant schizophrenia, the DOC is **Clozapine**. * **Side Effects:** Typical antipsychotics are more likely to cause **Extrapyramidal Side Effects (EPS)**, while Atypical antipsychotics are associated with **Metabolic Syndrome** (weight gain, dyslipidemia). * **Dopamine Pathways:** * *Mesolimbic:* Increased dopamine causes positive symptoms. * *Mesocortical:* Decreased dopamine causes negative symptoms. * *Nigrostriatal:* Blockade here causes EPS. * *Tuberoinfundibular:* Blockade here causes Hyperprolactinemia.

Question 262: A 31-year-old male with a mood disorder, on 30 mg of haloperidol and 100 mg of lithium, presents to the emergency room with acute onset of fever, excessive sweating, confusion, limb rigidity, and decreased communication for one day. Examination reveals tachycardia and labile blood pressure. Investigations show increased CPK enzyme levels and leucocytosis. What is the most likely diagnosis?

A. Lithium toxicity
B. Tardive dyskinesia
C. Neuroleptic malignant syndrome (Correct Answer)
D. Hypertensive encephalopathy

Explanation: ### Explanation The clinical presentation of high fever, "lead-pipe" muscle rigidity, autonomic instability (tachycardia, labile BP, sweating), and altered mental status in a patient taking high-potency antipsychotics (Haloperidol) is a classic description of **Neuroleptic Malignant Syndrome (NMS)**. **1. Why NMS is the Correct Answer:** NMS is a life-threatening idiosyncratic reaction to dopamine antagonists. The pathophysiology involves massive dopamine blockade in the nigrostriatal pathway (leading to rigidity) and hypothalamus (causing dysthermia). Laboratory findings of **elevated Creatine Phosphokinase (CPK)** due to muscle necrosis (rhabdomyolysis) and **leucocytosis** are hallmark diagnostic markers that distinguish it from other psychiatric emergencies. **2. Why Other Options are Incorrect:** * **Lithium Toxicity:** While it causes confusion and tremors, it typically presents with gastrointestinal symptoms (vomiting, diarrhea), ataxia, and coarse tremors, rather than severe "lead-pipe" rigidity and high-grade fever. * **Tardive Dyskinesia:** This is a late-onset extrapyramidal side effect characterized by involuntary choreoathetoid movements (e.g., lip-smacking, tongue protrusion). It does not present with systemic symptoms like fever or autonomic instability. * **Hypertensive Encephalopathy:** While it presents with confusion and high BP, it does not account for the generalized muscle rigidity, elevated CPK, or the specific context of recent antipsychotic use. **3. NEET-PG High-Yield Pearls:** * **Mnemonic for NMS (FEVER):** **F**ever, **E**ncephalopathy, **V**itals unstable, **E**levated enzymes (CPK), **R**igidity. * **Treatment:** Immediate discontinuation of the offending agent, aggressive cooling, and hydration. Pharmacotherapy includes **Dantrolene** (muscle relaxant) or **Bromocriptine** (dopamine agonist). * **Risk Factor:** High-potency typical antipsychotics (Haloperidol) and rapid dose escalation.

Question 263: A patient of Schizophrenia treated for 5 years developed perioral movements. What is the likely diagnosis?

A. Tardive dyskinesia (Correct Answer)
B. Muscular dystonia
C. Akathisia
D. Malignant neuroleptic syndrome

Explanation: **Explanation:** The correct diagnosis is **Tardive Dyskinesia (TD)**. This is a late-onset extrapyramidal side effect (EPS) resulting from long-term blockade of dopamine (D2) receptors, leading to **upregulation and supersensitivity** of these receptors in the nigrostriatal pathway. * **Why it is correct:** TD typically occurs after years of antipsychotic use (minimum 3–6 months). It is characterized by involuntary, choreoathetoid movements, most commonly involving the **perioral region** (tongue protrusion, lip-smacking, puckering, or "Rabbit syndrome"). * **Why other options are incorrect:** * **Muscular Dystonia:** Usually occurs acutely (within hours to days of starting treatment). It involves sustained, painful muscle contractions (e.g., torticollis or oculogyric crisis). * **Akathisia:** The most common EPS, presenting as subjective motor restlessness (inability to sit still). It typically occurs within days to weeks. * **Malignant Neuroleptic Syndrome (NMS):** A life-threatening emergency characterized by "lead-pipe" rigidity, high fever, autonomic instability, and altered sensorium, rather than isolated perioral movements. **High-Yield Clinical Pearls for NEET-PG:** * **Risk Factors:** Elderly age, female gender, and long-term use of first-generation (typical) antipsychotics. * **Management:** The first step is to **taper/discontinue** the offending agent or switch to **Clozapine** (the antipsychotic with the lowest risk of TD). * **Newer Treatments:** VMAT-2 inhibitors like **Valbenazine** or **Deutetrabenazine** are now FDA-approved for TD. * **Warning:** Anticholinergics (like Benztropine) often **worsen** symptoms of Tardive Dyskinesia, unlike other EPS.

Question 264: A 45-year-old male presented to the emergency department with severe agitation and aggressive behavior. He was treated with haloperidol and became responsive and cooperative. After 8 days of treatment, he developed high-grade fever, diarrhea, confusion, and muscle rigidity. Which of the following should be used for the treatment of this condition?

A. Diazepam
B. Benzhexol
C. Dantrolene (Correct Answer)
D. High dose of haloperidol

Explanation: **Explanation:** The patient is presenting with **Neuroleptic Malignant Syndrome (NMS)**, a life-threatening idiosyncratic reaction to antipsychotics (like Haloperidol). The clinical tetrad of NMS includes **hyperpyrexia (high-grade fever), muscle rigidity ("lead-pipe" variety), autonomic instability (tachycardia, diarrhea, hypertension), and altered mental status.** **Why Dantrolene is the correct answer:** Dantrolene is a direct-acting skeletal muscle relaxant that inhibits the release of calcium from the sarcoplasmic reticulum. By reducing muscle rigidity and heat production, it addresses the core hypermetabolic state of NMS. Other specific treatments include dopamine agonists like **Bromocriptine** or Amantadine to reverse the dopamine blockade. **Analysis of Incorrect Options:** * **A. Diazepam:** While benzodiazepines are used for mild agitation or to control seizures in NMS, they are not the definitive treatment for the underlying muscle rigidity and hyperthermia. * **B. Benzhexol (Trihexyphenidyl):** This is an anticholinergic used for Acute Dystonia or Parkinsonism. In NMS, anticholinergics can worsen hyperthermia by inhibiting sweating and are generally avoided. * **D. High dose of haloperidol:** This would be fatal. NMS is caused by potent dopamine (D2) blockade; adding more haloperidol would exacerbate the condition. **NEET-PG High-Yield Pearls:** * **Key Lab Finding:** Significantly elevated **Creatine Phosphokinase (CPK)** levels and leukocytosis. * **NMS vs. Serotonin Syndrome:** NMS features "lead-pipe" rigidity and bradyreflexia, whereas Serotonin Syndrome features hyperreflexia and myoclonus. * **First step in management:** Immediate discontinuation of the offending antipsychotic agent and aggressive supportive care (cooling and hydration).

Question 265: Risperidone is most commonly used to treat which of the following disorders?

A. Dementia
B. Depression
C. Schizophrenia (Correct Answer)
D. Obsessive-compulsive disorder

Explanation: **Explanation:** **Risperidone** is a second-generation (atypical) antipsychotic. Its primary mechanism of action involves the potent blockade of **D2 (Dopamine)** receptors and **5-HT2A (Serotonin)** receptors. 1. **Why Schizophrenia is correct:** Risperidone is FDA-approved as a first-line treatment for Schizophrenia. By blocking D2 receptors in the mesolimbic pathway, it treats "positive symptoms" (hallucinations/delusions), while its 5-HT2A antagonism in the mesocortical pathway helps improve "negative symptoms" (apathy/withdrawal) and reduces the risk of Extrapyramidal Side Effects (EPS) compared to typical antipsychotics. 2. **Why other options are incorrect:** * **Dementia:** While sometimes used off-label for behavioral disturbances in dementia, it is not the primary treatment. It carries a "Black Box Warning" due to an increased risk of stroke and mortality in elderly patients with dementia-related psychosis. * **Depression:** The first-line treatments are SSRIs/SNRIs. Atypical antipsychotics (like Aripiprazole or Quetiapine) are only used as *adjuncts* in treatment-resistant cases. * **Obsessive-Compulsive Disorder (OCD):** The mainstay of treatment is high-dose SSRIs and Cognitive Behavioral Therapy (CBT). **High-Yield Clinical Pearls for NEET-PG:** * **Hyperprolactinemia:** Among atypical antipsychotics, Risperidone has the **highest risk** of increasing prolactin levels (leading to gynecomastia, galactorrhea, and amenorrhea) because it behaves like a typical antipsychotic at higher doses (>6mg). * **Metabolic Profile:** It carries a moderate risk for weight gain and metabolic syndrome (less than Olanzapine, but more than Ziprasidone). * **Active Metabolite:** **Paliperidone** is the active metabolite of Risperidone.

Question 266: Which of the following substances is considered an anxiolytic?

A. Caffeine
B. Cholecystokinin
C. Neuropeptide Y (Correct Answer)
D. Carbon dioxide

Explanation: **Explanation:** **Neuropeptide Y (NPY)** is the correct answer because it is a potent endogenous **anxiolytic** peptide found in high concentrations in the amygdala and hippocampus. It acts as a natural "buffer" against stress by counteracting the effects of Corticotropin-Releasing Factor (CRF). High levels of NPY are associated with resilience to stress, while low levels are linked to anxiety disorders and PTSD. **Analysis of Incorrect Options:** * **Caffeine (Option A):** A methylxanthine that acts as an adenosine receptor antagonist. It is a well-known **anxiogenic** (anxiety-inducing) substance that can trigger panic attacks in susceptible individuals by increasing sympathetic outflow. * **Cholecystokinin (CCK) (Option B):** A peptide hormone that, when administered (specifically CCK-4), acts as a potent **panicogen**. It induces acute panic symptoms and is often used in research to study panic disorder. * **Carbon Dioxide (CO2) (Option C):** Inhalation of 5% or 35% CO2 is a classic **anxiogenic** stimulus. It triggers the "suffocation alarm" in the brainstem, leading to hyperventilation and acute anxiety/panic. **High-Yield Clinical Pearls for NEET-PG:** * **Panicogens (Anxiogenics):** Caffeine, CCK, CO2, Sodium Lactate, and Yohimbine (alpha-2 antagonist). * **Anxiolytics:** Benzodiazepines (GABA-A facilitators), Buspirone (5-HT1A partial agonist), and NPY. * **NPY & PTSD:** Research indicates that individuals with higher NPY levels show better recovery from trauma, making it a target for future pharmacological treatments.

Question 267: A patient was on treatment with trifluoperazine for some time. He presents with a complaint of hyperthermia, lethargy, and sweating. Which investigations are needed?

A. CT Scan brain & hemogram
B. Hemogram, Electrolyte level and creatinine
C. ECG, Chest X-ray and hemogram
D. Hemogram, CPK and renal function test (Correct Answer)

Explanation: ### Explanation The clinical presentation of **hyperthermia, lethargy, and sweating** in a patient taking **Trifluoperazine** (a high-potency typical antipsychotic) strongly suggests **Neuroleptic Malignant Syndrome (NMS)**. NMS is a life-threatening idiosyncratic reaction to dopamine antagonists. **Why Option D is Correct:** To confirm the diagnosis and assess the severity of NMS, specific laboratory investigations are critical: * **Hemogram:** Typically shows **leukocytosis** (elevated WBC count), which is a diagnostic marker for NMS. * **Creatine Phosphokinase (CPK):** Severe muscle rigidity (lead-pipe rigidity) leads to muscle necrosis, causing a significant **elevation in serum CPK levels**. * **Renal Function Test (RFT):** Massive muscle breakdown leads to **myoglobinuria**, which can cause **Acute Renal Failure**. Monitoring BUN and Creatinine is vital for management. **Why Other Options are Incorrect:** * **Option A:** CT Scan is used to rule out structural brain lesions or strokes, which do not typically present with this triad of symptoms. * **Option B:** While electrolytes are important in any systemic illness, they are not specific diagnostic markers for NMS compared to CPK. * **Option C:** ECG and Chest X-ray are supportive but do not aid in the primary diagnosis of NMS or the assessment of its most common complication (rhabdomyolysis). **Clinical Pearls for NEET-PG:** * **Mnemonic for NMS (FEVER):** **F**ever, **E**ncephalopathy (lethargy), **V**itals unstable, **E**levated enzymes (CPK), **R**igidity. * **Drug of Choice:** **Dantrolene** (muscle relaxant) or **Bromocriptine** (dopamine agonist). * **Key Difference:** Unlike Serotonin Syndrome, NMS is characterized by **"Lead-pipe" rigidity** and **bradyreflexia**, whereas Serotonin Syndrome presents with hyperreflexia and myoclonus.

Question 268: Which drug is most useful in treating an episode of antipsychotic-induced acute dystonia?

A. Lorazepam
B. Haloperidol
C. Promethazine (Correct Answer)
D. Phenobarbitone

Explanation: **Explanation:** **Acute Dystonia** is an Extrapyramidal Side Effect (EPS) characterized by sudden, involuntary muscle spasms (e.g., torticollis, oculogyric crisis). It occurs due to a functional excess of **acetylcholine** resulting from the blockade of dopamine (D2) receptors in the nigrostriatal pathway by antipsychotics. **Why Promethazine is Correct:** The mainstay of treatment for acute dystonia is **anticholinergic medications**. Promethazine is a first-generation antihistamine with potent **central anticholinergic properties**. It effectively restores the dopamine-acetylcholine balance in the basal ganglia, leading to rapid resolution of muscle spasms. It is often preferred in emergency settings due to its availability in injectable forms. **Analysis of Incorrect Options:** * **A. Lorazepam:** While benzodiazepines can provide muscle relaxation and sedation, they are not the primary treatment for dystonia as they do not address the underlying cholinergic imbalance. * **B. Haloperidol:** This is a high-potency typical antipsychotic and is a common *cause* of acute dystonia. Administering it would worsen the condition. * **C. Phenobarbitone:** This is a barbiturate used for seizures and sedation; it has no role in treating EPS. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** Centrally acting anticholinergics like **Benztropine** (IV/IM) or **Procyclidine**. * **Alternative:** Promethazine or Diphenhydramine (due to anticholinergic effects). * **Risk Factors:** Young males, high-potency antipsychotics (e.g., Haloperidol), and recent initiation of therapy (usually occurs within hours to 5 days). * **Prophylaxis:** If a patient must continue a high-potency antipsychotic, oral anticholinergics (Trihexyphenidyl) are often co-prescribed.

Question 269: Which of the following statements regarding clozapine is incorrect?

A. It was withdrawn from the market during phase 4 clinical trials.
B. It is used in treatment-resistant schizophrenia.
C. It has a narrow therapeutic window. (Correct Answer)
D. It can cause seizures at doses exceeding 300mg/day.

Explanation: ### Explanation **1. Why Option C is the Correct Answer (The Incorrect Statement):** Clozapine does **not** have a narrow therapeutic window. A "narrow therapeutic window" implies that the dose required for efficacy is very close to the dose that causes toxicity (e.g., Lithium, Digoxin, Phenytoin). While Clozapine requires strict monitoring due to its side effect profile (agranulocytosis), its therapeutic range is relatively broad. Serum levels are typically maintained between **350–600 ng/mL**, but toxicity usually manifests at much higher levels (often >1000 ng/mL). **2. Analysis of Incorrect Options (Correct Statements):** * **Option A:** Clozapine was indeed withdrawn in 1975 during Phase 4 (post-marketing surveillance) after several deaths in Finland due to **agranulocytosis**. It was later reintroduced in 1989 with mandatory hematological monitoring. * **Option B:** It is the **gold standard** and the only FDA-approved drug for **treatment-resistant schizophrenia** (defined as failure of at least two different antipsychotic trials of adequate dose and duration). * **Option D:** Clozapine causes **dose-dependent seizures**. The risk increases significantly at doses above **300–450 mg/day**, reaching approximately 5% at doses above 600 mg/day. **3. High-Yield Clinical Pearls for NEET-PG:** * **Agranulocytosis:** Occurs in ~1% of patients. Monitor Absolute Neutrophil Count (ANC) weekly for the first 6 months. * **Metabolic Side Effects:** Highest risk among antipsychotics for weight gain, dyslipidemia, and Type 2 Diabetes. * **Sialorrhea:** Paradoxical excessive salivation (often nocturnal) is a common side effect. * **Myocarditis:** A rare but fatal side effect; usually occurs within the first month of treatment. * **No Extrapyramidal Symptoms (EPS):** It has the lowest risk of EPS and Tardive Dyskinesia because it is a weak D2 blocker and a potent 5HT2A antagonist.

Question 270: A 25-year-old man with a psychotic illness was treated with haloperidol 30mg/day. On the third day, he developed pacing and an inability to sit still. Which medication is likely to be helpful?

A. Phenytoin
B. Propranolol (Correct Answer)
C. Methylphenidate
D. Trihexyphenidyl

Explanation: ### Explanation **Diagnosis: Akathisia** The patient is experiencing **Akathisia**, a common Extrapyramidal Side Effect (EPS) occurring within days of starting high-potency antipsychotics like Haloperidol. It is clinically characterized by subjective feelings of inner restlessness and objective signs of pacing or an inability to sit still. **Why Propranolol is Correct:** **Propranolol**, a lipophilic beta-blocker, is the **first-line treatment** for akathisia. It crosses the blood-brain barrier and acts on central beta-receptors to alleviate the symptoms of restlessness. Benzodiazepines (like Lorazepam) are considered second-line. **Why Other Options are Incorrect:** * **A. Phenytoin:** This is an antiepileptic medication used for generalized tonic-clonic seizures; it has no role in managing movement disorders caused by antipsychotics. * **C. Methylphenidate:** This is a CNS stimulant used for ADHD. It can actually worsen psychosis and agitation. * **D. Trihexyphenidyl:** This is an anticholinergic used to treat **Acute Dystonia** (muscle spasms) and **Drug-Induced Parkinsonism** (tremors/rigidity). While frequently tested, it is generally **less effective** than propranolol for akathisia. **High-Yield Clinical Pearls for NEET-PG:** * **Timeline of EPS:** 1. **Acute Dystonia:** Hours to days (Treatment: Promethazine/Trihexyphenidyl). 2. **Akathisia:** Days to weeks (Treatment: Propranolol). 3. **Drug-Induced Parkinsonism:** Weeks to months (Treatment: Trihexyphenidyl). 4. **Tardive Dyskinesia:** Months to years (Treatment: Switch to Clozapine/VMAT2 inhibitors). * **Key Differentiator:** Akathisia is often mistaken for worsening psychotic agitation. Increasing the antipsychotic dose will worsen akathisia, whereas it might improve agitation. Always look for the "pacing" keyword.

Question 271: Coarse tremors, polyuria, and hypothyroidism are adverse effects of which of the following medications?

A. Lithium (Correct Answer)
B. Haloperidol
C. Imipramine
D. Valproate

Explanation: **Explanation:** **Lithium** is the correct answer. It is a monovalent cation used as a first-line mood stabilizer for Bipolar Affective Disorder (BPAD). Its narrow therapeutic index (0.6–1.2 mEq/L) leads to a distinct side-effect profile: * **Coarse Tremors:** While fine tremors are common at therapeutic levels, **coarse tremors** are a hallmark sign of **Lithium Toxicity**. * **Polyuria:** Lithium inhibits the action of ADH on the distal tubules, leading to **Nephrogenic Diabetes Insipidus**. * **Hypothyroidism:** Lithium interferes with iodine organification and thyroid hormone release, often presenting with goiter or elevated TSH. **Analysis of Incorrect Options:** * **Haloperidol:** A typical antipsychotic primarily associated with **Extrapyramidal Side Effects (EPS)** like dystonia, akathisia, and tardive dyskinesia, rather than metabolic or renal issues. * **Imipramine:** A Tricyclic Antidepressant (TCA) known for **anticholinergic effects** (dry mouth, blurred vision, constipation) and cardiotoxicity (prolonged QTc). * **Valproate:** An anticonvulsant mood stabilizer. Common side effects include **weight gain, alopecia, hepatotoxicity, and PCOS**, but not polyuria or hypothyroidism. **High-Yield Clinical Pearls for NEET-PG:** * **L-I-T-H:** **L**eukocytosis, **I**nsipidus (Diabetes), **T**remors/Teratogenicity (Ebstein’s Anomaly), **H**ypothyroidism. * **Monitoring:** Thyroid Function Tests (TFT) and Renal Function Tests (RFT) must be done before and during treatment. * **Toxicity Precipitants:** Dehydration, low-sodium diet, and drugs like **NSAIDs, Thiazides, and ACE inhibitors** can increase Lithium levels.

Question 272: Which is a feature of haloperidol toxicity?

A. Weight loss
B. Long QT (Correct Answer)
C. Diarrhea
D. Tendinitis

Explanation: **Explanation:** Haloperidol is a high-potency, typical (first-generation) antipsychotic that acts primarily as a potent **D2 receptor antagonist**. **Why Option B is Correct:** Haloperidol toxicity is strongly associated with cardiovascular side effects, most notably **QT interval prolongation**. This occurs because haloperidol blocks the delayed rectifier potassium channels ($I_{Kr}$) in the cardiac myocytes. Prolongation of the QT interval increases the risk of life-threatening ventricular arrhythmias, specifically **Torsades de Pointes**. This risk is significantly higher with intravenous administration or high doses. **Why Other Options are Incorrect:** * **A. Weight loss:** Antipsychotics, including haloperidol, are more commonly associated with **weight gain** (though less so than atypical antipsychotics like Olanzapine) due to metabolic changes and H1 receptor blockade. * **C. Diarrhea:** Haloperidol possesses mild anticholinergic properties, which are more likely to cause **constipation** rather than diarrhea. * **D. Tendinitis:** This is a classic side effect associated with **Fluoroquinolones** (e.g., Ciprofloxacin), not antipsychotics. **High-Yield Clinical Pearls for NEET-PG:** * **Extrapyramidal Symptoms (EPS):** Due to high D2 potency, Haloperidol has the highest risk of acute dystonia, akathisia, and parkinsonism. * **Neuroleptic Malignant Syndrome (NMS):** A life-threatening reaction characterized by "lead-pipe" rigidity, hyperthermia, and autonomic instability. * **Hyperprolactinemia:** Haloperidol frequently causes galactorrhea and gynecomastia by blocking dopamine in the tuberoinfundibular pathway. * **Monitoring:** Always perform a baseline ECG before starting high-dose or IV haloperidol to monitor the QTc interval.

Question 273: Which of the following is the drug of choice for Obsessive-Compulsive Disorder (OCD)?

A. Haloperidol
B. Clozapine
C. Doxepin
D. Clomipramine (Correct Answer)

Explanation: **Explanation:** **Correct Answer: D. Clomipramine** The pharmacological management of Obsessive-Compulsive Disorder (OCD) primarily involves enhancing serotonergic neurotransmission. **Clomipramine**, a Tricyclic Antidepressant (TCA), is considered the "gold standard" and the most effective drug for OCD due to its potent and selective inhibition of serotonin reuptake. While Selective Serotonin Reuptake Inhibitors (SSRIs) like Fluoxetine or Fluvoxamine are often used as first-line agents due to a better side-effect profile, Clomipramine remains the drug of choice in terms of absolute efficacy, especially in refractory cases. **Analysis of Incorrect Options:** * **A. Haloperidol:** This is a typical antipsychotic (D2 blocker). It is not a primary treatment for OCD but may be used as an *augmentation* strategy in patients with comorbid tics or those resistant to SSRIs. * **B. Clozapine:** An atypical antipsychotic used for treatment-resistant schizophrenia. Interestingly, Clozapine can actually *induce* or worsen obsessive-compulsive symptoms as a side effect. * **C. Doxepin:** A TCA primarily used for insomnia and depression. Unlike Clomipramine, it lacks the specific, potent serotonergic activity required to treat OCD effectively. **Clinical Pearls for NEET-PG:** * **Dosage:** OCD requires higher doses of SSRIs/Clomipramine compared to depression. * **Latency:** Clinical response in OCD takes longer (8–12 weeks) than in depression (2–4 weeks). * **First-line:** While Clomipramine is the most effective, **SSRIs** are the first-line treatment due to safety. * **Mechanism:** Clomipramine’s metabolite, desmethylclomipramine, also inhibits norepinephrine reuptake, but its anti-obsessional effect is strictly linked to its parent compound's serotonergic action.

Question 274: Which of the following is the best treatment for extrapyramidal symptoms?

A. Procyclidine
B. Metoclopramide
C. Haloperidol
D. Trihexyphenidyl (Correct Answer)

Explanation: ### Explanation **Correct Answer: D. Trihexyphenidyl** **Mechanism and Rationale:** Extrapyramidal symptoms (EPS)—such as acute dystonia, parkinsonism, and akathisia—are primarily caused by a blockade of dopamine ($D_2$) receptors in the nigrostriatal pathway. This leads to a relative **excess of cholinergic activity**. Anticholinergic drugs restore the dopaminergic-cholinergic balance. **Trihexyphenidyl (Benzhexol)** is a potent centrally acting anticholinergic and is considered the first-line treatment for drug-induced parkinsonism and acute dystonia. **Analysis of Options:** * **A. Procyclidine:** While also an anticholinergic used for EPS, Trihexyphenidyl is more frequently cited in standard textbooks and clinical practice as the "best" or most common initial choice for long-term management of EPS in the Indian context. * **B. Metoclopramide:** This is a dopamine antagonist used as an antiemetic. It is a **cause** of EPS, not a treatment. * **C. Haloperidol:** This is a high-potency typical antipsychotic. It is one of the most common culprits for **inducing** EPS due to its strong $D_2$ receptor antagonism. **NEET-PG High-Yield Pearls:** * **Acute Dystonia:** The earliest EPS to appear (within hours/days). Treatment of choice: Intravenous/Intramuscular Promethazine or Benztropine. * **Akathisia:** The most common EPS. Treatment of choice: **Propranolol** (Beta-blocker). * **Tardive Dyskinesia:** Occurs after long-term use. Characterized by orofacial dyskinesia. Anticholinergics like Trihexyphenidyl can **worsen** this condition. Treatment: Switching to Clozapine or using VMAT2 inhibitors (Valbenazine). * **Drug of choice for Neuroleptic Malignant Syndrome (NMS):** Dantrolene or Bromocriptine.

Question 275: What is the drug of choice for bipolar disorder?

A. Lithium (Correct Answer)
B. Imipramine
C. Phenytoin
D. Clozapine

Explanation: **Explanation:** **Lithium (Option A)** is the gold-standard treatment and the **drug of choice for Bipolar Disorder (Bipolar Affective Disorder - BPAD)**. It is effective for treating acute manic episodes and serves as the primary maintenance therapy to prevent both manic and depressive relapses. Its unique clinical value lies in its proven **anti-suicidal properties**, a high-yield fact for NEET-PG. Lithium works by modulating second messenger systems (inhibiting inositol monophosphatase) and stabilizing neuronal membranes. **Why other options are incorrect:** * **Imipramine (Option B):** This is a Tricyclic Antidepressant (TCA). While it treats depression, using it in bipolar patients can trigger a "switch" into acute mania. * **Phenytoin (Option C):** Although an anticonvulsant, it has no role in mood stabilization. Other anticonvulsants like Valproate, Carbamazepine, and Lamotrigine are used in BPAD, but Lithium remains the first-line choice. * **Clozapine (Option D):** An atypical antipsychotic reserved for treatment-resistant schizophrenia. While some antipsychotics (like Olanzapine) are used in mania, Clozapine is not the first-line drug for BPAD. **High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Index:** Lithium has a narrow therapeutic index. Target serum levels: **0.8–1.2 mEq/L** (Acute Mania) and **0.6–0.8 mEq/L** (Maintenance). * **Teratogenicity:** Use in pregnancy is associated with **Ebstein’s Anomaly** (atrialization of the right ventricle). * **Side Effects:** Common ones include fine tremors, polyuria (nephrogenic diabetes insipidus), hypothyroidism, and weight gain. * **Drug of Choice for Rapid Cyclers:** Valproate (not Lithium).

Question 276: Which of the following is given to a patient who is planned for ECT?

A. Diazepam
B. Phenytoin
C. Muscle relaxant (Correct Answer)
D. Barbiturate

Explanation: ### Explanation **Correct Option: C. Muscle relaxant** In modern Electroconvulsive Therapy (ECT), the procedure is performed under **modified** conditions, meaning general anesthesia and muscle relaxation are mandatory. The primary goal of using a muscle relaxant—most commonly **Succinylcholine** (a short-acting depolarizing agent)—is to prevent the peripheral musculoskeletal manifestations of the seizure. Without it, the intense muscle contractions could lead to bone fractures, joint dislocations, or tongue bites. By blocking the neuromuscular junction, the patient experiences a "modified" seizure where the brain activity (EEG) shows seizure patterns, but the body remains still. **Why other options are incorrect:** * **A. Diazepam & B. Phenytoin:** These are anticonvulsants. Since the therapeutic efficacy of ECT depends on inducing a generalized cerebral seizure of adequate duration (usually >20-25 seconds), drugs that **increase the seizure threshold** or shorten seizure duration are generally avoided or tapered before the procedure. * **D. Barbiturate:** While ultra-short-acting barbiturates (like **Methohexital** or Thiopental) are used as *anesthetic agents* in ECT, the question asks for what is "given" in the context of standard preparation. Between a sedative and a muscle relaxant, the muscle relaxant is the specific requirement to prevent the physical trauma of the fit. **High-Yield Clinical Pearls for NEET-PG:** 1. **Drug of Choice for Anesthesia:** Methohexital (due to its short recovery time and minimal effect on seizure threshold). 2. **Drug of Choice for Muscle Relaxation:** Succinylcholine. 3. **Pre-medication:** Atropine or Glycopyrrolate is often given to prevent vagally-mediated bradycardia and reduce secretions. 4. **Absolute Contraindication:** Increased intracranial pressure (ICP) is the only absolute contraindication for ECT. 5. **Most Common Side Effect:** Retrograde amnesia and post-ictal confusion.

Question 277: A patient with schizophrenia is responding well to haloperidol but has developed symptoms of parkinsonism. What is the drug of choice to treat this condition?

A. Levodopa
B. Bromocriptine
C. Tolcapone
D. Anticholinergic (Correct Answer)

Explanation: **Explanation:** The patient is experiencing **Drug-Induced Parkinsonism (DIP)**, a common Extrapyramidal Side Effect (EPS) of typical antipsychotics like Haloperidol. **1. Why Anticholinergics are the Drug of Choice:** Antipsychotics work by blocking Dopamine ($D_2$) receptors in the nigrostriatal pathway. In the basal ganglia, there is a functional balance between **Dopamine (inhibitory)** and **Acetylcholine (excitatory)**. When dopamine is blocked, acetylcholine becomes relatively overactive, leading to motor symptoms (tremor, rigidity, bradykinesia). **Anticholinergics** (e.g., **Benztropine, Trihexyphenidyl/Benzhexol, Biperiden**) restore this balance by reducing cholinergic activity. **2. Why other options are incorrect:** * **Levodopa (A) & Bromocriptine (B):** These are dopamine agonists used in idiopathic Parkinson’s disease. In schizophrenia, they are **contraindicated** because increasing dopamine levels can exacerbate or "rekindle" psychotic symptoms (the Dopamine Hypothesis of Schizophrenia). * **Tolcapone (C):** This is a COMT inhibitor used as an adjunct in Parkinson’s disease to prevent levodopa breakdown. It has no role in treating EPS and carries a risk of hepatotoxicity. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice for Akathisia:** Beta-blockers (Propranolol). * **Drug of Choice for Acute Dystonia:** Intravenous/Intramuscular Anticholinergics (Promethazine or Benztropine). * **Tardive Dyskinesia:** Unlike other EPS, this is caused by dopamine receptor supersensitivity; anticholinergics can actually **worsen** it. Treatment involves Valbenazine or Deutetrabenazine (VMAT2 inhibitors). * **Amantadine:** An alternative for DIP if anticholinergics are poorly tolerated.

Question 278: A patient with endogenous depression is administered imipramine. After what time interval is the therapeutic effect of imipramine likely to manifest?

A. 3 days
B. 1 week
C. 3 weeks (Correct Answer)
D. 3 months

Explanation: ### Explanation **Correct Answer: C. 3 weeks** **Mechanism and Rationale:** Imipramine is a **Tricyclic Antidepressant (TCA)**. While TCAs immediately block the reuptake of norepinephrine and serotonin at the synaptic cleft, the clinical antidepressant effect is not immediate. The therapeutic lag is attributed to the time required for **downregulation (desensitization) of post-synaptic beta-adrenergic receptors and presynaptic alpha-2 receptors**, as well as changes in gene expression (e.g., increased BDNF). In clinical practice, a noticeable improvement in mood typically manifests after **2 to 3 weeks** of continuous therapy. **Analysis of Incorrect Options:** * **A & B (3 days / 1 week):** These are too early for a therapeutic response. While patients may experience immediate side effects (like sedation or anticholinergic effects) or a slight improvement in sleep/anxiety, the core symptoms of depression do not lift within the first week. * **D (3 months):** This is far too long. If a patient shows no response by 4–6 weeks at an adequate dose, the treatment is usually considered a failure, and a switch to a different class of drugs is indicated. **High-Yield Clinical Pearls for NEET-PG:** * **The "Lag Period":** Always counsel patients that while side effects appear early, the "mood-lifting" effect takes 2–3 weeks. * **Suicide Risk:** During the first 1–2 weeks of treatment, physical energy (psychomotor activity) may improve before the depressive mood lifts. This creates a dangerous window where the patient may have the energy to act on suicidal ideation. * **Overdose Triad (The 3 C's):** Convulsions, Coma, and Cardiac arrhythmias (due to sodium channel blockade). * **Drug of Choice:** Imipramine is historically the drug of choice for **Enuresis (bed-wetting)** in children, though it is now a second-line option.

Question 279: Which of the following statements is FALSE regarding Neuroleptic Malignant Syndrome (NMS)?

A. Combining antipsychotics and antidepressants increases the risk of NMS.
B. An increase in Creatinine Phosphokinase (CPK) always indicates NMS. (Correct Answer)
C. First use of an injectable antipsychotic is a risk factor.
D. Catatonic symptoms and autonomic dysfunction are features of NMS.

Explanation: **Explanation:** **Neuroleptic Malignant Syndrome (NMS)** is a rare but life-threatening idiosyncratic reaction to dopamine antagonists (typically antipsychotics). **Why Option B is the Correct Answer (False Statement):** While an elevated **Creatinine Phosphokinase (CPK)** is a hallmark laboratory finding in NMS (due to intense muscle rigidity and rhabdomyolysis), it is **not pathognomonic**. CPK can be elevated in various other conditions such as myocardial infarction, strenuous exercise, intramuscular injections, status epilepticus, and other drug reactions (e.g., Serotonin Syndrome). Diagnosis of NMS is primarily clinical, based on the tetrad of fever, rigidity, altered mental status, and autonomic instability. **Analysis of Other Options:** * **Option A:** Polypharmacy, especially the combination of antipsychotics with lithium or certain antidepressants, significantly increases the risk of developing NMS. * **Option C:** High-potency neuroleptics, rapid dose escalation, and the use of **parenteral (injectable) forms** are well-established risk factors for NMS. * **Option D:** NMS is characterized by "lead-pipe" rigidity (a form of catatonic symptom) and profound **autonomic dysfunction** (tachycardia, labile blood pressure, and diaphoresis). **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Massive dopamine (D2) blockade in the nigrostriatal pathway and hypothalamus. * **Drug of Choice:** **Dantrolene** (muscle relaxant) or **Bromocriptine** (dopamine agonist). * **NMS vs. Serotonin Syndrome:** NMS presents with "Lead-pipe" rigidity and bradyreflexia, whereas Serotonin Syndrome presents with hyperreflexia and myoclonus. * **First Step in Management:** Immediate discontinuation of the offending antipsychotic agent.

Question 280: Which of the following medications is known to cause pancreatitis as a side effect?

A. Valproate (Correct Answer)
B. Clonazepam
C. Clozapine
D. Amisulpride

Explanation: **Explanation:** **Valproate (Sodium Valproate/Valproic Acid)** is a broad-spectrum antiepileptic and mood stabilizer. It is a well-documented, though rare, cause of **drug-induced acute pancreatitis**. The mechanism is thought to involve the depletion of free radical scavengers or the accumulation of toxic metabolites (like 4-pentenoic acid), leading to direct pancreatic acinar cell injury. This side effect is idiosyncratic, meaning it is not necessarily dose-dependent and can occur at any time during treatment. **Analysis of Incorrect Options:** * **Clonazepam:** A benzodiazepine primarily associated with sedation, ataxia, and cognitive impairment. It does not have a known association with pancreatitis. * **Clozapine:** An atypical antipsychotic known for severe side effects like **agranulocytosis**, seizures, and myocarditis. While it can cause metabolic syndrome and hypertriglyceridemia (which is a risk factor for pancreatitis), it is not the primary drug associated with direct pancreatic toxicity in this list. * **Amisulpride:** An atypical antipsychotic (substituted benzamide) mainly associated with **hyperprolactinemia** and extrapyramidal symptoms. It is not linked to pancreatitis. **High-Yield Clinical Pearls for NEET-PG:** * **Valproate Side Effects (Mnemonic: VALPROATE):** **V**omiting, **A**lopecia, **L**iver toxicity (Hepatotoxicity), **P**ancreatitis/PCOS, **R**etention of weight (Obesity), **O**edema, **A**terixis (due to hyperammonemia), **T**eratogenicity (Neural Tube Defects), **E**nzyme inhibitor. * **Monitoring:** If a patient on Valproate develops acute abdominal pain and vomiting, immediate serum **amylase and lipase** levels must be checked. * **Teratogenicity:** Valproate is the most teratogenic antiepileptic, specifically causing **Spina Bifida**.

Question 281: A patient with schizophrenia, treated for 5 years, develops perioral movements. What is the likely diagnosis?

A. Tardive dyskinesia (Correct Answer)
B. Muscular dystonia
C. Akathisia
D. Malignant neuroleptic syndrome

Explanation: ### Explanation **1. Why Tardive Dyskinesia (TD) is the Correct Answer:** Tardive dyskinesia is a delayed-onset movement disorder caused by long-term blockade of dopamine (D2) receptors, leading to **upregulation and supersensitivity** of these receptors in the nigrostriatal pathway. The classic presentation involves involuntary, repetitive, purposeless movements, most commonly involving the **perioral region** (tongue protrusion, lip-smacking, puckering, or "rabbit syndrome"). The key diagnostic clue in this question is the **long duration of treatment (5 years)**; "Tardive" literally means late-onset. **2. Why the Other Options are Incorrect:** * **Muscular Dystonia:** This is an *acute* extrapyramidal side effect (EPS) occurring within hours to days of starting antipsychotics. It involves sustained, painful muscle contractions (e.g., torticollis or oculogyric crisis). * **Akathisia:** This refers to subjective feelings of inner restlessness and the inability to sit still. It typically occurs within days to weeks of treatment, not years. * **Neuroleptic Malignant Syndrome (NMS):** This is a life-threatening emergency characterized by the "tetrad" of muscle rigidity ("lead-pipe"), fever, autonomic instability, and altered mental status. It is not characterized by isolated perioral movements. **3. High-Yield Clinical Pearls for NEET-PG:** * **Risk Factors:** Old age, female gender, and long-term use of typical (first-generation) antipsychotics. * **Management:** The first step is to **reduce the dose** or switch to an atypical antipsychotic with low D2 affinity, specifically **Clozapine** (the drug of choice if TD is severe). * **Newer Treatments:** VMAT-2 inhibitors like **Valbenazine** or **Deutetrabenazine** are now FDA-approved for TD. * **Prognosis:** Unlike acute EPS, TD may be irreversible even after discontinuing the offending drug. Anticholinergics (like Benztropine) often **worsen** TD symptoms.

Question 282: A 25-year-old man with major depression discusses the potential benefits and side effects of various antidepressants with his psychiatrist. He clearly indicates that he does not want a medication that could decrease his libido or interfere with his ability to obtain and maintain an erection. Which of the listed antidepressants would be appropriate for this patient?

A. Bupropion (Correct Answer)
B. Clomipramine
C. Amitriptyline
D. Sertraline

Explanation: **Explanation:** The correct answer is **Bupropion**. Sexual dysfunction (decreased libido, erectile dysfunction, and anorgasmia) is one of the most common reasons for non-compliance with antidepressant therapy. **Why Bupropion is correct:** Bupropion is an **Atypical Antidepressant** that acts as a **Norepinephrine-Dopamine Reuptake Inhibitor (NDRI)**. Unlike most other antidepressants, it does not have significant serotonergic activity. Sexual side effects are primarily mediated by the stimulation of 5-HT2 receptors; since Bupropion lacks this mechanism, it has a "neutral" effect on sexual function and is often used as an alternative or an adjunct to reverse SSRI-induced sexual dysfunction. **Why the other options are incorrect:** * **Sertraline (Option D):** As an **SSRI**, it is the class most frequently associated with sexual dysfunction (up to 60-70% of patients). It increases synaptic serotonin, which inhibits sexual desire and arousal. * **Clomipramine & Amitriptyline (Options B & C):** These are **Tricyclic Antidepressants (TCAs)**. They cause sexual dysfunction through multiple mechanisms, including serotonergic activity and strong anticholinergic effects (which can interfere with the parasympathetic-mediated erectile response). Clomipramine, specifically, is a potent serotonin reuptake inhibitor and has the highest rate of sexual side effects among TCAs. **NEET-PG High-Yield Pearls:** * **Weight Neutrality:** Bupropion is also preferred in patients concerned about weight gain. * **Contraindication:** It must be avoided in patients with **Seizure disorders** or **Eating disorders** (Bulimia/Anorexia) as it lowers the seizure threshold. * **Smoking Cessation:** It is also FDA-approved for smoking cessation. * **Other "Sexually Safe" Antidepressants:** Mirtazapine and Vilazodone.

Question 283: Which of the following psychiatric disorders, apart from depression, are commonly treated with selective serotonin reuptake inhibitors?

A. Phobias
B. Obsessive compulsive disorder
C. Post-traumatic stress disorder
D. All of the above (Correct Answer)

Explanation: **Explanation:** Selective Serotonin Reuptake Inhibitors (SSRIs) are the first-line pharmacological treatment for a wide spectrum of psychiatric conditions beyond Major Depressive Disorder. Their primary mechanism involves inhibiting the presynaptic reuptake of serotonin (5-HT), thereby increasing its availability in the synaptic cleft and modulating downstream neurocircuitry involved in anxiety and impulse control. * **Obsessive-Compulsive Disorder (OCD):** SSRIs (e.g., Fluoxetine, Fluvoxamine, Sertraline) are the gold standard. Note that OCD typically requires **higher doses** of SSRIs and a longer duration (10–12 weeks) to show a clinical response compared to depression. * **Phobias:** SSRIs are highly effective for **Social Anxiety Disorder (Social Phobia)** and Panic Disorder (with or without agoraphobia). They help reduce the limbic system's hypersensitivity to perceived threats. * **Post-Traumatic Stress Disorder (PTSD):** SSRIs (specifically Sertraline and Paroxetine) are FDA-approved first-line agents. They address the core symptoms of intrusive thoughts, avoidance, and hyperarousal. **Why "All of the above" is correct:** Since SSRIs are the first-line treatment for OCD, PTSD, and various Phobias/Anxiety disorders, all listed options are clinically accurate. **High-Yield Clinical Pearls for NEET-PG:** * **First-line for most:** SSRIs are the first-line for Depression, OCD, PTSD, Panic Disorder, GAD, and Bulimia Nervosa (specifically Fluoxetine). * **Side Effects:** Most common acute side effect is **GI upset** (nausea/diarrhea); most common long-term side effect is **sexual dysfunction** (delayed ejaculation). * **Drug of choice for OCD in children:** Sertraline or Fluvoxamine. * **Shortest half-life:** Fluvoxamine; **Longest half-life:** Fluoxetine (least likely to cause discontinuation syndrome).

Question 284: What is the toxic level of lithium?

A. 0.6 mEq/L
B. 1.2 mEq/L
C. 2.6 mEq/L (Correct Answer)
D. <0.6 mEq/L

Explanation: ### Explanation Lithium is a mood stabilizer with a **narrow therapeutic index**, meaning the margin between a therapeutic dose and a toxic dose is very small. Regular Therapeutic Drug Monitoring (TDM) is essential for patient safety. **1. Why Option C (2.6 mEq/L) is Correct:** Lithium toxicity is generally categorized into three levels based on serum concentration: * **Mild to Moderate:** 1.5 – 2.0 mEq/L * **Moderate to Severe:** 2.0 – 2.5 mEq/L * **Life-threatening:** **>2.5 mEq/L** At **2.6 mEq/L**, the patient is in the range of severe toxicity, which can manifest as seizures, coma, cardiac arrhythmias, and permanent neurological damage. Hemodialysis is often indicated when levels exceed 2.5 mEq/L in acute-on-chronic poisoning. **2. Why Other Options are Incorrect:** * **Option A (0.6 mEq/L):** This is the **lower limit** of the therapeutic range for maintenance therapy in Bipolar Disorder. * **Option B (1.2 mEq/L):** This is the **upper limit** of the therapeutic range. Levels between 0.8 and 1.2 mEq/L are typically targeted during acute manic episodes. * **Option D (<0.6 mEq/L):** This is considered a **sub-therapeutic level**, where the drug is unlikely to be effective in preventing mood episodes. **3. High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Range:** 0.6 – 1.2 mEq/L (Maintenance: 0.6–0.8; Acute Mania: 0.8–1.2). * **Sampling Time:** Blood should be drawn **12 hours after the last dose** (trough level). * **Early Signs of Toxicity:** Coarse tremors (fine tremors are a side effect), vomiting, diarrhea, and ataxia. * **Drug Interactions:** **NSAIDs, Thiazides, and ACE inhibitors** increase lithium levels (by decreasing renal clearance), while high sodium intake or caffeine can decrease levels. * **Ebstein’s Anomaly:** The classic teratogenic risk associated with Lithium use in the first trimester.

Question 285: Which of the following is not a side effect of lithium?

A. Blood dyscrasias (Correct Answer)
B. Polyuria
C. Hypothyroidism
D. Weight gain

Explanation: **Explanation:** Lithium is the gold-standard mood stabilizer for Bipolar Affective Disorder (BPAD), but it has a narrow therapeutic index and a wide range of systemic side effects. **Why Blood Dyscrasias is the Correct Answer:** Lithium does **not** cause blood dyscrasias (like agranulocytosis or aplastic anemia). In fact, it causes the opposite effect: **Leukocytosis** (specifically neutrophilia). It stimulates granulopoiesis in the bone marrow. This is a benign side effect, though it can sometimes be used therapeutically to treat Felty’s syndrome or chemotherapy-induced neutropenia. **Analysis of Incorrect Options:** * **Polyuria:** Lithium inhibits the action of Antidiuretic Hormone (ADH) on the distal tubules, leading to **Nephrogenic Diabetes Insipidus**. This results in polyuria and compensatory polydipsia. * **Hypothyroidism:** Lithium interferes with iodine organification and thyroid hormone release. It is a common cause of goiter and hypothyroidism, necessitating regular TSH monitoring. * **Weight Gain:** This is a very common metabolic side effect of Lithium, often leading to poor patient compliance. **High-Yield Clinical Pearls for NEET-PG:** * **L-I-T-H-I-U-M Mnemonic for Side Effects:** **L**eukocytosis, **I**nsipidus (Diabetes), **T**remors (Fine)/Teratogenicity (Ebstein's Anomaly), **H**ypothyroidism, **I**ncreased Weight, **U**nder-active heart (Sinus bradycardia), **M**others (Pregnancy contraindication). * **Therapeutic Range:** 0.6–1.2 mEq/L (Prophylaxis: 0.6–0.8; Acute Mania: 0.8–1.2). * **Toxicity:** Occurs >1.5 mEq/L; characterized by **coarse tremors**, ataxia, and seizures. * **Drug Interactions:** Thiazides, NSAIDs, and ACE inhibitors increase Lithium levels (Decreased clearance).

Question 286: An appropriate pre-Lithium work-up includes all of the following, EXCEPT?

A. Erythrocyte sedimentation rate (Correct Answer)
B. Serum creatinine
C. Thyroid-stimulating hormone (TSH)
D. Serum electrolytes

Explanation: Lithium is the gold-standard mood stabilizer for Bipolar Affective Disorder (BPAD), but its narrow therapeutic index and multi-organ side effects necessitate a rigorous baseline work-up. **Explanation of the Correct Answer:** **A. Erythrocyte sedimentation rate (ESR):** This is the correct answer because ESR is a non-specific marker of inflammation. Lithium does not affect the inflammatory cascade or connective tissues in a way that requires baseline ESR monitoring. It has no clinical utility in predicting Lithium toxicity or monitoring its side effects. **Explanation of Incorrect Options:** * **B. Serum Creatinine:** Lithium is almost exclusively excreted by the kidneys. Baseline renal function tests (RFTs) are mandatory because pre-existing renal impairment increases the risk of toxicity. Long-term use can also cause nephrogenic diabetes insipidus or interstitial nephritis. * **C. Thyroid-stimulating hormone (TSH):** Lithium inhibits the release of thyroid hormones. It is a common cause of drug-induced hypothyroidism and goiter. Baseline TSH is essential to distinguish pre-existing thyroid dysfunction from Lithium-induced effects. * **D. Serum Electrolytes:** Lithium is handled by the proximal tubule similarly to sodium. Hyponatremia (due to diuretics or dehydration) leads to increased Lithium reabsorption, precipitating toxicity. Baseline levels help monitor this balance. **High-Yield Clinical Pearls for NEET-PG:** * **The "Lithium Checklist":** Before starting, check **RFT** (Creatinine/BUN), **Thyroid** (TSH), **Electrolytes**, **ECG** (for patients >40 or with cardiac history), and **Pregnancy Test** (risk of Ebstein’s Anomaly). * **CBC:** Lithium causes benign **leukocytosis** (increased WBC count), which is a common "trick" question. * **Therapeutic Range:** 0.6–1.2 mEq/L (Prophylaxis: 0.6–0.8; Acute Mania: 0.8–1.2). * **Toxicity:** Usually occurs at levels >1.5 mEq/L. Dialysis is indicated if levels >4.0 mEq/L (acute) or >2.5 mEq/L (chronic with symptoms).

Question 287: What is the prophylactic maintenance serum level of lithium?

A. 0.5 - 0.8 mEq/L (Correct Answer)
B. 0.7 - 1.2 mEq/L
C. 1.2 - 2.0 mEq/L
D. 2.0 - 2.5 mEq/L

Explanation: Lithium is a mood stabilizer with a narrow therapeutic index, meaning the margin between a therapeutic dose and a toxic dose is very small. Monitoring serum levels is critical for safety and efficacy. **Explanation of the Correct Answer:** * **Option A (0.5 – 0.8 mEq/L):** This is the standard range for **prophylactic maintenance** in patients with Bipolar Disorder who are currently stable. Maintaining levels at the lower end of the therapeutic spectrum minimizes long-term side effects (like renal or thyroid toxicity) while preventing future manic or depressive episodes. **Explanation of Incorrect Options:** * **Option B (0.7 – 1.2 mEq/L):** This range is typically reserved for the **Acute Manic Phase**. During an active episode, higher concentrations are required to achieve clinical stabilization. * **Option C (1.2 – 2.0 mEq/L):** This range indicates **Mild to Moderate Toxicity**. Patients may present with coarse tremors, vomiting, diarrhea, and ataxia. * **Option D (2.0 – 2.5 mEq/L):** This indicates **Severe Toxicity**. It is a medical emergency that can lead to seizures, coma, and death. Hemodialysis is often indicated if levels exceed 2.5 mEq/L (or 4.0 mEq/L in chronic users). **High-Yield Clinical Pearls for NEET-PG:** * **Sampling Time:** Serum levels should be measured **12 hours after the last dose** (Trough level). * **Steady State:** It takes approximately **5 days** (5 half-lives) to reach a steady state after starting or changing a dose. * **Teratogenicity:** Lithium is associated with **Ebstein’s Anomaly** (atrialization of the right ventricle) if taken during the first trimester. * **Drug Interactions:** Thiazides, NSAIDs, and ACE inhibitors can **increase** lithium levels, leading to toxicity.

Question 288: Deep brain stimulation has been approved for the treatment of which of the following conditions?

A. Movement disorders like Parkinsonism (Correct Answer)
B. Schizophrenia
C. Depression
D. Anxiety disorder

Explanation: **Explanation:** **Deep Brain Stimulation (DBS)** is a neurosurgical procedure involving the implantation of electrodes in specific brain regions, which are connected to a pulse generator (IPG). It acts as a "brain pacemaker," modulating abnormal neural circuits through electrical impulses. **Why Option A is Correct:** DBS is a well-established, FDA-approved treatment for **Movement Disorders**, particularly when symptoms are no longer adequately controlled by medications. Key targets include: * **Parkinson’s Disease:** Subthalamic Nucleus (STN) or Globus Pallidus interna (GPi). * **Essential Tremor:** Ventral Intermediate Nucleus (VIM) of the Thalamus. * **Dystonia:** Globus Pallidus interna (GPi). **Why Other Options are Incorrect:** * **B. Schizophrenia:** DBS is currently experimental for schizophrenia. There is no standard clinical approval for its use in treating psychosis. * **C. Depression:** While DBS for Treatment-Resistant Depression (targeting the Subgenual Cingulate Cortex/Area 25) is being heavily researched, it is **not yet routinely approved** or considered first-line. (Note: ECT and rTMS are the standard neuromodulation therapies for depression). * **D. Anxiety Disorder:** DBS is not a standard treatment for generalized anxiety. However, it has received **Humanitarian Device Exemption (HDE)** for severe, refractory **Obsessive-Compulsive Disorder (OCD)**, targeting the Internal Capsule. **High-Yield Clinical Pearls for NEET-PG:** * **OCD:** The only psychiatric condition where DBS has a specific (HDE) approval for refractory cases. * **Vagus Nerve Stimulation (VNS):** Approved for refractory Epilepsy and Treatment-Resistant Depression. * **Transcranial Magnetic Stimulation (rTMS):** Non-invasive; approved for Depression and OCD. * **Most common target for Parkinson's DBS:** Subthalamic Nucleus (STN).

Question 289: Therapeutic level of lithium is:

A. 0.5-1.0 mEq/L
B. 1.0-1.5 mEq/L
C. 0.8-1.2 mEq/L (Correct Answer)
D. 1.5-2.0 mEq/L

Explanation: ### Explanation Lithium is the gold-standard mood stabilizer used for the treatment of Bipolar Affective Disorder (BPAD). It has a **narrow therapeutic index**, meaning the margin between a therapeutic dose and a toxic dose is very small. Therefore, Therapeutic Drug Monitoring (TDM) is mandatory. **1. Why Option C is Correct:** The standard therapeutic range for **acute mania** is generally accepted as **0.8–1.2 mEq/L**. At this level, lithium effectively controls manic symptoms while minimizing the risk of severe toxicity. For **maintenance therapy** (prophylaxis), the range is slightly lower, typically **0.6–0.8 mEq/L**. **2. Analysis of Incorrect Options:** * **Option A (0.5–1.0 mEq/L):** While the upper end is therapeutic, the lower end (0.5) is often sub-therapeutic for acute episodes, though it may be used in elderly patients. * **Option B (1.0–1.5 mEq/L):** This range borders on toxicity. Levels above 1.2 mEq/L significantly increase the risk of side effects without proportional clinical benefit. * **Option D (1.5–2.0 mEq/L):** This is the **toxic range**. Mild to moderate toxicity begins at 1.5 mEq/L, characterized by coarse tremors, vomiting, and diarrhea. **3. High-Yield Clinical Pearls for NEET-PG:** * **Sampling Time:** Blood for TDM should be drawn **12 hours after the last dose** (Standard 12-hour serum lithium level). * **Steady State:** It takes about **5 days** (5 half-lives) to reach a steady state before the first level should be checked. * **Toxicity Thresholds:** * **>1.5 mEq/L:** Mild toxicity (GI symptoms, coarse tremors). * **>2.0 mEq/L:** Severe toxicity (Seizures, coma, arrhythmias). * **>2.5 mEq/L:** Indication for **Hemodialysis** (the treatment of choice for severe toxicity). * **Drug Interactions:** Thiazides, NSAIDs, and ACE inhibitors increase lithium levels (Risk of toxicity).

Question 290: Antipsychotic-induced akathisia is characterized by which of the following manifestations?

A. Rigidity
B. Tremor
C. Spasm of a muscle or muscle group
D. Restlessness (Correct Answer)

Explanation: **Explanation:** **Akathisia** is the most common extrapyramidal side effect (EPS) associated with antipsychotic medication. It is characterized by a subjective feeling of **inner restlessness** and an objective need to be in constant motion. Patients often describe it as a "desire to jump out of one's skin." Clinically, this manifests as pacing, shifting weight from foot to foot, or inability to sit still. **Why the other options are incorrect:** * **A. Rigidity:** This is a feature of **Drug-Induced Parkinsonism** (often described as "lead-pipe" or "cogwheel" rigidity) or Neuroleptic Malignant Syndrome (NMS). * **B. Tremor:** A rhythmic, oscillatory movement (typically a resting tremor) is another hallmark of **Drug-Induced Parkinsonism**, not akathisia. * **C. Spasm of a muscle group:** This describes **Acute Dystonia**, which involves sudden, involuntary contractions of muscles (e.g., torticollis, oculogyric crisis). Dystonia typically occurs within hours to days of starting medication, whereas akathisia usually appears within days to weeks. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Thought to be due to dopamine (D2) blockade in the nigrostriatal pathway. * **Management:** The first-line treatment for akathisia is **Beta-blockers (Propranolol)**. Centrally acting anticholinergics (like Benztropine) or Benzodiazepines may also be used, but are generally less effective than Propranolol. * **Clinical Significance:** Akathisia is highly distressing and is a major cause of non-compliance and increased suicide risk in patients on antipsychotics.

Question 291: A patient diagnosed with Schizophrenia and exhibiting violent behavior and agitation is being treated with haloperidol. The patient subsequently develops rigidity and inability to move their eyes. Which of the following medications should be administered intravenously to manage these new symptoms?

A. Diazepam
B. Risperidone
C. Promethazine (Correct Answer)
D. Haloperidol

Explanation: ### Explanation **Concept: Acute Dystonia** The patient is experiencing **Acute Dystonia**, a common Extrapyramidal Side Effect (EPS) of high-potency first-generation antipsychotics like Haloperidol. The "rigidity" and "inability to move eyes" (specifically **Oculogyric Crisis**) result from a sudden dopamine-acetylcholine imbalance in the nigrostriatal pathway, leading to excessive cholinergic activity. **Why Promethazine is Correct:** The management of acute dystonia requires an **anticholinergic agent**. Promethazine is a first-generation antihistamine with potent central anticholinergic properties. When administered intravenously (or intramuscularly), it rapidly restores the dopamine-acetylcholine balance, relieving the muscle spasms. Other standard treatments include Benztropine or Diphenhydramine. **Analysis of Incorrect Options:** * **A. Diazepam:** While a benzodiazepine can help with general agitation or muscle relaxation, it is not the specific antidote for the cholinergic excess seen in dystonia. * **B. Risperidone:** This is an atypical antipsychotic. Adding another antipsychotic would worsen the blockade of D2 receptors and potentially exacerbate EPS. * **D. Haloperidol:** This is the offending agent. Administering more would worsen the patient's condition and increase the risk of Neuroleptic Malignant Syndrome (NMS). **High-Yield NEET-PG Pearls:** * **Acute Dystonia:** Occurs within hours to days of starting treatment (the "4-hour" rule). * **Oculogyric Crisis:** A specific type of dystonia where the eyes are fixed upward; it is a medical emergency due to patient distress. * **Risk Factors:** Young males and those receiving high-potency neuroleptics are at highest risk. * **Prophylaxis:** In clinical practice, Promethazine is often co-administered with Haloperidol injections to prevent these reactions.

Question 292: Which of the following medications is NOT used for the management of tardive dyskinesia?

A. Fluphenazine (Correct Answer)
B. Clozapine
C. Vitamin E
D. Quetiapine

Explanation: **Explanation:** **Tardive Dyskinesia (TD)** is a delayed-onset extrapyramidal side effect caused by the long-term blockade of dopamine (D2) receptors, leading to **dopamine receptor supersensitivity** in the nigrostriatal pathway. **1. Why Fluphenazine is the Correct Answer:** Fluphenazine is a **high-potency, first-generation (typical) antipsychotic**. Because it is a potent D2 receptor antagonist, it is a primary **cause** of tardive dyskinesia. While increasing the dose of a typical antipsychotic might temporarily "mask" TD symptoms by blocking the supersensitive receptors, it ultimately worsens the underlying pathology. Therefore, it is never used as a treatment. **2. Analysis of Other Options:** * **Clozapine:** This is the drug of choice for patients with severe TD who still require antipsychotic treatment. It has low D2 affinity and rapid dissociation, which helps in the gradual reversal of receptor supersensitivity. * **Quetiapine:** Similar to clozapine, quetiapine is a second-generation antipsychotic with low D2 receptor binding potential and is considered a safe alternative when TD develops. * **Vitamin E:** It is often used as an adjunctive treatment based on the theory that free radical damage contributes to the neurotoxicity seen in TD. **Clinical Pearls for NEET-PG:** * **First-line treatment for TD:** Valbenazine or Deutetrabenazine (VMAT2 inhibitors). * **Risk Factors:** Old age, female gender, and long-term use of typical antipsychotics (e.g., Haloperidol, Fluphenazine). * **Clinical Feature:** Choreoathetoid movements, most commonly involving the mouth and tongue (oro-facial dyskinesia). * **Management Strategy:** Prevention is key. If TD occurs, the first step is to reduce the dose or switch to Clozapine/Quetiapine.

Question 293: A patient with schizophrenia who is currently on chlorpromazine (CPZ) therapy presents with a recurrence of auditory hallucinations. Which medication would be the most appropriate next choice?

A. Haloperidol
B. Clozapine (Correct Answer)
C. Sulpiride
D. Tianeptin

Explanation: ### Explanation **Correct Answer: B. Clozapine** **Why it is correct:** The patient is experiencing a recurrence of symptoms (auditory hallucinations) while on Chlorpromazine, a typical antipsychotic. This indicates **Treatment-Resistant Schizophrenia (TRS)**. Clinically, TRS is defined as a failure of at least two adequate trials of antipsychotic medications (at least one being a second-generation antipsychotic, though failure of a potent typical antipsychotic also qualifies). **Clozapine** is the "gold standard" and the drug of choice for treatment-resistant schizophrenia. It is the only antipsychotic proven to be effective in patients who do not respond to standard dopamine-D2 receptor antagonists. **Why the other options are incorrect:** * **A. Haloperidol:** This is a high-potency typical antipsychotic. If a patient fails on one typical antipsychotic (Chlorpromazine), switching to another typical antipsychotic (Haloperidol) is unlikely to provide significant benefit in resistant cases and increases the risk of Extrapyramidal Side Effects (EPS). * **C. Sulpiride:** This is an atypical antipsychotic (substituted benzamide) primarily acting on D2/D3 receptors. While it has a lower EPS profile, it is not the preferred choice for treatment resistance compared to Clozapine. * **D. Tianeptine:** This is an antidepressant (selective serotonin reuptake enhancer - SSRE). It has no role in treating the primary psychotic symptoms of schizophrenia. **High-Yield Clinical Pearls for NEET-PG:** * **Clozapine Monitoring:** The most serious side effect is **agranulocytosis** (1%). Absolute Neutrophil Count (ANC) must be monitored weekly for the first 6 months. * **Other Side Effects:** Clozapine is associated with the highest risk of **seizures** (dose-dependent), **sialorrhea** (excessive drooling), and **metabolic syndrome**, but it has the **lowest risk of EPS** and Tardive Dyskinesia. * **Indication:** Clozapine is also the drug of choice for schizophrenia associated with persistent **suicidality**.

Question 294: Which drug is known to cause agranulocytosis?

A. Pimozide
B. Clozapine (Correct Answer)
C. Risperidone
D. Olanzapine

Explanation: **Explanation:** **Clozapine** is an atypical (second-generation) antipsychotic reserved for treatment-resistant schizophrenia. Its most serious and life-threatening side effect is **agranulocytosis** (a severe decrease in the absolute neutrophil count <500/mm³), which occurs in approximately 0.8–1% of patients. The mechanism is thought to be an immune-mediated destruction of granulocytes. Due to this risk, mandatory hematological monitoring (ANC levels) is required—weekly for the first 6 months, biweekly for the next 6 months, and monthly thereafter. **Analysis of Incorrect Options:** * **A. Pimozide:** A typical antipsychotic primarily used for Tourette’s disorder. Its main concern is QT interval prolongation and sudden cardiac death, not agranulocytosis. * **C. Risperidone:** An atypical antipsychotic known for causing significant hyperprolactinemia and extrapyramidal symptoms (EPS) at higher doses, but it does not carry a significant risk of bone marrow suppression. * **D. Olanzapine:** Structurally similar to clozapine but lacks the significant risk of agranulocytosis. Its primary side effects are significant weight gain, sedation, and metabolic syndrome. **High-Yield Clinical Pearls for NEET-PG:** * **Clozapine** is the only antipsychotic proven to reduce **suicidal behavior** in schizophrenia. * **Seizures** are a dose-dependent side effect of Clozapine (highest risk at doses >600mg). * **Sialorrhea** (excessive salivation) is a paradoxical but common side effect. * **Myocarditis** is another rare but fatal complication of Clozapine, usually occurring within the first month of treatment.

Question 295: Clozapine therapy should be stopped when the WBC count falls lower than what value?

A. 3000 / mm3 (Correct Answer)
B. 1500 / mm3
C. 2000 / mm3
D. 1000 / mm3

Explanation: **Explanation:** Clozapine is an atypical antipsychotic reserved for treatment-resistant schizophrenia. Its most serious side effect is **agranulocytosis** (a life-threatening drop in white blood cell count), which occurs in approximately 0.8–1% of patients. To mitigate this risk, strict hematological monitoring is mandatory. **Why Option A is correct:** According to standard clinical guidelines (and frequently tested NEET-PG protocols), Clozapine therapy must be **immediately interrupted** if the **Total Leukocyte Count (WBC) falls below 3000/mm³** or if the **Absolute Neutrophil Count (ANC) falls below 1500/mm³**. This threshold acts as a safety buffer to prevent progression to severe agranulocytosis. **Analysis of Incorrect Options:** * **Option B (1500 / mm³):** This is the threshold for the **ANC (Absolute Neutrophil Count)**, not the total WBC count. Confusing WBC and ANC values is a common examiner trap. * **Option C (2000 / mm³):** While this indicates moderate leukopenia, the protocol mandates stopping the drug earlier (at 3000) to ensure patient safety. * **Option D (1000 / mm³):** An ANC below 500–1000/mm³ is defined as severe agranulocytosis. Waiting for the count to reach this level before stopping the drug would put the patient at extreme risk of fatal sepsis. **High-Yield Clinical Pearls for NEET-PG:** * **Monitoring Schedule:** Weekly for the first 6 months, every 2 weeks for the next 6 months, and monthly thereafter. * **Other Side Effects:** Sialorrhea (hypersalivation), sedation, weight gain, and lowering of the seizure threshold (dose-dependent). * **Drug of Choice:** Clozapine is the gold standard for **treatment-resistant schizophrenia** and for reducing **suicidal behavior** in schizophrenic patients. * **Note:** Clozapine is the only antipsychotic that does *not* cause Tardive Dyskinesia and has minimal Extrapyramidal Side Effects (EPS).

Question 296: A 30-year-old man with schizophrenia has been very withdrawn and apathetic for more than 10 years. He is currently taking an antipsychotic agent that is helping him to be more outgoing and sociable. However, the patient is experiencing seizures and agranulocytosis. Which antipsychotic agent is this patient most likely to be taking?

A. risperidone
B. thioridazine
C. olanzapine
D. clozapine (Correct Answer)

Explanation: **Explanation:** The patient is most likely taking **Clozapine**, which is the "gold standard" for treatment-resistant schizophrenia. **Why Clozapine is the Correct Answer:** 1. **Efficacy on Negative Symptoms:** The patient has been "withdrawn and apathetic" (negative symptoms) for 10 years. Clozapine is highly effective in improving social withdrawal and treatment-refractory cases where other antipsychotics have failed. 2. **Agranulocytosis:** This is the most characteristic and life-threatening side effect of Clozapine (occurring in ~1% of patients). It necessitates mandatory weekly WBC monitoring for the first six months. 3. **Seizures:** Clozapine significantly lowers the seizure threshold in a dose-dependent manner. **Why Other Options are Incorrect:** * **Risperidone (A):** An atypical antipsychotic commonly causing hyperprolactinemia and extrapyramidal symptoms (EPS) at higher doses, but not typically associated with agranulocytosis. * **Thioridazine (B):** A typical antipsychotic known for causing pigmentary retinopathy and QTc prolongation. While it can lower the seizure threshold, it does not cause agranulocytosis. * **Olanzapine (C):** Closely related to clozapine but lacks the risk of agranulocytosis. Its primary side effects are significant weight gain and metabolic syndrome. **NEET-PG High-Yield Pearls:** * **Clozapine** is the only antipsychotic proven to reduce **suicidal behavior** in schizophrenia. * **Side Effect Profile:** Sialorrhea (excessive salivation), weight gain, myocarditis, and constipation (can lead to paralytic ileus). * **Monitoring:** Absolute Neutrophil Count (ANC) must be >1500/mm³ to initiate therapy. * It has the **least potential** for causing Extrapyramidal Symptoms (EPS) and Tardive Dyskinesia.

Question 297: Which of the following is an example of an atypical antipsychotic?

A. Olanzapine (Correct Answer)
B. Haloperidol
C. Amitriptyline
D. Zuclopenthixol

Explanation: **Explanation:** **Correct Answer: A. Olanzapine** Olanzapine is a Second-Generation Antipsychotic (SGA), also known as an **atypical antipsychotic**. Unlike typical antipsychotics that primarily block D2 receptors, atypical agents like Olanzapine act as **Serotonin-Dopamine Antagonists (SDAs)**. They block both 5-HT2A and D2 receptors. This dual mechanism provides efficacy against both positive and negative symptoms of schizophrenia and significantly reduces the risk of Extrapyramidal Side Effects (EPS). **Analysis of Incorrect Options:** * **B. Haloperidol:** A potent First-Generation Antipsychotic (FGA) or "typical" antipsychotic. It is a high-potency D2 receptor antagonist known for a high incidence of EPS and hyperprolactinemia. * **C. Amitriptyline:** A Tricyclic Antidepressant (TCA). It inhibits the reuptake of Serotonin and Norepinephrine and is used for depression and neuropathic pain, not as an antipsychotic. * **D. Zuclopenthixol:** A typical antipsychotic belonging to the Thioxanthene class. It is often used in long-acting injectable (depot) forms for acute psychosis or maintenance therapy. **High-Yield Clinical Pearls for NEET-PG:** * **Metabolic Profile:** Olanzapine is associated with significant **weight gain**, hyperglycemia, and dyslipidemia (highest risk among SGAs along with Clozapine). * **Clozapine:** The first atypical antipsychotic and the "Gold Standard" for **treatment-resistant schizophrenia**. It requires monitoring for agranulocytosis. * **Aripiprazole:** A unique atypical antipsychotic that acts as a **D2 partial agonist**. * **Side Effect Rule:** Typical antipsychotics = High EPS risk; Atypical antipsychotics = High Metabolic risk.

Question 298: Electroconvulsive therapy is currently advocated as a line of treatment in the following conditions except -

A. Catatonic schizophrenia
B. Severe depression with psychosis
C. Manic-depressive disorder
D. Obsessive-compulsive disorder (Correct Answer)

Explanation: **Explanation:** Electroconvulsive Therapy (ECT) is a highly effective biological treatment in psychiatry, primarily indicated for conditions requiring a rapid clinical response or where medications have failed. **Why OCD is the correct answer:** Obsessive-Compulsive Disorder (OCD) is **not** a primary indication for ECT. The first-line treatments for OCD are Selective Serotonin Reuptake Inhibitors (SSRIs) and Cognitive Behavioral Therapy (CBT), specifically Exposure and Response Prevention (ERP). ECT is generally ineffective for the core symptoms of OCD unless it is comorbid with severe, treatment-resistant depression. **Analysis of other options:** * **Catatonic Schizophrenia:** ECT is a first-line treatment for catatonia (regardless of the underlying cause) if benzodiazepines (Lorazepam) fail. It provides rapid relief from life-threatening stupor or excitement. * **Severe Depression with Psychosis:** ECT is considered the "gold standard" for severe depression, especially when associated with psychotic features, high suicide risk, or refusal to eat/drink. * **Manic-Depressive Disorder (Bipolar Disorder):** ECT is indicated for both severe mania (especially delirious mania) and severe bipolar depression when pharmacological interventions are contraindicated or ineffective. **High-Yield NEET-PG Pearls:** * **Absolute Contraindication:** There are no absolute contraindications to ECT, but **Increased Intracranial Pressure (ICP)** is the most significant relative contraindication. * **Most Common Side Effect:** Retrograde amnesia (usually transient). * **Mortality Rate:** Approximately 0.01% (similar to minor general anesthesia). * **Electrode Placement:** Bilateral ECT is more effective but has more cognitive side effects; Unilateral (d'Elia placement) has fewer side effects.

Question 299: Which of the following statements are true regarding lithium treatment in mania?

A. Commonest neurological side effect is tremor.
B. Toxic level is less than 1.5 mg/dL serum level.
C. Amiloride is the drug of choice for lithium-induced diabetes insipidus.
D. Lithium is 90% protein bound. (Correct Answer)

Explanation: **Explanation:** **1. Why Option D is Correct:** Lithium is a unique psychotropic agent because it is a simple monovalent cation. Unlike most psychiatric medications, **Lithium does not bind to plasma proteins** (0% protein bound). It is distributed in total body water and excreted almost entirely by the kidneys. *(Note: In many standard medical examinations, if a question asks for a "true" statement and provides "90% protein bound," it is often a distractor or a typographical error in the source material, as Lithium is actually **0% protein bound**. However, based on the provided key, we must analyze the clinical context of the other options.)* **2. Why the Other Options are Incorrect:** * **Option A:** While tremors are common, the **most common** side effects overall are often gastrointestinal (nausea, diarrhea) or polyuria/polydipsia. Fine resting tremors are the most common *neurological* side effect, but the phrasing in exams often distinguishes between "most common" and "earliest sign of toxicity" (coarse tremors). * **Option B:** The therapeutic index of Lithium is narrow. Toxicity typically manifests at serum levels **above 1.5 mEq/L** (not mg/dL). Levels between 0.8–1.2 mEq/L are considered therapeutic for acute mania. * **Option C:** Amiloride is indeed used for Lithium-induced Nephrogenic Diabetes Insipidus (NDI) because it blocks the epithelial sodium channels (ENaC) in the collecting duct, preventing lithium from entering the cells. However, the first step is usually discontinuation of lithium or hydration; Amiloride is the specific pharmacological intervention. **3. High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Inhibits Inositol Monophosphatase (IP3 pathway). * **Teratogenicity:** Ebstein’s Anomaly (tricuspid valve displacement). * **Monitoring:** Check Thyroid Function Tests (Goiter/Hypothyroidism) and Renal Function Tests (NDI/Interstitial Nephritis) before and during treatment. * **Excretion:** 80% is reabsorbed in the proximal tubule; therefore, **Thiazides, NSAIDs, and ACE inhibitors** can increase lithium levels and lead to toxicity.

Question 300: What is the best drug therapy for paranoid schizophrenia in a thin-built 21-year-old young male?

A. Chlorpromazine
B. Risperidone
C. Olanzapine (Correct Answer)
D. Quetiapine

Explanation: ### Explanation **Correct Option: C. Olanzapine** The clinical scenario highlights a **thin-built** young male with paranoid schizophrenia. In psychiatric practice, the choice of antipsychotic is often guided by the patient’s physical profile and the drug's side-effect spectrum. **Olanzapine** is a highly effective Second-Generation Antipsychotic (SGA). Its most significant metabolic side effect is **marked weight gain** and increased appetite (via H1 and 5-HT2C blockade). In a "thin-built" patient, this side effect is clinically leveraged as a benefit to improve the patient's nutritional status and body mass index (BMI) while treating the core psychotic symptoms. **Why other options are incorrect:** * **Chlorpromazine (A):** A low-potency First-Generation Antipsychotic (FGA). It is rarely the first choice today due to high sedation, significant alpha-blockade (orthostatic hypotension), and anticholinergic effects. * **Risperidone (B):** While a first-line SGA, it is more frequently associated with **Hyperprolactinemia** (leading to gynecomastia or sexual dysfunction), which may be distressing for a 21-year-old male. * **Quetiapine (D):** Generally less potent than Olanzapine for acute psychosis and requires high doses for antipsychotic efficacy. It is more commonly used when sedation is the primary goal or in Parkinson’s disease-related psychosis. --- ### NEET-PG High-Yield Pearls: * **Metabolic Syndrome:** Olanzapine and Clozapine carry the **highest risk** of weight gain, dyslipidemia, and diabetes. * **Weight Neutrality:** Ziprasidone and Aripiprazole are the most "weight-neutral" SGAs. * **Drug of Choice:** While Olanzapine is excellent for thin patients, **Clozapine** remains the gold standard for **Treatment-Resistant Schizophrenia** (but requires monitoring for agranulocytosis). * **Paranoid Schizophrenia:** This subtype generally has a better prognosis and later age of onset compared to the hebephrenic (disorganized) subtype.

Question 301: What is the best drug therapy for paranoid schizophrenia in a thin-built 21-year-old young male?

A. Chlorpromazine
B. Risperidone
C. Olanzapine (Correct Answer)
D. Quetiapine

Explanation: **Explanation:** The core clinical challenge in this scenario is managing schizophrenia in a **thin-built** patient. In psychiatry, the side-effect profile of a drug is often utilized as a therapeutic advantage. **Why Olanzapine is the correct answer:** Olanzapine is a highly effective Second-Generation Antipsychotic (SGA). Its most significant side effect is **marked weight gain** and metabolic syndrome (due to H1 and 5HT2C blockade). In a "thin-built" patient, this side effect is clinically desirable to help the patient reach a healthier BMI. Furthermore, as an SGA, it has a lower risk of Extrapyramidal Symptoms (EPS) compared to typical antipsychotics, making it a preferred first-line choice for a young patient. **Analysis of Incorrect Options:** * **Chlorpromazine:** A low-potency typical antipsychotic. It is rarely a first-line choice due to significant sedation, alpha-blockade (orthostatic hypotension), and anticholinergic side effects. * **Risperidone:** A potent SGA. While effective, it is the SGA most likely to cause **Hyperprolactinemia** (leading to gynecomastia/galactorrhea) and EPS at higher doses, which may be less ideal for a young male compared to Olanzapine. * **Quetiapine:** While it also causes weight gain, it is generally less potent than Olanzapine for acute psychosis and is frequently associated with significant sedation, often requiring slow titration. **NEET-PG High-Yield Pearls:** * **Weight Gain Potential:** Clozapine > Olanzapine > Quetiapine > Risperidone. * **Metabolic Neutrality:** Ziprasidone and Aripiprazole are the preferred SGAs if the patient is already obese or has diabetes. * **Drug of Choice:** For treatment-resistant schizophrenia, the answer is always **Clozapine**. * **Young Patients:** Always prioritize SGAs to minimize the risk of Tardive Dyskinesia and acute dystonias associated with older drugs like Haloperidol.

Question 302: Selective serotonin reuptake inhibitors are the drug of choice for all of the following conditions EXCEPT?

A. Acute panic attack (Correct Answer)
B. Social phobia
C. Post traumatic stress disorder
D. Generalized anxiety disorder

Explanation: **Explanation:** The correct answer is **A. Acute panic attack**. **1. Why "Acute panic attack" is the correct answer:** While SSRIs are the first-line treatment for the long-term management and prevention of Panic Disorder, they are **not** used for an acute panic attack. SSRIs have a delayed onset of action (typically 2–4 weeks) and can initially cause "jitteriness" or increased anxiety. For the immediate termination of an acute panic attack, fast-acting **Benzodiazepines** (e.g., Alprazolam or Lorazepam) are the drugs of choice due to their rapid sedative effect. **2. Why the other options are incorrect:** * **B, C, and D:** SSRIs (such as Sertraline, Escitalopram, or Paroxetine) are considered the **first-line maintenance therapy** for Social Phobia (Social Anxiety Disorder), PTSD, and Generalized Anxiety Disorder (GAD). They are preferred over other classes due to their superior safety profile, lower side-effect burden, and lack of dependency risk compared to benzodiazepines. **3. High-Yield Clinical Pearls for NEET-PG:** * **DOC for OCD:** SSRIs (in higher doses than used for depression). Fluoxetine is commonly used. * **DOC for Bulimia Nervosa:** Fluoxetine (High dose: 60mg). * **DOC for Premature Ejaculation:** SSRIs (specifically Dapoxetine due to its rapid action). * **Side Effects:** Sexual dysfunction (most common long-term), GI upset, and SIADH (especially in elderly). * **Serotonin Syndrome:** Characterized by the triad of autonomic instability, neuromuscular hyperactivity (clonus/hyperreflexia), and mental status changes. Treatment involves Cyproheptadine.

Question 303: Selective Serotonin Reuptake Inhibitors (SSRIs) are useful in the treatment of which of the following conditions?

A. Erectile dysfunction
B. Premature ejaculation (Correct Answer)
C. Retrograde ejaculation
D. Infertility

Explanation: **Explanation:** **Correct Answer: B. Premature ejaculation** **Mechanism and Rationale:** Selective Serotonin Reuptake Inhibitors (SSRIs) work by increasing the synaptic concentration of serotonin (5-HT). While their primary use is for depression and anxiety, a common side effect of SSRIs is **delayed ejaculation**. This occurs because serotonin exerts an inhibitory effect on the spinal centers governing the ejaculatory reflex. In clinical practice, this "side effect" is utilized therapeutically to treat premature ejaculation (PE). **Dapoxetine** is a unique, short-acting SSRI specifically approved for the "on-demand" treatment of PE due to its rapid onset and short half-life. **Analysis of Incorrect Options:** * **A. Erectile dysfunction (ED):** SSRIs do not improve erections; in fact, they can occasionally cause or worsen ED as a side effect. ED is primarily managed with PDE-5 inhibitors like Sildenafil. * **C. Retrograde ejaculation:** This is a condition where semen enters the bladder instead of exiting the urethra, often caused by alpha-blockers or surgery (like TURP). SSRIs have no role in its treatment. * **D. Infertility:** SSRIs do not treat infertility. Some studies even suggest that long-term SSRI use might negatively impact sperm quality (DNA fragmentation). **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** While many SSRIs (Paroxetine, Sertraline, Fluoxetine) are used off-label for PE, **Dapoxetine** is the specific SSRI designed for this indication. * **Sexual Side Effects:** SSRIs are notorious for causing sexual dysfunction, most commonly **delayed ejaculation** in men and **anorgasmia** in women. * **Management of SSRI-induced sexual dysfunction:** If a patient develops sexual side effects while being treated for depression, the physician may switch them to **Bupropion** or **Mirtazapine**, as these drugs have minimal impact on serotonin and a lower incidence of sexual side effects.

Question 304: Which of the following is a contraindication for the use of ECT?

A. Pheochromocytoma (Correct Answer)
B. Catatonic schizophrenia
C. Mania
D. Schizophrenia

Explanation: **Explanation:** **1. Why Pheochromocytoma is the Correct Answer:** Electroconvulsive therapy (ECT) induces a significant physiological stress response. Immediately following the electrical stimulus, there is a brief parasympathetic surge (bradycardia), followed by a robust **sympathetic surge** (tachycardia and hypertension). In patients with **Pheochromocytoma**, this surge can trigger a massive release of catecholamines from the adrenal tumor, leading to a potentially fatal hypertensive crisis, cardiac arrhythmias, or stroke. While ECT has very few absolute contraindications, Pheochromocytoma is considered a major relative contraindication (and often cited as the most significant one in exams) due to this hemodynamic instability. **2. Why the Other Options are Incorrect:** * **Catatonic Schizophrenia (B):** This is actually one of the **strongest indications** for ECT. It is highly effective for rapid symptom resolution in catatonic patients who are not eating or drinking. * **Mania (C):** ECT is an effective second-line treatment for acute mania, especially when it is refractory to lithium or antipsychotics, or when rapid control is needed (e.g., delirious mania). * **Schizophrenia (D):** ECT is indicated for schizophrenia, particularly when symptoms are resistant to pharmacotherapy or when there is a high risk of suicide. **3. Clinical Pearls for NEET-PG:** * **Absolute Contraindication:** There are technically **no absolute contraindications** for ECT according to the APA, but **Increased Intracranial Pressure (ICP)** is traditionally taught as the most significant risk (due to risk of brain herniation). * **High-Yield Risks:** Recent Myocardial Infarction (within 3 months), unstable angina, and intracranial aneurysms are major relative contraindications. * **Safe in Pregnancy:** ECT is considered safe and is often the treatment of choice for severe depression or psychosis during pregnancy. * **Gold Standard Indication:** Severe depression with high suicidal risk or psychotic features.

Question 305: Which atypical antipsychotic agent has a low risk of weight gain?

A. Quetiapine
B. Clozapine
C. Aripiprazole (Correct Answer)
D. None of the above

Explanation: **Explanation:** The metabolic profile of atypical antipsychotics (Second Generation Antipsychotics - SGAs) is a high-yield topic for NEET-PG. While SGAs are preferred over typical antipsychotics due to fewer extrapyramidal side effects (EPS), they are frequently associated with metabolic syndrome, including weight gain, dyslipidemia, and hyperglycemia. **Why Aripiprazole is correct:** Aripiprazole is a **D2 partial agonist**. It is considered "metabolically neutral." Along with **Ziprasidone** and **Lurasidone**, it has the lowest risk of weight gain among atypical antipsychotics. This is largely due to its minimal affinity for Histamine (H1) and Serotonin (5-HT2C) receptors, which are the primary mediators of drug-induced hyperphagia and weight gain. **Analysis of incorrect options:** * **Clozapine:** This agent carries the **highest risk** of significant weight gain and metabolic syndrome. It is reserved for treatment-resistant schizophrenia due to the risk of agranulocytosis. * **Quetiapine:** This agent has a **moderate-to-high risk** of weight gain. Its strong H1 receptor antagonism leads to significant sedation and increased appetite. * **Olanzapine (Relevant Mention):** Though not an option here, it is frequently tested as the SGA with the second-highest risk of weight gain after Clozapine. **High-Yield Clinical Pearls for NEET-PG:** * **Weight Gain Hierarchy:** Clozapine > Olanzapine > Quetiapine > Risperidone > Aripiprazole/Ziprasidone. * **Monitoring:** Patients on SGAs should have their BMI, waist circumference, and fasting blood glucose/lipid profile monitored regularly (ADA/APA guidelines). * **Ziprasidone:** Notable for the lowest weight gain but carries a specific risk of **QTc prolongation**. * **Aripiprazole:** Also unique for causing **Akathisia** more frequently than other SGAs despite its low metabolic risk.

Question 306: Which of the following conditions is typically managed with blockers?

A. Phobia
B. Schizophrenia
C. Anxiety (Correct Answer)
D. Mania

Explanation: ### Explanation The correct answer is **Anxiety**. **1. Why Anxiety is Correct:** In psychiatry, Beta-blockers (specifically **Propranolol**) are used to manage the **peripheral autonomic symptoms** of anxiety. These symptoms include palpitations, tremors, tachycardia, and sweating, which are mediated by the sympathetic nervous system. Beta-blockers are particularly effective for **Performance Anxiety** (a subtype of Social Anxiety Disorder), such as stage fright or exam nerves, as they control the physical manifestations without causing the sedation associated with benzodiazepines. **2. Why Other Options are Incorrect:** * **Phobia:** While Beta-blockers can help with the physical symptoms of Social Phobia, the primary treatment for specific phobias is **Systemic Desensitization** (Behavioral therapy). For generalized phobias, SSRIs are the first-line pharmacological choice. * **Schizophrenia:** This is a psychotic disorder primarily managed with **Antipsychotics** (Dopamine D2 receptor antagonists). While Propranolol is sometimes used as an adjunct to treat antipsychotic-induced **Akathisia**, it is not a treatment for the condition itself. * **Mania:** Acute mania is managed with **Mood Stabilizers** (Lithium, Valproate) and **Antipsychotics**. Beta-blockers have no role in stabilizing mood or reducing the core symptoms of mania. **3. NEET-PG High-Yield Pearls:** * **Drug of Choice for Akathisia:** Propranolol (Beta-blocker) is the gold standard treatment for antipsychotic-induced akathisia. * **Performance Anxiety:** Propranolol should be taken 30–60 minutes before the stressful event. * **Contraindications:** Always screen for **Asthma** or **COPD** before prescribing Propranolol, as it can cause bronchospasm. * **Lithium Tremors:** Propranolol is also the treatment of choice for fine tremors induced by Lithium therapy.

Question 307: Which of the following SSRIs is used in the management of panic disorder?

A. Paroxetine (Correct Answer)
B. Clomipramine
C. Imipramine
D. Trazodone

Explanation: **Explanation:** **1. Why Paroxetine is Correct:** Selective Serotonin Reuptake Inhibitors (SSRIs) are the **first-line pharmacological treatment** for Panic Disorder due to their superior safety profile and efficacy. **Paroxetine** is specifically FDA-approved for panic disorder. It works by inhibiting the reuptake of serotonin at the presynaptic cleft, leading to down-regulation of postsynaptic receptors, which eventually reduces the frequency and intensity of panic attacks. **2. Why Other Options are Incorrect:** * **Clomipramine & Imipramine (Options B & C):** These are **Tricyclic Antidepressants (TCAs)**. While they are effective in treating panic disorder (Imipramine was historically the gold standard), they are no longer first-line due to their significant side effect profile (anticholinergic effects, cardiotoxicity in overdose, and weight gain). The question specifically asks for an SSRI; TCAs do not belong to this class. * **Trazodone (Option D):** This is a Serotonin Antagonist and Reuptake Inhibitor (SARI). It is primarily used as a sedative-hypnotic for insomnia or as an adjunct in depression, but it is not indicated for the management of panic disorder. **High-Yield Clinical Pearls for NEET-PG:** * **First-line for Panic Disorder:** SSRIs (e.g., Paroxetine, Sertraline, Fluoxetine) and SNRIs (e.g., Venlafaxine). * **The "Jitteriness Syndrome":** When starting SSRIs in panic disorder, patients may experience an initial increase in anxiety. Therefore, therapy should be started at **half the usual antidepressant dose**. * **Acute Management:** For immediate relief of a panic attack, **Benzodiazepines** (e.g., Alprazolam, Clonazepam) are used, but they are avoided for long-term maintenance due to dependence risk. * **Most Sedating SSRI:** Paroxetine (also has the most anticholinergic activity among SSRIs). * **Shortest Half-life SSRI:** Fluvoxamine/Paroxetine (highest risk of discontinuation syndrome).

Question 308: A 32-year-old patient with schizophrenia was started on haloperidol 15 mg per day. A week later, he was found to have high-grade fever, rigidity, and blood tests revealed leucocytosis and increased CPK levels. What is the usual cause of death in such patients?

A. Myocardial infarction
B. Respiratory failure
C. Acute renal failure (Correct Answer)
D. Cardiac arrhythmias

Explanation: **Explanation:** The patient is presenting with the classic tetrad of **Neuroleptic Malignant Syndrome (NMS)**: high-grade fever, "lead-pipe" muscle rigidity, autonomic instability, and altered mental status, triggered by a high-potency antipsychotic (Haloperidol). **Why Acute Renal Failure (ARF) is the correct answer:** The hallmark of NMS is intense, generalized muscle rigidity. This extreme muscle contraction leads to **Rhabdomyolysis** (breakdown of skeletal muscle), which releases massive amounts of **myoglobin** into the bloodstream. Myoglobin is nephrotoxic; it precipitates in the renal tubules, causing acute tubular necrosis. **Acute Renal Failure** secondary to myoglobinuria is the most common cause of mortality in NMS patients. **Analysis of Incorrect Options:** * **Myocardial Infarction:** While the heart is under stress due to tachycardia and hyperthermia, primary ischemia is not the typical cause of death. * **Respiratory Failure:** Can occur due to chest wall rigidity or aspiration pneumonia, but it is statistically less common as the primary cause of death compared to renal failure. * **Cardiac Arrhythmias:** These can occur due to electrolyte imbalances (like hyperkalemia from muscle breakdown), but they are usually secondary complications. **Clinical Pearls for NEET-PG:** * **Key Lab Findings:** Elevated Creatine Phosphokinase (CPK) is the most sensitive lab marker; Leucocytosis is also common. * **Treatment of Choice:** Immediate discontinuation of the offending drug, aggressive hydration, and cooling. Pharmacotherapy includes **Dantrolene** (muscle relaxant) or **Bromocriptine** (D2 agonist). * **Differential Diagnosis:** Unlike Serotonin Syndrome, NMS is characterized by "lead-pipe" rigidity and bradyreflexia (rather than hyperreflexia and myoclonus).

Question 309: Which of the following is a true statement regarding lithium toxicity?

A. Toxicity is increased by increased serum sodium levels.
B. Toxicity is increased by decreased serum sodium levels. (Correct Answer)
C. Toxicity is increased in acute tubular necrosis.
D. Toxicity appears when the serum levels become triple the dose of therapeutic levels.

Explanation: **Explanation:** The correct answer is **B: Toxicity is increased by decreased serum sodium levels.** **Mechanism of Action:** Lithium is a monovalent cation that is handled by the kidneys in a manner very similar to sodium. It is filtered by the glomerulus and approximately 80% is reabsorbed in the **proximal convoluted tubule (PCT)**. Lithium and sodium compete for the same transport mechanisms. When serum sodium levels are low (hyponatremia), the body attempts to conserve sodium by increasing its reabsorption in the PCT. Consequently, the kidneys inadvertently increase the reabsorption of lithium as well, leading to toxic serum levels. **Analysis of Incorrect Options:** * **Option A:** Increased serum sodium levels (hypernatremia) or high salt intake actually promote lithium excretion, thereby *decreasing* lithium levels. * **Option C:** While renal failure affects lithium clearance, the question specifically asks for a "true statement regarding lithium toxicity" in the context of physiological triggers. While ATN reduces clearance, the relationship with sodium (Option B) is a more fundamental pharmacological principle frequently tested in NEET-PG. * **Option D:** Lithium has a **narrow therapeutic index** (0.6–1.2 mEq/L). Toxicity does not require "triple" the dose; clinical signs of toxicity can appear at levels as low as 1.5 mEq/L, and severe toxicity occurs above 2.0 mEq/L. **High-Yield Clinical Pearls for NEET-PG:** * **Drugs that increase Lithium levels:** Thiazide diuretics (most common trigger), NSAIDs (except Aspirin/Sulindac), and ACE inhibitors. * **Early signs of toxicity:** Coarse tremors (fine tremors are a side effect), nausea, vomiting, and diarrhea. * **Late signs:** Ataxia, dysarthria, seizures, and coma. * **Management:** Hemodialysis is the treatment of choice for severe toxicity (levels >3.5 mEq/L or >2.5 mEq/L with symptoms).

Question 310: What is true about neuroleptic malignant syndrome?

A. General antipsychotics are more associated.
B. Symptoms include rigidity, fever, and palpitations.
C. Dantrolene improves symptoms.
D. All of the above. (Correct Answer)

Explanation: **Neuroleptic Malignant Syndrome (NMS)** is a life-threatening idiosyncratic reaction to antipsychotic medications, characterized by a tetrad of clinical features: mental status changes, muscular rigidity, hyperthermia, and autonomic instability. **Explanation of Options:** * **Option A:** While all dopamine antagonists can cause NMS, **first-generation (typical) antipsychotics** (e.g., Haloperidol, Fluphenazine) are more frequently associated with the condition due to their potent D2 receptor antagonism. * **Option B:** The clinical presentation typically includes "lead-pipe" **rigidity**, high-grade **fever** (hyperpyrexia), and signs of autonomic dysfunction such as **palpitations** (tachycardia), labile blood pressure, and diaphoresis. * **Option C:** Management begins with immediate discontinuation of the offending agent and supportive care. Pharmacologically, **Dantrolene** (a direct-acting muscle relaxant) is used to reduce hyperthermia and rigidity. Dopamine agonists like **Bromocriptine** or Amantadine are also used to restore dopaminergic tone. Since all statements are clinically accurate, **Option D** is the correct answer. **High-Yield NEET-PG Pearls:** 1. **Laboratory Hallmark:** Significantly elevated **Creatine Phosphokinase (CPK)** levels due to rhabdomyolysis. Leukocytosis and metabolic acidosis are also common. 2. **Mnemonic (FEVER):** **F**ever, **E**ncephalopathy, **V**itals unstable, **E**levated CPK, **R**igidity. 3. **Differential Diagnosis:** Unlike Serotonin Syndrome (which presents with hyperreflexia and myoclonus), NMS is characterized by **hyporeflexia** and "lead-pipe" rigidity. 4. **Risk Factors:** Rapid dose escalation, high-potency drugs, and dehydration.

Question 311: A patient on antipsychotic for the past 4 weeks presents to the emergency department with acute onset of fever, excessive sweating, confusion, rigidity of limbs, and decreased communication. Examination reveals a temperature of 104°F, pulse rate of 120/min, blood pressure of 150/100 mmHg, and disorientation. What is the most probable diagnosis?

A. Lithium toxicity
B. Aggravation of psychosis
C. Dystonia
D. Neuroleptic malignant syndrome (Correct Answer)

Explanation: ### Explanation **Correct Option: D. Neuroleptic Malignant Syndrome (NMS)** The clinical presentation is a classic triad of **Neuroleptic Malignant Syndrome (NMS)**, a life-threatening idiosyncratic reaction to antipsychotics (neuroleptics). The diagnosis is based on the presence of: 1. **Hyperthermia:** High-grade fever (104°F). 2. **Autonomic Instability:** Tachycardia (120/min), hypertension (150/100 mmHg), and diaphoresis. 3. **Muscle Rigidity:** Characteristically described as "lead-pipe" rigidity. 4. **Altered Mental Status:** Confusion, disorientation, and decreased communication (mutism). NMS typically occurs within the first few weeks of starting or increasing the dose of dopamine antagonists. The underlying pathophysiology involves massive dopamine blockade in the nigrostriatal pathway (rigidity) and hypothalamus (temperature dysregulation). **Why Incorrect Options are Wrong:** * **A. Lithium toxicity:** Usually presents with gastrointestinal symptoms (vomiting, diarrhea), coarse tremors, ataxia, and seizures. It does not typically cause "lead-pipe" rigidity or extreme hyperthermia. * **B. Aggravation of psychosis:** While patients may be confused, psychosis alone does not cause autonomic instability, high fever, or muscular rigidity. * **C. Dystonia:** This is an Extrapyramidal Side Effect (EPS) characterized by sudden, involuntary muscle contractions (e.g., torticollis, oculogyric crisis). It does not involve systemic symptoms like fever or autonomic dysfunction. **High-Yield Clinical Pearls for NEET-PG:** * **Key Lab Finding:** Elevated **Creatine Phosphokinase (CPK)** levels and leukocytosis are common. * **Treatment of Choice:** Immediate discontinuation of the offending drug, aggressive cooling, and pharmacological intervention with **Dantrolene** (muscle relaxant) or **Bromocriptine** (dopamine agonist). * **Mnemonic (FEVER):** **F**ever, **E**ncephalopathy, **V**itals unstable, **E**levated enzymes (CPK), **R**igidity.

Question 312: Which of the following is NOT used in the management of tardive dyskinesia?

A. Flupenthixol (Correct Answer)
B. Clonazepam
C. Vitamin E
D. Ondansetron

Explanation: **Explanation:** **Tardive Dyskinesia (TD)** is a delayed-onset extrapyramidal side effect caused by the long-term blockade of dopamine (D2) receptors, leading to **dopamine receptor supersensitivity** in the nigrostriatal pathway. **Why Flupenthixol is the correct answer:** Flupenthixol is a **typical (first-generation) antipsychotic** that acts as a potent D2 receptor antagonist. Since TD is caused by prolonged D2 blockade and subsequent receptor up-regulation, administering more D2 antagonists like Flupenthixol will eventually worsen the underlying pathophysiology, even if it temporarily "masks" the symptoms. Therefore, it is contraindicated in the management of TD. **Analysis of other options:** * **Clonazepam:** Benzodiazepines are used as adjunctive therapy to reduce the severity of dyskinetic movements by enhancing GABAergic inhibitory neurotransmission. * **Vitamin E:** It is used based on the theory that TD involves free-radical-mediated neuronal damage. High-dose Vitamin E (Alpha-tocopherol) acts as an antioxidant to prevent further damage. * **Ondansetron:** This 5-HT3 receptor antagonist has shown efficacy in some clinical trials for reducing TD symptoms, likely through its indirect modulation of the dopaminergic system. **High-Yield Clinical Pearls for NEET-PG:** 1. **First step in management:** Prevention is key. If TD occurs, the first step is to **taper and stop** the offending antipsychotic or switch to **Clozapine** (the antipsychotic with the lowest risk of TD). 2. **Drug of Choice:** **VMAT-2 inhibitors** (e.g., Valbenazine, Deutetrabenazine) are now considered the first-line FDA-approved treatments for TD. 3. **Risk Factors:** Old age, female gender, and the use of first-generation antipsychotics. 4. **Note:** Anticholinergics (like Trihexyphenidyl) **worsen** TD, unlike other extrapyramidal symptoms where they are used as treatment.

Question 313: Which of the following drugs is known to cause hypothyroidism?

A. Haloperidol
B. Clozapine
C. Lithium carbonate (Correct Answer)
D. Amoxapine

Explanation: **Explanation** **Lithium carbonate** is the correct answer. Lithium is a mood stabilizer primarily used for Bipolar Affective Disorder (BPAD). It is well-known for its endocrine side effects, specifically its ability to cause **hypothyroidism** and goiter. **Mechanism:** Lithium interferes with thyroid function at multiple levels: 1. It inhibits the uptake of iodine into follicular cells. 2. It interferes with the iodination of tyrosine. 3. Most significantly, it **inhibits the release of thyroid hormones (T3 and T4)** from the thyroid gland by interfering with thyroglobulin pinocytosis. This leads to a compensatory rise in TSH, which can cause a goiter. **Analysis of Incorrect Options:** * **Haloperidol (A):** A typical antipsychotic (D2 blocker). Its primary side effects are Extrapyramidal Symptoms (EPS) and hyperprolactinemia, not thyroid dysfunction. * **Clozapine (B):** An atypical antipsychotic. Its "dreaded" side effects include agranulocytosis, seizures, and metabolic syndrome (weight gain, diabetes), but it does not cause hypothyroidism. * **Amoxapine (D):** A tricyclic antidepressant (TCA) with dopamine-blocking properties. It is associated with EPS and anticholinergic effects, but not thyroid suppression. **High-Yield Clinical Pearls for NEET-PG:** * **Monitoring:** Before starting Lithium, baseline **Thyroid Function Tests (TFTs)** and Renal Function Tests (RFTs) are mandatory. * **Management:** If a patient develops hypothyroidism on Lithium, you do **not** necessarily stop the drug. Instead, continue Lithium and add **Levothyroxine** supplementation. * **Other Endocrine Effect:** Lithium can also cause **hyperparathyroidism** (leading to hypercalcemia). * **Renal Effect:** It is a common cause of **Nephrogenic Diabetes Insipidus** (treated with Amiloride).

Question 314: Which of the following antipsychotics is available as a depot injection?

A. Fluphenazine (Correct Answer)
B. Ziprasidone
C. Trifluperazine
D. Aripiprazone

Explanation: **Explanation:** **Correct Answer: A. Fluphenazine** Fluphenazine (as Fluphenazine Decanoate) is a classic first-generation (typical) antipsychotic available as a long-acting injectable (LAI) or **depot injection**. Depot formulations are esterified in oil, allowing for slow release from the muscle into the bloodstream, typically administered every 2–4 weeks. This is a crucial strategy in psychiatry to manage **non-adherence** in patients with chronic schizophrenia. **Analysis of Incorrect Options:** * **B. Ziprasidone:** While an intramuscular (IM) formulation exists, it is used for **acute agitation** (short-acting) and is not available as a long-acting depot. * **C. Trifluperazine:** This is a high-potency typical antipsychotic, but it is administered only via oral or short-acting IM routes; no depot formulation exists. * **D. Aripiprazone:** This is a distractor based on spelling. **Aripiprazole** (the correct spelling) is indeed available as a depot (Aripiprazole Maintena), but "Aripiprazone" is a non-existent drug name. **High-Yield Clinical Pearls for NEET-PG:** * **Common Depot Antipsychotics:** * *Typical:* Fluphenazine decanoate, Haloperidol decanoate, Flupenthixol, Zuclopenthixol. * *Atypical:* Risperidone, Paliperidone, Olanzapine, and Aripiprazole. * **Post-injection Delirium Sedation Syndrome (PDSS):** A specific risk associated with **Olanzapine pamoate** depot, requiring 3 hours of mandatory observation post-injection. * **Indication:** Depot injections are the gold standard for patients with frequent relapses due to poor medication compliance.

Question 315: A psychiatric patient taking medication develops tremor, thyroid enlargement, and leukocytosis. Which drug is most likely implicated?

A. Clomipramine
B. Haloperidol
C. Lithium (Correct Answer)
D. Olanzapine

Explanation: **Explanation:** The correct answer is **Lithium**. This classic triad of symptoms—**fine tremors, goiter (thyroid enlargement), and leukocytosis**—is a hallmark of Lithium therapy. 1. **Why Lithium is correct:** * **Tremors:** Fine hand tremors are the most common side effect of Lithium. (Coarse tremors, however, indicate toxicity). * **Thyroid Enlargement:** Lithium inhibits the release of thyroid hormones (T3 and T4) by interfering with iodination and coupling. This leads to increased TSH levels, resulting in goiter and potentially hypothyroidism. * **Leukocytosis:** Lithium causes a benign, reversible increase in the white blood cell count (specifically neutrophils) by stimulating granulopoiesis. This is sometimes used therapeutically in Felty’s syndrome. 2. **Why other options are incorrect:** * **Clomipramine (TCA):** Typically causes anticholinergic side effects (dry mouth, blurred vision, constipation) and cardiac arrhythmias in overdose. * **Haloperidol (Typical Antipsychotic):** Primarily causes Extrapyramidal Symptoms (EPS) like acute dystonia, parkinsonism (resting tremor), and akathisia, but not thyroid enlargement or leukocytosis. * **Olanzapine (Atypical Antipsychotic):** Associated with significant weight gain, dyslipidemia, and metabolic syndrome. **NEET-PG High-Yield Pearls:** * **Therapeutic Index:** Lithium has a narrow therapeutic index (0.6–1.2 mEq/L). * **Teratogenicity:** Causes **Ebstein’s Anomaly** (atrialization of the right ventricle). * **Renal Side Effect:** Can cause Nephrogenic Diabetes Insipidus (treated with Amiloride). * **L-nemonic:** **L**eukocytosis, **I**nsipidus (Diabetes), **T**remors/Teratogenic, **H**ypothyroidism.

Question 316: A 32-year-old woman presents with high-grade fever, muscle rigidity, and altered sensorium. She is on chlorpromazine therapy for psychosis. What is the likely diagnosis?

A. Neuroleptic malignant syndrome (Correct Answer)
B. Malignant hyperthermia
C. Akathisia
D. Tardive dyskinesia

Explanation: ### Explanation **Neuroleptic Malignant Syndrome (NMS)** is the correct diagnosis. It is a life-threatening idiosyncratic reaction to antipsychotic drugs (neuroleptics), most commonly high-potency typical antipsychotics like Chlorpromazine or Haloperidol. The pathophysiology involves massive dopamine blockade in the nigrostriatal pathway and hypothalamus. The classic clinical tetrad (mnemonic: **FEVER**) includes: * **F**ever (High-grade hyperpyrexia) * **E**ncephalopathy (Altered sensorium/confusion) * **V**itals instability (Autonomic dysfunction: tachycardia, hypertension) * **E**levated CPK (due to muscle breakdown) * **R**igidity ("Lead-pipe" muscle rigidity) #### Why other options are incorrect: * **Malignant Hyperthermia:** While it presents similarly (fever, rigidity), it is triggered by **volatile inhalational anesthetics** (e.g., halothane) or succinylcholine, not antipsychotics. It involves a genetic defect in the ryanodine receptor. * **Akathisia:** An Extrapyramidal Side Effect (EPS) characterized by subjective feelings of inner restlessness and the urge to move. It does not cause fever or altered sensorium. * **Tardive Dyskinesia:** A late-onset EPS involving involuntary choreoathetoid movements (e.g., lip-smacking, tongue protrusion) after long-term neuroleptic use. It is not an acute febrile emergency. #### High-Yield Clinical Pearls for NEET-PG: * **Treatment of Choice:** Immediate discontinuation of the offending drug, aggressive cooling, and **Dantrolene** (muscle relaxant) or **Bromocriptine** (dopamine agonist). * **Laboratory Hallmark:** Significantly elevated **Creatine Phosphokinase (CPK)** and leukocytosis. * **NMS vs. Serotonin Syndrome:** NMS is characterized by "Lead-pipe" rigidity and bradyreflexia, whereas Serotonin Syndrome presents with hyperreflexia and myoclonus.

Question 317: A 30-year-old patient with mania, prescribed haloperidol three months ago, has become restless and has been pacing for the last day. On examination, hand tremors are noted. What is the most likely diagnosis?

A. Anhedonia
B. Dystonia
C. Restless leg syndrome
D. Akathisia (Correct Answer)

Explanation: **Explanation:** The patient is presenting with classic features of **Akathisia**, a common Extrapyramidal Side Effect (EPS) associated with typical antipsychotics like Haloperidol. **Why Akathisia is the correct answer:** Akathisia is characterized by a subjective feeling of inner restlessness and an objective need to move. Clinically, this manifests as pacing, inability to sit still, and shifting weight from foot to foot. It typically occurs within days to weeks of starting or increasing the dose of a dopamine (D2) receptor antagonist. The presence of hand tremors further suggests drug-induced Parkinsonism, which often co-exists with akathisia. **Why the other options are incorrect:** * **Anhedonia:** This is a negative symptom of schizophrenia or a feature of depression characterized by the inability to feel pleasure. It does not involve motor restlessness. * **Dystonia:** This involves acute, involuntary, sustained muscle contractions (e.g., torticollis, oculogyric crisis). It usually occurs within hours to days of starting medication, not months later, and presents with "spasms" rather than "pacing." * **Restless Leg Syndrome (RLS):** While similar in sensation, RLS typically occurs at night, is relieved by movement, and is not specifically linked to antipsychotic initiation in the same temporal pattern as akathisia. **High-Yield Clinical Pearls for NEET-PG:** * **Management of Akathisia:** The first-line treatment is **Propranolol** (Beta-blocker). Benzodiazepines or anticholinergics (like Benztropine) are second-line. * **Timeline of EPS:** 1. *Acute Dystonia:* Hours to days. 2. *Akathisia/Parkinsonism:* Days to weeks. 3. *Tardive Dyskinesia:* Months to years (chronic). * **Key Differentiator:** Akathisia is the most common EPS and is often misdiagnosed as worsening agitation/psychosis, leading to a dangerous increase in the offending drug's dose.

Question 318: What is the therapeutic serum level of lithium in acute mania?

A. 0.2-0.5 mEq/L
B. 0.8-1.5 mEq/L (Correct Answer)
C. 1-2 mEq/L
D. 2-5 mEq/L

Explanation: **Explanation:** Lithium is the gold-standard mood stabilizer used for the treatment of Bipolar Affective Disorder (BPAD). It has a **narrow therapeutic index**, meaning the difference between a therapeutic dose and a toxic dose is very small, necessitating regular Therapeutic Drug Monitoring (TDM). 1. **Why Option B is Correct:** In the **acute phase of mania**, higher serum levels are required to control symptoms effectively. The established therapeutic range is **0.8 to 1.2 mEq/L** (often extended up to **1.5 mEq/L** in severe cases). Once the patient is stabilized, the maintenance dose is lower, typically **0.6 to 1.2 mEq/L**. 2. **Why Other Options are Incorrect:** * **Option A (0.2-0.5 mEq/L):** These levels are sub-therapeutic and will not provide clinical improvement in mania. * **Option C (1-2 mEq/L):** While it overlaps with the therapeutic range, levels above 1.5 mEq/L are generally considered the threshold for early toxicity. * **Option D (2-5 mEq/L):** These are toxic levels. Levels >2.0 mEq/L indicate severe toxicity, and levels >3.5 mEq/L are life-threatening emergencies requiring hemodialysis. **High-Yield Clinical Pearls for NEET-PG:** * **Sampling Time:** Blood for TDM should be drawn **12 hours after the last dose** (Steady-state is reached in 4-5 days). * **Side Effects:** Most common acute side effect is **fine tremors**; most common endocrine side effect is **hypothyroidism**. * **Teratogenicity:** Causes **Ebstein’s Anomaly** (atrialization of the right ventricle) if taken during pregnancy. * **Toxicity Precipitants:** Dehydration, low sodium intake, and drugs like **NSAIDs, Thiazides, and ACE inhibitors** can increase lithium levels.

Question 319: Long term use of lithium is known to cause which of the following?

A. Peripheral neuropathy
B. Hypothyroidism (Correct Answer)
C. Anaemia
D. Jaundice

Explanation: **Explanation:** Lithium is the gold-standard mood stabilizer for Bipolar Affective Disorder (BPAD), but its long-term use is associated with specific endocrine and renal side effects due to its narrow therapeutic index. **Why Hypothyroidism is Correct:** Lithium interferes with thyroid function at multiple levels. It inhibits the uptake of iodine into follicular cells, interferes with the iodination of tyrosine, and—most significantly—**inhibits the release of T3 and T4** from the thyroid gland. Over time, this leads to a compensatory rise in Thyroid Stimulating Hormone (TSH), resulting in **Lithium-induced hypothyroidism** (seen in 5–15% of patients) and occasionally a non-toxic goiter. **Analysis of Incorrect Options:** * **A. Peripheral neuropathy:** This is not a classic side effect of Lithium. Lithium toxicity typically presents with central nervous system symptoms like coarse tremors, ataxia, and dysarthria. * **C. Anaemia:** Lithium does not cause anemia; in fact, it is known to cause **leukocytosis** (increased WBC count) by stimulating granulopoiesis, which is sometimes used therapeutically in Felty’s syndrome. * **D. Jaundice:** Lithium is not metabolized by the liver (it is excreted unchanged by the kidneys); therefore, it is not hepatotoxic and does not cause jaundice. **High-Yield Clinical Pearls for NEET-PG:** * **Renal Side Effects:** Long-term use can cause **Nephrogenic Diabetes Insipidus** (resistance to ADH) and chronic interstitial nephritis. * **Monitoring:** Before starting Lithium, baseline **Thyroid Function Tests (TFTs)** and **Renal Function Tests (RFTs)** are mandatory. * **Teratogenicity:** Use in pregnancy is linked to **Ebstein’s Anomaly** (atrialization of the right ventricle). * **Therapeutic Range:** 0.6–1.2 mEq/L (Prophylaxis: 0.6–0.8; Acute Mania: 0.8–1.2). Toxicity usually starts >1.5 mEq/L.

Question 320: A 28-year-old woman with bipolar disorder has a lithium level of 2.3 mEq/L (normal range 0.6-1.25 mEq/L). Which of the following side effects is most likely to occur?

A. mania
B. depression
C. tremor (Correct Answer)
D. hyponatremia

Explanation: **Explanation:** The patient presents with **Lithium Toxicity**, as evidenced by a serum lithium level of **2.3 mEq/L**. The therapeutic range for lithium is narrow (0.6–1.2 mEq/L), and levels above 1.5 mEq/L are generally considered toxic. **Why Tremor is Correct:** Tremors are a hallmark side effect of lithium. While a **fine resting tremor** can occur at therapeutic doses, a **coarse (gross) intention tremor** is a classic sign of worsening lithium toxicity. As levels rise (especially >2.0 mEq/L), neurological symptoms become prominent, including ataxia, dysarthria, confusion, and seizures. **Analysis of Incorrect Options:** * **A & B (Mania/Depression):** Lithium is a mood stabilizer used to *treat* these conditions. While toxicity indicates the drug is at dangerous levels, it does not typically trigger an acute switch into mania or depression; rather, it causes systemic and neurological dysfunction. * **D (Hyponatremia):** Lithium does not cause hyponatremia; instead, **hyponatremia causes lithium toxicity**. Because lithium is handled by the kidneys similarly to sodium, low sodium levels lead to increased proximal tubule reabsorption of lithium, raising serum levels to toxic ranges. **NEET-PG High-Yield Pearls:** * **Therapeutic Range:** 0.6–1.2 mEq/L (Prophylaxis: 0.6–0.8; Acute Mania: 0.8–1.2). * **Toxicity Levels:** >1.5 (Mild), >2.0 (Moderate), >3.5 (Severe/Life-threatening). * **Management:** For levels >2.5 mEq/L (or >4.0 in chronic users), **Hemodialysis** is the treatment of choice. * **Drug Interactions:** Thiazides, NSAIDs, and ACE inhibitors increase lithium levels (the "TAN" mnemonic). * **Early Sign of Toxicity:** Persistent GI upset (nausea/vomiting) often precedes neurological signs.

Question 321: Which of the following medications is known to cause sialorrhea?

A. Amisulpride
B. Olanzapine
C. Aripiprazole
D. Clozapine (Correct Answer)

Explanation: **Explanation:** **Clozapine** is the correct answer. While most antipsychotics cause dry mouth (xerostomia) due to potent muscarinic blockade, Clozapine is unique for causing **sialorrhea (excessive salivation)**, particularly at night. **Underlying Mechanism:** The exact mechanism is paradoxical. Although Clozapine has anticholinergic properties, its metabolite acts as a **full agonist at M1 receptors** and an **antagonist at alpha-2 adrenergic receptors**. Alpha-2 blockade prevents the inhibition of salivary secretion, leading to hypersecretion. Additionally, Clozapine impairs the swallowing reflex during sleep, causing "wet pillow syndrome." **Analysis of Incorrect Options:** * **Amisulpride:** A substituted benzamide that primarily blocks D2/D3 receptors. It has minimal affinity for muscarinic receptors and is more likely to cause hyperprolactinemia than salivary changes. * **Olanzapine:** A thienobenzodiazepine derivative. Like most atypical antipsychotics, its side effect profile includes weight gain and metabolic syndrome, but it typically causes dry mouth due to anticholinergic activity. * **Aripiprazole:** A partial D2 agonist. It is generally "weight-neutral" and has a low side-effect profile regarding autonomic symptoms; it does not cause sialorrhea. **High-Yield Clinical Pearls for NEET-PG:** 1. **Management of Clozapine Sialorrhea:** Treat with sublingual **Atropine drops** or oral **Glycopyrrolate** (peripherally acting anticholinergics). 2. **Clozapine Monitoring:** Mandatory WBC count monitoring is required due to the risk of **Agranulocytosis** (most serious side effect). 3. **Seizures:** Clozapine is associated with dose-dependent lowering of the seizure threshold. 4. **Indication:** It is the gold standard for **Treatment-Resistant Schizophrenia**.

Question 322: Raj Mohan has recently been on an increased regime of antipsychotics for Schizophrenia. Which of the following complications is NOT associated with the combined use of more than one antipsychotic?

A. Neuroleptic Malignant Syndrome
B. Renal Tubular Necrosis (Correct Answer)
C. Paralytic ileus
D. QTc Prolongation in ECG

Explanation: **Explanation:** The use of multiple antipsychotics (antipsychotic polypharmacy) significantly increases the risk of cumulative side effects due to additive pharmacodynamic and pharmacokinetic interactions. **Why Renal Tubular Necrosis (RTN) is the correct answer:** Renal Tubular Necrosis is **not** a recognized complication of antipsychotic therapy. While certain psychotropic drugs like Lithium are associated with nephrotoxicity (e.g., Nephrogenic Diabetes Insipidus), antipsychotics are primarily metabolized by the liver and excreted via the kidneys without causing direct tubular damage. If renal failure occurs in a psychiatric patient, it is usually secondary to **Rhabdomyolysis** (seen in NMS), not a direct toxic effect of the medication on the tubules. **Analysis of Incorrect Options:** * **Neuroleptic Malignant Syndrome (NMS):** This is a life-threatening idiosyncratic reaction. High doses or rapid escalation of multiple dopamine (D2) antagonists increase the risk of severe dopamine depletion in the nigrostriatal pathway and hypothalamus. * **Paralytic Ileus:** Many antipsychotics (especially low-potency typicals like Chlorpromazine and atypicals like Clozapine) have potent **anticholinergic** properties. Combining them leads to "anticholinergic overload," which can cause severe constipation or life-threatening paralytic ileus. * **QTc Prolongation:** Most antipsychotics (notably Thioridazine, Ziprasidone, and Haloperidol) block potassium channels in the heart. Polypharmacy increases the risk of Torsades de Pointes and sudden cardiac death. **High-Yield Clinical Pearls for NEET-PG:** * **NMS Pentad:** Muscle rigidity ("Lead-pipe"), Hyperthermia, Autonomic instability, Altered sensorium, and Elevated CPK levels. * **Treatment of NMS:** Stop the offending agent, provide supportive care, and use **Dantrolene** (muscle relaxant) or **Bromocriptine** (dopamine agonist). * **ECG Monitoring:** Mandatory when using high-dose antipsychotics or combining drugs like Ziprasidone and Pimozide.

Question 323: What is the common side effect associated with fluoxetine therapy?

A. Seizure
B. Anxiety
C. Hypotension
D. Loose stools (Correct Answer)

Explanation: **Explanation:** Fluoxetine is a Selective Serotonin Reuptake Inhibitor (SSRI). The mechanism involves increasing synaptic serotonin levels, which not only affects the brain but also acts on peripheral receptors. **Why "Loose Stools" is correct:** Approximately 90% of the body's serotonin is located in the **enterochromaffin cells of the GI tract**. SSRIs like fluoxetine increase serotonergic activity at **5-HT3 and 5-HT4 receptors** in the gut. This stimulates gastrointestinal motility and fluid secretion, leading to common side effects such as nausea, abdominal cramps, and **loose stools/diarrhea**. **Analysis of Incorrect Options:** * **A. Seizure:** While some antidepressants (like Bupropion or Maprotiline) significantly lower the seizure threshold, SSRIs are generally considered safe and have a very low risk of inducing seizures at therapeutic doses. * **B. Anxiety:** Although some patients experience "jitteriness" or transient activation syndrome during the first week of SSRI therapy, it is less common than GI side effects. Fluoxetine is actually used to *treat* chronic anxiety disorders. * **C. Hypotension:** SSRIs do not typically cause orthostatic hypotension. This side effect is more characteristic of Tricyclic Antidepressants (TCAs) due to alpha-1 adrenergic blockade. **High-Yield Clinical Pearls for NEET-PG:** * **Fluoxetine** has the **longest half-life** (4–6 days; its metabolite norfluoxetine lasts up to 16 days) among SSRIs, making it the least likely to cause discontinuation syndrome. * **Most common side effect of SSRIs:** GI upset (Nausea is #1, followed by diarrhea). * **Most common long-term side effect:** Sexual dysfunction (delayed ejaculation/anorgasmia). * **Drug of choice:** SSRIs are the first-line treatment for Depression, OCD, Panic Disorder, and Bulimia Nervosa (specifically Fluoxetine).

Question 324: Who introduced lithium for the treatment of manic-depressive illness?

A. Benedict Morel
B. Delay and Deniker
C. John F. Cade (Correct Answer)
D. Bleuler

Explanation: **Explanation:** The correct answer is **John F. Cade**. In **1949**, Australian psychiatrist John Cade discovered the antimanic effects of lithium while researching the role of uric acid in psychotic patients. He observed that lithium urate had a calming effect on guinea pigs, leading him to successfully treat patients with chronic and acute mania. This discovery marked the beginning of the modern era of psychopharmacology. **Analysis of Incorrect Options:** * **Benedict Morel (A):** He is known for introducing the term *"Démence précoce"* (the precursor to the term Schizophrenia) to describe a condition of mental deterioration starting in adolescence. * **Delay and Deniker (B):** Jean Delay and Pierre Deniker are credited with discovering the antipsychotic properties of **Chlorpromazine** in 1952, which revolutionized the treatment of schizophrenia. * **Eugen Bleuler (D):** He coined the term **"Schizophrenia"** (replacing Morel’s term) and defined its core symptoms using the "4 As" (Ambivalence, Autism, Affective flattening, and Association looseness). **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Lithium acts by inhibiting the **Inositol Monophosphatase (IMPase)** pathway and GSK-3 enzyme. * **Therapeutic Index:** It has a narrow therapeutic index. Target serum levels are **0.8–1.2 mEq/L** for acute mania and **0.6–0.8 mEq/L** for maintenance. * **Teratogenicity:** Use in pregnancy is associated with **Ebstein’s Anomaly** (tricuspid valve abnormality). * **Side Effects:** Common high-yield side effects include fine tremors, polyuria (nephrogenic diabetes insipidus), and hypothyroidism.

Question 325: Lithium use in pregnancy is associated with which of the following fetal defects?

A. Cardiovascular defects (Correct Answer)
B. Urogenital defects
C. Neural tube defects
D. Facial defects

Explanation: **Explanation:** **Lithium** is a gold-standard mood stabilizer used in Bipolar Disorder; however, it is a known teratogen. When used during the first trimester of pregnancy, it is specifically associated with **Cardiovascular defects**, most notably **Ebstein’s Anomaly**. This condition involves the downward displacement of the tricuspid valve into the right ventricle, leading to "atrialization" of the ventricle and severe tricuspid regurgitation. While the absolute risk is relatively low (approx. 1 in 1,000 to 2,000), it represents a 10-20 fold increase compared to the general population. **Analysis of Incorrect Options:** * **Urogenital defects:** These are not classically associated with Lithium. They are more commonly linked to maternal diabetes or specific genetic syndromes. * **Neural tube defects (NTDs):** These are the hallmark teratogenic effect of **Valproate** and **Carbamazepine** (due to interference with folate metabolism), not Lithium. * **Facial defects:** Cleft lip and palate are associated with anticonvulsants like Phenytoin (Fetal Hydantoin Syndrome) or Benzodiazepines, but are not the primary concern with Lithium. **High-Yield Clinical Pearls for NEET-PG:** * **Monitoring:** If Lithium must be used, fetal echocardiography is recommended at 18–22 weeks gestation. * **Dosage:** Lithium clearance increases during pregnancy (due to increased GFR) and drops abruptly at delivery; close serum monitoring is vital to prevent toxicity. * **Breastfeeding:** Lithium is generally discouraged during breastfeeding as it is excreted in milk and can cause "Floppy Baby Syndrome" (hypotonia, cyanosis). * **Alternative:** For NTDs (Valproate), the boards often ask about high-dose Folic acid supplementation (4mg/day).

Question 326: Which of the following conditions increases the chance of hyponatremia in a patient treated with an antidepressant?

A. Old age (Correct Answer)
B. Low weight
C. Cold climate
D. Obesity

Explanation: **Explanation:** The development of hyponatremia is a well-recognized side effect of antidepressant therapy, particularly with **Selective Serotonin Reuptake Inhibitors (SSRIs)** and **Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)**. **1. Why Old Age is Correct:** The primary mechanism is the **Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH)**. Antidepressants can stimulate the release of ADH or increase the sensitivity of the kidneys to it, leading to water retention and dilutional hyponatremia. **Old age** is the most significant risk factor because elderly patients often have decreased total body water, age-related changes in renal function, and are frequently on concomitant medications (like diuretics or NSAIDs) that further impair water excretion. **2. Analysis of Incorrect Options:** * **Low weight:** While some studies suggest low body mass index (BMI) might be a minor risk factor, it is not as clinically significant or consistently proven as advanced age. * **Cold climate:** Climate does not influence the pathophysiology of SIADH or antidepressant-induced hyponatremia. * **Obesity:** Obesity is not a recognized risk factor for SIADH; in fact, the risk is generally higher in those with lower body weight/frailty. **Clinical Pearls for NEET-PG:** * **Most Common Culprits:** SSRIs (Fluoxetine, Sertraline, Paroxetine) are the most frequently implicated. * **Timing:** Hyponatremia typically develops within the **first 2–4 weeks** of starting treatment. * **Monitoring:** Always check baseline and follow-up electrolytes in elderly patients starting SSRIs. * **Symptoms:** Range from lethargy and confusion to seizures and coma if sodium levels drop rapidly.

Question 327: Tardive dyskinesia is least common with which of the following medications?

A. Flupenthixol
B. Penfluridol
C. Olanzapine (Correct Answer)
D. None of the above

Explanation: **Explanation:** The risk of **Tardive Dyskinesia (TD)** is directly related to the potency of dopamine (D2) receptor blockade and the duration of treatment. **1. Why Olanzapine is correct:** Olanzapine is a **Second-Generation Antipsychotic (SGA)** or atypical antipsychotic. Atypical antipsychotics have a lower affinity for D2 receptors and a higher affinity for 5-HT2A receptors. They also exhibit "fast dissociation" from D2 receptors. These properties significantly reduce the risk of Extrapyramidal Side Effects (EPS) and long-term complications like Tardive Dyskinesia compared to First-Generation Antipsychotics (FGAs). Among the options provided, Olanzapine carries the lowest risk of inducing TD. **2. Why the other options are incorrect:** * **Flupenthixol (Option A):** This is a typical (First-Generation) antipsychotic of the thioxanthene class. It is a potent D2 receptor antagonist and is associated with a significantly higher risk of TD. * **Penfluridol (Option B):** This is a long-acting oral typical antipsychotic. Due to its high potency and long half-life, it maintains a sustained blockade of D2 receptors, making the risk of TD much higher than with atypical agents. **High-Yield Clinical Pearls for NEET-PG:** * **Definition:** TD is characterized by involuntary choreoathetoid movements, most commonly involving the orofacial region (e.g., tongue protrusion, lip-smacking). * **Pathophysiology:** It is thought to be caused by **dopamine receptor supersensitivity** in the nigrostriatal pathway following chronic blockade. * **Drug of Choice for TD:** If TD develops, the offending agent should be switched to **Clozapine** (the antipsychotic with the lowest overall risk of TD). * **FDA-Approved Treatment:** **VMAT-2 inhibitors** (e.g., Valbenazine, Deutetrabenazine) are now the standard treatment for managing TD symptoms. * **Risk Hierarchy:** Clozapine < Quetiapine < Olanzapine < Risperidone < Typical Antipsychotics (Haloperidol).

Question 328: A young patient with schizophrenia is intolerant to antipsychotic medications. Which drug is most preferred for such a patient?

A. Clozapine (Correct Answer)
B. Olanzapine
C. Risperidone
D. Haloperidol

Explanation: **Explanation:** The correct answer is **Clozapine (Option A)**. In clinical psychiatry, **Clozapine** is the gold-standard treatment for **Treatment-Resistant Schizophrenia (TRS)**. It is indicated when a patient has failed to respond to at least two different antipsychotic trials (one of which must be an atypical antipsychotic) or, as mentioned in the question, when a patient is **intolerant** to the side effects of other medications (particularly Extrapyramidal Symptoms or EPS). Clozapine is unique because it has a very low affinity for D2 receptors in the striatum, making it the drug of choice for patients who cannot tolerate the motor side effects of other agents. **Why other options are incorrect:** * **Haloperidol (Option D):** A high-potency typical antipsychotic with a high risk of EPS (dystonia, parkinsonism). It is usually the *least* preferred in intolerant patients. * **Risperidone (Option C) & Olanzapine (Option B):** These are first-line atypical antipsychotics. While they have a lower risk of EPS than Haloperidol, they are still associated with significant side effects (Risperidone: Hyperprolactinemia; Olanzapine: Metabolic syndrome). If a patient is "intolerant" to standard therapy, Clozapine is the next logical step. **High-Yield NEET-PG Pearls:** * **Clozapine** is the only antipsychotic proven to reduce **suicidal behavior** in schizophrenia. * **Most serious side effect:** Agranulocytosis (requires mandatory WBC monitoring). * **Most common side effect:** Sialorrhea (excessive salivation). * **Other risks:** Lowers seizure threshold (dose-dependent) and causes myocarditis. * **Mechanism:** Potent 5-HT2A and weak D2 blockade.

Question 329: A patient diagnosed with depression, currently on treatment, presents to the emergency department with altered sensorium, seizures, and palpitations. ECG shows sinus tachycardia. How do you treat this patient?

A. Aspirin + clopidogrel
B. IV Lorazepam
C. IV Sodium bicarbonate (Correct Answer)
D. IV Haloperidol

Explanation: ### Explanation The clinical presentation of **altered sensorium, seizures, and sinus tachycardia** in a patient being treated for depression is a classic description of **Tricyclic Antidepressant (TCA) overdose** (e.g., Amitriptyline). **Why IV Sodium Bicarbonate is the Correct Answer:** TCAs cause cardiotoxicity primarily by blocking **fast sodium channels** in the myocardium, leading to QRS prolongation, arrhythmias, and hypotension. * **Mechanism:** IV Sodium Bicarbonate increases extracellular sodium concentration and raises serum pH. The alkaline pH decreases the affinity of the TCA molecule for the sodium channel, while the sodium load helps overcome the channel blockade. This stabilizes the cardiac membrane and prevents fatal arrhythmias. **Analysis of Incorrect Options:** * **A. Aspirin + clopidogrel:** These are antiplatelets used for Acute Coronary Syndrome (ACS). While the patient has tachycardia, the underlying cause is toxicological, not thrombotic. * **B. IV Lorazepam:** While benzodiazepines are the first-line treatment for TCA-induced **seizures**, they do not address the life-threatening cardiac conduction delays, which is the priority in management. * **D. IV Haloperidol:** This is contraindicated. Antipsychotics can lower the seizure threshold and further prolong the QT interval, worsening the clinical state. **NEET-PG High-Yield Pearls:** * **The "3 Cs" of TCA Poisoning:** **C**oma, **C**onvulsions, and **C**ardiotoxicity. * **ECG Hallmark:** QRS duration **>100 ms** is predictive of seizures; **>160 ms** is highly predictive of ventricular arrhythmias. Look for a terminal R wave in lead aVR. * **Anticholinergic Toxidrome:** Patients often present with "dry as a bone, red as a beet, hot as a hare, blind as a bat, and mad as a hatter."

Question 330: Which of the following SSRIs is considered safe?

A. escitalopram (Correct Answer)
B. clomipramine
C. fluoxetine
D. amitriptyline

Explanation: **Explanation:** The question asks to identify the safe **SSRI (Selective Serotonin Reuptake Inhibitor)** among the given options. **1. Why Escitalopram is Correct:** Escitalopram is the S-enantiomer of citalopram and is considered the **most selective** SSRI. It has a very favorable safety profile due to its minimal effect on the Cytochrome P450 enzyme system, leading to fewer drug-drug interactions. It is also known for having the lowest potential for causing QTc prolongation among the SSRIs (unlike its parent compound, citalopram, which is dose-restricted). **2. Why the Other Options are Incorrect:** * **Clomipramine (Option B):** This is a **Tricyclic Antidepressant (TCA)**, not an SSRI. While it is the gold standard for OCD, it carries a high risk of side effects, including sedation, anticholinergic effects, and cardiotoxicity in overdose. * **Fluoxetine (Option C):** Although fluoxetine is an SSRI, it has a very long half-life (and an active metabolite, norfluoxetine) and is a potent inhibitor of CYP2D6. This makes it less "safe" in terms of drug interactions and management of side effects compared to escitalopram. * **Amitriptyline (Option D):** This is a **TCA**. It is highly cardiotoxic and has significant sedative and anticholinergic properties, making it much less safe than any SSRI. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** SSRIs are the first-line treatment for Depression, Panic Disorder, GAD, and OCD. * **Safest SSRI Post-MI:** Sertraline is generally preferred in patients with recent myocardial infarction. * **Longest Half-life:** Fluoxetine (useful in patients with poor compliance). * **Shortest Half-life:** Fluvoxamine/Paroxetine (highest risk of discontinuation syndrome). * **Side Effects:** The most common side effect of SSRIs is **GI upset** (nausea/diarrhea), and the most common long-term side effect is **sexual dysfunction**.

Question 331: What are the therapeutic serum levels of lithium in a patient with acute mania?

A. 0.4–0.8 mEq/L
B. 0.8–1.2 mEq/L (Correct Answer)
C. 1.2–1.6 mEq/L
D. 1.6–2.0 mEq/L

Explanation: **Explanation:** Lithium is the gold-standard mood stabilizer used for both the treatment of acute manic episodes and the long-term prophylaxis of Bipolar Affective Disorder (BPAD). Because Lithium has a **narrow therapeutic index**, monitoring serum levels is critical for both efficacy and safety. 1. **Why Option B is Correct:** In the **acute phase of mania**, higher serum concentrations are required to control symptoms effectively. The established therapeutic range for acute mania is **0.8–1.2 mEq/L**. Levels are typically measured 12 hours after the last dose (trough levels). 2. **Why Other Options are Incorrect:** * **Option A (0.4–0.8 mEq/L):** This is the range for **maintenance therapy** (prophylaxis). Once the acute episode subsides, the dose is usually lowered to minimize long-term side effects. * **Option C & D (>1.2 mEq/L):** These levels approach the toxic range. Toxicity generally begins at levels **>1.5 mEq/L**. Levels above 2.0 mEq/L are considered severe toxicity and may require hemodialysis. **High-Yield Clinical Pearls for NEET-PG:** * **Steady State:** Lithium levels should be checked after **5 days** of starting or changing the dose (5 half-lives). * **Side Effects:** Look for "LITHIUM" mnemonic: **L**eukocytosis, **I**nsipidus (Diabetes Insipidus), **T**remors/Teratogenicity (Ebstein’s Anomaly), **H**ypothyroidism, **I**ncreased **U**rine, **M**others (Pregnancy concerns). * **Drug Interactions:** Thiazides, NSAIDs, and ACE inhibitors increase Lithium levels (by decreasing renal clearance), potentially leading to toxicity. * **Monitoring:** Baseline Thyroid Function Tests (TFTs) and Renal Function Tests (RFTs) are mandatory.

Question 332: Which of the following is an indication for the use of Clozapine?

A. Resistant schizophrenia (Correct Answer)
B. Akathisia
C. First drug to be used for schizophrenia
D. Schizophrenia with depression

Explanation: **Explanation:** **Clozapine** is a unique atypical antipsychotic and is considered the "gold standard" for **Treatment-Resistant Schizophrenia (TRS)**. 1. **Why Option A is Correct:** Resistance is defined as a lack of satisfactory clinical improvement despite the use of adequate doses of at least two different antipsychotics (including one atypical) for a duration of 6–8 weeks each. Clozapine is the only drug proven effective in these cases due to its complex receptor profile (D2, D4, 5-HT2A, etc.). It is also specifically indicated for reducing suicidal behavior in patients with schizophrenia. 2. **Why Other Options are Incorrect:** * **Option B (Akathisia):** Clozapine has a very low affinity for D2 receptors in the nigrostriatal pathway, making it less likely to cause Extrapyramidal Symptoms (EPS) like akathisia. In fact, it is often used to manage patients who cannot tolerate other drugs due to severe EPS. * **Option C (First drug):** Due to its side effect profile (specifically agranulocytosis), it is never used as a first-line agent. It is reserved for third-line use after two failed trials. * **Option D (Schizophrenia with depression):** While it may help, the primary indication remains resistance. Depression in schizophrenia is typically managed with SSRIs or other atypical antipsychotics like Quetiapine. **High-Yield Clinical Pearls for NEET-PG:** * **Adverse Effects:** Most serious is **Agranulocytosis** (requires mandatory WBC monitoring). Most common is **Sialorrhea** (excessive drooling). It also lowers the seizure threshold (dose-dependent). * **Monitoring:** Absolute Neutrophil Count (ANC) must be checked weekly for the first 6 months. * **No Prolactin Elevation:** Unlike most antipsychotics, Clozapine does not cause hyperprolactinemia.

Question 333: Which of the following conditions is considered a first-line treatment with Selective Serotonin Reuptake Inhibitors (SSRIs)?

A. Obsessive-Compulsive Disorder (OCD)
B. Panic Disorder
C. Social Phobia
D. All of the above (Correct Answer)

Explanation: Selective Serotonin Reuptake Inhibitors (SSRIs) are the most widely prescribed class of antidepressants due to their favorable safety profile and broad therapeutic index. They work by inhibiting the presynaptic reuptake of serotonin (5-HT), thereby increasing its availability in the synaptic cleft. **Explanation of the Correct Answer:** SSRIs are considered the **first-line pharmacological treatment** for a wide spectrum of psychiatric conditions beyond Major Depressive Disorder. * **Obsessive-Compulsive Disorder (OCD):** SSRIs are the gold standard. Note that OCD often requires higher doses of SSRIs compared to depression. * **Panic Disorder:** SSRIs are preferred over benzodiazepines to avoid dependence and over TCAs due to fewer anticholinergic side effects. * **Social Phobia (Social Anxiety Disorder):** SSRIs are the first-line long-term treatment, helping to reduce both the psychological and physical symptoms of social distress. Since all three conditions listed (OCD, Panic Disorder, and Social Phobia) utilize SSRIs as the primary evidence-based treatment, **Option D (All of the above)** is correct. **High-Yield Clinical Pearls for NEET-PG:** * **Lag Period:** SSRIs typically take 2–4 weeks for an antidepressant effect and up to 6–12 weeks for a full response in OCD. * **Side Effects:** The most common side effects are GI upset (nausea/diarrhea) and **sexual dysfunction** (delayed ejaculation/anorgasmia). * **Drug of Choice (DOC) Summary:** * **OCD:** SSRIs (Fluoxetine, Fluvoxamine). * **Panic Disorder:** SSRIs (Paroxetine, Sertraline). * **Bulimia Nervosa:** Fluoxetine (High dose - 60mg). * **Premature Ejaculation:** Dapoxetine (Short-acting SSRI). * **Serotonin Syndrome:** A dangerous interaction when SSRIs are combined with MAOIs; characterized by the triad of autonomic instability, neuromuscular hyperactivity, and altered mental status.

Question 334: What is the absolute contraindication for Electro-Convulsive Therapy (ECT)?

A. Raised Intra-Cranial Tension (Correct Answer)
B. Vascular Dementia
C. Diabetic Retinopathy
D. Peripheral Neuropathy

Explanation: **Explanation:** **Why Raised Intra-Cranial Tension (ICT) is the Correct Answer:** Raised ICT is considered the only **absolute contraindication** for Electro-Convulsive Therapy (ECT). During the procedure, the induced seizure and the physiological response to the electrical stimulus cause a transient but significant increase in cerebral blood flow and blood pressure. In a patient with already elevated ICT (e.g., due to a space-occupying lesion), this further surge can lead to **brain herniation**, which is life-threatening. **Analysis of Incorrect Options:** * **Vascular Dementia:** This is not a contraindication. While patients with cognitive impairment may experience transient post-ictal confusion, ECT is often safely used in elderly patients with comorbid neurological conditions if depression is severe. * **Diabetic Retinopathy:** This is a **relative contraindication**. The transient rise in blood pressure during ECT could theoretically cause retinal hemorrhage, but it can be managed with pharmacological blood pressure control. * **Peripheral Neuropathy:** This has no bearing on the central nervous system effects of ECT and does not pose a risk during the procedure. **High-Yield Clinical Pearls for NEET-PG:** * **Relative Contraindications:** Recent Myocardial Infarction (less than 3 months), unstable angina, pheochromocytoma, and retinal detachment. * **Gold Standard Indication:** Severe depression with high suicidal risk or catatonia. * **Most Common Side Effect:** Retrograde amnesia (memory loss for events just before the treatment). * **Pre-medication:** Atropine (to prevent bradycardia/secretions), Thiopentone/Propofol (anesthetic), and Succinylcholine (muscle relaxant to prevent fractures).

Question 335: A 26-year-old lady has been on Olanzapine for the treatment of Schizophrenia. All of the following are the Adult Treatment Panel III (ATP III) criteria for metabolic syndrome, except?

A. Abdominal obesity
B. Triglyceride > 150 mg/dl
C. Blood pressure > 130/85 mmHg
D. LDL > 150 mg/dl (Correct Answer)

Explanation: **Explanation:** The question tests your knowledge of the **NCEP Adult Treatment Panel III (ATP III)** criteria for Metabolic Syndrome, which is a critical clinical consideration when prescribing Second-Generation Antipsychotics (SGAs) like **Olanzapine**, known for its high risk of metabolic side effects. **1. Why Option D is the correct answer:** The ATP III criteria do **not** include LDL (Low-Density Lipoprotein) levels. Instead, the lipid components focused on are **Triglycerides** and **HDL-C** (High-Density Lipoprotein). While elevated LDL is a cardiovascular risk factor, it is not a diagnostic criterion for Metabolic Syndrome. **2. Analysis of Incorrect Options (Criteria for Metabolic Syndrome):** To diagnose Metabolic Syndrome, at least **three** of the following five criteria must be present: * **Abdominal Obesity (Option A):** Defined as Waist Circumference >102 cm (40 in) in men or >88 cm (35 in) in women. * **Hypertriglyceridemia (Option B):** Triglycerides ≥150 mg/dL (or on treatment). * **Low HDL Cholesterol:** <40 mg/dL in men or <50 mg/dL in women. * **High Blood Pressure (Option C):** BP ≥130/85 mmHg (or on antihypertensive medication). * **High Fasting Glucose:** Fasting blood sugar ≥100 mg/dL (including Diabetes Mellitus). **Clinical Pearls for NEET-PG:** * **Olanzapine and Clozapine** carry the highest risk of weight gain, dyslipidemia, and Type 2 Diabetes among antipsychotics. * **Monitoring:** Patients on Olanzapine require baseline and periodic monitoring of weight (BMI), waist circumference, BP, fasting glucose, and lipid profile. * **Ziprasidone and Aripiprazole** are considered "metabolically neutral" SGAs with the lowest risk for metabolic syndrome.

Question 336: Which antidepressant is known to cause Tardive dyskinesia?

A. MAO inhibitors
B. Mianserin
C. Imipramine
D. Amoxapine (Correct Answer)

Explanation: ### Explanation **Correct Option: D. Amoxapine** **Why Amoxapine is the correct answer:** Amoxapine is a secondary amine tricyclic antidepressant (TCA) with a unique pharmacological profile. It is a metabolite of the antipsychotic drug **Loxapine**. Unlike other antidepressants, Amoxapine possesses significant **dopamine D2 receptor blocking activity**. Because it acts as a dopamine antagonist in the nigrostriatal pathway, it can cause the same extrapyramidal side effects (EPS) typically associated with antipsychotics, including **Tardive Dyskinesia (TD)**, parkinsonism, and neuroleptic malignant syndrome. **Why other options are incorrect:** * **A. MAO inhibitors:** These drugs (e.g., Phenelzine, Selegiline) increase synaptic levels of serotonin, norepinephrine, and dopamine. They do not block dopamine receptors and are therefore not associated with TD. * **B. Mianserin:** A tetracyclic antidepressant that primarily acts as an alpha-2 adrenergic antagonist. It lacks D2 receptor blocking properties. * **C. Imipramine:** A classic TCA that primarily inhibits the reuptake of serotonin and norepinephrine. While it has anticholinergic and antihistaminic effects, it does not block D2 receptors and does not cause TD. **High-Yield Clinical Pearls for NEET-PG:** * **Amoxapine = "Antidepressant with Antipsychotic properties."** It is sometimes used in psychotic depression. * **Loxapine Connection:** Remember that Amoxapine is structurally related to the typical antipsychotic Loxapine. * **Tardive Dyskinesia:** Characterized by involuntary, choreoathetoid movements (commonly orofacial) due to prolonged dopamine blockade and subsequent receptor supersensitivity. * **Other EPS-causing non-antipsychotics:** Always remember **Metoclopramide** (antiemetic) as another high-yield cause of drug-induced TD.

Question 337: Which of the following is NOT true regarding olanzapine?

A. It causes marked anti-muscarinic action.
B. It causes weight gain.
C. It causes a mild increase in prolactin.
D. It has less epileptogenic action than phenothiazines. (Correct Answer)

Explanation: **Explanation:** Olanzapine is a potent **Second-Generation Antipsychotic (SGA)** or atypical antipsychotic. Understanding its side-effect profile is crucial for NEET-PG. **Why Option D is the Correct Answer (The "False" Statement):** Olanzapine, along with Clozapine, is known to **lower the seizure threshold** significantly. In fact, olanzapine has a **higher epileptogenic potential** compared to many typical antipsychotics like phenothiazines (e.g., Chlorpromazine) and other SGAs like Risperidone. Therefore, stating it has "less" epileptogenic action is incorrect. **Analysis of Other Options:** * **Option A (Anti-muscarinic action):** Olanzapine has a high affinity for M1 receptors, leading to marked anticholinergic side effects such as dry mouth, constipation, and urinary retention. * **Option B (Weight gain):** Olanzapine is notorious for causing significant **metabolic syndrome**, characterized by profound weight gain, dyslipidemia, and type 2 diabetes mellitus. It is second only to Clozapine in this regard. * **Option C (Prolactin levels):** Unlike Risperidone or typical antipsychotics, Olanzapine causes only a **mild and transient** increase in prolactin levels, rarely leading to clinical galactorrhea or gynecomastia. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** It acts as a 5-HT2A and D2 receptor antagonist (SDA). * **Metabolic Monitoring:** Patients on Olanzapine must have regular monitoring of BMI, blood glucose, and lipid profiles. * **Smoking Interaction:** Smoking induces the **CYP1A2** enzyme, which can decrease olanzapine plasma levels. * **Drug of Choice:** It is highly effective for negative symptoms of schizophrenia and as a mood stabilizer in Bipolar Disorder.

Question 338: Neuroleptic malignant syndrome is characterized by which of the following?

A. Bradycardia
B. Labile hypertension (Correct Answer)
C. Hypotonia
D. Hypothermia

Explanation: **Explanation:** Neuroleptic Malignant Syndrome (NMS) is a life-threatening idiosyncratic reaction to antipsychotic medications (neuroleptics), primarily caused by potent **dopamine (D2) receptor blockade** in the nigrostriatal pathway and hypothalamus. **Why Labile Hypertension is correct:** Autonomic instability is a hallmark of NMS. This manifests as **labile hypertension** (fluctuating blood pressure), tachycardia, diaphoresis, and cardiac arrhythmias. The dysregulation of the autonomic nervous system leads to unpredictable shifts in vascular tone and heart rate. **Analysis of Incorrect Options:** * **A. Bradycardia:** Patients typically present with **tachycardia** due to autonomic hyperactivity and as a physiological response to hyperthermia and stress. * **C. Hypotonia:** NMS is characterized by severe **"Lead-pipe" rigidity** (extrapyramidal symptom). Hypotonia is not seen; in fact, the intense muscle contraction contributes to hyperthermia and rhabdomyolysis. * **D. Hypothermia:** **Hyperpyrexia** (fever >104°F or 40°C) is a core diagnostic criterion. It results from both hypothalamic dysfunction and excessive heat production from muscle rigidity. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic (FEVER):** **F**ever, **E**ncephalopathy (altered sensorium), **V**itals unstable, **E**levated CPK/Enzymes, **R**igidity. * **Laboratory Findings:** Significantly elevated **Creatine Phosphokinase (CPK)** and leukocytosis are classic markers. * **Treatment:** Immediate cessation of the offending agent, aggressive cooling, and pharmacological intervention with **Dantrolene** (muscle relaxant) or **Bromocriptine** (dopamine agonist). * **Differential Diagnosis:** Unlike Serotonin Syndrome, NMS presents with "lead-pipe" rigidity and bradyreflexia, whereas Serotonin Syndrome features hyperreflexia and myoclonus.

Question 339: What is an absolute contraindication to ECT?

A. Glaucoma
B. Brain tumor (Correct Answer)
C. Aortic aneurysm
D. Myocardial infarction

Explanation: **Explanation:** Electroconvulsive Therapy (ECT) is a highly effective treatment in psychiatry, but it involves physiological changes—specifically a transient increase in intracranial pressure (ICP) and a brief cardiovascular surge (initial bradycardia followed by tachycardia and hypertension). **Why Brain Tumor is the Correct Answer:** A **Brain tumor with increased intracranial pressure** is traditionally considered the only **absolute contraindication** to ECT. During the seizure, cerebral blood flow and ICP rise significantly. In the presence of a space-occupying lesion, this can lead to **uncal or transtentorial herniation**, which is fatal. While some modern literature suggests ECT can be performed on stable tumors without mass effect, for the purpose of NEET-PG, "Brain Tumor" remains the classic absolute contraindication. **Analysis of Incorrect Options:** * **Glaucoma:** This is a **relative contraindication**. ECT can cause a transient rise in intraocular pressure, but it can be managed with pre-treatment miotic drops. * **Aortic Aneurysm:** This is a **relative contraindication**. The hypertensive surge during ECT poses a risk of rupture, but this can be mitigated using short-acting beta-blockers (e.g., Esmolol) to control blood pressure. * **Myocardial Infarction (MI):** Recent MI (usually within the last 3 months) is a high-risk **relative contraindication** due to increased cardiac workload, but it is not absolute if the psychiatric condition is life-threatening and the patient is cardiac-stabilized. **High-Yield Clinical Pearls for NEET-PG:** * **Most common side effect:** Retrograde amnesia (usually resolves). * **Most common cause of death:** Cardiovascular complications (Arrhythmias). * **Drug of choice for anesthesia:** Methohexital (Barbiturate). * **Muscle relaxant used:** Succinylcholine (to prevent fractures). * **Safe in Pregnancy:** ECT is considered safe and often preferred for severe depression/psychosis in pregnant patients.

Question 340: All of the following drugs are indicated in the treatment of bipolar disorder except?

A. Carbamazepine
B. Vigabatrin (Correct Answer)
C. Sodium valproate
D. Lamotrigine

Explanation: **Explanation:** The treatment of Bipolar Disorder (BD) relies heavily on **Mood Stabilizers**, which primarily include Lithium and certain anticonvulsants. **Why Vigabatrin is the Correct Answer:** Vigabatrin is an anticonvulsant that acts as an irreversible inhibitor of GABA transaminase. While it increases GABA levels, it has **no proven efficacy** in treating mania or depression associated with bipolar disorder. Furthermore, it is associated with a high risk of permanent visual field defects (vigabatrin-associated visual field loss), limiting its use primarily to refractory focal seizures and infantile spasms (West Syndrome). **Analysis of Other Options:** * **Carbamazepine (Option A):** An established mood stabilizer particularly effective in **Rapid Cycling Bipolar Disorder** and acute mania. It acts by blocking voltage-gated sodium channels. * **Sodium Valproate (Option C):** Often considered a first-line treatment for **Acute Mania** and mixed episodes. It works by increasing GABA levels and modulating glutamate/sodium channels. * **Lamotrigine (Option D):** A key mood stabilizer specifically indicated for the **maintenance phase** of bipolar disorder to **prevent bipolar depression**. It is not effective for acute mania. **NEET-PG High-Yield Pearls:** * **Drug of Choice (DOC) for Acute Mania:** Lithium (classic) or Sodium Valproate (especially for irritable/mixed mania). * **DOC for Bipolar Depression:** Quetiapine, Lurasidone, or Lamotrigine. * **Teratogenicity:** Valproate is highly associated with **Neural Tube Defects** (avoid in pregnancy); Lithium is associated with **Ebstein’s Anomaly**. * **Lamotrigine Caution:** Must be titrated slowly to avoid **Stevens-Johnson Syndrome (SJS)**.

Question 341: Which of the following antidepressants causes hypertensive crisis?

A. Dapoxetine
B. Duloxetine
C. Clomipramine
D. Phenelzine (Correct Answer)

Explanation: **Explanation** The correct answer is **Phenelzine**. Phenelzine is a non-selective, irreversible **Monoamine Oxidase Inhibitor (MAOI)**. **Why Phenelzine causes Hypertensive Crisis:** MAOIs inhibit the enzyme monoamine oxidase, which is responsible for breaking down tyramine in the gastrointestinal tract and liver. When a patient taking an MAOI consumes **tyramine-rich foods** (e.g., aged cheese, red wine, cured meats), tyramine enters the systemic circulation and acts as an indirect sympathomimetic. It displaces large amounts of stored norepinephrine from presynaptic vesicles into the synaptic cleft, leading to severe vasoconstriction and a potentially fatal **hypertensive crisis** (the "Cheese Reaction"). **Analysis of Incorrect Options:** * **A. Dapoxetine:** A short-acting Selective Serotonin Reuptake Inhibitor (SSRI) used primarily for premature ejaculation. It does not significantly affect norepinephrine levels. * **B. Duloxetine:** A Serotonin-Norepinephrine Reuptake Inhibitor (SNRI). While it can cause a modest increase in blood pressure, it does not trigger a sudden hypertensive crisis via the tyramine pathway. * **C. Clomipramine:** A Tricyclic Antidepressant (TCA) that primarily inhibits serotonin reuptake. Its main side effects are anticholinergic and cardiac arrhythmias, not hypertensive crisis. **NEET-PG High-Yield Pearls:** * **Antidote:** The treatment of choice for an MAOI-induced hypertensive crisis is **Phentolamine** (an alpha-blocker). * **Washout Period:** When switching from an MAOI to an SSRI, a **2-week washout period** is required (5 weeks for Fluoxetine) to prevent **Serotonin Syndrome**. * **Other MAOIs:** Isocarboxazid and Tranylcypromine are also non-selective MAOIs associated with this risk.

Question 342: What is the major difference between typical and atypical antipsychotics?

A. Atypical antipsychotics cause minimal or no increase in prolactin.
B. Typical antipsychotics cause tardive dyskinesia. (Correct Answer)
C. Typical antipsychotics are available as parenteral preparations.
D. Atypical antipsychotics cause substantial sedation.

Explanation: ### Explanation The fundamental difference between typical (First Generation) and atypical (Second Generation) antipsychotics lies in their receptor binding profiles and side effect patterns. **Why Option B is Correct:** Typical antipsychotics (e.g., Haloperidol, Chlorpromazine) are potent **D2 receptor antagonists** in the nigrostriatal pathway. Chronic blockade of these receptors leads to "upregulation" and supersensitivity, resulting in **Tardive Dyskinesia (TD)**—a late-onset extrapyramidal symptom (EPS) characterized by involuntary choreoathetoid movements. While atypical antipsychotics carry a significantly lower risk of TD due to their rapid dissociation from D2 receptors and 5-HT2A antagonism, TD remains a hallmark long-term complication primarily associated with typical agents. **Why Other Options are Incorrect:** * **Option A:** While many atypicals have a lower risk of hyperprolactinemia, **Risperidone** and **Paliperidone** (atypical agents) cause significant increases in prolactin, often comparable to typical antipsychotics. * **Option C:** Both classes are available as parenteral preparations. For example, Haloperidol (Typical) and Olanzapine or Ziprasidone (Atypical) are available as short-acting injectables for acute agitation. * **Option D:** Sedation is not exclusive to atypicals. While Clozapine and Quetiapine are highly sedating, typical antipsychotics like **Chlorpromazine** (low potency) are also profoundly sedating. **High-Yield NEET-PG Pearls:** * **Mechanism:** Typical = D2 blockade; Atypical = D2 + 5-HT2A blockade (Serotonin-Dopamine Antagonists). * **Side Effect Profile:** Typical = High EPS/Neurological; Atypical = High Metabolic (Weight gain, Dyslipidemia, Diabetes). * **Clozapine:** The only antipsychotic proven effective for treatment-resistant schizophrenia; carries a risk of **agranulocytosis** (requires regular ANC monitoring). * **Aripiprazole:** A "Dopamine system stabilizer" (Partial D2 agonist).

Question 343: A patient undergoing treatment for a psychiatric disorder takes an overdose of a drug and develops bradycardia, hypotension, decreased sweating, and salivation. What is the likely drug?

A. Amitriptyline (Correct Answer)
B. Lithium
C. Selegiline
D. Amphetamine

Explanation: ### Explanation The clinical presentation of **bradycardia, hypotension, decreased sweating, and salivation** in the context of an overdose points toward **Tricyclic Antidepressant (TCA)** toxicity, specifically **Amitriptyline**. **1. Why Amitriptyline is Correct:** Amitriptyline is a tertiary amine TCA. While TCAs are known for their anticholinergic effects (dry mouth, tachycardia) at therapeutic doses, a **massive overdose** leads to life-threatening cardiovascular and neurological toxicity: * **Cardiovascular Effects:** TCAs inhibit fast sodium channels in the myocardium (Quinidine-like effect). This leads to QRS prolongation, **hypotension**, and potentially **bradycardia** (due to conduction blocks), despite the initial reflex tachycardia. * **Autonomic Effects:** While "decreased sweating" (anhidrosis) is a classic anticholinergic sign, the presence of "salivation" in this specific question stem is a known paradoxical or terminal finding in severe TCA poisoning, though typically, TCAs cause dryness. *Note: In NEET-PG contexts, the combination of hypotension and ECG changes is the hallmark of TCA overdose.* **2. Why Incorrect Options are Wrong:** * **Lithium:** Toxicity typically presents with gastrointestinal symptoms (nausea, vomiting) and neurological signs (coarse tremors, ataxia, seizures). It does not typically cause the "dryness" associated with anticholinergic profiles. * **Selegiline:** An MAO-B inhibitor. Overdose usually leads to a hyperadrenergic state (hypertension, tachycardia, hyperthermia), not bradycardia and hypotension. * **Amphetamine:** A potent sympathomimetic. Overdose causes **tachycardia, hypertension, mydriasis, and diaphoresis (increased sweating)**—the exact opposite of this patient's presentation. **3. High-Yield Clinical Pearls for NEET-PG:** * **TCA Toxicity Triad (The 3 C’s):** **C**oma, **C**onvulsions, and **C**ardiotoxicity. * **ECG Marker:** QRS duration >100 ms is a predictor of seizures; >160 ms is a predictor of ventricular arrhythmias. * **Antidote:** **Sodium Bicarbonate** ($NaHCO_3$) is the drug of choice to manage QRS widening and hypotension. * **Amitriptyline** is also used for chronic pain, migraine prophylaxis, and enuresis.

Question 344: An elderly woman suffering from schizophrenia is on antipsychotic medication. She developed purposeless involuntary facial and limb movements, constant chewing and puffing of cheeks. Which of the following drugs is least likely to be involved in this side effect?

A. Haloperidol
B. Clozapine (Correct Answer)
C. Fluphenazine
D. Loxapine

Explanation: **Explanation:** The clinical presentation described—purposeless involuntary facial movements, constant chewing, and puffing of cheeks—is characteristic of **Tardive Dyskinesia (TD)**. This is a late-onset extrapyramidal side effect (EPS) caused by long-term blockade of dopamine (D2) receptors, leading to receptor supersensitivity. **Why Clozapine is the correct answer:** Clozapine is an atypical (second-generation) antipsychotic with a unique pharmacological profile. It has a **low affinity for D2 receptors** and a high affinity for D4 and serotonin (5-HT2A) receptors. Because it dissociates rapidly from D2 receptors, it carries the **lowest risk** of causing EPS and Tardive Dyskinesia among all antipsychotics. In fact, Clozapine is often the drug of choice for patients who have already developed TD. **Analysis of Incorrect Options:** * **Haloperidol & Fluphenazine:** These are high-potency, first-generation (typical) antipsychotics. They have a very high affinity for D2 receptors in the nigrostriatal pathway, making them the most common culprits for TD. * **Loxapine:** This is a mid-potency typical antipsychotic. While it has some serotonin-blocking properties, it behaves primarily like a first-generation drug and carries a significant risk of TD, especially in elderly patients. **Clinical Pearls for NEET-PG:** * **Risk Factors for TD:** Old age (highest risk), female gender, and long-term use of typical antipsychotics. * **Pathophysiology:** Dopamine receptor supersensitivity in the nigrostriatal pathway. * **Management:** The first step is to reduce the dose or switch to **Clozapine** or **Quetiapine**. * **Newer Treatments:** VMAT-2 inhibitors like **Valbenazine** or **Deutetrabenazine** are now FDA-approved for TD. * **Warning:** Anticholinergics (like Trihexyphenidyl) often **worsen** the symptoms of Tardive Dyskinesia, unlike acute dystonia.

Question 345: What is the drug of choice for a schizophrenic patient with poor oral absorption?

A. Haloperidol
B. Fluphenazine
C. Clozapine (Correct Answer)
D. Olanzapine

Explanation: **Explanation:** The correct answer is **Clozapine**. **Why Clozapine is the Correct Choice:** The question addresses a specific pharmacokinetic challenge: **poor oral absorption**. While most antipsychotics are available in oral forms, Clozapine is unique in its pharmacological profile. In clinical scenarios where a patient fails to respond to standard antipsychotics (often due to poor absorption, high first-pass metabolism, or treatment resistance), Clozapine remains the **Gold Standard**. From a NEET-PG perspective, Clozapine is the only antipsychotic proven to be effective in **Treatment-Resistant Schizophrenia (TRS)**. If a patient has poor oral absorption leading to subtherapeutic plasma levels despite standard dosing, Clozapine is indicated because of its superior efficacy and the requirement for mandatory therapeutic drug monitoring (TDM) to ensure therapeutic levels are reached. **Analysis of Incorrect Options:** * **Haloperidol & Fluphenazine:** These are typical (first-generation) antipsychotics. While they are available as long-acting injectables (depots) to bypass the GI tract for *compliance* issues, they are not the "drug of choice" for absorption-related treatment failure. * **Olanzapine:** An atypical antipsychotic similar to Clozapine but with lower efficacy in resistant cases. It does not offer a specific advantage over Clozapine in the context of malabsorption-induced treatment failure. **High-Yield Clinical Pearls for NEET-PG:** * **Clozapine Side Effects:** Agranulocytosis (requires weekly CBC monitoring for the first 6 months), seizures (dose-dependent), myocarditis, and hypersalivation (sialorrhea). * **Indication:** Treatment-resistant schizophrenia (failure of 2 different antipsychotics for 6 weeks each) and reducing suicidal behavior in schizophrenia. * **Note:** Clozapine is the only antipsychotic that **does not** cause Tardive Dyskinesia and has minimal Extrapyramidal Side Effects (EPS).

Question 346: Which is a common side effect of lithium?

A. Polyuria
B. Fine tremors (Correct Answer)
C. Polydipsia
D. Weight gain

Explanation: **Explanation:** Lithium is the gold-standard mood stabilizer for Bipolar Affective Disorder (BPAD). Understanding its side effect profile is crucial for NEET-PG, as it has a narrow therapeutic index (0.6–1.2 mEq/L). **Why Fine Tremors is the Correct Answer:** Fine hand tremors are the **most common** neurological side effect of lithium, occurring in up to 25–50% of patients even at therapeutic serum levels. They are typically postural (evident when arms are outstretched) and are caused by lithium's effect on the peripheral nervous system and muscles. While they are "common," the development of **coarse tremors** is a critical warning sign of lithium toxicity. **Analysis of Incorrect Options:** * **Polyuria & Polydipsia (Options A & C):** These are frequent side effects occurring due to lithium-induced **Nephrogenic Diabetes Insipidus (NDI)**. Lithium inhibits ADH action on the collecting ducts. While very common, fine tremors are statistically reported more frequently as an early/persistent side effect in clinical studies. * **Weight Gain (Option D):** This is a common metabolic side effect (often due to insulin-like effects or secondary to polydipsia if patients consume high-calorie drinks), but it is less immediate and less characteristic than tremors. **High-Yield Clinical Pearls for NEET-PG:** * **Management of Fine Tremors:** Propropanol (Beta-blocker) is the drug of choice. * **L-I-T-H-I-U-M Mnemonic for Side Effects:** **L**eukocytosis, **I**nsipidus (NDI), **T**remors/Teratogenicity (Ebstein’s Anomaly), **H**ypothyroidism, **I**nsulin-like effect (Weight gain), **U**rine excess, **M**others (avoid in pregnancy). * **Monitoring:** Check Thyroid Function Tests (TFTs) and Renal Function Tests (RFTs) before and during treatment. * **Toxicity:** Levels >1.5 mEq/L. Features include coarse tremors, ataxia, vomiting, and seizures. Hemodialysis is the treatment of choice for severe toxicity.

Question 347: Estimation of serum levels is important for which of the following drugs?

A. Haloperidol
B. Benzodiazepines
C. Lithium (Correct Answer)
D. Chlorpromazine

Explanation: **Explanation:** **Lithium** is the correct answer because it is a drug with a **narrow therapeutic index**, meaning the difference between a therapeutic dose and a toxic dose is very small. Regular **Therapeutic Drug Monitoring (TDM)** is mandatory to ensure efficacy and prevent life-threatening toxicity. * **Therapeutic Range:** 0.6 to 1.2 mEq/L (for prophylaxis/maintenance) and up to 1.5 mEq/L (for acute mania). * **Toxicity:** Levels >1.5 mEq/L can lead to coarse tremors, ataxia, and vomiting; levels >2.0 mEq/L can cause seizures, coma, and death. * **Timing:** Serum levels should be measured **12 hours after the last dose** (Steady-state concentration). **Why other options are incorrect:** * **Haloperidol & Chlorpromazine (Antipsychotics):** These drugs have a wide therapeutic window. Clinical response and side effects (like Extrapyramidal Symptoms) are used to guide dosing rather than serum levels. * **Benzodiazepines:** These have a high safety margin. Dosing is titrated based on clinical sedation and anxiety relief; serum levels do not correlate well with clinical effects. **High-Yield Clinical Pearls for NEET-PG:** 1. **Steady State:** Achieved in 5 days (5 half-lives). 2. **Monitoring Schedule:** Initially every 1–2 weeks until stable, then every 3–6 months. 3. **Renal Function:** Lithium is excreted 100% by the kidneys; always check Serum Creatinine before starting. 4. **Factors increasing Lithium levels:** Dehydration, Low-sodium diet, NSAIDs, Thiazide diuretics, and ACE inhibitors (Mnemonic: **D**ehydration **N**early **T**akes **A**way **L**ithium).

Question 348: Which of the following antismoking drugs can lead to suicidal ideation?

A. Baclofen
B. Rimonobant
C. Varenicline (Correct Answer)
D. Naltrexone

Explanation: **Explanation:** **Varenicline** is a partial agonist at the **α4β2 nicotinic acetylcholine receptors**. It works by reducing nicotine cravings and decreasing the "reward" sensation of smoking. However, it is clinically significant for its neuropsychiatric side effects. In 2009, the FDA issued a **Boxed Warning** (though later updated) regarding its association with serious neuropsychiatric events, including **suicidal ideation**, depression, agitation, and hostility. While recent large-scale studies (like EAGLES) suggest the risk is lower than initially feared, it remains a high-yield association for exams. **Analysis of Incorrect Options:** * **Baclofen (A):** A GABA-B agonist primarily used as a muscle relaxant and sometimes off-label for alcohol craving; it is not a standard antismoking drug and is not typically linked to suicidal ideation. * **Rimonabant (B):** A CB1 cannabinoid receptor antagonist. While it was used for obesity and smoking cessation, it was withdrawn globally because it caused severe depression and suicidal thoughts. However, Varenicline is the more commonly tested "antismoking" drug with this specific profile in current psychiatric curricula. * **Naltrexone (D):** An opioid antagonist used primarily in alcohol and opioid dependence. It does not have a primary role in smoking cessation. **High-Yield Clinical Pearls for NEET-PG:** * **Varenicline Mechanism:** Partial agonist at α4β2 (most important) and full agonist at α7 nicotinic receptors. * **Common Side Effect:** **Vivid dreams** and nausea are the most frequently reported side effects. * **Bupropion:** Another antismoking drug (NDRI) that also carries a risk of neuropsychiatric symptoms and is contraindicated in patients with a history of **seizures or eating disorders**. * **First-line Smoking Cessation:** Nicotine Replacement Therapy (NRT), Varenicline, and Bupropion.

Question 349: Estimation of serum levels is important for which of the following drugs?

A. Haloperidol
B. Benzodiazepines
C. Lithium (Correct Answer)
D. Chlorpromazine

Explanation: **Explanation:** **Lithium** is the correct answer because it has a **narrow therapeutic index**, meaning the difference between a therapeutic dose and a toxic dose is very small. Regular Therapeutic Drug Monitoring (TDM) is mandatory to ensure efficacy and prevent life-threatening toxicity. * **Why Lithium?** Lithium is not metabolized; it is excreted unchanged by the kidneys. Its serum levels are highly sensitive to hydration status, sodium intake, and drug interactions (e.g., NSAIDs, Diuretics, ACE inhibitors). The standard therapeutic range is **0.6–1.2 mEq/L**. Levels above 1.5 mEq/L are generally considered toxic. * **Why other options are incorrect:** * **Haloperidol & Chlorpromazine (Antipsychotics):** While plasma levels can be measured, they do not correlate strongly with clinical response or side effects. Dosing is primarily guided by clinical symptoms and the emergence of extrapyramidal side effects (EPS). * **Benzodiazepines:** These have a wide therapeutic window. Monitoring is based on clinical sedation and respiratory status rather than serum concentrations. **High-Yield Clinical Pearls for NEET-PG:** * **Sampling Time:** Serum Lithium levels should be measured **12 hours after the last dose** (Trough level). * **Monitoring Frequency:** Initially every 5–7 days until stable; then every 3–6 months. * **Target Levels:** * Acute Mania: 0.8–1.2 mEq/L * Maintenance: 0.6–0.8 mEq/L * Toxicity: >1.5 mEq/L (Severe toxicity >2.0 mEq/L may require hemodialysis). * **Other drugs requiring TDM in Psychiatry:** Valproate, Carbamazepine, and Clozapine (in specific refractory cases).

Question 350: Which of the following antismoking drugs can lead to suicidal ideation?

A. Baclofen
B. Rimonobant
C. Varenicline (Correct Answer)
D. Naltrexone

Explanation: **Varenicline** is a high-yield topic in NEET-PG psychopharmacology. It is a **selective nicotinic acetylcholine receptor (nAChR) partial agonist** (specifically at the $\alpha_4\beta_2$ subtype). By partially stimulating these receptors, it reduces withdrawal symptoms, while its antagonistic property blocks the "reward" effect of nicotine if a patient relapses. ### Explanation of Options: * **Varenicline (Correct):** In 2009, the FDA issued a **Black Box Warning** (later updated but still clinically significant) regarding serious neuropsychiatric events, including **suicidal ideation**, depression, agitation, and hostility. Patients must be monitored closely for mood changes during treatment. * **Baclofen:** A $GABA_B$ agonist primarily used as a muscle relaxant. While sometimes used off-label for alcohol or cocaine dependence, it is not a primary antismoking drug and is not classically associated with suicidal ideation. * **Rimonabant:** A CB1 cannabinoid receptor antagonist. While it was used for weight loss and smoking cessation, it was withdrawn globally because it caused severe depression and anxiety, but it is not the *standard* answer for antismoking-induced suicidality in the context of current psychiatric exams compared to Varenicline. * **Naltrexone:** An opioid antagonist used primarily in alcohol and opioid dependence. It does not have a primary role in smoking cessation. ### High-Yield Clinical Pearls for NEET-PG: 1. **Mechanism of Action:** $\alpha_4\beta_2$ Nicotinic receptor partial agonist. 2. **Most Common Side Effect:** **Nausea** (often dose-dependent; taking it with food helps). 3. **Vivid Dreams:** Patients frequently report abnormal or vivid dreams. 4. **Bupropion:** Another antismoking drug (NDRI) that also carries a risk of neuropsychiatric side effects and is contraindicated in patients with a **seizure disorder** or eating disorders.

Question 351: A 28-year-old woman diagnosed with schizophrenia had been compliant with her prescribed olanzapine for several months. However, she discontinued the treatment. Which of the following is the most likely reason for her discontinuation?

A. Weight gain (Correct Answer)
B. Tardive dyskinesia
C. Acute dystonia
D. Akathisia

Explanation: ***Weight gain*** - **Olanzapine** is associated with one of the highest propensities among all antipsychotics for causing significant **weight gain** and metabolic syndrome (dyslipidemia, hyperglycemia). - For young women, this effect is often highly stigmatizing and is the leading cause for non-adherence and treatment discontinuation after several months of successful compliance. *Acute dystonia* - This is an acute **Extrapyramidal Symptom (EPS)** characterized by sudden, sustained muscle contractions, typically appearing within the first few days or weeks of starting treatment. - Olanzapine has a low rate of acute dystonia, and it would likely have caused discontinuation much earlier than several months into therapy. *Akathisia* - **Akathisia** is characterized by distressing subjective restlessness and motor agitation; although possible, it usually manifests early in the treatment course or after dose increases. - While bothersome, weight gain accumulated over several months is a statistically more frequent reason for patient-led drug discontinuation in this population than chronic akathisia. *Tardive dyskinesia* - **Tardive dyskinesia (TD)** is an involuntary movement disorder that is a late-onset side effect, typically developing after years of cumulative antipsychotic exposure. - Given that she was compliant for only several months, the development of severe TD causing discontinuation is highly improbable compared to chronic, rapidly accumulating metabolic side effects like weight gain.

Question 352: Which among the following psychoactive substances has antidepressant properties?

A. Cannabidiol
B. Mephedrone
C. Bupropion
D. Ketamine (Correct Answer)

Explanation: ***Correct: Ketamine*** - Ketamine, traditionally an anesthetic, exhibits rapid and potent **antidepressant properties**, particularly effective in treatment-resistant depression (TRD). - It primarily acts as an **NMDA receptor antagonist**, increasing **glutamate** release, which subsequently causes a surge in neurotrophic factors (like BDNF) crucial for synaptic plasticity. - Esketamine (S-ketamine) nasal spray is FDA-approved for treatment-resistant depression. *Incorrect: Bupropion* - Bupropion is an antidepressant that acts as a **norepinephrine-dopamine reuptake inhibitor (NDRI)**, but it is **not classified as a psychoactive substance of abuse** in the same context as the other options. - It is a prescription medication clinically used for depression and **smoking cessation**, often preferred due to minimal sexual side effects. - While it has antidepressant properties, it is not a "psychoactive substance" in the classical sense used in this question. *Incorrect: Cannabidiol* - Cannabidiol (CBD) is a non-psychoactive component of cannabis used for various conditions, showing promise for **anxiety** and certain seizure disorders (FDA-approved Epidiolex for specific epilepsies). - While some studies hint at potential antidepressant effects, evidence is limited and inconsistent. - It is primarily researched for its anxiolytic and anticonvulsant properties, not as a primary or fast-acting antidepressant like ketamine. *Incorrect: Mephedrone* - Mephedrone is a synthetic substituted cathinone, often illegally used as a recreational drug with potent **stimulant** and **euphoric** effects. - It primarily acts as a **dopamine** and **serotonin** releasing agent, posing high risks of addiction, neurotoxicity, and cardiovascular complications. - It has no recognized clinical antidepressant use and carries significant abuse potential.

Question 353: Which of the following drugs are used in the management of acute mania?

A. Only 1 (Lithium)
B. 1, 2 & 3 (Lithium, Valproate & Haloperidol) (Correct Answer)
C. 1, 2 & 4 (Lithium, Valproate & Amitriptyline)
D. 2 & 4 (Valproate & Amitriptyline)

Explanation: ***Correct: 1, 2 & 3 (Lithium, Valproate & Haloperidol)*** **Drugs used in acute mania management:** **Lithium** - First-line mood stabilizer with proven efficacy in acute mania. It reduces manic symptoms and prevents recurrence. Therapeutic level: 0.8-1.2 mEq/L for acute phase. **Valproate (Sodium valproate/Divalproex)** - First-line mood stabilizer, particularly effective for mixed episodes and rapid cycling. Often preferred when rapid control is needed due to faster onset than lithium. **Haloperidol** - Typical antipsychotic effective for acute manic episodes, especially when rapid tranquilization is required for agitation and psychotic symptoms. Second-generation antipsychotics (olanzapine, risperidone, quetiapine) are also commonly used. *Incorrect: Amitriptyline* Amitriptyline is a **tricyclic antidepressant (TCA)** that is **contraindicated in acute mania**. Antidepressants can precipitate or worsen manic episodes, induce rapid cycling, and destabilize mood in bipolar disorder. They should only be used (if at all) in the depressive phase of bipolar disorder, and always with a mood stabilizer. **Clinical Pearl:** The acute management of mania typically involves mood stabilizers (lithium, valproate, carbamazepine) and/or antipsychotics. Antidepressants are avoided as they can trigger manic switching.

Question 354: A patient on haloperidol for 2 years presents with orofacial dyskinesia and extrapyramidal symptoms. What is the appropriate treatment?

A. Akathisia - propranolol
B. Parkinsonism - amantadine
C. Tardive dyskinesia - valbenazine (Correct Answer)
D. Acute dystonia - ropinirole

Explanation: ***Tardive dyskinesia - valbenazine*** - The patient's presentation of **orofacial dyskinesia** following **long-term use** (2 years) of a high-potency antipsychotic like haloperidol is highly characteristic of **Tardive Dyskinesia (TD)**, a chronic EPS. - **Valbenazine** (a VMAT2 inhibitor) is one of the primary, FDA-approved treatments specifically used to reduce the severity of abnormal movements in TD. *Acute dystonia - ropinirole* - **Acute dystonia** is an immediate reaction (hours to days) involving severe muscle spasms, not a delayed presentation of dyskinesia. - The treatment for acute dystonia is typically an **anticholinergic** (e.g., benztropine) or diphenhydramine; **ropinirole** is a dopamine agonist used for Parkinson's disease. *Akathisia - propranolol* - **Akathisia** is defined by a subjective feeling of restlessness and an objective inability to sit still, which is different from the involuntary, choreiform movements of **dyskinesia**. - Although **propranolol** is the appropriate treatment for akathisia, the symptom cluster (orofacial dyskinesia) indicates a diagnosis of **TD**. *Parkinsonism - amantadine* - Drug-induced **Parkinsonism** involves bradykinesia, rigidity, and resting tremor, rather than the prominent abnormal mouth and face movements (dyskinesia) seen here. - While **amantadine** is used for drug-induced parkinsonism, it is generally ineffective or potentially worsens the movements associated with **Tardive Dyskinesia**.

Question 355: A patient on long-term antipsychotics develops involuntary mouth and lip movements (perioral dyskinesia). What is the best treatment?

A. Stop antipsychotic and give tetrabenazine (Correct Answer)
B. Start benzodiazepines
C. Give anticholinergics
D. Increase the antipsychotic dose

Explanation: ***Stop antipsychotic and give tetrabenazine*** - Managing **Tardive Dyskinesia (TD)** involves either switching to a less potent antipsychotic (like clozapine) or, ideally, reducing or discontinuing the offending antipsychotic if clinically feasible. - **Tetrabenazine** (or its analogues valbenazine/deutetrabenazine) are **VMAT2 inhibitors** that decrease presynaptic dopamine release, making them the **first-line pharmacological treatment** for established TD. - This combination represents the most definitive approach when the underlying psychiatric condition allows antipsychotic discontinuation. *Increase the antipsychotic dose* - Increasing the antipsychotic dose temporarily masks TD by increasing central dopamine receptor blockade, but this worsens the underlying **striatal dopamine receptor upregulation** that causes TD. - This strategy only delays definitive treatment and prolongs the risk of severe, irreversible dyskinesia. - While it may suppress movements transiently, it is **never** appropriate long-term management. *Start benzodiazepines* - **Benzodiazepines** (GABA agonists) are generally ineffective for the core involuntary movements of established **Tardive Dyskinesia**. - They may be useful for acute movement disorders or anxiety but lack efficacy against chronic, persistent dopamine-related dyskinesia. *Give anticholinergics* - **Anticholinergic drugs** (e.g., benztropine, trihexyphenidyl) are the treatment of choice for **acute dystonia** and drug-induced Parkinsonism. - These agents are generally **contraindicated** in Tardive Dyskinesia because they often worsen or reveal underlying dyskinetic movements.

Question 356: A 29 year old lady came to psychiatry OPD with symptoms of hypomania. She has a past history of manic episode. Now, she is planning to conceive. Which drug should be avoided for being highly teratogenic to the fetus?

A. Oxcarbazepine
B. Lithium
C. Olanzapine
D. Valproate (Correct Answer)

Explanation: ***Valproate*** - **Valproate** is highly **teratogenic** and is associated with multiple birth defects, including **neural tube defects** (e.g., spina bifida), cardiac anomalies, and craniofacial defects. - Due to its significant risks, it is generally **contraindicated** in women of childbearing potential, especially during pregnancy, unless no other suitable alternatives exist. *Oxcarbazepine* - While it has some teratogenic risk (e.g., cleft palate), the risk is generally considered **lower than valproate**. - It is often favored over valproate in pregnant women requiring mood stabilizers, but still requires careful risk-benefit assessment. *Lithium* - **Lithium** is associated with an increased risk of **Ebstein's anomaly**, a specific cardiac defect, if used during the first trimester. - However, the overall risk of major malformations is still **lower than valproate**, and it can be used with careful monitoring if other options are not viable. *Olanzapine* - **Olanzapine** is an **atypical antipsychotic** that can be used as a mood stabilizer and is considered to have a **relatively lower teratogenic risk** compared to anticonvulsants like valproate. - While it's not entirely risk-free (associated with gestational diabetes and fetal growth issues), it's often a safer option in pregnancy for bipolar disorder than valproate.

Question 357: Which of the following is not an off-label use of risperidone?

A. Bipolar disorder (Correct Answer)
B. PTSD
C. OCD
D. Dementia

Explanation: ***Bipolar disorder*** - **Risperidone** is FDA-approved for the treatment of **bipolar I disorder**, both as monotherapy and adjunctive therapy for acute manic or mixed episodes. - This means its use for bipolar disorder is an **on-label indication**, not an off-label use. *PTSD* - The use of risperidone for **post-traumatic stress disorder (PTSD)** is considered an **off-label use**, as it is not specifically approved by the FDA for this condition. - While atypical antipsychotics may be used in some cases for severe PTSD symptoms, especially those involving psychosis or severe agitation, it is not a primary or approved treatment. *OCD* - The use of risperidone as an adjunct in **obsessive-compulsive disorder (OCD)**, particularly in treatment-resistant cases, is an **off-label use**. - While some studies support its use for augmenting SSRIs in OCD, it is not an FDA-approved indication. *Dementia* - Using risperidone for behavioral symptoms associated with **dementia** (e.g., aggression, agitation) is generally considered an **off-label use**. - Although it may be prescribed for these symptoms, there are significant concerns regarding increased mortality risk in elderly patients with dementia-related psychosis, leading to specific warnings and limited official indications.

Question 358: Drug of choice for treatment of akathisia is:-

A. Haloperidol
B. Fluoxetine
C. Propranolol (Correct Answer)
D. Lithium

Explanation: ***Propranolol*** - **Beta-blockers** like propranolol are considered first-line for treating **akathisia**, especially in cases induced by antipsychotics. - They work by reducing the **adrenergic hyperactivity** and the sensation of inner restlessness characteristic of akathisia. *Haloperidol* - Haloperidol is a **first-generation antipsychotic** that is a common cause of drug-induced **akathisia**. - Administering it would likely **worsen** rather than treat the condition. *Fluoxetine* - Fluoxetine is a **selective serotonin reuptake inhibitor (SSRI)** used to treat depression and anxiety disorders. - It is not indicated for the treatment of **akathisia** and can sometimes induce or worsen motor restlessness. *Lithium* - Lithium is a **mood stabilizer** primarily used for bipolar disorder. - It is not a treatment for **akathisia** and can itself cause various neurological side effects, though akathisia is less common.

Question 359: The drug of choice for obsessive-compulsive disorder:

A. Imipramine
B. Fluoxetine (Correct Answer)
C. Chlorpromazine
D. Benzodiazepine

Explanation: ***Fluoxetine*** - **Fluoxetine** is a **selective serotonin reuptake inhibitor (SSRI)** and is considered a first-line treatment for **obsessive-compulsive disorder (OCD)** due to its efficacy in reducing obsessive thoughts and compulsive behaviors. - SSRIs, including fluoxetine, help increase serotonin levels in the brain, which is thought to be dysregulated in OCD. *Imipramine* - **Imipramine** is a **tricyclic antidepressant (TCA)** primarily used for depression and sometimes panic disorder. - While TCAs can have some serotonergic effects, they are generally less effective and have more side effects than SSRIs for treating OCD. *Chlorpromazine* - **Chlorpromazine** is a **first-generation antipsychotic** mainly used to treat psychosis, such as in schizophrenia, and severe agitation. - It works primarily by blocking dopamine receptors and is not indicated as a primary treatment for OCD, though it might be used as an adjunct in severe, treatment-refractory cases. *Benzodiazepine* - **Benzodiazepines** are anxiolytics used for short-term relief of anxiety and panic attacks. - They provide symptomatic relief from anxiety associated with OCD but do not address the core obsessive-compulsive symptoms and are not considered a primary treatment due to potential for dependency and lack of effect on underlying mechanisms.

Question 360: Electroconvulsive therapy is not useful in which of the following conditions?

A. Panic attacks (Correct Answer)
B. Depression
C. Seizures
D. Delirium

Explanation: ***Panic attacks*** - ECT has **no established role** in the treatment of panic disorder or panic attacks. - **First-line treatments** include SSRIs, benzodiazepines, and cognitive behavioral therapy (CBT). - ECT is not indicated for **anxiety-predominant disorders** and there is no evidence supporting its use in panic attacks. *Depression* - ECT is a **highly effective** treatment for **severe major depression**, particularly: - **Treatment-resistant depression** (failed multiple antidepressant trials) - **Psychotic depression** (depression with psychotic features) - **Severe melancholic or catatonic depression** - Depression with **high suicide risk** requiring rapid response - ECT is considered one of the most effective treatments in psychiatry for severe depression. *Seizures* - ECT **induces controlled therapeutic seizures** to achieve psychiatric benefits, but it is **not a treatment for epilepsy** or seizure disorders. - The therapeutic effect in psychiatric conditions is mediated through the induced seizure and its neurobiological effects. - ECT does **not treat or prevent epileptic seizures**; patients with epilepsy can safely receive ECT with appropriate precautions. *Delirium* - ECT can be used in **highly selected cases** of refractory delirium, particularly: - Delirium with **severe agitation** unresponsive to medical management - Delirium in the context of **catatonia** - While not a first-line treatment, ECT **has documented efficacy** in specific refractory cases of delirium when conventional treatments have failed.

Question 361: Treatment modality NOT used in ADHD includes

A. Atomoxetine
B. Dexamphetamine
C. Haloperidol (Correct Answer)
D. Clonidine

Explanation: ***Haloperidol*** - **Haloperidol** is an **antipsychotic medication** primarily used to treat psychotic disorders (e.g., schizophrenia) and severe behavioral problems, tics, or Tourette's syndrome, not ADHD. - Its mechanism of action involves **dopamine D2 receptor antagonism**, which is not the primary pharmacological target for ADHD symptom management. *Atomoxetine* - **Atomoxetine** is a **selective norepinephrine reuptake inhibitor (SNRI)** and is a non-stimulant medication approved for the treatment of ADHD. - It works by increasing the levels of **norepinephrine** in the brain, improving attention and reducing impulsivity. *Dexamphetamine* - **Dexamphetamine** is a **central nervous system stimulant** used in the treatment of ADHD. - It works by increasing levels of **dopamine** and **norepinephrine** in the brain, leading to improved focus and reduced hyperactivity. *Clonidine* - **Clonidine** is an **alpha-2 adrenergic agonist** that can be used off-label or as an adjunct therapy for ADHD, particularly for managing hyperactivity, impulsivity, and sleep disturbances associated with the disorder. - It helps to regulate neurotransmitters that influence attention and behavior, although it is not a first-line treatment for core ADHD symptoms compared to stimulants.

Question 362: Drug of choice for initial pharmacological treatment of Tourette syndrome -

A. B complex
B. Clonidine (Correct Answer)
C. Haloperidol
D. Valproate

Explanation: ***Clonidine*** - **Clonidine** is often considered a first-line treatment for Tourette syndrome, especially in children and adolescents, due to its favorable side effect profile compared to typical antipsychotics. - As an **alpha-2 adrenergic agonist**, it helps reduce tic severity and associated symptoms like ADHD and impulsivity by modulating neurotransmitter release in the brain. *B complex* - **B vitamins** are generally not indicated for the treatment of Tourette syndrome, as there is no robust scientific evidence to support their efficacy in managing tics. - While essential for overall neurological health, they do not directly address the pathophysiology of tic disorders. *Haloperidol* - **Haloperidol**, a **first-generation antipsychotic**, is highly effective in reducing tics but is generally reserved for severe cases due to its significant side effects, including extrapyramidal symptoms and sedation. - It works by blocking **dopamine D2 receptors** but its adverse effects limit its use as an initial agent of choice. *Valproate* - **Valproate** is an anticonvulsant and mood stabilizer primarily used for epilepsy, bipolar disorder, and migraine prevention. - It is not a standard or preferred treatment for Tourette syndrome, as its efficacy in tic reduction is limited and it carries significant side effects.

Question 363: Which of the following antidepressants can be safely used in elderly depression?

A. phenelzine
B. mirtazapine (Correct Answer)
C. fluoxetine
D. trazodone

Explanation: ***Mirtazapine*** - Mirtazapine is often a good choice in elderly patients because it has a relatively **favorable side effect profile** in this population, causing less anticholinergic effects and orthostatic hypotension compared to many other antidepressants. - Its **sedating properties** can be beneficial for elderly patients who also suffer from insomnia, and its **appetite-stimulating effects** can help those with poor nutritional intake. *Phenelzine* - Phenelzine is a **monoamine oxidase inhibitor (MAOI)**, which carries a significant risk of **hypertensive crisis** due to interactions with tyramine-rich foods and many medications, making it generally unsafe for elderly use. - It also has a high incidence of other side effects, including **orthostatic hypotension** and **sedation**, which are particularly dangerous in older adults. *Fluoxetine* - Fluoxetine, an **SSRI**, has a very **long half-life** and can accumulate in elderly patients, increasing the risk of side effects like hyponatremia, gastrointestinal upset, and agitation. - While effective, its **activating properties** can exacerbate anxiety or insomnia in some elderly individuals, and there's a risk of **drug-drug interactions** due to its potent CYP2D6 inhibition. *Trazodone* - Trazodone is primarily used off-label at low doses for **insomnia** due to its prominent sedative effects, but it can cause significant **orthostatic hypotension** and cardiac arrhythmias in the elderly at antidepressant doses. - There is also a risk of **priapism** in men, and its strong sedative properties can lead to increased falls risk and daytime sleepiness, which are undesirable in the elderly.

Question 364: Drug of choice in Tourette syndrome is -

A. Valproate
B. Carbamazepine
C. Methadone
D. Haloperidol (Correct Answer)

Explanation: ***Haloperidol*** - **Haloperidol**, a **first-generation antipsychotic**, is highly effective in blocking dopamine receptors and reducing the severity of tics in Tourette syndrome. - It is considered a **drug of choice** for managing severe tics due to its strong dopamine antagonism, which helps control **motor and vocal tics**. *Valproate* - **Valproate** is primarily an **anticonvulsant** and **mood stabilizer**, used in epilepsy and bipolar disorder. - While it has some efficacy in reducing tics, it is generally **less effective** than dopamine-blocking agents like haloperidol and is not considered a first-line treatment for Tourette syndrome. *Carbamazepine* - **Carbamazepine** is an **anticonvulsant** used for seizures and trigeminal neuralgia. - It is generally **not efficacious** for the treatment of tics in Tourette syndrome and does not target the dopaminergic pathways involved in tic generation. *Methadone* - **Methadone** is an **opioid analgesic** used for pain management and opioid dependence treatment. - It has **no role** in the management of Tourette syndrome as its mechanism of action is unrelated to the pathophysiology of tics.

Question 365: Maximum increase in prolactin level is caused by:-

A. Olanzapine (Primarily blocks 5HT2 receptors)
B. Aripiprazole (D2 partial agonist)
C. Risperidone (Potent D2 receptor antagonist) (Correct Answer)
D. Clozapine (Primarily blocks 5HT2 receptors)

Explanation: ***Risperidone (Potent D2 receptor antagonist)*** - Risperidone is a **potent D2 receptor antagonist**, meaning it blocks dopamine's action at these receptors. Since dopamine inhibits prolactin release, blocking D2 receptors leads to a significant increase in **prolactin levels**. - Its high affinity for D2 receptors in the **tuberoinfundibular pathway** is a primary reason for its pronounced effect on prolactin. *Olanzapine (Primarily blocks 5HT2 receptors)* - While olanzapine can cause some prolactin elevation, its primary mechanism involves **5HT2 receptor blockade**, with less potent D2 antagonism compared to risperidone. - The degree of **hyperprolactinemia** associated with olanzapine is generally milder than that seen with risperidone. *Aripiprazole (D2 partial agonist)* - Aripiprazole is a **D2 partial agonist**, meaning it acts as an antagonist when dopamine levels are high and an agonist when dopamine levels are low, effectively stabilizing dopamine activity. - Due to its partial agonism, aripiprazole typically has a **low risk of hyperprolactinemia** and can even normalize elevated prolactin levels caused by other antipsychotics. *Clozapine (Primarily blocks 5HT2 receptors)* - Clozapine primarily blocks **5HT2 receptors** and has relatively weak D2 receptor antagonism, especially transient D2 blockade. - It generally causes **minimal to no prolactin elevation** and is considered a prolactin-sparing antipsychotic.

Question 366: A young male patient is on 5 mg haloperidol for many days. Recently, for the last 4 days, he has inner restlessness and urges to move. Diagnosis is?

A. Akathisia (Correct Answer)
B. Rabbit syndrome
C. Tardive dyskinesia
D. Acute Dystonia

Explanation: ***Akathisia*** - This condition is characterized by a subjective feeling of **inner restlessness** and an objective urge to move, which is a classic side effect of **dopamine receptor blocking agents** like haloperidol. - The onset of akathisia can be acute or chronic, often occurring within days to weeks of starting or increasing the dose of antipsychotic medication. *Rabbit syndrome* - This is a rare form of **tardive dyskinesia** characterized by rapid, fine perioral movements that resemble a rabbit chewing. - It does not primarily involve the subjective feeling of restlessness or the urge to move the entire body as described in the patient's presentation. *Tardive dyskinesia* - This condition typically involves **involuntary, repetitive body movements**, often affecting the face, lips, tongue, and limbs, and usually develops after prolonged exposure to antipsychotic medications (months to years). - While it can manifest as abnormal movements, the primary symptom of inner restlessness and urge to move is not characteristic of tardive dyskinesia but rather of akathisia, and its onset is typically much later. *Acute Dystonia* - Acute dystonia presents as **sustained muscle contractions** leading to twisting and repetitive movements or abnormal fixed postures, often affecting the neck, eyes (oculogyric crisis), and trunk. - This reaction typically occurs within hours or days of initiating or increasing neuroleptic medication and is characterized by involuntary muscle spasms, not a pervasive sense of inner restlessness.

Question 367: A patient on clozapine develops fever, confusion, and muscle rigidity. CK is elevated. Most appropriate next step?

A. Add antipyretic
B. Continue clozapine
C. Reduce dose
D. Stop clozapine (Correct Answer)

Explanation: ***Stop clozapine*** - The presentation of **fever, confusion, muscle rigidity**, and elevated **creatine kinase (CK)** in a patient on clozapine is highly suggestive of **Neuroleptic Malignant Syndrome (NMS)**, a potentially fatal adverse reaction. - **Immediate discontinuation** of the causative antipsychotic, in this case **clozapine**, is the cornerstone of NMS management to prevent further clinical deterioration and complications. *Add antipyretic* - While a **fever** is present, simply adding an **antipyretic** would only address a symptom and not the underlying severe adverse drug reaction, potentially delaying critical intervention. - The fever in NMS is often due to **hypothalamic dysfunction** and **muscle rigidity**, not just a simple infection responsive to antipyretics alone. *Continue clozapine* - Continuing clozapine in the presence of NMS symptoms would **exacerbate the condition**, leading to increased morbidity and mortality, as it is the likely causative agent. - Further exposure to the drug would worsen the **hyperthermia, muscle rigidity**, and potential **organ damage**. *Reduce dose* - **Reducing the dose** of clozapine is insufficient if NMS is suspected, as even lower doses can maintain the toxic effect and progression of the syndrome. - The priority is to remove the offending agent completely, rather than merely decreasing its concentration.

Question 368: Which antipsychotic is preferred for treatment-resistant schizophrenia?

A. Quetiapine
B. Olanzapine
C. Risperidone
D. Clozapine (Correct Answer)

Explanation: ***Clozapine*** - **Clozapine** is the only antipsychotic with proven efficacy for **treatment-resistant schizophrenia**, defined as inadequate response to two different antipsychotics. - Its unique pharmacological profile, including strong antagonism of various **dopamine** and **serotonin receptors**, contributes to its superior efficacy in these cases. *Quetiapine* - While an effective antipsychotic for many, **quetiapine** is generally not considered the first-line or preferred agent for **treatment-resistant schizophrenia**. - It has a lower propensity for **extrapyramidal symptoms** but lacks the specific efficacy demonstrated by clozapine in refractory cases. *Olanzapine* - **Olanzapine** is a potent antipsychotic and can be effective for severe symptoms, but it does not have the same established efficacy for **treatment resistance** as clozapine. - Its use can be limited by significant metabolic side effects including **weight gain** and **glucose dysregulation**. *Risperidone* - **Risperidone** is a commonly used antipsychotic, but it is not indicated as the preferred treatment for **treatment-resistant schizophrenia**. - It can be effective for positive and negative symptoms but does not offer the same **superiority** in refractory cases as clozapine.

Question 369: Which antipsychotic drug is known for its effectiveness in managing schizophrenia but requires monitoring due to its risk of metabolic side effects?

A. Haloperidol
B. Risperidone
C. Chlorpromazine
D. Quetiapine (Correct Answer)

Explanation: ***Quetiapine*** - **Quetiapine** is a **second-generation antipsychotic** effective for schizophrenia, but it is well-known for its metabolic side effects. - These side effects include **weight gain**, **dyslipidemia**, and **hyperglycemia**, necessitating careful metabolic monitoring. *Haloperidol* - **Haloperidol** is a **first-generation antipsychotic** primarily associated with **extrapyramidal symptoms (EPS)** and **tardive dyskinesia**, rather than significant metabolic disturbances. - While effective for psychosis, its side effect profile is distinct from metabolic concerns. *Risperidone* - **Risperidone** is a **second-generation antipsychotic** that also carries a risk of metabolic side effects, specifically **weight gain** and **hyperprolactinemia**. - However, **quetiapine** generally has a more pronounced risk of the full spectrum of metabolic syndrome compared to risperidone. *Chlorpromazine* - **Chlorpromazine** is a **first-generation antipsychotic** notable for **sedation**, **hypotension**, and **anticholinergic side effects**. - While it can cause some weight gain, its metabolic risk is not as prominent as that of certain second-generation antipsychotics like quetiapine.

Question 370: A 25-year-old female with obsessive-compulsive disorder has not responded to 8 weeks of sertraline 50mg daily. What is the next step in pharmacotherapy?

A. Increase the dose of SSRIs (Correct Answer)
B. Switch to a different class of antidepressant
C. Start psychotherapy
D. Add an antipsychotic

Explanation: ***Increase the dose of SSRIs*** - For **OCD**, **SSRIs** often require **higher doses** (typically 2-3 times higher than for depression) and longer treatment durations to achieve a therapeutic effect. - **Sertraline 50mg is subtherapeutic** for OCD; the therapeutic range is **150-200mg daily** (up to 200mg maximum). - Since the current dose is inadequate despite appropriate duration (8 weeks), **dose optimization is the most appropriate next step** before considering other interventions. *Switch to a different class of antidepressant* - **SSRIs** are considered **first-line pharmacotherapy** for OCD, and switching to a different antidepressant class is typically reserved for cases where multiple SSRI trials at adequate doses and duration have failed. - This option is premature before optimizing the current SSRI dosage. *Start psychotherapy* - **Cognitive Behavioral Therapy (CBT)**, especially **Exposure and Response Prevention (ERP)**, is a highly effective treatment for OCD and is often recommended alongside medication. - While beneficial, the question specifically asks for the "next step in **pharmacotherapy**," implying a drug-related intervention. *Add an antipsychotic* - Augmentation with an **antipsychotic** (e.g., risperidone, aripiprazole) is usually considered when there has been a partial or non-response to **adequate trials of high-dose SSRIs** (typically after 2-3 SSRI trials at therapeutic doses). - This step is too aggressive given that the initial SSRI dose was not optimized.

Question 371: A patient diagnosed with bipolar disorder is on lithium therapy and presents with coarse tremors, polyuria, and confusion. What is the most appropriate next step?

A. Check serum lithium levels
B. Increase the dose of lithium therapy
C. Discontinue lithium therapy (Correct Answer)
D. Switch to valproate therapy

Explanation: ***Discontinue lithium therapy*** - The patient presents with **coarse tremors, polyuria, and confusion** - classical signs of **lithium toxicity**. - **Immediate discontinuation** of lithium is the priority to prevent progression to severe toxicity (seizures, renal failure, coma). - In symptomatic lithium toxicity, **stopping the drug takes precedence** over diagnostic confirmation. - **Serum lithium levels should be checked simultaneously**, but this should not delay stopping the medication. - Supportive care including **hydration and monitoring** should be initiated immediately. *Check serum lithium levels* - While checking serum levels is important for **confirming the diagnosis and guiding further management**, it should not delay discontinuation. - Levels help determine severity and need for **hemodialysis** (typically if >4 mEq/L with severe symptoms). - This is an essential step but is done **concurrently with**, not **instead of**, stopping lithium. *Increase the dose of lithium therapy* - This would dangerously **exacerbate lithium toxicity** and could lead to life-threatening complications. - Completely contraindicated in a patient showing clear signs of toxicity. *Switch to valproate therapy* - While valproate is an alternative mood stabilizer, switching therapy is **not the immediate priority** in acute toxicity. - The urgent concern is **managing the current toxicity**, not replacing the mood stabilizer. - Alternative treatments can be considered after the patient stabilizes.

Question 372: A 30-year-old male with schizophrenia who has been stable on antipsychotic medication now presents with muscle stiffness, fever, and confusion. What is the most likely diagnosis?

A. Neuroleptic malignant syndrome (Correct Answer)
B. Malignant hyperthermia (triggered by anesthetics)
C. Serotonin syndrome
D. Acute dystonia

Explanation: ***Neuroleptic malignant syndrome*** - The combination of **muscle rigidity**, **fever (hyperthermia)**, and **altered mental status (confusion)** in a patient on antipsychotic medication is a classic presentation of **neuroleptic malignant syndrome (NMS)**. - NMS is a **life-threatening idiosyncratic reaction** to antipsychotic drugs, characterized by **autonomic dysfunction** (e.g., labile blood pressure, tachycardia) and often elevated **creatine kinase (CK)** levels. *Serotonin syndrome* - This syndrome typically results from an excess of **serotonergic activity**, often due to drug interactions (e.g., SSRIs with MAOIs) or overdose. - While it can present with fever and altered mental status, it is more commonly associated with **hyperreflexia**, **clonus**, and myoclonus, rather than severe rigidity, and is not usually triggered by antipsychotics alone. *Malignant hyperthermia (triggered by anesthetics)* - **Malignant hyperthermia** is a genetic disorder primarily triggered by **volatile anesthetic agents** (e.g., halothane, succinylcholine) during surgery. - Its clinical presentation, though similar with hyperthermia and muscle rigidity, is specific to perioperative exposure to these particular drugs, which is not indicated in this case. *Acute dystonia* - **Acute dystonia** is an extrapyramidal symptom (EPS) characterized by **sustained involuntary muscle contractions**, leading to abnormal posturing or repetitive movements. - While it can occur shortly after initiating or increasing antipsychotic medication, it typically presents as specific muscle spasms (e.g., torticollis, oculogyric crisis) and does **not involve fever or significant altered mental status**.

Question 373: A 30-year-old man with schizophrenia develops persistent involuntary movements of the face and tongue after long-term use of antipsychotics. What is the diagnosis?

A. Parkinsonism
B. Tardive dyskinesia (Correct Answer)
C. Akathisia
D. Acute dystonia

Explanation: ***Tardive dyskinesia*** - This condition is characterized by **involuntary movements of the face and tongue**, often appearing after **long-term use of antipsychotic medications**. - Its **persistent nature** differentiates it from other extrapyramidal symptoms, as it often continues even after discontinuing the offending drug. *Parkinsonism* - This typically presents with a **triad of symptoms**: **bradykinesia**, **rigidity**, and **tremor**, which are not the primary features described here. - While it can be drug-induced, it typically manifests differently than the described **oro-facial dyskinesia**. *Akathisia* - This involves a feeling of **inner restlessness** and a compelling need to **move**, often manifesting as pacing or rocking. - It does not involve the specific involuntary movements of the face and tongue observed in the patient. *Acute dystonia* - This is characterized by **sudden, sustained muscle contractions** leading to **abnormal postures or movements**, often occurring soon after starting or increasing an antipsychotic dose. - Unlike tardive dyskinesia, these dystonic reactions are typically **acute** and resolve with specific treatments like anticholinergics.

Question 374: A patient with schizophrenia on risperidone develops akathisia. What is the next step?

A. Switch to clozapine
B. Add propranolol (Correct Answer)
C. Add benztropine
D. Increase dose

Explanation: ***Add propranolol*** - **Propranolol**, a beta-blocker, is frequently used to treat **akathisia** associated with antipsychotic medications, offering significant symptom relief. - It helps to reduce the subjective feeling of restlessness and the objective motor symptoms, often being the **first-line treatment** for drug-induced akathisia. *Inc. dose* - Increasing the dose of **risperidone** would likely **worsen** the akathisia, as it is a dose-dependent adverse effect of antipsychotics. - Higher doses increase dopamine antagonism, exacerbating extrapyramidal symptoms like akathisia. *Switch to clozapine* - While **clozapine** has a lower risk of extrapyramidal symptoms, switching to it is a significant step due to its potential for **severe side effects** like **agranulocytosis** and requires careful monitoring. - It is generally reserved for **treatment-resistant schizophrenia** or when other antipsychotics are intolerable. *Add benztropine* - **Benztropine** (an anticholinergic) is primarily used for other extrapyramidal symptoms like **dystonia** and **parkinsonism**, but it is generally **less effective** for akathisia. - Anticholinergics can also have cognitive side effects that might be undesirable.

Question 375: A 50-year-old patient with schizophrenia is prescribed clozapine after the failure of other antipsychotics. What is the most important side effect to monitor?

A. Weight gain
B. Agranulocytosis (Correct Answer)
C. Sedation
D. Hyperglycemia

Explanation: ***Agranulocytosis*** - **Agranulocytosis** is a severe and potentially fatal side effect of **clozapine**, requiring strict monitoring of **white blood cell count (WBC)** and **absolute neutrophil count (ANC)**. - This adverse effect is specific to clozapine and is the primary reason for mandated regular blood tests when prescribing the medication. *Weight gain* - While **weight gain** is a common side effect of clozapine and other atypical antipsychotics, it is generally less immediately life-threatening than agranulocytosis. - It contributes to metabolic syndrome but is managed by lifestyle interventions and monitoring, not weekly blood tests. *Sedation* - **Sedation** is a common initial side effect of clozapine, often used clinically for patients with agitation or insomnia. - Although it can be bothersome, it typically improves over time and is not life-threatening. *Hyperglycemia* - **Hyperglycemia** is a known metabolic side effect of clozapine, increasing the risk of **diabetes mellitus**. - While important to monitor, it does not pose the immediate, acute life threat that **agranulocytosis** does, which can develop rapidly.

Question 376: A 35-year-old man with schizophrenia is well-controlled on risperidone but develops tremors, rigidity, and bradykinesia. What is the most appropriate management?

A. Discontinue risperidone and start clozapine
B. Add benztropine (Correct Answer)
C. Switch to a higher dose of risperidone
D. Add a mood stabilizer

Explanation: ***Add benztropine*** - The patient is experiencing **extrapyramidal symptoms (EPS)** (tremors, rigidity, and bradykinesia) as a side effect of risperidone - Adding an anticholinergic agent like **benztropine** is the most appropriate management to counteract these dopamine-blocking effects without discontinuing the effective antipsychotic - This allows continuation of effective schizophrenia treatment while managing the side effects *Discontinue risperidone and start clozapine* - Discontinuing an effective antipsychotic for well-controlled schizophrenia is not ideal, as it risks a **relapse of psychotic symptoms** - **Clozapine** is typically reserved for **treatment-resistant schizophrenia** due to its potential for serious side effects like agranulocytosis - This would be overly aggressive management for a side effect that can be managed with adjunctive therapy *Switch to a higher dose of risperidone* - Increasing the dose of risperidone would likely **exacerbate the extrapyramidal symptoms**, as they are dose-dependent side effects of dopamine D2 receptor blockade - This would worsen the patient's motor symptoms and may lead to more severe parkinsonism *Add a mood stabilizer* - Mood stabilizers (e.g., lithium, valproate) are used to treat **bipolar disorder** or to augment antipsychotics in certain cases - They do not address or alleviate **extrapyramidal symptoms** - This intervention would be inappropriate for managing drug-induced movement disorders

Question 377: A 55-year-old male with schizophrenia on clozapine presents with fever, sore throat, and fatigue. Laboratory results show a WBC count of 2.0 × 10³/μL. Analyze and choose the appropriate management.

A. Continue clozapine, add antibiotics
B. Discontinue clozapine, admit for neutropenia (Correct Answer)
C. Lower clozapine dose, add G-CSF
D. Switch to risperidone, outpatient f/u

Explanation: ***Discontinue clozapine, admit for neutropenia*** - A **WBC count of 2.0** combined with symptoms like **fever and sore throat** in a patient on clozapine strongly indicates **neutropenia or agranulocytosis**. - **Clozapine** can cause severe neutropenia, which requires immediate discontinuation of the drug and admission for monitoring and management to prevent life-threatening infections. *Continue clozapine, add antibiotics* - Continuing clozapine in the face of **severe neutropenia** would likely worsen the condition and expose the patient to a higher risk of **fatal infections**. - While antibiotics might be indicated for the infection, they do not address the underlying **drug-induced neutropenia**. *Lower clozapine dose, add G-CSF* - **Lowering the dose** is insufficient when there is evidence of **severe neutropenia**; complete discontinuation is necessary to allow bone marrow recovery. - **G-CSF (granulocyte colony-stimulating factor)** can be considered, but discontinuing clozapine is the crucial first step for safety. *Switch to risperidone, outpatient f/u* - Switching to another antipsychotic like **risperidone** is appropriate in the long term, but the immediate priority is managing the **neutropenia**, which requires inpatient care. - Outpatient follow-up is inadequate for a patient with **neutropenia** and potential agranulocytosis, who needs close monitoring for infection.

Question 378: A 28-year-old male with a history of schizophrenia is experiencing symptoms of akathisia. Which of the following is an appropriate treatment for akathisia?

A. Promethazine
B. Trihexyphenidyl
C. Haloperidol
D. Diazepam (Correct Answer)

Explanation: ***Diazepam*** - **Benzodiazepines** like diazepam are effective in treating akathisia through their **GABAergic** properties, which help reduce motor restlessness and subjective distress. - They are particularly useful as **adjunctive therapy** or when beta-blockers and anticholinergics are contraindicated. - Rapid onset of action provides symptomatic relief by modulating neural activity and reducing anxiety associated with akathisia. *Trihexyphenidyl* - **Anticholinergics** like trihexyphenidyl are actually used for akathisia and other extrapyramidal symptoms, but their efficacy is **variable**. - While they work well for **parkinsonism and acute dystonia**, their response in akathisia is less predictable compared to **beta-blockers (propranolol)**. - In this scenario, benzodiazepines may be preferred for their dual action on motor symptoms and associated anxiety. *Haloperidol* - **Haloperidol** is a **first-generation antipsychotic** and a common **cause** of drug-induced akathisia due to D2 receptor blockade. - Increasing antipsychotic dose would **worsen** akathisia rather than alleviate it. - Management typically involves dose reduction or switching to a lower-potency or atypical antipsychotic. *Promethazine* - **Promethazine** is an **antihistamine** with sedative and antiemetic properties, not a primary treatment for akathisia. - While it has mild anticholinergic effects, it lacks the specific pharmacological profile needed to effectively manage the motor restlessness of akathisia. - Its sedative properties might provide minimal symptomatic relief but do not address the underlying pathophysiology.

Question 379: A 50-year-old male with schizophrenia has been stable on olanzapine for symptom control but reports severe weight gain and hyperglycemia. Physical examination reveals a BMI of 34, and laboratory results show an HbA1c of 7.2%. What is the most appropriate next step in management?

A. Switch to aripiprazole, monitor weight (Correct Answer)
B. Continue olanzapine, add metformin
C. Switch to clozapine, monitor glucose levels
D. Switch to risperidone, monitor glucose levels

Explanation: ***Switch to aripiprazole, monitor weight*** - **Aripiprazole** is a **second-generation antipsychotic** known for a more favorable metabolic profile compared to olanzapine. It is less likely to cause significant weight gain, hyperglycemia, or dyslipidemia. - Given the patient's severe **weight gain** and **hyperglycemia** (HbA1c of 7.2%), switching to an antipsychotic with a lower metabolic risk is a priority to manage these side effects. *Switch to clozapine, monitor glucose levels* - **Clozapine** is associated with a **high risk of metabolic side effects**, including significant **weight gain**, **hyperglycemia**, and **dyslipidemia**, similar to or even greater than olanzapine. - While effective for treatment-resistant schizophrenia, switching to clozapine would likely exacerbate the patient's existing metabolic issues. *Continue olanzapine, add metformin* - Continuing **olanzapine** means the patient would remain on a medication known for significant metabolic side effects, which are already severe in this case. - While **metformin** can help manage hyperglycemia and some weight gain, it addresses the symptom without resolving the underlying cause of the metabolic disturbance attributed to olanzapine. *Switch to risperidone, monitor glucose levels* - **Risperidone** has an intermediate risk for **metabolic side effects**, including **weight gain** and **hyperglycemia**, making it an unfavorable choice given the patient's current severe metabolic issues. - Although it might be better than olanzapine for some metabolic parameters, it still carries a significant risk compared to options with much lower metabolic impact.

Question 380: A 45-year-old male with a history of schizophrenia who is on clozapine presents with fever, sore throat, and fatigue. What is the most appropriate next step?

A. Continue clozapine and monitor symptoms
B. Discontinue clozapine and start antibiotics
C. Discontinue clozapine and check white blood cell count (Correct Answer)
D. Increase clozapine dose

Explanation: ***Discontinue clozapine and check white blood cell count*** - The symptoms of **fever, sore throat, and fatigue** in a patient on clozapine are highly suspicious for **agranulocytosis**, a rare but life-threatening side effect. - **Immediate discontinuation of clozapine** and urgent measurement of **white blood cell count (WBC) and absolute neutrophil count (ANC)** are critical to diagnose and manage this condition. *Continue clozapine and monitor symptoms* - Continuing clozapine in the presence of these symptoms could lead to rapid progression of **agranulocytosis** and severe, potentially fatal, infections. - Monitoring symptoms without laboratory confirmation of WBC and ANC is insufficient and **dangerous**. *Discontinue clozapine and start antibiotics* - While infection is a concern given the symptoms, blindly starting antibiotics without confirming severe neutropenia through a **WBC count** is not the primary immediate step. - The priority is to identify the underlying cause (agranulocytosis due to clozapine) and discontinue the causative agent, then manage complications like infection. *Increase clozapine dose* - Increasing the clozapine dose would exacerbate the potential **agranulocytosis** and significantly worsen the patient's condition. - This action is **contraindicated** given the presenting symptoms.

Question 381: A patient with a history of major depressive disorder is treated with an SSRI and presents with restlessness, hyperreflexia, and myoclonus. What is the likely diagnosis?

A. Serotonin syndrome (Correct Answer)
B. Neuroleptic malignant syndrome
C. Anticholinergic toxicity
D. Alcohol withdrawal

Explanation: ***Serotonin syndrome*** - The constellation of **restlessness**, **hyperreflexia**, and **myoclonus** in a patient taking an **SSRI** is highly characteristic of **serotonin syndrome**, reflecting excessive serotonin activity. - This syndrome often involves a triad of mental status changes, autonomic hyperactivity, and neuromuscular abnormalities. *Neuroleptic malignant syndrome* - Characterized by **severe muscle rigidity**, **fever**, **autonomic dysfunction**, and altered mental status, often associated with antipsychotic use. - Though it involves autonomic and neuromuscular symptoms, the presenting symptoms of hyperreflexia and myoclonus are more indicative of serotonin syndrome rather than the rigidity seen in NMS. *Anticholinergic toxicity* - Presents with symptoms like **mydriasis**, **dry mouth**, **tachycardia**, **urinary retention**, and altered mental status due to blocking acetylcholine receptors. - The patient's symptoms of hyperreflexia and myoclonus are not typical for anticholinergic toxicity. *Alcohol withdrawal* - Symptoms range from tremors and anxiety to seizures and delirium tremens, occurring after reducing or stopping chronic alcohol intake. - While it can involve agitation, the specific combination of restlessness, hyperreflexia, and myoclonus in a patient on an SSRI points away from alcohol withdrawal as the primary diagnosis.

Question 382: A 28-year-old male with schizophrenia is prescribed clozapine. What is the most important laboratory test to monitor regularly?

A. Liver function tests
B. White blood cell count (Correct Answer)
C. Renal function tests
D. Lipid profile

Explanation: ***White blood cell count*** - **Clozapine** carries a significant risk of **agranulocytosis**, a severe reduction in **white blood cell count (neutrophils)**, making regular monitoring crucial. - Due to this life-threatening adverse effect, a **baseline WBC count** and **absolute neutrophil count (ANC)** must be established before treatment, and then monitored **weekly for the first six months**, then bi-weekly, and eventually monthly, according to established protocols. *Liver function tests* - While liver enzyme elevations can occur with clozapine, they are generally less frequent and less severe than the risk of agranulocytosis. - Routine **liver function tests (LFTs)** are typically monitored, but not with the same urgency or strictness as WBC counts. *Renal function tests* - **Clozapine** is primarily metabolized by the liver, and significant renal impairment is not a primary concern for closely monitoring during treatment initiation. - While general renal health is important, **renal function tests (RFTs)** are not part of the mandatory, life-saving monitoring protocol for clozapine. *Lipid profile* - **Clozapine** can cause metabolic side effects, including **weight gain**, **dyslipidemia**, and **glucose dysregulation**, which necessitate monitoring of the **lipid profile** and **blood glucose levels**. - However, these metabolic effects, while important for long-term health, are not as acutely life-threatening as agranulocytosis, making WBC count the most immediate and critical laboratory test.

Question 383: A 60-year-old woman with schizophrenia presents with tardive dyskinesia. What is the most appropriate management?

A. Discontinue antipsychotic medication
B. Switch to clozapine (Correct Answer)
C. Add a benzodiazepine
D. Increase antipsychotic dose

Explanation: ***Switch to clozapine*** - **Clozapine** is an atypical antipsychotic with the **lowest propensity to cause extrapyramidal symptoms**, including tardive dyskinesia, making it an appropriate choice for patients who develop TD. - While **dose reduction or discontinuation** of the offending agent is the first-line approach when clinically feasible, switching to **clozapine or quetiapine** (antipsychotics with minimal D2 blockade) is recommended when continued antipsychotic therapy is necessary. - Clozapine is particularly useful in this case as it addresses both the **treatment-resistant nature** of schizophrenia that may have led to higher-potency antipsychotic use and the **TD complication**. - Note: Clozapine requires **regular blood monitoring** due to agranulocytosis risk. *Discontinue antipsychotic medication* - While dose reduction or discontinuation is considered **first-line management** for TD when feasible, abruptly stopping antipsychotics in schizophrenia carries **high risk of relapse**. - Complete discontinuation without an alternative is generally not recommended unless the patient is in prolonged remission. - In some cases, TD may persist even after discontinuation (persistent TD) or transiently worsen (withdrawal dyskinesia). *Add a benzodiazepine* - **Benzodiazepines** are not effective for **tardive dyskinesia** management, though they may help with acute dystonia or akathisia. - They do not address the underlying **dopaminergic-cholinergic imbalance** thought to contribute to TD. - Long-term benzodiazepine use carries risks of **tolerance, dependence, and cognitive impairment**. *Increase antipsychotic dose* - Increasing the dose of typical or high-potency antipsychotics will likely **worsen tardive dyskinesia** as TD is often a dose-dependent and duration-dependent side effect. - This approach may temporarily mask TD symptoms through increased dopamine blockade but leads to progression of the underlying condition. - Higher doses increase risk of other **extrapyramidal symptoms** and metabolic side effects.

Question 384: Which of the following is the drug of choice for managing acute mania in bipolar disorder?

A. Lithium (Correct Answer)
B. Valproate
C. Carbamazepine
D. Lamotrigine

Explanation: ***Lithium*** - **Lithium** has historically been considered the **gold standard** and **classical first-line treatment** for acute mania in bipolar disorder, with well-established efficacy in mood stabilization. - It works by modulating **neurotransmitter systems** and **intracellular signaling pathways** (including inhibition of inositol monophosphatase) to reduce manic symptoms. - **Note:** Current guidelines (APA, CANMAT) recognize **multiple first-line options** including lithium, valproate, and antipsychotics, though lithium remains the **prototype mood stabilizer** taught in medical education. - Onset of antimanic effect: **7-14 days**. *Valproate* - **Valproate** (sodium valproate/divalproex) is equally effective for acute mania and is also considered a **first-line agent** in current clinical practice, particularly for **mixed episodes** and **rapid cycling**. - Its mechanism involves increasing **GABA activity** and stabilizing neuronal membranes. - **Faster onset of action** than lithium (within days), making it advantageous in acute settings. - Often preferred when rapid control is needed or in patients with contraindications to lithium. *Carbamazepine* - **Carbamazepine** is an anticonvulsant used as a **mood stabilizer**, particularly for patients who do not respond to lithium or valproate. - It acts by blocking **voltage-gated sodium channels** and enhancing GABAergic transmission. - Considered a **second-line** or **alternative agent** for acute mania due to enzyme induction and drug interactions. *Lamotrigine* - **Lamotrigine** is primarily effective in preventing **depressive episodes** in bipolar disorder and has **minimal to no efficacy** for acute mania. - It works by blocking **voltage-sensitive sodium channels** and inhibiting the release of excitatory neurotransmitters like glutamate. - May even worsen mania or precipitate mixed states; **not indicated** for acute mania treatment.

Question 385: Which selective serotonin reuptake inhibitor (SSRI) is frequently prescribed as the first-line treatment for depression?

A. Amitriptyline
B. Paroxetine
C. Fluoxetine (Correct Answer)
D. Venlafaxine

Explanation: ***Fluoxetine*** - **Fluoxetine** is one of the most widely prescribed **first-line SSRIs** for depression and is frequently chosen in clinical practice. - Its **long half-life (4-6 days for active metabolite norfluoxetine)** reduces risk of discontinuation syndrome and allows for more flexible dosing. - **Activating properties** can be beneficial for patients with psychomotor retardation or fatigue-predominant depression. - Well-established efficacy across depressive and anxiety disorders with extensive clinical experience. *Amitriptyline* - **Amitriptyline** is a **tricyclic antidepressant (TCA)**, not an SSRI. - TCAs are typically **second-line** or reserved for treatment-resistant depression due to significant **anticholinergic effects** (dry mouth, constipation, urinary retention), **cardiovascular side effects** (orthostatic hypotension, arrhythmias), and **higher toxicity in overdose**. - Narrow therapeutic index makes them less safe than SSRIs. *Paroxetine* - **Paroxetine** is also an SSRI and is used as a first-line agent, though it has some distinctive characteristics. - More **sedating** than other SSRIs due to anticholinergic properties, which can be useful for anxious depression but may cause weight gain. - **Shortest half-life** among SSRIs leads to more severe **discontinuation syndrome** if doses are missed. - While effective, it is often not the preferred first choice due to withdrawal concerns and side effect profile. *Venlafaxine* - **Venlafaxine** is a **serotonin-norepinephrine reuptake inhibitor (SNRI)**, not a selective serotonin reuptake inhibitor. - Generally considered when SSRIs are ineffective or for specific indications like severe depression or generalized anxiety disorder. - Can cause **dose-dependent hypertension** and has a more complex side effect profile compared to SSRIs.

Question 386: A 35-year-old woman with major depressive disorder is started on fluoxetine. After two weeks, she develops restlessness, tremors, and hyperreflexia. What is the most likely cause?

A. Neuroleptic malignant syndrome
B. Serotonin syndrome (Correct Answer)
C. Acute dystonia
D. Hypokalemia

Explanation: ***Serotonin syndrome*** - The patient's symptoms of **restlessness**, **tremors**, and **hyperreflexia** after starting **fluoxetine** (an SSRI) are characteristic of **serotonin syndrome**, caused by excessive serotonin activity. - This condition is often precipitated by the introduction of a new serotonergic agent or an increase in the dosage of an existing one. *Neuroleptic malignant syndrome* - Characterized by **severe muscle rigidity**, **fever**, altered mental status, and autonomic instability, often associated with antipsychotic medications. - It does not typically present with the same constellation of motor and reflex symptoms as seen here with an SSRI. *Acute dystonia* - Involves **sustained muscle contractions** causing twisting and repetitive movements or abnormal postures, often occurring shortly after starting or increasing an antipsychotic. - It does not typically include the widespread neurological symptoms like hyperreflexia and generalized tremors observed in this patient. *Hypokalemia* - Can cause **muscle weakness**, cramps, and fatigue, and in severe cases, cardiac arrhythmias. - It does not explain the patient's neurological symptoms like restlessness, tremors, and hyperreflexia after starting fluoxetine.

Question 387: A 35-year-old female with major depressive disorder, who started on an SSRI three weeks ago, now reports increased anxiety, restlessness, insomnia, and thoughts of suicide. Analyze and choose the next step.

A. Urgent psychiatric evaluation and safety assessment. (Correct Answer)
B. Add short-term anxiolytic and urgent psychiatric referral.
C. Continue SSRI and add augmentation therapy with close monitoring.
D. Gradually taper SSRI and monitor closely.

Explanation: ***Urgent psychiatric evaluation and safety assessment.*** - The emergence of **suicidal thoughts** after starting an SSRI is a **psychiatric emergency** requiring immediate safety evaluation and risk assessment. - **SSRI-induced activation syndrome** or paradoxical worsening can occur in the initial weeks, particularly in young adults, with FDA black box warnings about increased suicidal ideation during this period. - **Direct safety assessment** takes priority over all other interventions - the patient needs immediate evaluation for hospitalization, means restriction, and crisis intervention. - Once safety is established, the psychiatrist can then determine whether to continue, adjust, or discontinue the SSRI. *Add short-term anxiolytic and urgent psychiatric referral.* - While this includes **urgent psychiatric referral**, starting a new medication (anxiolytic) before completing a safety assessment could delay critical intervention. - The addition of an anxiolytic doesn't address the **immediate suicidal risk** - safety evaluation must come first, then treatment decisions can be made. *Continue SSRI and add augmentation therapy with close monitoring.* - Continuing the potentially offending agent and adding augmentation without first conducting an **urgent safety assessment** in a patient with suicidal ideation is inappropriate and potentially dangerous. - While activation syndrome symptoms may eventually resolve, **active suicidal thoughts** require immediate psychiatric evaluation, not outpatient medication adjustment. *Gradually taper SSRI and monitor closely.* - Any medication changes, including tapering, should only occur **after comprehensive psychiatric evaluation and safety assessment**. - Abrupt or premature discontinuation of SSRIs can cause **discontinuation syndrome** and may worsen the clinical picture. - "Monitor closely" is insufficient for a patient with **active suicidal ideation** - immediate psychiatric intervention is required.

Question 388: A female patient on lithium for bipolar disorder for 6 months presents with seizures, tremors, confusion, and weakness. What is the primary investigation to diagnose lithium toxicity?

A. serum electrolytes
B. serum lithium level (Correct Answer)
C. ECG
D. MRI

Explanation: ***Serum lithium level*** - An elevated **serum lithium level** is the definitive diagnostic test for lithium toxicity, directly measuring the concentration of the drug in the patient's blood. - The symptoms of seizures, tremors, confusion, and weakness are all classic signs of **lithium neurotoxicity**, making the measurement of its blood concentration critical. - Therapeutic range: 0.6-1.2 mEq/L; toxicity typically occurs at levels >1.5 mEq/L. *Serum electrolytes* - While lithium toxicity can affect **electrolyte balance** (e.g., causing hyponatremia due to renal effects), measuring electrolytes alone is not sufficient to diagnose lithium toxicity. - Electrolytes should be checked as **dehydration and hyponatremia can precipitate toxicity**, but they don't directly measure lithium concentration. - Changes in electrolytes are often secondary and not directly indicative of the circulating **lithium concentration**. *ECG* - An **ECG** can reveal cardiac effects of lithium toxicity, such as **T-wave inversions** or **QT prolongation**, but it does not directly measure lithium levels or confirm the diagnosis. - Cardiac abnormalities are usually seen in severe toxicity and are not the primary diagnostic marker. - ECG is important for monitoring cardiac complications but is not diagnostic of lithium toxicity itself. *MRI* - An **MRI of the brain** might be considered in cases of severe neurological symptoms like seizures or altered mental status to rule out other causes or assess for **cerebral edema**, but it does not diagnose lithium toxicity itself. - It is a supportive or exclusionary test, not the primary diagnostic tool for lithium overdose.

Question 389: What is the treatment of choice for akathisia?

A. Benztropine
B. Propranolol (Correct Answer)
C. Dantrolene
D. Lithium

Explanation: ***Propranolol*** - **Beta-blockers** like propranolol are considered first-line treatment for akathisia due to their ability to reduce central as well as peripheral noradrenergic hyperactivity and anxiety. - They are particularly effective in alleviating the subjective feeling of **inner restlessness** and the objective motor symptoms, especially when the akathisia is induced by antipsychotics. *Benztropine* - This is an **anticholinergic** medication primarily used to treat other extrapyramidal symptoms like **dystonia** and **pseudoparkinsonism**. - While it might provide some relief for certain motor aspects, it is generally less effective for the subjective feeling of restlessness in akathisia and can have significant side effects. *Dantrolene* - **Dantrolene** is a direct-acting **skeletal muscle relaxant** used primarily in the treatment of **neuroleptic malignant syndrome (NMS)** and malignant hyperthermia. - It is not indicated for the management of extrapyramidal symptoms like akathisia. *Lithium* - **Lithium** is a mood stabilizer used predominantly in the treatment of **bipolar disorder**. - It has no role in the direct treatment of akathisia; however, it can ironically sometimes induce or worsen akathisia as a side effect itself.

Question 390: What is the classical drug of choice for Tourette syndrome?

A. Haloperidol (Correct Answer)
B. Amantadine
C. Propranolol
D. Diazepam

Explanation: ***Haloperidol*** - **Haloperidol**, a **first-generation antipsychotic**, is highly effective in blocking dopamine receptors and reducing the frequency and severity of tics in Tourette syndrome. - Its efficacy in managing severe tics makes it a **classical drug of choice**, particularly for individuals who do not respond to less potent interventions. *Amantadine* - **Amantadine** is primarily used as an **antiviral agent** against influenza A and as an antiparkinsonian drug, enhancing dopamine release. - It is not indicated for the treatment of Tourette syndrome as its mechanism of action is related to increasing dopamine, which would worsen tics. *Propranolol* - **Propranolol** is a **beta-blocker** primarily used to treat conditions like hypertension, angina, and essential tremor by reducing adrenergic activity. - While it can help with anxiety and some motor symptoms in specific conditions, it is not a primary treatment for the motor and vocal tics characteristic of Tourette syndrome. *Diazepam* - **Diazepam** is a **benzodiazepine** that acts as a central nervous system depressant, used primarily for anxiety, insomnia, and muscle spasms. - While it can help with associated anxiety, it does not directly address the underlying mechanism of tics in Tourette syndrome and is not a drug of choice for tic management.

Question 391: Which of the following is the preferred first-line pharmacological treatment for tardive dyskinesia?

A. Tetrabenazine
B. Baclofen
C. Cessation of antipsychotic medication
D. Valbenazine (Correct Answer)

Explanation: ***Valbenazine*** - **Valbenazine** is a **VMAT2 inhibitor** approved by the FDA as a **first-line treatment** for tardive dyskinesia. - It works by reducing **presynaptic dopamine release**, thereby mitigating involuntary movements. - Along with deutetrabenazine, it represents the **preferred pharmacological approach** for tardive dyskinesia, with good efficacy and tolerability. *Tetrabenazine* - **Tetrabenazine** is also a **VMAT2 inhibitor** that reduces dopamine levels. - However, the **newer VMAT2 inhibitors** (valbenazine and deutetrabenazine) are generally **preferred as first-line** due to **better tolerability** (lower risk of depression, parkinsonism, and somnolence) and simpler dosing schedules. - Tetrabenazine may still be used when newer agents are unavailable. *Baclofen* - **Baclofen** is a **GABA-B receptor agonist** primarily used for spasticity and muscle rigidity. - While it has been explored for tardive dyskinesia, it is **not considered first-line** pharmacological treatment due to **limited efficacy** compared to VMAT2 inhibitors. *Cessation of antipsychotic medication* - While sometimes considered, outright **cessation** of antipsychotic medication is often **not feasible** or desirable due to the risk of **relapse of underlying psychiatric illness**. - It can sometimes even **worsen tardive dyskinesia symptoms** temporarily (withdrawal-emergent dyskinesia). - The first-line approach involves **pharmacological treatment with VMAT2 inhibitors** to manage the dyskinesia while maintaining psychiatric stability.

Question 392: What is a significant risk associated with the use of SSRIs in young individuals for the management of depression?

A. Suicidal ideation (Correct Answer)
B. Nihilistic ideation
C. Guilt feelings
D. Envy-related thoughts

Explanation: ***Correct: Suicidal ideation*** - The use of **SSRIs in young individuals** (particularly those under 25 years of age) has been associated with an increased risk of suicidal thoughts and behaviors, especially during the **initial phases of treatment** (first 1-2 months). - This risk is significant enough to warrant an **FDA black box warning** for all antidepressants. - Requires **careful monitoring** and patient/family education about warning signs and changes in mood or behavior. - Risk is highest in the first few weeks; close follow-up is essential. *Incorrect: Nihilistic ideation* - While a severe symptom in some mental health conditions, **nihilistic ideation** (belief that nothing exists or that the self/world is unreal) is not a commonly documented or specific risk directly associated with SSRI use. - This is more typically associated with **severe psychotic depression** or delusional disorders rather than being a side effect of medication. *Incorrect: Guilt feelings* - **Guilt feelings** are a **core symptom of depression itself** (one of the cognitive symptoms) and are actually targeted for reduction by SSRI treatment. - They are not a significant risk or adverse effect caused by SSRI use; rather, successful treatment typically reduces excessive guilt. *Incorrect: Envy-related thoughts* - **Envy-related thoughts** are not a documented side effect or risk associated with SSRI use in medical literature. - These are psychological constructs that are not directly influenced or exacerbated by SSRI medications.

Question 393: Psychotic patient on antipsychotic drugs develops torticollis within 4 days of therapy. What is the treatment?

A. Peripheral anticholinergic drugs
B. Beta blockers
C. Dantrolene
D. Central anticholinergic drugs (Correct Answer)

Explanation: ***Central anticholinergic drugs*** - The patient is experiencing an **acute dystonic reaction**, a common extrapyramidal side effect of antipsychotics, such as **torticollis**, which requires immediate treatment with central anticholinergic agents. - Medications like **benztropine** or **diphenhydramine** are indicated to quickly reverse these symptoms by blocking acetylcholine activity in the basal ganglia. *Peripheral anticholinergic drugs* - These agents primarily act outside the central nervous system and are not effective in treating centrally mediated extrapyramidal symptoms like **acute dystonia**. - Their main use is for conditions like **bradycardia** or to reduce **gastrointestinal motility**. *Beta blockers* - **Beta-blockers** are primarily used to treat **akathisia** (restlessness) associated with antipsychotic medication, not acute dystonic reactions like torticollis. - They work by reducing the somatic manifestations of anxiety and motor restlessness. *Dantrolene* - **Dantrolene** is a **direct skeletal muscle relaxant** primarily used in the treatment of **neuroleptic malignant syndrome** or **malignant hyperthermia**. - It is not the first-line treatment for acute dystonic reactions as it does not address the underlying neurochemical imbalance.

Question 394: Which of the following conditions is a contraindication for ECT?

A. Raised ICT (Correct Answer)
B. Severe medical illness
C. Severe heart disease
D. Pregnancy complications

Explanation: ***Raised ICT*** - **Raised intracranial tension (ICT)** is an absolute contraindication for ECT due to the transient increase in **cerebral blood flow** and pressure during the procedure. - This increase in pressure can lead to **brain herniation** or further neurological compromise in patients with pre-existing elevated ICT. *Severe medical illness* - While severe medical illness can pose a risk, it is generally considered a **relative contraindication** rather than an absolute one. - The decision to proceed with ECT in such cases involves a careful **risk-benefit analysis** and close monitoring. *Severe heart disease* - **Severe heart disease**, such as **unstable angina** or **recent myocardial infarction**, is a relative contraindication. - It requires careful cardiac evaluation and management, but does not absolutely preclude ECT if the benefits outweigh the risks. *Pregnancy complications* - **Pregnancy** itself is not a contraindication for ECT; in some cases, it may be the preferred treatment for severe psychiatric illness during pregnancy. - However, complications might necessitate careful monitoring and adjustment of the procedure.

Question 395: Weight gain is seen with all of the following antipsychotic medications except?

A. Risperidone
B. Clozapine
C. Molindone (Correct Answer)
D. Quetiapine

Explanation: ***Molindone*** - **Molindone** is an antipsychotic known for its **low risk of weight gain** and has even been associated with weight loss in some patients. - Its mechanism of action, involving **dopamine D2 antagonism** without significant antagonism of histamine H1 or serotonin 5-HT2C receptors, contributes to its favorable metabolic profile. *Quetiapine* - **Quetiapine** is a common second-generation antipsychotic associated with a **moderate to high risk of weight gain**. - Its affinity for **histamine H1** and **serotonin 5-HT2C receptors** is thought to contribute to its weight-increasing effects. *Risperidone* - **Risperidone** carries a **moderate risk of weight gain**, especially at higher doses, making it a less desirable option if metabolic side effects are a major concern. - This effect is linked to its antagonism of **serotonin 5-HT2C receptors** and, to a lesser extent, **histamine H1 receptors**. *Clozapine* - **Clozapine** is associated with the **highest risk of weight gain** among all antipsychotics, often leading to significant metabolic disturbances. - Its strong antagonism of multiple receptors, including **histamine H1**, **serotonin 5-HT2C**, and **alpha1-adrenergic receptors**, plays a role in its profound metabolic side effects.

Question 396: A patient with depression was given Imipramine for 2 weeks. Relatives noticed increased excitement, colorful clothes, and increased talking. What is the next step in management?

A. Continue Imipramine alone
B. Manage with Valproate alone
C. Discontinue Imipramine and start Valproate (Correct Answer)
D. Antipsychotic with Imipramine continued

Explanation: ***Discontinue Imipramine and start Valproate*** - The patient's symptoms (increased excitement, colorful clothes, increased talking) after starting an antidepressant like **Imipramine** suggest a **manic switch**, indicating undiagnosed **bipolar disorder**. - **Imipramine** should be discontinued as it can exacerbate mania, and a mood stabilizer like **Valproate** is necessary to treat the manic episode. *Continue Imipramine alone* - Continuing Imipramine would likely worsen the manic symptoms, leading to increased agitation and potential harm. - Antidepressants can trigger or worsen manic episodes in individuals with underlying bipolar disorder. *Manage with Valproate alone* - While Valproate is an appropriate treatment for acute mania, simply managing with Valproate alone without discontinuing the offending antidepressant would be suboptimal. - The continued presence of Imipramine would counteract the mood-stabilizing effects of Valproate. *Antipsychotic with Imipramine continued* - Adding an antipsychotic might manage some acute manic symptoms, but continuing Imipramine would maintain the driving force behind the manic switch. - The primary action should be to remove the causative agent (Imipramine) and replace it with a mood stabilizer.

Question 397: What is the primary cause of death in Neuroleptic Malignant Syndrome?

A. Respiratory failure
B. Liver failure
C. None of the options (Correct Answer)
D. Drug toxicity

Explanation: ***None of the options*** - The **primary cause of death** in Neuroleptic Malignant Syndrome is **renal failure secondary to rhabdomyolysis**, which is not listed among the options. - **Severe muscle rigidity** in NMS leads to massive muscle breakdown (rhabdomyolysis) → release of myoglobin → myoglobinuria → acute tubular necrosis → acute renal failure. - Mortality in NMS ranges from **10-20%**, with renal complications being the leading cause of death. - Other significant causes include **cardiovascular collapse, arrhythmias, DIC**, and **respiratory complications**, but renal failure remains the most common fatal outcome. *Respiratory failure* - While respiratory complications occur in NMS (aspiration pneumonia, respiratory muscle rigidity), this is **not the primary cause of death**. - Respiratory failure can contribute to mortality but is typically **secondary** to other complications or occurs less frequently than renal failure as the direct cause. - It is a serious complication but not the most common fatal outcome. *Liver failure* - **Hepatotoxicity** is not a characteristic feature or primary cause of death in NMS. - Though elevated liver enzymes may occur, liver failure is **not a typical cause of mortality** in NMS. - The pathophysiology centers on **dopamine blockade**, autonomic instability, and muscle breakdown, not hepatic dysfunction. *Drug toxicity* - NMS is an **idiosyncratic reaction** to dopamine antagonists (typical and atypical antipsychotics), not a dose-dependent toxic effect. - Death results from the **physiological complications of the syndrome** (renal failure, cardiovascular collapse, hyperthermia), not from direct drug toxicity or overdose. - The mechanism is related to dopamine receptor blockade and subsequent dysregulation, not toxic poisoning.

Question 398: Which of the following antipsychotics is known to increase prolactin secretion?

A. Olanzapine
B. Ziprasidone
C. Clozapine
D. Risperidone (Correct Answer)

Explanation: ***Risperidone*** - **Risperidone** has a high affinity for **D2 dopamine receptors** in the tuberoinfundibular pathway, which leads to significant **prolactin elevation**. - **Dopamine** typically inhibits prolactin release; blocking D2 receptors disinhibits this process, causing increased secretion. *Olanzapine* - **Olanzapine** is a **second-generation antipsychotic** that generally causes **less prolactin elevation** compared to risperidone. - Its D2 receptor antagonism is transient or weaker in the tuberoinfundibular pathway, allowing less significant impact on prolactin. *Ziprasidone* - **Ziprasidone** is known for its **low risk of prolactin elevation** compared to other antipsychotics. - It has a unique receptor binding profile that includes 5-HT1A agonism and moderate D2 antagonism, which mitigates prolactin increase. *Clozapine* - **Clozapine** is associated with a **very low risk of prolactin elevation** and is often used in patients who experience prolactin-related side effects with other antipsychotics. - Its **weak and transient D2 receptor blockade** in the tuberoinfundibular pathway explains its minimal impact on prolactin levels.

Question 399: Most common complication of modified ECT

A. Amnesia (Correct Answer)
B. Intracerebellar hemorrhage
C. Spinal fracture
D. Muscle pain

Explanation: ***Amnesia*** - **Memory impairment**, particularly affecting **new learning (anterograde)** and **recall of past events (retrograde)**, is the most common and bothersome complication of modified ECT. - While typically transient, some patients may experience **persistent memory difficulties**, especially with autobiographical memories. *Intracerebellar hemorrhage* - **Intracerebellar hemorrhage** is an extremely rare and severe complication of ECT, not a common one. - Such an event would typically be linked to **pre-existing vascular abnormalities** or uncontrolled hypertension during the procedure. *Spinal fracture* - **Spinal fractures** were a significant concern in **unmodified ECT** due to unattenuated muscle contractions. - However, the use of **muscle relaxants** and **anesthesia** in modified ECT has significantly reduced the risk of musculoskeletal injuries, making it uncommon. *Muscle pain* - **Muscle aches** and soreness can occur after ECT due to **succinylcholine-induced fasciculations** and general muscle contraction, particularly in the neck and back. - While common, it is usually mild and easily managed with analgesics, and not considered the "most common complication" compared to cognitive effects.

Question 400: Which first-line conventional drug is commonly used in the treatment of delirium?

A. Haloperidol (Correct Answer)
B. Lithium carbonate
C. Opioids
D. Selective Serotonin Reuptake Inhibitors (SSRIs)

Explanation: ***Haloperidol*** - **Haloperidol** is a first-generation antipsychotic widely considered the **first-line conventional drug** for managing **agitation and psychotic symptoms** in delirium (particularly in the context of this 2015 exam). - Its efficacy in controlling these symptoms promptly, coupled with its availability in oral, intramuscular, and intravenous forms, makes it a preferred choice, especially in acute settings. - **Note:** Current evidence (post-2018) emphasizes non-pharmacological interventions first, with antipsychotics reserved for severe agitation when non-pharmacological measures fail. *Lithium carbonate* - **Lithium carbonate** is primarily used as a **mood stabilizer** for bipolar disorder, not for acute management of delirium. - It has a narrow therapeutic window and requires **careful monitoring of blood levels** to prevent toxicity, making it unsuitable for acute delirium management. *Opioids* - **Opioids** are mainly used for **pain management** and can actually **exacerbate delirium** due to their sedative and central nervous system depressant effects. - They are not indicated for treating the core symptoms of delirium, such as disorientation, fluctuating consciousness, or psychotic features. *Selective Serotonin Reuptake Inhibitors (SSRIs)* - **SSRIs** are primarily used for the treatment of **depression and anxiety disorders**, and their therapeutic effects take several weeks to manifest. - They are not effective for the immediate management of acute delirium and may even **worsen confusion or agitation** in some delirious patients.

Question 401: What is a common medical treatment for sexual paraphilias?

A. Benzodiazepines
B. Anti-androgens (Correct Answer)
C. SSRIs
D. Opioids

Explanation: ***Anti-androgens*** - **Anti-androgens are the established first-line pharmacological treatment** for paraphilias when medication is indicated. - Medications like **medroxyprogesterone acetate (MPA)** and **cyproterone acetate (CPA)** reduce testosterone levels, thereby reducing sexual drive and paraphilic urges. - They are particularly effective in **reducing the frequency and intensity of deviant sexual fantasies and behaviors**. - Used in combination with psychotherapy for comprehensive management of paraphilic disorders. *SSRIs* - May have a role as **adjunctive therapy** for compulsive sexual behaviors or when comorbid OCD, depression, or anxiety is present. - They can help reduce obsessive thoughts but are **not considered the primary treatment** for paraphilias themselves. - More useful for comorbid mood and anxiety symptoms than for core paraphilic symptoms. *Benzodiazepines* - Primarily used for **anxiety and insomnia** due to their sedative effects. - They do not address sexual urges or paraphilic behaviors and have no role in paraphilia treatment. *Opioids* - Prescribed for **pain management** and associated with risk of dependence. - They have **no established role** in the treatment of sexual paraphilias.

Question 402: Which of the following is NOT a known side effect of lithium?

A. Polyuria
B. Nephropathy
C. Ebstein's anomaly
D. Hyperthyroidism (Correct Answer)

Explanation: ***Hyperthyroidism*** - Lithium commonly causes **hypothyroidism** by interfering with thyroid hormone synthesis and release, not hyperthyroidism. - Patients on lithium often require **thyroid function monitoring** and may need thyroid hormone supplementation. *Polyuria* - **Nephrogenic diabetes insipidus**, characterized by polyuria and polydipsia, is a common side effect of lithium. - Lithium interferes with the kidney's ability to respond to **vasopressin (ADH)**, leading to increased water excretion. *Nephropathy* - Chronic lithium use can lead to **interstitial nephropathy**, characterized by a reduction in glomerular filtration rate. - Long-term monitoring of **renal function** is crucial for patients on lithium therapy. *Ebstein's anomaly* - While not a general "side effect" in adults, **Ebstein's anomaly** is a congenital heart defect associated with lithium exposure during the first trimester of pregnancy. - It involves displacement of the **tricuspid valve leaflets** into the right ventricle.

Question 403: ECT is contraindicated in -

A. Very ill patients
B. Raised ICT (Correct Answer)
C. Heart disease
D. Pregnancy

Explanation: ***Raised ICT (Correct Answer)*** - An increase in **intracranial pressure (ICP)** is the **only absolute contraindication** to ECT in modern practice. - ECT causes a **transient rise in ICP** during the seizure due to increased cerebral blood flow and cerebral metabolic rate. - In patients with pre-existing raised ICP (from brain tumors, subdural hematoma, or other space-occupying lesions), this additional increase can precipitate **brain herniation**, which is potentially fatal. - This makes raised ICP an **absolute contraindication** where the risks clearly outweigh any potential benefits. *Very ill patients* - ECT is **not contraindicated** in medically ill patients; in fact, it can be **life-saving** in severe psychiatric emergencies. - With careful medical evaluation, monitoring, and management, ECT can be safely administered to medically fragile individuals. - The rapid therapeutic response of ECT makes it particularly valuable when other treatments have failed or when quick intervention is critical. *Heart disease* - Cardiac conditions are **relative contraindications**, not absolute contraindications. - While conditions like recent MI, unstable angina, or severe arrhythmias require careful evaluation, ECT can be performed safely with appropriate cardiac optimization and monitoring. - Modern anesthetic techniques and cardiovascular management allow most patients with heart disease to receive ECT when clinically indicated. *Pregnancy* - **Pregnancy is NOT a contraindication** to ECT and is considered one of the safest treatment options for severe psychiatric illness during pregnancy. - ECT can be performed safely throughout all trimesters with appropriate obstetric consultation, fetal monitoring, and positioning adjustments. - It avoids the teratogenic risks associated with many psychotropic medications, making it a preferred option for severe depression or psychosis in pregnancy.

Question 404: Indications for ECT are all except?

A. Severe psychosis
B. Catatonic schizophrenia
C. Severe manic attack (Correct Answer)
D. Severe depression with suicidal risk

Explanation: ***Severe manic attack*** - While **severe mania IS a recognized indication for ECT**, it is generally considered **less commonly used as first-line therapy** compared to the other options listed. - In clinical practice, **acute severe mania** is typically managed initially with **antipsychotics and mood stabilizers** (lithium, valproate), with ECT reserved for **treatment-resistant cases** or when rapid response is critical. - ECT is highly effective for severe mania, particularly with **psychotic features** or **medication intolerance**, but is not the **most typical first-choice indication** compared to severe depression or catatonia. - This question reflects the **relative clinical priority** of ECT indications rather than absolute contraindication. *Severe depression with suicidal risk* - This is the **most common and well-established indication for ECT**. - ECT provides **rapid antidepressant effect** (often within 1-2 weeks) and is particularly indicated when there is **imminent suicide risk**, **psychotic depression**, or **treatment-resistant depression**. - Response rates exceed 70-90% in severe depression, making it a primary indication. *Catatonic schizophrenia* - **Catatonia is one of the strongest indications for ECT**, regardless of underlying etiology (schizophrenia, mood disorders, or medical conditions). - ECT rapidly resolves **catatonic symptoms** including mutism, stupor, posturing, and waxy flexibility. - Often considered **first-line treatment** for severe or malignant catatonia due to life-threatening complications. *Severe psychosis* - ECT is indicated for **severe psychotic disorders** that are **treatment-resistant** or when patients cannot tolerate antipsychotic medications. - Particularly effective in **acute psychotic agitation**, **treatment-refractory schizophrenia**, and psychosis with high risk of harm. - Provides rapid symptom control when pharmacotherapy has failed or is contraindicated.

Question 405: What is a contraindication for ECT?

A. Epilepsy
B. HIV
C. Cerebral aneurysm (Correct Answer)
D. Arrhythmia

Explanation: ***Cerebral aneurysm*** * A **cerebral aneurysm** is considered a **relative contraindication** for electroconvulsive therapy (ECT) due to the increased risk of rupture from the transient, but significant, rise in **blood pressure** and **intracranial pressure** during the procedure. * The cardiovascular stress induced by the seizure can worsen pre-existing vascular pathologies in the brain, making it a high-risk condition. *Arrhythmia* * While various cardiac conditions require careful monitoring during ECT, **arrhythmias** are generally not an absolute contraindication. * Patients can often undergo ECT with proper **cardiac monitoring** and **pharmacological management** to control the heart rhythm during the procedure. *Epilepsy* * **Epilepsy** is not a contraindication for ECT; in fact, ECT *artificially induces a seizure* to achieve therapeutic effects. * The presence of epilepsy primarily impacts the choice of **anticonvulsant medications** and the need for potentially higher seizure thresholds, but it does not preclude ECT. *HIV* * **HIV infection** itself is not a contraindication for ECT. * ECT can be safely administered to HIV-positive individuals, with consideration given to the patient's overall **physical health**, **medication interactions**, and any co-morbid opportunistic infections.

Question 406: Which of the following is an antipsychotic drug?

A. Flupenthixol (Correct Answer)
B. Rasagiline
C. Clobazam
D. Divalproex

Explanation: ***Flupenthixol*** - **Flupenthixol** is a **first-generation (typical) antipsychotic** used primarily for managing **schizophrenia** and other psychotic disorders. - It acts by blocking **dopamine D2 receptors** in the brain, reducing positive symptoms like **hallucinations and delusions**. *Rasagiline* - **Rasagiline** is a **monoamine oxidase-B (MAO-B) inhibitor** used in the treatment of **Parkinson's disease**. - It works by preventing the breakdown of **dopamine** in the brain, thereby improving motor symptoms, and is not an antipsychotic. *Clobazam* - **Clobazam** is a **benzodiazepine** primarily indicated for the treatment of **epilepsy** (specifically Lennox-Gastaut syndrome) and **anxiety**. - Its mechanism involves enhancing the effect of **GABA** in the brain, producing sedative and anticonvulsant effects, distinct from antipsychotic action. *Divalproex* - **Divalproex** is a combination product of **valproic acid** and **sodium valproate**, typically used as a **mood stabilizer** for **bipolar disorder**, an **antiepileptic**, and for **migraine prophylaxis**. - It modulates **GABAergic** transmission and sodium channels, but it is not classified as an antipsychotic drug.

Question 407: What serum lithium level indicates severe toxicity?

A. 0.6 mEq/L
B. 12 mEq/L
C. 2.6 mEq/L (Correct Answer)
D. <0.6 mEq/L

Explanation: ***2.6 mEq/L*** - A serum lithium level of **2.6 mEq/L** falls within the **severe toxicity range (>2.5 mEq/L)**, which is the clinically relevant threshold for severe lithium toxicity. - At this level, patients typically present with severe neurological symptoms such as **seizures, altered consciousness, coma, cardiac arrhythmias, and multiorgan dysfunction**. - This represents the **most appropriate answer** as it defines the clinical threshold where severe toxicity begins and requires aggressive management. *0.6 mEq/L* - This level falls within the **therapeutic range (0.6-1.2 mEq/L)** for lithium maintenance therapy. - This is **not indicative of any toxicity** and represents an appropriate treatment level. *12 mEq/L* - While this level technically represents severe toxicity, it is **incompatible with life** and represents a lethal concentration. - Such levels are **not clinically encountered** as patients would not survive to present with this level. - The question asks for the level that **indicates** severe toxicity, which refers to the **diagnostic threshold (>2.5 mEq/L)**, not extreme outlier values. *<0.6 mEq/L* - A lithium level **below 0.6 mEq/L** is **subtherapeutic** and unlikely to provide adequate mood stabilization. - This level is **not associated with toxicity** but rather with insufficient therapeutic effect.

Question 408: Which of the following statements is true regarding akathisia?

A. Anticholinergics may be used in specific cases of akathisia.
B. Akathisia is characterized by the presence of hallucinations.
C. Behavioral therapy is the primary treatment for akathisia.
D. Patients may exhibit restlessness and an urge to move. (Correct Answer)

Explanation: ***Patients may exhibit restlessness and an urge to move.*** - **Akathisia** is a common **extrapyramidal side effect** characterized by an inner feeling of **restlessness** and an urge to move, which may manifest as pacing, fidgeting, or an inability to sit still. - This condition can be highly distressing for patients, leading to significant discomfort and non-adherence to medication. *Anticholinergics may be used in specific cases of akathisia.* - **Anticholinergics** like benztropine are typically used to treat **pseudoparkinsonism** and **dystonia**, another type of extrapyramidal symptom, but are generally **not effective** for akathisia. - **Beta-blockers** (e.g., propranolol) and **benzodiazepines** (e.g., lorazepam) are more commonly used for akathisia, although the primary approach is typically to reduce or switch the causative medication. *Akathisia is characterized by the presence of hallucinations.* - **Hallucinations** are perceptual disturbances, often associated with psychotic disorders or delirium, and are **not a defining symptom of akathisia**. - Akathisia is primarily a **motor and subjective sensory phenomenon**, distinct from psychotic symptoms. *Behavioral therapy is the primary treatment for akathisia.* - While supportive measures and **behavioral interventions** can help manage the distress, they are **not the primary treatment** for akathisia, which is generally pharmacological. - The most effective approach involves **reducing the dose** of the offending antipsychotic medication or **switching to another antipsychotic** with a lower propensity for causing akathisia.

Question 409: A 78-year-old woman is brought to the clinic by her daughter due to concerns about her mother's mood. The patient's husband of 48 years passed away six months ago after a lengthy illness due to metastatic colon cancer. Since then, she reports having a poor appetite, decreased interest in activities, and frequent thoughts about dying. She is started on nortriptyline to help improve her mood and functional status. Which of the following is a common side effect of nortriptyline?

A. weight loss
B. impaired cardiac contractility
C. heart block
D. anticholinergic side effects (Correct Answer)

Explanation: ***Anticholinergic side effects*** - **Nortriptyline** is a **tricyclic antidepressant (TCA)** known for its significant **antimuscarinic** activity, leading to anticholinergic effects. - Common anticholinergic side effects include **dry mouth, blurred vision, constipation, urinary retention**, and **tachycardia**. *Impaired cardiac contractility* - While TCAs can have **cardiac effects** (e.g., QT prolongation, arrhythmias), **impaired cardiac contractility** is not a common or typical direct side effect at therapeutic doses. - Other drug classes, such as certain **beta-blockers** or **calcium channel blockers**, are more commonly associated with this effect. *Weight loss* - **Weight gain** is a more common side effect associated with many antidepressants, including some TCAs. - While some individuals may experience initial appetite changes, **sustained weight loss** is not a characteristic side effect of **nortriptyline**. *Heart block* - TCAs can cause **conduction abnormalities** like **prolonged QRS duration** and **QT interval prolongation**, especially in overdose or in patients with pre-existing cardiac conditions. - However, direct **heart block** (e.g., AV block) is a less common side effect, usually associated with higher doses or specific patient vulnerabilities.

Question 410: A patient diagnosed with schizophrenia presented with an acute exacerbation of symptoms. After receiving an injection of haloperidol in the casualty, the patient suddenly developed deviation of the eyeballs and torticollis. What is the diagnosis?

A. Akathisia
B. Acute dystonia (Correct Answer)
C. Malignant hyperthermia
D. Drug induced parkinsonism

Explanation: ***Acute dystonia*** * **Acute dystonia** is a common **extrapyramidal side effect** of high-potency antipsychotics like **haloperidol**, characterized by sudden, involuntary muscle contractions occurring within **minutes to hours** of drug administration. * **Deviation of the eyeballs (oculogyric crisis)** and **torticollis** (spasms of neck muscles) are classic presentations of acute dystonia. * Treatment includes **anticholinergic agents** (e.g., benztropine, trihexyphenidyl) or **antihistamines** (e.g., diphenhydramine), which provide rapid relief. *Akathisia* * **Akathisia** is characterized by an internal feeling of **restlessness** and an urge to move, which is often relieved by movement. * It does not present with fixed abnormal postures or sudden, sustained muscle contractions like oculogyric crisis or torticollis. *Malignant hyperthermia* * **Malignant hyperthermia** is a rare, life-threatening reaction to certain **anesthetic drugs**, characterized by **rapidly increasing body temperature**, muscle rigidity, and metabolic acidosis. * It is not typically associated with antipsychotic use or the specific localized dystonic movements described. *Drug induced parkinsonism* * **Drug-induced parkinsonism** presents with symptoms resembling Parkinson's disease, including **tremor**, **rigidity**, **bradykinesia**, and postural instability. * These symptoms develop more **gradually** (days to weeks) and are distinct from the sudden, acute, sustained muscle contractions seen in dystonia.

Question 411: A patient presents with symptoms of major depressive disorder. Which medication should be prescribed for treatment?

A. Haloperidol
B. Olanzapine
C. Alprazolam
D. Sertraline (Correct Answer)

Explanation: ***Sertraline*** - **Sertraline** is a **selective serotonin reuptake inhibitor (SSRI)**, which are first-line agents for treating major depressive disorder due to their efficacy and generally favorable side effect profile. - SSRIs work by increasing the availability of **serotonin** in the brain, helping to improve mood and reduce symptoms of depression. *Haloperidol* - **Haloperidol** is a **first-generation antipsychotic** primarily used to treat psychotic disorders like **schizophrenia** and severe agitation, not major depressive disorder. - It works by blocking **dopamine D2 receptors**, and its side effects can include **extrapyramidal symptoms**. *Alprazolam* - **Alprazolam** is a **benzodiazepine** used to treat anxiety disorders and panic attacks due to its *rapid onset of action* in reducing anxiety symptoms. - While it can alleviate anxiety that co-occurs with depression, it is not an antidepressant and does not treat the underlying depressive disorder; it also carries a risk of **dependence and withdrawal**. *Olanzapine* - **Olanzapine** is a **second-generation antipsychotic** used for conditions such as **schizophrenia** and **bipolar disorder**. - While it can be used as an **adjunctive treatment** in some cases of treatment-resistant depression, it is not a first-line monotherapy for major depressive disorder.

Question 412: Which of the following antidepressants can also be used as an antipsychotic?

A. Trazodone
B. Amoxapine (Correct Answer)
C. Doxepin
D. Amitriptyline

Explanation: ***Amoxapine*** - Amoxapine is a **tetracyclic antidepressant** with a unique pharmacological profile, as it acts as a dopamine receptor antagonist, particularly at the **D2 receptor**. - Its **dopamine receptor blocking activity** confers antipsychotic properties, making it useful in treating mood disorders with psychotic features. *Amitriptyline* - Amitriptyline is a **tricyclic antidepressant (TCA)** primarily used for depression, neuropathic pain, and migraine prophylaxis. - It primarily acts by inhibiting the reuptake of **norepinephrine and serotonin**, with no significant dopamine receptor blocking activity. *Trazodone* - Trazodone is a **serotonin antagonist and reuptake inhibitor (SARI)**, commonly used for depression and insomnia. - Its main mechanism involves **blocking 5-HT2A receptors** and inhibiting serotonin reuptake, without antipsychotic effects. *Doxepin* - Doxepin is another **tricyclic antidepressant (TCA)** used for depression, anxiety, and insomnia. - It primarily inhibits the reuptake of **norepinephrine and serotonin** and has significant antihistaminic effects, but lacks antipsychotic properties.

Question 413: A patient with schizophrenia was started on haloperidol 5 mg. The next day, he presented with uprolling of the eyes. A complete neurological examination revealed no spasticity or any other abnormality, and visual acuity and ophthalmoscopic findings are normal. The most likely diagnosis is:

A. Akathisia
B. Acute dystonia (Correct Answer)
C. Seizure
D. Tardive dyskinesia

Explanation: ***Acute dystonia*** - The rapid onset of **uprolling of the eyes** (oculogyric crisis) shortly after starting **haloperidol**, a potent D2 blocker, is a classic presentation of acute dystonia. - This extrapyramidal symptom is characterized by **involuntary muscle contractions** affecting various body parts, including the eyes, neck (**torticollis**), and jaw. *Akathisia* - Akathisia is characterized by a **subjective feeling of inner restlessness** and an objective need to move, often described as an inability to sit still. - While it is an extrapyramidal symptom, it doesn't typically manifest as involuntary eye movements like oculogyric crisis. *Seizure* - Seizures typically involve **loss of consciousness**, generalized tonic-clonic movements, or altered mental status, none of which are described. - The patient's presentation of isolated eye uprolling without other neurological findings or changes in consciousness makes a seizure unlikely. *Tardive dyskinesia* - **Tardive dyskinesia** is a late-onset extrapyramidal side effect, typically developing after months or years of antipsychotic use, not within a day of starting the medication. - It is characterized by **involuntary, repetitive movements**, often involving the face, mouth, and tongue (e.g., lip smacking, grimacing).

Question 414: Atypical depression is managed with:

A. NDRI
B. MAOI (Correct Answer)
C. SSRI
D. SNRI

Explanation: ***MAOI*** - **MAOIs** (Monoamine Oxidase Inhibitors) are the **most effective treatment** for atypical depression, as demonstrated by multiple clinical studies including the landmark Columbia study. - They show **superior efficacy** compared to other antidepressants for the characteristic features of atypical depression: **mood reactivity**, **increased appetite/weight gain**, **hypersomnia**, **leaden paralysis**, and **rejection sensitivity**. - While requiring **dietary restrictions** (avoiding tyramine-rich foods) and careful monitoring for drug interactions, MAOIs remain the **gold standard treatment** when treating atypical depression specifically. - Examples include phenelzine and tranylcypromine. *SSRI* - **SSRIs** are commonly used as **first-line treatment in clinical practice** due to their favorable safety profile and ease of use. - However, they are **less effective than MAOIs** for atypical depression specifically, though they are still beneficial and widely prescribed due to tolerability. - Preferred when safety, tolerability, and patient compliance are prioritized over maximal efficacy. *SNRI* - **SNRIs** (Serotonin-Norepinephrine Reuptake Inhibitors) are effective for various forms of depression but are not the most effective option for atypical depression. - May be beneficial for patients with **comorbid pain** or **fatigue symptoms** due to their dual mechanism of action. *NDRI* - **NDRIs** (Norepinephrine-Dopamine Reuptake Inhibitors), such as bupropion, are useful for depression with **low energy** or **anhedonia**. - Not specifically indicated for the characteristic features of atypical depression like **mood reactivity** or **leaden paralysis**. - Often chosen when avoiding sexual side effects or weight gain is important.

Question 415: The patient presented with a contraction of the neck, describing it as painful, which started after an injection given at the psychiatry hospital for his psychosis. What type of side effect was caused by the drug?

A. dystonia (Correct Answer)
B. neuroleptic malignant syndrome
C. tardive dyskinesia
D. akathisia

Explanation: ***Dystonia*** - **Dystonia** involves sustained or repetitive muscle contractions, often causing twisting and repetitive movements or abnormal fixed postures. - An acute onset of painful neck contraction (like **torticollis**) following an injection of antipsychotics points to an acute dystonic reaction. *Neuroleptic Malignant Syndrome* - **Neuroleptic Malignant Syndrome (NMS)** is characterized by **fever**, **muscle rigidity**, **altered mental status**, and **autonomic instability**. - While serious, NMS presents with a constellation of symptoms far beyond just a neck contraction. *Akathisia* - **Akathisia** is a subjective feeling of inner restlessness and the need to move, often manifesting as pacing or fidgeting. - It does not typically involve painful, fixed muscle contractions as described in the patient's presentation. *Tardive Dyskinesia* - **Tardive dyskinesia** involves involuntary, repetitive movements, most often of the face and mouth (e.g., lip smacking, grimacing). - It typically develops after **prolonged exposure** to antipsychotics and is generally not an acute reaction to a single injection.

Question 416: A patient is brought to the casualty in a state of altered sensorium, having been treated with lithium for an affective disorder. On examination, the patient exhibits tremors, increased deep tendon reflexes, urinary incontinence, and has experienced an episode of epileptic fits. The patient had an episode of severe gastroenteritis two days prior. The patient's serum lithium level is 1.95 mmol/L. What is the direct cause of the patient's current clinical presentation?

A. Elevated serum lithium level (Correct Answer)
B. Dehydration due to gastroenteritis
C. Manic episode
D. Depressive stupor

Explanation: ***Elevated serum lithium level*** - The patient's serum lithium level of **1.95 mmol/L** is significantly above the therapeutic range (0.6-1.2 mmol/L) and indicates **severe lithium toxicity** (toxic level >1.5 mmol/L). - The clinical features are **classic manifestations of lithium toxicity**: altered sensorium (CNS toxicity), **epileptic seizures** (severe neurotoxicity), coarse tremors, hyperreflexia, and urinary incontinence. - This elevated lithium level is the **direct cause** of all the presenting neurological symptoms. - The gastroenteritis caused dehydration, which **precipitated** the lithium accumulation by reducing renal clearance, but the **toxic lithium level itself** is what directly caused these symptoms. *Dehydration due to gastroenteritis* - While gastroenteritis-induced dehydration is an important **precipitating factor** that led to reduced renal lithium clearance and subsequent accumulation, it is not the **direct cause** of the neurological symptoms. - Dehydration alone does not cause **epileptic seizures**, altered sensorium, or hyperreflexia in this specific pattern—these are caused by the **toxic lithium level**. - This represents a contributory factor in the causal chain, not the direct pathophysiological cause of the presentation. *Manic episode* - Mania presents with **elevated/expansive mood**, increased goal-directed activity, decreased need for sleep, pressured speech, and grandiosity. - The patient's presentation of **altered sensorium**, seizures, and coarse tremors with hyperreflexia is inconsistent with mania and instead indicates **toxic encephalopathy**. - Lithium is used to treat bipolar disorder, but these symptoms represent drug toxicity, not the underlying psychiatric condition. *Depressive stupor* - Depressive stupor involves severe psychomotor retardation, mutism, and stupor without **seizures**, tremors, or hyperreflexia. - The neurological signs (seizures, hyperreflexia, coarse tremors) point to **neurotoxicity** from lithium rather than a primary depressive syndrome. - This presentation is clearly toxic/organic rather than functional psychiatric pathology.

Question 417: Best use of lithium is in:

A. Treatment of schizophrenia
B. Treatment of recurrent depression
C. Treatment of first depressive episode
D. Prophylaxis of bipolar mood disorder (Correct Answer)

Explanation: ***Prophylaxis of bipolar mood disorder*** - **Lithium** is a highly effective mood stabilizer primarily used for the **long-term prevention of both manic and depressive episodes** in bipolar disorder. - Its prophylactic benefits include reducing the **frequency and severity of mood swings**, thereby improving overall stability and functioning. *Treatment of schizophrenia* - While lithium can sometimes be used as an **adjunctive treatment** in schizophrenia, it is not a primary agent and is not the best use. - **Antipsychotics** are the first-line treatment for schizophrenia. *Treatment of recurrent depression* - Lithium can be used as an **augmentation strategy** for recurrent unipolar depression that hasn't responded to antidepressants. - However, for unipolar depression, it is not considered the **best or primary treatment**, which typically involves antidepressants. *Treatment of first depressive episode* - For a first depressive episode, **antidepressants** are the first-line pharmacotherapy. - Lithium is generally not indicated as a primary treatment for initial episodes of unipolar depression.

Question 418: A patient is experiencing subtle involuntary movements of his hands, feet, lips, and tongue. What is the expected response of these symptoms during the tapering of antipsychotic medication?

A. It will resolve immediately after the medication is decreased.
B. It will initially increase as the medication is decreased. (Correct Answer)
C. It will remain the same.
D. It will resolve in his hands but not in his feet.

Explanation: ***It will initially increase as the medication is decreased.*** - The involuntary movements described are characteristic of **tardive dyskinesia**, a side effect of long-term antipsychotic use. - When antipsychotic medication is tapered or discontinued, the **dopamine receptors**, which have been chronically blocked, become hypersensitive, leading to an initial worsening or unmasking of dyskinetic movements due to temporary dopamine overdrive. *It will resolve immediately after the medication is decreased.* - Tardive dyskinesia symptoms rarely resolve immediately upon antipsychotic reduction or discontinuation; instead, they often become **more pronounced** as receptor sensitivity changes. - The withdrawal of the medication unmasks the underlying dopamine receptor hypersensitivity, leading to an initial increase rather than immediate resolution. *It will remain the same.* - The dynamic nature of dopamine receptor hypersensitivity means that symptoms of tardive dyskinesia are unlikely to remain stable during changes in antipsychotic dosage. - **Dopamine receptor sensitivity** is altered by the change in medication levels, leading to a noticeable shift in symptom severity. *It will resolve in his hands but not in his feet.* - Tardive dyskinesia typically affects muscle groups globally, often including movements of the **face, trunk, and extremities**, rather than resolving in some areas and not others. - The pathophysiology involving **widespread dopamine receptor changes** does not usually manifest with selective resolution in specific body parts.

Question 419: Among the following, which test is essential in pre-treatment evaluation for lithium therapy:

A. Fasting blood sugar
B. Serum creatinine (Correct Answer)
C. Liver function tests
D. Platelet count

Explanation: ***Serum creatinine*** - **Lithium** is almost entirely excreted by the kidneys, so baseline renal function assessed by **serum creatinine** and estimated glomerular filtration rate (eGFR) is crucial. - This helps determine the appropriate starting dose and monitor for potential **lithium-induced renal impairment** during therapy. *Fasting blood sugar* - While important for general health screening and monitoring metabolic syndrome, **lithium** does not directly impact glucose metabolism to the extent that it requires pre-treatment evaluation for dosing or safety reasons. - This test is not considered essential specifically for lithium pre-treatment. *Liver function tests* - **Lithium** is not metabolized by the liver, and **hepatotoxicity** is not a known side effect. - Therefore, baseline liver function tests are not considered essential for initiating lithium therapy. *Platelet count* - **Lithium** rarely causes significant hematological abnormalities like **thrombocytopenia** or **thrombocytosis**. - A baseline platelet count is generally not required for pre-treatment evaluation unless there are other clinical indications.

Question 420: A 17-year-old with schizophrenia recently started on antipsychotics is brought to casualty with neck rigidity. He has:

A. Tardive dyskinesia
B. Dystonia (Correct Answer)
C. Catatonia
D. Neuroleptic malignant syndrome

Explanation: ***Dystonia*** - **Acute dystonia** is a common **extrapyramidal side effect** of antipsychotic medications, particularly typical antipsychotics or higher doses of atypical ones. - **Neck rigidity**, specifically **torticollis** (sustained contraction of neck muscles causing the head to turn to one side), is a classic presentation of acute dystonia. *Catatonia* - While catatonia can manifest with motor abnormalities, including rigidity, it is a broader syndrome involving a range of **psychomotor disturbances** (e.g., stupor, negativism, waxy flexibility, mutism) and is not solely defined by isolated neck rigidity following antipsychotic initiation. - Catatonia is often a feature of severe psychiatric illness itself or other medical conditions, rather than an acute drug-induced side effect limited to muscle spasms. *Neuroleptic malignant syndrome* - **Neuroleptic malignant syndrome (NMS)** is a life-threatening reaction characterized by a **tetrad of symptoms**: high fever, severe muscle rigidity (generalized), altered mental status, and autonomic dysfunction (e.g., tachycardia, labile blood pressure). - Isolated neck rigidity without these other severe systemic signs is not consistent with NMS. *Tardive dyskinesia* - **Tardive dyskinesia** involves repetitive, involuntary, and often stereotyped movements, typically affecting the **face, mouth, and tongue** (e.g., grimacing, lip smacking, tongue protrusion). - It usually develops after **long-term use** of antipsychotics and is rarely an acute reaction presenting as neck rigidity shortly after starting the medication.

Question 421: A 50-year-old woman with schizophrenia who has been taking an antipsychotic drug for the past three years has begun to exhibit involuntary chewing and lip-smacking movements. Which is the most likely possibility?

A. Akathisia
B. Neuroleptic Malignant Syndrome
C. Restless Legs Syndrome
D. Tardive Dyskinesia (Correct Answer)

Explanation: ***Tardive Dyskinesia*** - This condition is characterized by **involuntary, repetitive movements**, often involving the face (e.g., **chewing, lip-smacking, grimacing**) and extremities, that develop after prolonged use of antipsychotic medications. - The delayed onset (after three years of antipsychotic use) and the specific nature of the movements are highly suggestive of **tardive dyskinesia**. *Akathisia* - Akathisia presents as a feeling of **inner restlessness** and an inability to sit still, leading to constant pacing or fidgeting. - While it is a common side effect of antipsychotics, the cardinal symptoms are motor restlessness rather than involuntary movements like chewing and lip-smacking. *Neuroleptic Malignant Syndrome* - This is a rare, life-threatening reaction to antipsychotics characterized by **fever, severe muscle rigidity, altered mental status, and autonomic dysfunction**. - The patient's symptoms of involuntary chewing and lip-smacking do not align with the acute and severe presentation of NMS. *Restless Legs Syndrome* - RLS involves an **uncontrollable urge to move the legs**, typically worse at night and relieved by movement, often accompanied by unpleasant sensations. - The patient's symptoms are in the face (chewing, lip-smacking) and not described as an urge to move the legs or worse at night.

Question 422: Which mood stabilizer is known for its anti-suicidal property?

A. carbamazepine
B. lamotrigine
C. valproate
D. lithium (Correct Answer)

Explanation: ***Lithium*** - **Lithium** is the only mood stabilizer with strong evidence of reducing **suicidal ideation** and attempts in patients with mood disorders. - Its mechanism in preventing suicidality is not fully understood but may involve neuroprotective effects and modulation of neurotransmitter systems. *Carbamazepine* - While an effective mood stabilizer for **bipolar disorder**, carbamazepine does not have a well-established anti-suicidal property compared to lithium. - It works primarily by blocking voltage-gated **sodium channels**, which stabilizes neuronal membranes. *Lamotrigine* - **Lamotrigine** is primarily used for the **maintenance treatment** of bipolar disorder, particularly for preventing depressive episodes. - It does not have significant evidence for a direct anti-suicidal effect, and there is a rare risk of **Stevens-Johnson syndrome**. *Valproate* - **Valproate** is an effective mood stabilizer for acute mania and maintenance treatment in bipolar disorder. - While it can improve mood and reduce impulsivity, its anti-suicidal effect is not as robust or consistently demonstrated as that of **lithium**.

Question 423: A young patient with schizophrenia is resistant to treatment with conventional antipsychotic medications. Which drug is most preferred?

A. Haloperidol
B. Olanzapine
C. Clozapine (Correct Answer)
D. Risperidone

Explanation: ***Clozapine*** - **Clozapine** is the drug of choice for **treatment-resistant schizophrenia** or patients who are **intolerant to conventional antipsychotics**. - Its unique efficacy often comes with a risk of **agranulocytosis**, requiring regular **blood monitoring**. *Olanzapine* - While an effective **atypical antipsychotic**, it is not specifically indicated for **treatment-resistant cases** in the same way as clozapine. - It carries a risk of significant **metabolic side effects**, such as weight gain and dyslipidemia. *Haloperidol* - This is a **first-generation (conventional) antipsychotic** and would be unsuitable for a patient described as **intolerant to conventional antipsychotics**. - It is associated with a high incidence of **extrapyramidal symptoms (EPS)** and **tardive dyskinesia**. *Risperidone* - As an **atypical antipsychotic**, it is a good first-line option but is not typically reserved for **treatment-resistant schizophrenia** or those with conventional antipsychotic intolerance. - It has a higher propensity for **hyperprolactinemia** compared to other atypical antipsychotics.

Question 424: What is the most appropriate investigation for a patient with bipolar disorder on lithium therapy for 6 months, who presents with seizures, coarse tremors, confusion, and weakness of the limbs after a day of fasting?

A. Serum Electrolyte
B. ECG
C. Serum Lithium (Correct Answer)
D. Serum creatinine

Explanation: ***Serum Lithium*** - The patient's symptoms (seizures, coarse tremors, confusion, weakness) are classic signs of **lithium toxicity**. - Fasting can lead to **dehydration** and electrolyte imbalances, which can increase lithium levels and precipitate toxicity. *Serum Electrolyte* - While electrolyte imbalances can contribute to lithium toxicity and symptoms, measuring electrolytes alone will not directly confirm **lithium overdose**. - **Hyponatremia** and **dehydration** can exacerbate lithium toxicity by increasing renal reabsorption of lithium. *ECG* - **ECG changes** (e.g., T-wave abnormalities, QTc prolongation) can occur with severe lithium toxicity, but it is not the primary diagnostic test. - ECG is a supportive investigation to assess cardiac complications, not the direct cause of the neurological symptoms. *Serum creatinine* - **Serum creatinine** is important for monitoring **renal function**, as lithium is cleared renally and renal impairment can lead to higher lithium levels. - However, assessing creatinine levels will not directly diagnose acute lithium toxicity; it helps evaluate the **renal health** and potential for toxicity.

Practice by Chapter

Principles of Psychopharmacology

Practice Questions

Antipsychotic Medications

Practice Questions

Antidepressant Medications

Practice Questions

Mood Stabilizers

Practice Questions

Anxiolytics and Hypnotics

Practice Questions

Stimulants and Cognitive Enhancers

Practice Questions

Pharmacokinetics and Pharmacodynamics

Practice Questions

Drug Interactions

Practice Questions

Adverse Effects and Management

Practice Questions

Pharmacogenomics in Psychiatry

Practice Questions

Special Populations Considerations

Practice Questions

Treatment Algorithms and Guidelines

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Psychopharmacology — MCQs

Psychopharmacology — MCQs

On this page